>P20334; 24 4-1BB LIGAND RECEPTOR PRECURSOR (T-CELL ANTIGEN 4-1BB). MGNNCYNVVVIVLLLVGCEKVGAVQNSCDNCQPGTFCRKYNPVCKSCPPSTFSSIGGQPN CNICRVCAGYFRFKKFCSSTHNAECECIEGFHCLGPQCTRCEKDCRPGQELTKQGCKTCS LGTFNDQNGTGVCRPWTNCSLDGRSVLKTGTTEKDVVCGPPVVSFSPSTTISVTPEGGPG GHSLQVLTLFLALTSALLLALIFITLLFSVLKWIRKKFPHIFKQPFKKTTGAAQEEDACS CRCPQEEEGGGGGYEL >P29240; 30 5'-NUCLEOTIDASE PRECURSOR (EC 3.1.3.5) (ECTO-NUCLEOTIDAS MPRVPSASATGSSALLSLLCAFSLGRAAPFQLTILHTNDVHARVEETNQDSGKCFTQSFA GVARRWTKIEELRARDKNVLLLDAGDQYQGTIWFNYYKGAEAAHFIEAVGYNAMALGNHE FDNGAEGLLDPFLLNVSFPVLSANLEQGEDQVPSLIGYYKPSTVLDVNGEKIGVVGYTSK ETPTLSSPGPHLIFKDEIQAVQHEVDILVSQGIDKIIALGHSGFETDKLIAQKVRGVDVV VGGHSNTFLYTGKAPSNDVPVGPYPFLVNSDDQRTIPVVQAYAYGKYLGYLKLTFDKGEV IKREGNPILLNSSIIQDPVLLAEVNKWKESLANFGKEVIGRTVVYLNGTTEECRNRECNM GNLICDAMIQQNIRNPDEKFWNHVSICIFQGGGIRAPINEQNNGTIQVDSLLAVLPFGST IDLLEVYGSTLRAAFDHSVRRYGQNTGEFLQVSGIQVQFNLKRPPGSRVVKIDVLCADCR VPHYQPLLDNKIYKIVTNSYIAEGGDGFTMLKNERLRYDTGSTDISVVSSYIKQMKVVYP AVEGRILFVENSATLPIINLKIGLSLFAFLTWFLHCS >P21588; 28 5'-NUCLEOTIDASE PRECURSOR (EC 3.1.3.5) (ECTO-NUCLEOTIDAS MRPAAATAPKWLLLALSALLPLWPTAKSWELTIMHTNDVHSRLEQTSDDSTKCLNASLCV GGVARLFTKVQQIRKEEPNVLLLDAGDQYQGTIWFTVYKGLEVAHFMNLLGYDAMALGNH EFDNGVEGLIDPLLRNVKFPILSANIKARGPLAPQISGLYLPYKVLSVGGEVVGIVGYTS KETPFLSNPGTNLVFEDEVTALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDV VVGGHTNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKVEFDDKG NVVTSYGNPILLNSTIREDAAIKADINQWRIKLDNYSTQELGRTIVYLNGSAQECRFREC NMGNLICDAMINNNLRHPDEMFWNHVSMCIVNGGGIRSPIDERNNGTITWENLAAVLPFG GTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDISRKPWDRVVQLKVLCTK CRVPIYEPLEMDKVYKVVLPSYLVNGGDGFQMIKDELLKHDSGDQDISVVSEYISKMKVI YPAVEGRIKFSAASHYQGSFPLIILSFWAVILVLYQ >P12961; 26 NEUROENDOCRINE PROTEIN 7B2 PRECURSOR (SECRETOGRANIN V). MASRLVSAMLSGLLFWLMFEWNPAFAYSPRTPDRVSETDIQRLLHGVMEQLGIARPRVEY PAHQAMNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDNIPKDFSEDQGYPDPPNPC PLGKTADDGCLENAPDTAEFSREFQLDQHLFDPEHDYPGLGKWNKKLLYEKMKGGQRRKR RSVNPYLQGKRLDNVVAKKSVPHFSEEEKEAE >P02764; 18 ALPHA-1-ACID GLYCOPROTEIN PRECURSOR (OROSOMUCOID) (OMD). MALHMVLVVLSLLPLLEAQNPEPANITLGIPITNETLKWLSDKWFYMGAAFRDPVFKQAV QTIQTEYFYLTPNLINDTIELREFQTTDDQCVYNFTHLGVQRENGTLSKCAGAVKIFAHL IVLKKHGTFMLAFNLTDENRGLSFYAKKPDLSPELRKIFQQAVKDVGMDESEIVFVDWTK DKCSEQQKQQLELEKETKKETKKDP >P22922; 16 ANTITRYPSIN PRECURSOR (AT). MKTIICLFTIAIAAMAAVTNLSNVLKNGNDNFTARMFTEVVKNNPGKSIVLSAFSVLPPL AQLALASDGETHEELLKAIGFPDDDAIRTEFASKSRDLRSIKGVELKMANKVYVHDGGKL DENFAVVSRDVFNSDVQNIDFSKNTVAAKSINDWVEENTNNRIKDLVNPDSLSSATAAVL VNAIYFKGAWSSKFDERLTSDRDFYVSKDKTIKVPMMYKRGDYKYGESAVLNAQLIEIPY KGDQSSLIVVLPKDKDGITQLQEALKDPKTLETAQQSMYSTEVDLYLPKFKIETETNLKD VLSNMNVNKIFNNDAQITRLLKGESLSVSEAIQKAFIEINEEGAEAAAANAFTMTRSSKV YVRPPIVFNANKPFYYALQVDGVIMFNGIFIN >P14046; 24 ALPHA-1-INHIBITOR III PRECURSOR. MKKDREAQLCLFSALLAFLPFASLLNGNSKYMVLVPSQLYTETPEKICLHLYHLNETVTV TASLISQRGTRKLFDELVVDKDLFHCVSFTIPRLPSSEEEESLDINIEGAKHKFSERRVV LVKNKESVVFVQTDKPMYKPGQSVKFRVVSMDKNLHPLNELFPLAYIEDPKMNRIMQWQD VKTENGLKQLSFSLSAEPIQGPYKIVILKQSGVKEEHSFTVMEFVLPRFGVDVKVPNAIS VYDEIINVTACATYTYGKPVPGHVKISLCHGNPTFSSETKSGCKEEDSRLDNNGCSTQEV NITEFQLKENYLKMHQAFHVNATVTEEGTGSEFSGSGRIEVERTRNKFLFLKADSHFRHG IPFFVKVRLVDIKGDPIPNEQVLIKARDAGYTNATTTDQHGLAKFSIDTNGISDYSLNIK VYHKEESSCIHSSCTAERHAEAHHTAYAVYSLSKSYIYLDTEAGVLPCNQIHTVQAHFIL KGQVLGVLQQIVFHYLVMAQGSILQTGNHTHQVEPGESQVQGNFALEIPVEFSMVPVAKM LIYTILPDGEVIADSVKFQVEKCLRNKVHLSFSPSQSLPASQTHMRVTASPQSLCGLRAV DQSVLLQKPEAELSPSLIYDLPGMQDSNFIASSNDPFEDEDYCLMYQPIAREKDVYRYVR ETGLMAFTNLKIKLPTYCNTDYDMVPLAVPAVALDSSTDRGMYESLPVVAVKSPLPQEPP RKDPPPKDPVIETIRNYFPETWIWDLVTVNSSGVTELEMTVPDTITEWKAGALCLSNDTG LGLSSVASFQAFQPFFVELTMPYSVIRGEAFTLKATVLNYLPTSLPMAVLLEASPDFTAV PVENNQDSYCLGANGRHTSSWLVTPKSLGNVNFSVSAEARQSPGPCGSEVATVPETGRKD TVVKVLIVEPEGIKKEHTFSSLLCASDAELSETLSLLLPPTVVKDSARAHFSVMGDILSS AIKNTQNLIQMPYGCGEQNMVLFAPNIYVLKYLNETQQLTEKIKSKALGYLRAGYQRELN YKHKDGSYSAFGDHNGQGQGNTWLTAFVLKSFAQARAFIFIDESHITDAFTWLSKQQKDS GCFRSSGSLLNNAMKGGVDDEITLSAYITMALLESSLPDTDPVVSKALSCLESSWENIEQ GGNGSFVYTKALMAYAFALAGNQEKRNEILKSLDKEAIKEDNSIHWERPQKPTKSEGYLY TPQASSAEVEMSAYVVLARLTAQPAPSPEDLALSMGTIKWLTKQQNSYGGFSSTQDTVVA LDALSKYGAATFSKSQKTPSVTVQSSGSFSQKFQVDKSNRLLLQQVSLPYIPGNYTVSVS GEGCVYAQTTLRYNVPLEKQQPAFALKVQTVPLTCNNPKGQNSFQISLEISYMGSRPASN MVIADVKMLSGFIPLKPTVKKLERLGHVSRTEVTTNNVLLYLDQVTNQTLSFSFIIQQDI PVKNLQPAIVKVYDYYETDEVAFAEYSSPCSSDDQNV >P08697; 27 ALPHA-2-ANTIPLASMIN PRECURSOR (ALPHA-2-PLASMIN INHIBITOR MALLWGLLVLSWSCLQGPCSVFSPVSAMEPLGRQLTSGPNQEQVSPLTLLKLGNQEPGGQ TALKSPPGVCSRDPTPEQTHRLARAMMAFTADLFSLVAQTSTCPNLILSPLSVALALSHL ALGAQNHTLQRLQQVLHAGSGPCLPHLLSRLCQDLGPGAFRLAARMYLQKGFPIKEDFLE QSEQLFGAKPVSLTGKQEDDLANINQWVKEATEGKIQEFLSGLPEDTVLLLLNAIHFQGF WRNKFDPSLTQRDSFHLDEQFTVPVEMMQARTYPLRWFLLEQPEIQVAHFPFKNNMSFVV LVPTHFEWNVSQVLANLSWDTLHPPLVWERPTKVRLPKLYLKHQMDLVATLSQLGLQELF QAPDLRGISEQSLVVSGVQHQSTLELSEVGVEAAAATSIAMSRMSLSSFSVNRPFLFFIF EDTTGLPLFVGSVRNPNPSAPRELKEQQDSPGNKDFLQSLKGFPRGDKLFGPDLKLVPPM EEDYPQFGSPK >Q99795; 21 CELL SURFACE A33 ANTIGEN PRECURSOR. MVGKMWPVLWTLCAVRVTVDAISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDK LLLTHTERVVIWPFSNKNYIHGELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVS LMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNI LNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVG IAVGVVAALIIIGIIIYCCCCRGKDDNTEDKEDARPNREAYEEPPEQLRELSREREEEDD YRQEEQRSTGRESPDHLDQ >P05067; 17 ALZHEIMER'S DISEASE AMYLOID A4 PROTEIN PRECURSOR (PROTEA MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTK TCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG EFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFR GVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPC RAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARD PVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQA KNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYER MNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTET KTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTN IKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN >P55000; 21 ARS(COMPONENT B)-81/S PRECURSOR (ANTI-NEOPLASTIC URINARY MASRWAVQLLLVAAWSMGCGEALKCYTCKEPMTSASCRTITRCKPEDTACMTTLVTVEAE YPFNQSPVVTRSCSSSCVATDPDSIGAAHLIFCCFRDLCNSEL >P42254; 25 ALPHA-L-ARABINOFURANOSIDASE A PRECURSOR (EC 3.2.1.55) (A MVAFSALSGVSAVSLLLSLVQNAHGISLKVSTQGGNSSSPILYGFMFEDINHSGDGGIYG QMLQNPGLQGTAPNLTAWAAVGDATIAIDGDSPLTSAIPSTIKLNIADDATGAVGLTNEG YWGIPVDGSEFHSSFWIKGDYSGDITVRLVGNYTGTEYGSTTITHTSTADNFTQASVKFP TTKAPDGNVLYELTVDGSVAAGSSLNFGYLTLFGETYKSRENGLKPQLANVLDDMKGSFL RFPGGNNLEGNSAENRWKWNETIGDLCDRPGREGTWTYYNTDGLGLHEYFYWCEDLGLVP VLGVWDGFALESGGNTPLTGDALTPYIDDVLNELEYILGDTSTTYGAWRAANGQEEPWNL TMVEIGNEDMLGGGCESYAERFTAFYDAIHAAYPDLILIASTSEADCLPESMPEGSWVDY HDYSTPDGLVGQFNYFDNLNRSVPYFIGEYSRWEIDWPNMKGSVAEAVFMIGFERNSDVV KMAAYAPLLQLINSTQWTPDLIGYTQSPGDIFLSTSYYVQEMFSRNRGDTIKEVTSDSDF GPLYWVASSAGDSYYVKLANYGSETQDLTVSIPGTSTGKLTVLADSDPDAYNSDTQTLVT PSESTVQASNGTFTFSLPAWAVAVLAAN >P42255; 18 ALPHA-L-ARABINOFURANOSIDASE B PRECURSOR (EC 3.2.1.55) (A MFSRRNLVALGLAATVSAGPCDIYEAGDTPCVAAHSTTRALYSSFSGALYQLQRGSDDTT TTISPLTAGGVADASAQDTFCANTTCLITIIYDQSGNGNHLTQAPPGGFDGPDVDGYDNL ASAIGAPVTLNGQKAYGVFMSPGTGYRNNEATGTATGDEPEGMYAVLDGTHYNDACCFDY GNAETSSTDTGAGHMEAIYLGNSTTWGYGAGDGPWIMVDMENNLFSGADEGYNSGDPSIS YSFVTAAVKGGADKWAIRGGNAASGSLSTYYSGARPDYSGYNPMSKEGAIILGIGGDNSN GAQGTFYEGVMTSGYPSDDVENSVQENIVAAKYVSGSLVSGPSFTSGEVVSLRVTTPGYT TRYIAHTDTTVNTQVVDDDSSTTLKEEASWTVVTGLANSQCFSFESVDTPGSYIRHYNFE LLLNANDGTKQFHEDATFCPQAPLNGEGTSLRSWSYPTRYFRHYENVLYAASNGGVQTFD SKTSFNNDVSFEIETAFAS >P19801; 19 AMILORIDE-SENSITIVE AMINE OXIDASE [COPPER-CONTAINING] PR MPALGWAVAAILMLQTAMAEPSPGTLPRKAGVFSDLSNQELKAVHSFLWSKKELRLQPSS TTTMAKNTVFLIEMLLPKKYHVLRFLDKGERHPVREARAVIFFGDQEHPNVTEFAVGPLP GPCYMRALSPRPGYQSSWASRPISTAEYALLYHTLQEATKPLHQFFLNTTGFSFQDCHDR CLAFTDVAPRGVASGQRRSWLIIQRYVEGYFLHPTGLELLVDHGSTDAGHWAVEQVWYNG KFYGSPEELARKYADGEVDVVVLEDPLPGGKGHDSTEEPPLFSSHKPRGDFPSPIHVSGP RLVQPHGPRFRLEGNAVLYGGWSFAFRLRSSSGLQVLNVHFGGERIAYEVSVQEAVALYG GHTPAGMQTKYLDVGWGLGSVTHELAPGIDCPETATFLDTFHYYDADDPVHYPRALCLFE MPTGVPLRRHFNSNFKGGFNFYAGLKGQVLVLRTTSTVYNYDYIWDFIFYPNGVMEAKMH ATGYVHATFYTPEGLRHGTRLHTHLIGNIHTHLVHYRVDLDVAGTKNSFQTLQMKLENIT NPWSPRHRVVQPTLEQTQYSWERQAAFRFKRKLPKYLLFTSPQENPWGHKRSYRLQIHSM ADQVLPPGWQEEQAITWARYPLAVTKYRESELCSSSIYHQNDPWHPPVVFEQFLHNNENI ENEDLVAWVTVGFLHIPHSEDIPNTATPGNSVGFLLRPFNFFPEDPSLASRDTVIVWPRD NGPNYVQRWIPEDRDCSMPPPFSYNGTYRPV >P04058; 21 ACETYLCHOLINESTERASE PRECURSOR (EC 3.1.1.7) (ACHE). MNLLVTSSLGVLLHLVVLCQADDHSELLVNTKSGKVMGTRVPVLSSHISAFLGIPFAEPP VGNMRFRRPEPKKPWSGVWNASTYPNNCQQYVDEQFPGFSGSEMWNPNREMSEDCLYLNI WVPSPRPKSTTVMVWIYGGGFYSGSSTLDVYNGKYLAYTEEVVLVSLSYRVGAFGFLALH GSQEAPGNVGLLDQRMALQWVHDNIQFFGGDPKTVTIFGESAGGASVGMHILSPGSRDLF RRAILQSGSPNCPWASVSVAEGRRRAVELGRNLNCNLNSDEELIHCLREKKPQELIDVEW NVLPFDSIFRFSFVPVIDGEFFPTSLESMLNSGNFKKTQILLGVNKDEGSFFLLYGAPGF SKDSESKISREDFMSGVKLSVPHANDLGLDAVTLQYTDWMDDNNGIKNRDGLDDIVGDHN VICPLMHFVNKYTKFGNGTYLYFFNHRASNLVWPEWMGVIHGYEIEFVFGLPLVKELNYT AEEEALSRRIMHYWATFAKTGNPNEPHSQESKWPLFTTKEQKFIDLNTEPMKVHQRLRVQ MCVFWNQFLPKLLNATACDGELSSSGTSSSKGIIFYVLFSILYLIF >P22966; 31 ANGIOTENSIN-CONVERTING ENZYME PRECURSOR, TESTIS-SPECIFIC MGQGWATAGLPSLLFLLLCYGHPLLVPSQEASQQVTVTHGTSSQATTSSQTTTHQATAHQ TSAQSPNLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIA NHTLKYGTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVA TVCHPNGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAAR LNGYVDAGDSWRSMYETPSLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEGP IPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLL PVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQ YFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMK MALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPG AKFHIPSSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLG FSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSE GPLPDSGRVSFLGLDLDAQQARVGQWLLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHG PQFGSEVELRHS >P09478; 21 ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-LIKE CHAIN 1 PRECU MGSVLFAAVFIALHFATGGLANPDAKRLYDDLLSNYNRLIRPVGNNSDRLTVKMGLRLSQ LIDVNLKNQIMTTNVWVEQEWNDYKLKWNPDDYGGVDTLHVPSEHIWHPDIVLYNNADGN YEVTIMTKAILHHTGKVVWKPPAIYKSFCEIDVEYFPFDEQTCFMKFGSWTYDGYMVDLR HLKQTADSDNIEVGIDLQDYYISVEWDIMRVPAVRNEKFYSCCEEPYLDIVFNLTLRRKT LFYTVNLIIPCVGISFLSVLVFYLPSDSGEKISLCISILLSLTVFFLLLAEIIPPTSLTV PLLGKYLLFTMMLVTLSVVVTIAVLNVNFRSPVTHRMAPWVQRLFIQILPKLLCIERPKK EEPEEDQPPEVLTDVYHLPPDVDKFVNYDSKRFSGDYGIPALPASHRFDLAAAGGISAHC FAEPPLPSSLPLPGADDDLFSPSGLNGDISPGCCPAAAAAAAADLSPTFEKPYAREMEKT IEGSRFIAQHVKNKDKFESVEEDWKYVAMVLDRMFLWIFAIACVVGTALIILQAPSLHDQ SQPIDILYSKIAKKKFELLKMGSENTL >P05377; 20 ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-1B CHAIN PRECURSOR MDYTASCLIFLFIAAGTVFGTDHETRLIGDLFANYNKVVRPVETYKDQVVVTVGLQLIQL INVDEVNQIVSTNIRLKQQWRDVNLKWDPAKYGGVKKIRIPSSDVWSPDLVLYNNADGDF AISKDTKILLEYTGKITWTPPAIFKSYCEIIVTYFPFDQQNCSMKFGTWTYDGSLLVINP ERDRPDLSNFMASGEWMMKDYRCWKHWVYYTCCPDKPYLDITYHFVLQRLPLYFIVNVII PCLLFSFLTGLVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLF TMVFVIASIIITVIVINTHHRSPSTHTMPPWVRKIFIETIPNIMFFSTMKRPSQEKQPQK TFAEEMDISHISGKLGPAAVTYQSPALKNPDVKSAIEGIKYIAETMKSDQESNKASEEWK FVAMVLDHILLAVFMTVCVIGTLAVFAGRIIEMNMQE >P09481; 22 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-3 CHAIN P MQSIHALLLTAAVCILFQGCGGSEPEHRLYAALFKNYNQFVRPVKNASDPVIIQFEVSMS QLVKVDEVNQIMETNLWLKHIWNDYKLRWNPVDYGGAEFIRVPSGQIWKPDIVLYNNAVG DFQVDDKTKALLKYTGDVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSWSYDKAKIDL VLIGSTMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYTDITYSLYIRRLPLFYTINMI IPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLVIPLIGEYLL FTMIFVTLSIVITVFVLNVHYRTPKTHTMPVWVRTIFLNLLPRIMFMTRPTSDEENNQKP KPFYTSEFSNLNCFNSSEIKCCKDGFVCQDMACSCCQYQRMKFSDFSGNLTRSSSSESVD PLFSFSVLSPEMRDAIESVKYIAENMKMQNEAKEIQDDWKYVAMVIDRIFLWVFILVCIL GTAGLFLQPLMTGDDM >P09482; 23 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-4 CHAIN P MGFLVSKGNLLLLLCASIFPAFGHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVR FGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPQEYENVTSIRIPSELIWRPDIVL YNNADGDFAVTHLTKAHLFYDGRIKWMPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYD KAKIDLVSMHSHVDQLDYWESGEWVIINAVGNYNSKKYECCTEIYPDITYSFIIRRLPLF YTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPL IGEYLLFTMIFVTLSIIITVFVLNVHHRSPRTHTMPDWVRRVFLDIVPRLLFMKRPSTVK DNCKKLIESMHKLTNSPRLWSETDMEPNFTTSSSPSPQSNEPSPTSSFCAHLEEPAKPMC KSPSGQYSMLHPEPPQVTCSSPKPSCHPLSDTQTTSISKGRSLSVQQMYSPNKTEEGSIR CRSRSIQYCYLQEDSSQTNGHSSASPASQRCHLNEEQPQHKPHQCKCKCRKGEAAGTPTQ GSKSHSNKGEHLVLMSPALKLAVEGVHYIADHLRAEDADFSVKEDWKYVAMVIDRIFLWM FIIVCLLGTVGLFLPPWLAGMI >P09479; 20 ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA CHAIN PRECURSOR. MELCRVLLLIFSAAGPALCYEHETRLVDDLFREYSKVVRPVENHRDAVVVTVGLQLIQLI NVDEVNQIVTTNVRLKQQWTDINLKWNPDDYGGVKQIRIPSDDIWRPDLVLYNNADGDFA IVKYTKVLLEHTGKITWTPPAIFKSYCEIIVTYFPFDQQNCSMKLGTWTYDGTMVVINPE SDRPDLSNFMESGEWVMKDYRGWKHWVYYACCPDTPYLDITYHFLMQRLPLYFIVNVIIP CLLFSFLTGFVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLFT MVFVIASIIITVIVINTHHRSPSTHTMPPWVRKIFIDTIPNIMFFSTMKRPSRDKPDKKI FAEDIDISEISGKQGPVPVNFYSPLTKNPDVKNAIEGIKYIAETMKSDQESSNAADEWKF VAMVLDHLLLVIFMLVCIIGTLAVFAGRLIELNQQG >P11230; 23 ACETYLCHOLINE RECEPTOR PROTEIN, BETA CHAIN PRECURSOR. MTPGALLMLLGALGPPLAPGVRGSEAEGRLREKLFSGYDSSVRPAREVGDRVRVSVGLIL AQLISLNEKDEEMSTKVYLDLEWTDYRLSWDPAEHDGIDSLRITAESVWLPDVVLLNNND GNFDVALDISVVVSSDGSVRWQPPGIYRSSCSIQVTYFPFDWQNCTMVFSSYSYDSSEVS LQTGLGPDGQGHQEIHIHEGTFIENGQWENIHKPSRLIQPPGDPRGGREGQRQEVIFYLI IRRKPLFYLVNVIAPCILITLLAIFVFYLPPDAGEKMGLSIFALLTLTVFLLLLADKVPE TSLSVPIIIKYLMFTMVLVTFSVILSVVVLNLHHRSPHTHQMPLWVRQIFIHKLPLYLRL KRPKPERDLMPEPPHCSSPGSGWGRGTDEYFIRKPPSDFLFPKPNRFQPELSAPDLRRFI DGPNRAVALLPELREVVSSISYIARQLQEQEDHDALKEDWQFVAMVVDRLFLWTFIIFTS VGTLVIFLDATYHLPPPDPFP >P02712; 24 ACETYLCHOLINE RECEPTOR PROTEIN, BETA CHAIN PRECURSOR. MENVRRMALGLVVMMALALSGVGASVMEDTLLSVLFETYNPKVRPAQTVGDKVTVRVGLT LTNLLILNEKIEEMTTNVFLNLAWTDYRLQWDPAAYEGIKDLRIPSSDVWQPDIVLMNNN DGSFEITLHVNVLVQHTGAVSWQPSAIYRSSCTIKVMYFPFDWQNCTMVFKSYTYDTSEV TLQHALDAKGEREVKEIVINKDAFTENGQWSIEHKPSRKNWRSDDPSYEDVTFYLIIQRK PLFYIVYTIIPCILISILAILVFYLPPDAGEKMSLSISALLAVTVFLLLLADKVPETSLS VPIIIRYLMFIMILVAFSVILSVVVLNLHHRSPNTHTMPNWIRQIFIETLPPFLWIQRPV TTPSPDSKPTIISRANDEYFIRKPAGDFVCPVDNARVAVQPERLFSEMKWHLNGLTQPVT LPQDLKEAVEAIKYIAEQLESASEFDDLKKDWQYVAMVADRLFLYVFFVICSIGTFSIFL DASHNVPPDNPFA >P02717; 18 ACETYLCHOLINE RECEPTOR PROTEIN, DELTA CHAIN PRECURSOR. MAVLLALFGALVLSGGLCVNQEERLIHHLFEERGYNKEVRPVASADEVVDVYLALTLSNL ISLKEVDETLTTNVWVEQSWTDYRLQWNTSEFGGVDVLRLLPEMLWLPEIVLENNNDGLF EVAYYCNVLVYNTGYVYWLPPAIFRSACPINVNFFPFDWQNCTLKFSSLAYNAQEINMHL KEESDPETEKNYRVEWIIIDPEGFTENGEWEIIHRPARKNIHPSYPTESSEHQDITFYLI IKRKPLFYVINIVTPCVLIAFMAILVFYLPADSGEKMTLVISVLLAQSVFLLLVSQRLPA TSHAIPLIGKYLLFIMLLVTAVVVICVVVLNFHFRTPSTHVMSDWVRGVFLEILPRLLHM SHPAESPAGAPCIRRCSSAGYIAKAEEYYSVKSRSELMFEKQSERHGLASRVTPARFAPA ATSEEQLYDHLKPTLDEANFIVKHMREKNSYNEEKDNWNRVARTLDRLCLFLITPMLVVG TLWIFLMGIYNHPPPLPFSGDPFDYREENKRYI >P20782; 20 ACETYLCHOLINE RECEPTOR PROTEIN, EPSILON CHAIN PRECURSOR. MAGALLGALLLLTLFGRSQGKNEELSLYHHLFDNYDPECRPVRRPEDTVTITLKVTLTNL ISLNEKEETLTTSVWIGIDWHDYRLNYSKDDFAGVGILRVPSEHVWLPEIVLENNIDGQF GVAYDSNVLVYEGGYVSWLPPAIYRSTCAVEVTYFPFDWQNCSLIFRSQTYNAEEVEFIF AVDDDGNTINKIDIDTAAFTENGEWAIDYCPGMIRRYEGGSTEGPGETDVIYTLIIRRKP LFYVINIIVPCVLISGLVLLAYFLPAQAGGQKCTVSINVLLAQTVFLFLIAQKIPETSLS VPLLGRYLIFVMVVATLIVMNCVIVLNVSLRTPTTHATSPRLRQILLELLPRLLGSSPPP EDPRTASPARRASSVGILLRAEELILKKPRSELVFEGQRHRHGTWTAALCQNLGAAAPEI RCCVDAVNFVAESTRDQEATGEELSDWVRMGKALDNVCFWAALVLFSVGSTLIFLGGYFN QVPDLPYPPCIQP >P05376; 17 ACETYLCHOLINE RECEPTOR PROTEIN, GAMMA CHAIN PRECURSOR. MDTVLLLVSLCISAAFCNNEEERLLNDLMKNYNKNLRPVEKDGDIISVSIKLTLTNLISL NEKEEALTTNVWVEMQWKDYRLSWDPNDYHGISMMRIPSTSVWLPDVGLENNVDGTFDIA LYTNTLVSSDGSMYWLPPAIYRSSCPVVVTYFPFDWQNCSIVFQSQTYSANEIELLLTVD EQTIEWIEIDPEAFTENGEWAIKHMPAKRIINHRLPRDDVNYQQIVFYLIIQRKPLFYII NIIVPCVLISFVSILVYFLPAKAGGQKCTVSINILLAQTVFLFLVAQKIPETSTSVPLIV KYLTFLMVVTITIVANAVIVLNISLRTPNTHSMSSTVRELCLRTVPRLLRMHLRPTDAAP PLAPLMRRSSSLGLMMKADEYMLRKPRSQLMFEKQKERDGLMKVVLDKIGRGMENNTSDD LVHSLNHAAPEIRTCVEACCHIASATREKNDFKSENEEWILMGRVIDRVCFLVMCFVFFL GTIGTFLAGHFNQAPAHPFPGDSKLYQPST >P09484; 18 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, BETA-2 CHAIN PR MALLRVLCLLAALRRSLCTDTEERLVEYLLDPTRYNKLIRPATNGSQLVTVQLMVSLAQL ISVHEREQIMTTNVWLTQEWEDYRLTWKPEDFDNMKKVRLPSKHIWLPDVVLYNNADGMY EVSFYSNAVISYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVL KSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRKPLFYTINLIIPCIL ITSLAILVFYLPSDCGEKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVGKYLMFTMVL VTFSIVTSVCVLNVHHRSPTTHTMPPWVRTLFLRKLPALLFMKQPQQNCARQRLRQRRQT QERAAAATLFLRAGARACACYANPGAAKAEGLNGYRERQGQGPDPPAPCGCGLEEAVEGV RFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTVGMFLQPLFQNYATNSL LQLGQGTPTSK >P13908; 30 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, NON-ALPHA-2 CHA MTLAVIGLFTLFTSIIAITPAREFVSLAEREDALLRELFQGYQRWVRPVQHANHSVKVRF GLKISQLVDVDEKNQLMTTNVWLWQEWLDYKLRWNPENYGGITSIRVPSESIWLPDIVLY ENADGRFEGSLMTKAIVRYNGMITWTPPASYKSACTMDVTFFPFDRQNCSMKFGSWTYDG NMVKLVLINQQVDRSDFFDNGEWEILSATGVKGSRQDSHLSYPYITYSFILKRLPLFYTL FLIIPCLGLSFLTVLVFYLPSDEGEKVSLSTSVLVSLTVFLLVIEEIIPSSSKVIPLIGE YLLFIMIFVTLSIIVTIFVINVHHRSSATYHPMSPWVRSLFLQRLPHLLCMRGNTDRYHY PELEPHSPDLKPRNKKGPPGPEGEGQALINLLEQATNSVRYISRHIKKEHFIREVVQDWK FVAQVLDRIFLWTFLTVSVLGTILIFTPALKMFLRTPPPPSP >P18257; 28 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, NON-ALPHA-3 CHA MKLQISGLLLVTAVAYATIEAPEEFVSLAEMEDTLLRNLFRGYQKWVRPILHANDTITVR FGLKISQLVDVDEKNHLMTTNVWLWQEWTDYKLRWNPEDYGGITSIRVPSETIWLPDIVL YENADGRFEGSLMTKAIVRFNGTIMWTPPASYKSSCTMDVTFFPFDRQNCSMKFGSWTYD GTMVDLTLLDAYVDRKDFFDNGEWEILNATGQRGSRRDGIYSYPYVTYSFILKRLPLFYT LFLIIPCLGLSFLTVLVFYLPSDEGEKLLLSTSVLVSLTVFLLVIEEIIPSSSKVIPLIG EYLLFIMIFVTFSIIVTLFVINVHHRSSATYHPMAPWVKSLFLQRLPRLLCMRGHTDRYQ YPDIELRSPELKRGMKKGQQKSAGGGRGGLKEDENQAWIALLEKATHSVHYISRHIKKEH FIREVVQDWKFVAQVLDRIFLWVFLTASVLGTILIFTPALHMYLST >P10323; 19 ACROSIN PRECURSOR (EC 3.4.21.10). MVEMLPTAILLVLAVSVVAKDNATCDGPCGLRFRQNPQGGVRIVGGKAAQHGAWPWMVSL QIFRYNSHRYHTCGGSLLNSRWVLTAAHCFVGKNNVHDWRLVFGAKEITYGNNKPVKAPL QERYVEKIIIHEKYNSATEGNDIALVEITPPISCGRFIGPGCLPHFKAGLPRGSQSCWVA GWGYIEEKAPRPSSILMEARVDLIDLDLCNSTQWYNGRVQPTNVCAGYPVGKIDTCQGDS GGPLMCKDSKESAYVVVGITSWGVGCALAKRPGIYTATWPYLNWIASKIGSNALRMIQSA TPPPPTTRPPPIRPPFSHPISAHLPWYFQPPPRPLPPRPPAAQPPPPPSPPPPPPPPASP LPPPPPPPPPTPSSTTKLPQGLSFAKRLQQLIEVLKGKTYSDGKNHYDMETTELPELTST S >P32781; 18 A-AGGLUTININ PRECURSOR. MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYK SVTFVSNCGSHPSTTSKGSPINTQYVF >P28351; 31 ALPHA-GALACTOSIDASE A PRECURSOR (EC 3.2.1.22) (MELIBIASE MIQGLESIMNQGTKRILLAATLAATPWQVYGSIEQPSLLPTPPMGFNNWARFMCDLNETL FTETADTMAANGLRDAGYNRINLDDCWMAYQRSDNGSLQWNTTKFPHGLPWLAKYVKAKG FHFGIYEDSGNMTCGGYPGSYNHEEQDANTFASWGIDYLKLDGCNVYATQGRTLEEEYKQ RYGHWHQVLSKMQHPLIFSESAPAYFAGTDNNTDWYTVMDWVPIYGELARHSTDILVYSG AGSAWDSIMNNYNYNTLLARYQRPGYFNDPDFLIPDHPGLTADEKRSHFALWASFSAPLI ISAYIPALSKDEIAFLTNEALIAVNQDPLAQQATLASRDDTLDILTRSLANGDRLLTVLN KGNTTVTRDIPVQWLGLTETDCTYTAEDLWDGKTQKISDHIKIELASHATAVFRLSLPQG CSSVVPTGLVFNTASGNCLTAASNSSVAFQSCNGETSQIWQVTPSGVIRPVSQTTQCLAA DGNLVKLQACDSTDSDGQKWTYPVTGNLKNAKTDGCLTEGSVQMKSCLYERDGQVFGLPS GVQLA >P06280; 31 ALPHA-GALACTOSIDASE A PRECURSOR (EC 3.2.1.22) (MELIBIASE MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDCQEEP DSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQL ANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENL ADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIK SILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDL RHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIG GPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENT MQMSLKDLL >P56526; 25 ALPHA-GLUCOSIDASE PRECURSOR (EC 3.2.1.20) (MALTASE). MVKLTHLLARAWLVPLAYGASQSLLSTTAPSQPQFTIPASADVGAQLIANIDDPQAADAQ SVCPGYKASKVQHNSRGFTASLQLAGRPCNVYGTDVESLTLSVEYQDSDRLNIQILPTHV DSTNASWYFLSENLVPRPKASLNASVSQSDLFVSWSNEPSFNFKVIRKATGDALFSTEGT VLVYENQFIEFVTALPEEYNLYGLGEHITQFRLQRNANLTIYPSDDGTPIDQNLYGQHPF YLDTRYYKGDRQNGSYIPVKSSEADASQDYISLSHGVFLRNSHGLEILLRSQKLIWRTLG GGIDLTFYSGPAPADVTRQYLTSTVGLPAMQQYNTLGFHQCRWGYNNWSDLADVVANFEK FEIPLEYIWTDIDYMHGYRNFDNDQHRFSYSEGDEFLSKLHESGRYYVPIVDAALYIPNP ENASDAYATYDRGAADDVFLKNPDGSLYIGAVWPGYTVFPDWHHPKAVDFWANELVIWSK KVAFDGVWYDMSEVSSFCVGSCGTGNLTLNPAHPSFLLPGEPGDIIYDYPEAFNITNATE AASASAGASSQAAATATTTSTSVSYLRTTPTPGVRNVEHPPYVINHDQEGHDLSVHAVSP NATHVDGVEEYDVHGLYGHQGLNATYQGLLEVWSHKRRPFIIGRSTFAGSGKWAGHWGGD NYSKWWSMYYSISQALSFSLFGIPMFGADTCGFNGNSDEELCNRWMQLSAFFPFYRNHNE LSTIPQEPYRWASVIEATKSAMRIRYAILPYFYTLFDLAHTTGSTVMRALSWEFPNDPTL AAVETQFMVGPAIMVVPVLEPLVNTVKGVFPGVGHGEVWYDWYTQAAVDAKPGVNTTISA PLGHIPVYVRGGNILPMQEPALTTREARQTPWALLAALGSNGTASGQLYLDDGESIYPNA TLHVDFTASRSSLRSSAQGRWKERNPLANVTVLGVNKEPSAVTLNGQAVFPGSVTYNSTS QVLFVGGLQNLTKGGAWAENWVLEW >P29064; 35 ALPHA-GLUCOSIDASE PRECURSOR (EC 3.2.1.20) (MALTASE). MRSIKAASLTPLLAALFTTLSSTLALPSSVWEHQLETNVLALRDTNNNGSSSTISPSFDV TKCPGYKLVGQPQQSQHGFTAQLSLAGDACNAYGVDIANLTLSVVYEKQHQLHVHIYDTA KQQYQLPNGLIFDRPGDNPADIQNGSTADQSDLVFHHTAENGTQSGNGGWAFWIARKSSG DVIFDTRASNIPTYNDGLSSVSSNTKRNTTAMPAHEMVFENQYLQISSALPTGANIYGLG EYVTGSFRRNPDETLQPFFTLDAGTPVDSNMYGYHPIYTEARRGSDGKLRTHSVHLQNTA GMDVLLRRGVIQYRAIGGTLDFRFFSGDQPASSSSSSSGNDKAVATVKNSPNTAIQQYVN FIGNPVIHPYWSYGFHLCRWGYNNVSETQAVIDAMRQNNIPLEVQWNDIDYLQEFRDFTT DPQRFPQKEFAAMIAKLKDNHQHYIPIIDMAIPKAPTNDTDVYYPGTRGDELDVFIKNRN GSQYIGEVWPGYTNFVDQQAENAGKWWTEAIRNFSEIVDFSGIWLDMNEPSSFVIGNAAG PETNLSNTPAYTAATSVAGWPQGYNNLTWGTSGNITVNGSYTYQQGPVQNNDGSKQRRSL LLSRDEDVLVQRDINVNGGNGDKFGPEDPNYQYANSSQRYLSNPPYAIHNGIHISETPLN VNLDKKTVAMEAVGVDGQRAFYDVHNLDGTLEEQHFYNALRDIRPQERPFLISRSTYPGA GKFTGHWLGDNYALWTILPGEEAYKAGAGMAQSIDGVLQFQIFGIHLIGADICGFNRNSD EELCNRWMMLGAFLPFMRNHNTIGAIAQEPFRWDSVANASRIAINKRYEILPSLYSHMAQ SAESGEPAVRALWYEFDEVFEQTKDYAHQFLFGDDLLVSPVLEPNVTQIKALFPNAGGKW RNVFSYEALDVEYNKNVTVDAALSTINVHLRPGKVLLTHSKPAYTVYETAQSPYGLIVNL NDQGEAKQTFYLDDGMTPAPTPNSTLTVSAGNNSVNGSIEGEYKAQQNLTYVVVLDVKQK PTQVMMGGNKTEFSWDQQKTLLNVTGLNADLNGSGRFRGLRLELSLLCED >P12285; 26 NEUROACTIVE POLYPROTEIN R15-2 PRECURSOR. MDSAGLHINFRLSHVLTVVTCILYILPPTTTAYSLPAPGKAAFQHQLSKRDVSDGSAERR PYTRMGSGGLKLHCQVHPANCPGGLMVTKKSDLLGALLSRNSPSSYGLPSRDMSTAYKRQ DVRQQLRMFDDLVQLRKLIETPSVYPSEEDEARLYD >P15287; 24 ATRIAL GLAND-SPECIFIC ANTIGEN PRECURSOR (AGSA). MSSCQRIISCYSNVVCWFCCLATAAPLTSKAAYLLKRNSLIEEDASRKLGAKIVLTNEEK VLDDFILAEKRKLMDDSRLNQTEYMPAASFYRSKDFIDTTFAYKVIQDMPKGGALHLHDL AIASLDWVVKNATYRDNVYMCMDKDNDVNLRVLQLIPPDPFCVWKLVATERANSGDVEAF DDWLKKNISYLSTDPVTQYATVDSVWVRFNKYFAQVIGLLFYAPIMRDYYRQALEEFRAD NVQYIELRSQLFGFFELDGTVHDAEFGLNLYKSVTEEFQREYPDFIGAKIILSGLRFKSQ EEILNEVKIAMDLHKKYPDFFLGYDLVGQEDPNFSLLHYLDALLYPSIQNPPYRLPYFST LLKPTGRRQRLTTTWRMPCCSTPQELAMGSLLSNTRGSQSWPKKMESLWRSILSLIRSWA SLETSGTTPWSP >P18829; 22 ADIPOKINETIC HORMONE I PRECURSOR [CONTAINS: ADIPOKINETIC MVQRCLVVALLVVVVAAALCSAQLNFTPNWGTGKRDAADFGDPYSFLYRLIQAEARKMSG CSN >P19872; 22 ADIPOKINETIC HORMONE III PRECURSOR [CONTAINS: ADIPOKINET MQVRAVLVLAVVALVAVATSRAQLNFTPWWGKRALGAPAAGDCVSASPQALLSILNAAQA EVQKLIDCSRFTSEANS >P02768; 18 SERUM ALBUMIN PRECURSOR. MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV AASQAALGL >P03973; 25 ANTILEUKOPROTEINASE 1 PRECURSOR (ALP) (HUSI-1) (SEMINAL MKSSGLFPFLVLLALGTLAPWAVEGSGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPGK KRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYGQCLMLNPPNFCEMDGQCKRDLKCCMG MCGKSCVSPVKA >P22952; 36 ALVEOLAR MACROPHAGE CHEMOTACTIC FACTOR II PRECURSOR (AMC MRLLTSRATRVPSPSGLLCAVLAMLLLTPSGPLASASPIEAAEAAVVRELRCMCLTTTPG IHPKMISDLQVIPAGPQCSKAEVIATLKNGKEVCLDPKAPLIKKIVQKMLDSGKKKN >P10529; 21 ALPHA-AMYLASE A PRECURSOR (EC 3.2.1.1) (TAKA-AMYLASE A) MMVAWWSLFLYGLQVAAPALAATPADWRSQSIYFLLTDRFARTDGSTTATCNTADQKYCG GTWQGIIDKLDYIQGMGFTAIWITPVTAQLPQTTAYGDAYHGYWQQDIYSLNENYGTADD LKALSSALHERGMYLMVDVVANHMGYDGAGSSVDYSVFKPFSSQDYFHPFCFIQNYEDQT QVEDCWLGDNTVSLPDLDTTKDVVKNEWYDWVGSLVSNYSIDGLRIDTVKHVQKDFWPGY NKAAGVYCIGEVLDGDPAYTCPYQNVMDGVLNYPIYYPLLNAFKSTSGSMDDLYNMINTV KSDCPDSTLLGTFVENHDNPRFASYTNDIALAKNVAAFIILNDGIPIIYAGQEQHYAGGN DPANREATWLSGYPTDSELYKLIASANAIRNYAISKDTGFVTYKNWPIYKDDTTIAMRKG TDGSQIVTILSNKGASGDSYTLSLSGAGYTAGQQLTEVIGCTTVTVGSDGNVPVPMAGGL PRVLYPTEKLAGSKICSSS >P23176; 18 GLUCOAMYLASE I PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA- MSFRSLLALSGLVCSGLANVISKRATLDSWLSNEATVARTAILNNIGADGAWVSGADSGI VVASPSTDNPDYFYTWTRDSGLVIKTLVDLFRNGDTDLLSTIEHYISSQAIIQGVSNPSG DLSSGGLGEPKFNVDETAYTGSWGRPQRDGPALRATAMIGFGQVLLDNGYTSAATEIVWP LVRNDLSYVAQYWNQTGYDLWEEVNGSSFFTIAVQHRALVEGSAFATAVGSSCSWCDSQA PQILCYLQSFWTGSYILANFDSRRSGKDTNTLLGSIHTFDPEAGCDDSTFQPCSPRALAN HKEVVDSFRSIYTLNDGLSDSEAVAVGRYPEDSYYNGNPWFQSTLAAAEQLYDALYQWDK QGSLEITDVSLDFFKALYSGAATGTYSSSSSTYSSIVSAVKTFADGFVSIVETHAASNGS LSEQFDKSDGDELSARDLTWSYAALLTANNRRNSVVPPSWGETSASSWPGTCAATSASGT YSSVTVTSWPSIVATGGTTTTATTTGSGGVTSTSKTTTTASKTSTTTSSTSCTTPTAVAV TFDLTATTTYGENIYLVGSISQLGDWETSDGIALSADKYTSSNPLWYVTVTLPAGESFEY KFIRVESDDSVEWESDPNREYTVPQACGESTATVTDTWR >Q03045; 29 GLUCOAMYLASE P PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA- MRLLPSSCAGALSLLCSLAIAAPTELKARDLSSFIASERAIALQGALNNIGPDGSAVPGA GAGFVVASPSKANPDYFYTWSRDSALTLKMIIDEFILGNTTLQTIIEQYIHAQAVLQTVS NPSGTFLPDGVGLGEPKFMVDGTRFNGPWGRPQRDGPALRAIALMTYSNWLIKNGQFAEA KTKIWPIIANDLSYVGQYWNQSGFDLWEETYASSFFTIQNQHRALVEGAQLAHDLGVTCT GCDQAPEVLCFLQSFWNGKYIVSNINVNNGRTGLDGNSILGAISTFDIDAYCDSPTLQPC HSQSLANFKVLTDTFRNLYTINAGIPEGQGVAVGRYAEDVYMGGNPWYLITTAAAEFLYD AVAQWKARHVLTVDETSLAFFKDIYPEVTVREYKSGNANSPFAQIMDAVTAYADSYVAIA EKYIPSNGSLSEQFNRDTGTPLSAIDLTWSYAAFITMSQRRAGQYPSSWGSRNALPPPTT CSASSTPGIYTPATAAGAPNVTSSCQVSITFNINATTYYGENLYVIGNSSDLGAWNIADA YPLSASAYTQDRPLWSAAIPLNAGEVISYQYVRQEDCDQPYIYETVNRTLTVPACGGAAV TTDDAWMGPVGSSGNC >P07683; 25 GLUCOAMYLASE PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALPHA-GL MQLFNLPLKVSFFLVLSYFSLLVSAASIPSSASVQLDSYNYDGSTFSGKIYVKNIAYSKK VTVIYADGSDNWNNNGNTIAASYSAPISGSNYEYWTFSASINGIKEFYIKYEVSGKTYYD NNNSANYQVSTSKPTTTTATATTTTAPSTSTTTPPSRSEPATFPTGNSTISSWIKKQEGI SRFAMLRNINPPGSATGFIAASLSTAGPDYYYAWTRDAALTSNVIVYEYNTTLSGNKTIL NVLKDYVTFSVKTQSTSTVCNCLGEPKFNPDASGYTGAWGRPQNDGPAERATTFILFADS YLTQTKDASYVTGTLKPAIFKDLDYVVNVWSNGCFDLWEEVNGVHFYTLMVMRKGLLLGA DFAKRNGDSTRASTYSSTASTIANKISSFWVSSNNWIQVSQSVTGGVSKKGLDVSTLLAA NLGSVDDGFFTPGSEKILATAVAVEDSFASLYPINKNLPSYLGNSIGRYPEDTYNGNGNS QGNSWFLAVTGYAELYYRAIKEWIGNGGVTVSSISLPFFKKFDSSATSGKKYTVGTSDFN NLAQNIALAADRFLSTVQLHAHNNGSLAEEFDRTTGLSTGARDLTWSHASLITASYAKAG APAA >P08017; 27 GLUCOAMYLASE GLU1 PRECURSOR (EC 3.2.1.3) (GLUCAN 1,4-ALP MKFGVLFSVFAAIVSALPLQEGPLNKRAYPSFEAYSNYKVDRTDLETFLDKQKEVSLYYL LQNIAYPEGQFNNGVPGTVIASPSTSNPDYYYQWTRDSAITFLTVLSELEDNNFNTTLAK AVEYYINTSYNLQRTSNPSGSFDDENHKGLGEPKFNTDGSAYTGAWGRPQNDGPALRAYA ISRYLNDVNSLNEGKLVLTDSGDINFSSTEDIYKNIIKPDLEYVIGYWDSTGFDLWEENQ GRHFFTSLVQQKALAYAVDIAKSFDDGDFANTLSSTASTLESYLSGSDGGFVNTDVNHIV ENPDLLQQNSRQGLDSATYIGPLLTHDIGESSSTPFDVDNEYVLQSYYLLLEDNKDRYSV NSAYSAGAAIGRYPEDVYNGDGSSEGNPWFLATAYAAQVPYKLAYDAKSASNDITINKIN YDFFNKYIVDLSTINSAYQSSDSVTIKSGSDEFNTVADNLVTFGDSFLQVILDHINDDGS LNEQLNRYTGYSTGAYSLTWSSGALLEAIRLRNKVKALA >P04746; 15 ALPHA-AMYLASE PANCREATIC PRECURSOR (EC 3.2.1.1) (1,4-ALP MKFFLLLFTIGFCWAQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPP NENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGN AVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGL LDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAG SKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWG FVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWP RQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQP FTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGI KIYVSDDGKAHFSISNSAEDPFIAIHAESKL >P54802; 23 ALPHA-N-ACETYLGLUCOSAMINIDASE PRECURSOR (EC 3.2.1.50) (N MEAVAVAAAVGVLLLAGAGGAAGDEAREAAAVRALVARLLGPGPAADFSVSVERALAAKP GLDTYSLGGGGAARVRVRGSTGVAAAAGLHRYLRDFCGCHVAWSGSQLRLPRPLPAVPGE LTEATPNRYRYYQNVCTQSYSFVWWDWARWEREIDWMALNGINLALAWSGQEAIWQRVYL ALGLTQAEINEFFTGPAFLAWGRMGNLHTWDGPLPPSWHIKQLYLQHRVLDQMRSFGMTP VLPAFAGHVPEAVTRVFPQVNVTKMGSWGHFNCSYSCSFLLAPEDPIFPIIGSLFLRELI KEFGTDHIYGADTFNEMQPPSSEPSYLAAATTAVYEAMTAVDTEAVWLLQGWLFQHQPQF WGPAQIRAVLGAVPRGRLLVLDLFAESQPVYTRTASFQGQPFIWCMLHNFGGNHGLFGAL EAVNGGPEAARLFPNSTMVGTGMAPEGISQNEVVYSLMAELGWRKDPVPDLAAWVTSFAA RRYGVSHPDAGAAWRLLLRSVYNCSGEACRGHNRSPLVRRPSLQMNTSIWYNRSDVFEAW RLLLTSAPSLATSPAFRYDLLDLTRQAVQELVSLYYEEARSAYLSKELASLLRAGGVLAY ELLPALDEVLASDSRFLLGSWLEQARAAAVSEAEADFYEQNSRYQLTLWGPEGNILDYAN KQLAGLVANYYTPRWRLFLEALVDSVAQGIPFQQHQFDKNVFQLEQAFVLSKQRYPSQPR GDTVDLAKKIFLKYYPGWVAGSW >P24259; 24 ATRIAL NATRIURETIC FACTOR PRECURSOR (ANF) (ATRIAL NATRIU MSSFTITVSFLLVLVFQFPGQTRANPVYGSVSNADLMDFKNLLDHLEDKMPLEDEAMPPQ VLSEQNEEVGAPLSPLLEVPPWTGEVNPAQRDGGALGRGPWDASDRSALLKSKLRALLAA PRSLRRSSCFGGRMDRIGAQSGLGCNSFRY >P03950; 24 ANGIOGENIN PRECURSOR (EC 3.1.27.-). MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLT SPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRA TAGFRNVVVACENGLPVHLDQSIFRRP >P01015; 24 ANGIOTENSINOGEN PRECURSOR. MTPTGAGLKATIFCILTWVSLTAGDRVYIHPFHLLYYSKSTCAQLENPSVETLPEPTFEP VPIQAKTSPVDEKTLRDKLVLATEKLEAEDRQRAAQVAMIANFMGFRMYKMLSEARGVAS GAVLSPPALFGTLVSFYLGSLDPTASQLQVLLGVPVKEGDCTSRLDGHKVLTALQAVQGL LVTQGGSSSQTPLLQSTVVGLFTAPGLRLKQPFVESLGPFTPAIFPRSLDLSTDPVLAAQ KINRFVQAVTGWKMNLPLEGVSTDSTLFFNTYVHFQGKMRGFSQLTGLHEFWVDNSTSVS VPMLSGTGNFQHWSDAQNNFSVTRVPLGESVTLLLIQPQCASDLDRVEVLVFQHDFLTWI KNPPPRAIRLTLPQLEIRGSYNLQDLLAQAKLSTLLGAEANLGKMGDTNPRVGEVLNSIL LELQAGEEEQPTESAQQPGSPEVLDVTLSSPFLFAIYERDSGALHFLGRVDNPQNVV >P02734; 21 ANTIFREEZE PEPTIDE 4 PRECURSOR. MRITEANPDPDAKAVPAAAAPSTASDAAAAAAATAATAAAAAAATAATAAAAAAATAATA AKAAALTAANAAAAAAATAAAAARG >P17342; 18 ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR PRECURSOR MPSLLVLTFSPCVLLGWALLAGGTGGGGVGGGGGGAGIGGGRQEREALPPQKIEVLVLLP QDDSYLFSLTRVRPAIEYALRSVEGNGTGRRLLPPGTRFQVAYEDSDCGNRALFSLVDRV AAARGAKPDLILGPVCEYAAAPVARLASHWDLPMLSAGALAAGFQHKDSEYSHLTRVAPA YAKMGEMMLALFRHHHWSRAALVYSDDKLERNCYFTLEGVHEVFQEEGLHTSIYSFDETK DLDLEDIVRNIQASERVVIMCASSDTIRSIMLVAHRHGMTSGDYAFFNIELFNSSSYGDG SWKRGDKHDFEAKQAYSSLQTVTLLRTVKPEFEKFSMEVKSSVEKQGLNMEDYVNMFVEG FHDAILLYVLALHEVLRAGYSKKDGGKIIQQTWNRTFEGIAGQVSIDANGDRYGDFSVIA MTDVEAGTQEVIGDYFGKEGRFEMRPNVKYPWGPLKLRIDENRIVEHTNSSPCKSCGLEE SAVTGIVVGALLGAGLLMAFYFFRKKYRITIERRTQQEESNLGKHRELREDSIRSHFSVA >P09031; 23 ANTIFREEZE PROTEIN PRECURSOR (AFP). MALSLFTVGQLIFLFWTLRITEANPDPAAKAAPAAVADPAAAAAAAVADTASDAAAAAAA TAAAAAKAAADTAAAAAKAAADTAAAAAEAAAATARG >Q03352; 17 ANTITHROMBIN-III PRECURSOR (ATIII) (FRAGMENT). MHLFIGVSLRPLGHGIPAPYAVEDICTAKPRDIPVNPICIYRNPEKKPQERRGAGAGEGQ DPGVHKPPASGSCPGPTRAFGRRSFLQAPGPTPRTMRRTSSCRPS >P01008; 32 ANTITHROMBIN-III PRECURSOR (ATIII). MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEK KATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFG DKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQ VLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDG FSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAV VIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK >P15358; 17 ANTISTASIN PRECURSOR (ATS) (XA/PROCLOTTING ENZYME INHIBI MIKLAILLLFTVAIVRCQGPFGPGCEEAGCPEGSACNIITDRCTCSGVRCRMHCPHGFQR SRYGCEFCKCRLEPMKATCDISECPEGMMCSRLTNKCDCKIDINCRKTCPNGLKRDKLGC EYCECRPKRKLIPRLS >P02647; 18 APOLIPOPROTEIN A-I PRECURSOR (APO-AI). MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGS ALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAK VQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHV DALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQ GLLPVLESFKVSFLSALEEYTKKLNTQ >P04638; 18 APOLIPOPROTEIN A-II PRECURSOR (APO-AII). MKLLAMVALLVTICSLEGALVRRQAAETDVQTLFSQYLQSLTDYGKDLMEKAQPSEIQNQ AKAYFQNAQERLTPFVQRTGTNLMDFLSRLMSPEEKPAPAAK >P02651; 20 APOLIPOPROTEIN A-IV PRECURSOR (APO-AIV). MFLKAVVLTVALVAITGTQAEVTSDQVANVMWDYFTQLSNNAKEAVEQLQKTDVTQQLNT LFQDKLGNINTYADDLQNKLVPFAVQLSGHLTKETERVREEIQKELEDLRANMMPHANKV SQMFGDNVQKLQEHLRPYATDLQAQINAQTQDMKRQLTPYIQRMQTTIQDNVENLQSSMV PFANELKEKFNQNMEGLKGQLTPRANELKATIDQNLEDLRSRLAPLAEGVQEKLNHQMEG LAFQMKKNAEELQTKVSTNIDQLQKNLAPLVEDVQSKLKGNTEGLQKSLEDLNKQLDQQV EVFRRAVEPLGDKFNMALVQQMEKFRQQLGSDSGDVESHLSFLEKNLREKVSSFMSTLQK KGSPDQPLALPLPEQVQEQVQEQVQPKPLES >P12279; 20 APOLIPOPROTEIN C-III PRECURSOR (APO-CIII). MQPRVLLVAALLALLASARALEEEDPSLLGLMQGYMQHATKTAQDTLTSVQESQVAQRAR GWMTDSFSSLKDYCSTFKGKFTGFWDSASEAKPTPASDAF >P23593; 20 APOLIPOPROTEIN D PRECURSOR. MATMLLLLATLAGLFTTTEGQSFHLGKCPSPPVQENFDVKKYLGRWYEIEKIPVSFEKGN CIQANYSLMENGNIKVLNKELRPDGTLNQVEGEAKQSNMSEPAKLEVQFFSLMPPAPYWI LATDYESYALVYSCTTFFWFFHVDYVWILGRNPYLPPETITYLKYILTSNDIDIAKITTK DQANCPDFL >P02649; 18 APOLIPOPROTEIN E PRECURSOR (APO-E). MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQT LSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQA RLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVY QAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMG SRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEK VQAAVGTSAAPVPSDNH >P80703; 23 APOLIPOPHORIN-III PRECURSOR (APOLP-III). MAAKYVFVVAACSALAQAGIVRRDASTPLQDLEKHAAEFQKTFSEQLNAFTNSKDTKEFN TALKEGSDSVLQQLNALASSLQKALNDANGKAKEALEQTRTNLERTAEELRRAHPDVERQ AGALRDRLQTAVQATVQETQKLAKTVGANLEETNKKLAPQIKSAYDDFVKQAQEVQKKLH EAASKQ >P10762; 16 APOLIPOPHORIN-IIIB PRECURSOR (APOLP-IIIB). MNTLLAVLMLAVAAQARPDAAGHVNIAEAVQQLNHTIVNAAHELHETLGLPTPDEALNLL TEQANAFKTKIAEVTTSLKQEAEKHQGSVAEQLNRFARNLNNSIHDAATSAQPADQLNSL QSALTNVGHQWQTSQPRPSVAQEAWAPVQSALQEAAEKTKEAAANLQNSIQSAVQKPAN >Q17043; 19 APLYSIANIN-A PRECURSOR. MAVRFLALGLLIFVTSCSGRRVCESQQSCDDEQCDETLNIAIVGAGPSGAYSAYKMRHSG KDVGLFEYCNRVGGRLYTYQLPNTPDVNLELGGMRYITGAHNILQEVTKELGLKSVLFTE GFGRPGRTRYFLRGQSLTHEEVQSGDVPYNLTTIEKLNQGRIYEYYLKELTGFDIGNGSI SREQLLKLRVSDGRLLYQLTFDEALDLVASPEGKEFARDVHVFHTEVTSDANAVSVFDDH LGEDGAGDAILTVEEGMQKVPKELIKEFKKTSASNQVQLNKYLQAIRSKSDHSFVLYFRP TSTVDGKTTILDYRPLQRVCARQVILALPVFALRRLDWPPLHEGRAETAYAAVRNMAASK VFMTFDQAWWLDRNFTDNTAFVTKGDTPFSQMYDWKKSNVSGDYILIASYADGNNTLYQK VLRDQGESINGSEPGANRVSEPLKNNILDHLSEAYGVDRSTIPEPKTAVSQFWTDYPFGC GWITWRAGYHFDDVMSTMRRPSLKDEVYVVGADYSWGLMSSWTEGALETADAVLKDYFKG ECAKPPSVDHLDSHMA >P08519; 19 APOLIPOPROTEIN(A) PRECURSOR (EC 3.4.21.-) (APO(A)) (LP(A MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQH NRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTP VPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEY YPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEA PSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGL IMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAP TEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCR NPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPG VQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVA APYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYH GNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYT RDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSY RGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVR WEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYST TVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNL TQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRT CQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDA EGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSS MTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVA PPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSH SRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTP VPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEY YPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEA PSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGL IMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAP TEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCR NPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPG VQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVA APYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYH GNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYT RDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSY RGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVR WEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYST TVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNL TQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRT CQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDA EGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSS MTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVA PPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSH SRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTP VPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEY YPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEA PSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGL IMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAP TEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCR NPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPG VQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVA APYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYH GNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYT RDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSY RGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVR WEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYST TVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNL TQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRT CQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDA EGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSS MTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVA PPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSH SRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVIL APSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPEN YPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEA SSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGL TRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQ DCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRP WCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGD GQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMD PSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRG ISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWE YCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTV TGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTR CSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRH STFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVE PKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSY KVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMV TARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGG PLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN >P17690; 19 BETA-2-GLYCOPROTEIN I PRECURSOR (APOLIPOPROTEIN H) (APO- MPPPALVLLLGFLCHVAIAGRTCPKPDELPFSTVVPLKRTYEPGEQIVFSCQPGYVSRGG IRRFTCPLTGLWPINTLKCMPRVCPFAGILENGTVRYTTFEYPNTISFSCHTGFYLKGAS SAKCTEEGKWSPDLPVCAPITCPPPPIPKFASLSVYKPLAGNNSFYGSKAVFKCLPHHAM FGNDTVTCTEHGNWTQLPECREVRCPFPSRPDNGFVNHPANPVLYYKDTATFGCHETYSL DGPEEVECSKFGNWSAQPSCKASCKLSIKRATVIYEGERVAIQNKFKNGMLHGQKVSFFC KHKEKKCSYTEDAQCIDGTIEIPKCFKEHSSLAFWKTDASDVKPC >P15289; 18 ARYLSULFATASE A PRECURSOR (EC 3.1.6.8) (ASA) (CEREBROSID MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTPNLDQLAAGGLRFT DFYVPVSLCTPSRAALLTGRLPVRMGMYPGVLVPSSRGGLPLEEVTVAEVLAARGYLTGM AGKWHLGVGPEGAFLPPHQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIP LLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTHYPQFSGQSFAE RSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETMRMSRGGCSGLLRC GKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGAPLPNVTLDGFDLSP LLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSL TAHEPPLLYDLSKDPGENYNLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARG EDPALQICCHPGCTPRPACCHCPDPHA >P29392; 20 ACIDIC SEMINAL FLUID PROTEIN PRECURSOR (ASFP). MKLSSVIPWALLLSTATVDSMDWLPRNTNCGGILKEESGVIATYYGPKTNCVWTIQMPPE YHVRVSIQYLQLNCNKESLEIIDGLPGSPVLGKICEGSLMDYRSSGSIMTVKYIREPEHP ASFYEVLYFQDPQA >P11163; 25 L-ASPARAGINASE II PRECURSOR (EC 3.5.1.1) (L-ASPARAGINE MRSLNTLLLSLFVAMSSGAPLLKIREEKNSSLPSIKIFGTGGTIASKGSTSATTAGYSVG LTVNDLIEAVPSLAEKANLDYLQVSNVGSNSLNYTHLIPLYHGISEALASDDYAGAVVTH GTDTMEETAFFLDLTINSEKPVCIAGAMRPATATSADGPMNLYQAVSIAASEKSLGRGTM ITLNDRIASGFWTTKMNANSLDTFRADEQGYLGYFSNDDVEFYYPPVKPNGWQFFDISNL TDPSEIPEVIILYSYQGLNPELIVKAVKDLGAKGIVLAGSGAGSWTATGSIVNEQLYEEY GIPIVHSRRTADGTVPPDDAPEYAIGSGYLNPQKSRILLQLCLYSGYGMDQIRSVFSGVY GG >P27039; 20 ACTIVIN RECEPTOR TYPE II PRECURSOR (EC 2.7.1.-) (ACTR-II MGAATKLAFAVFLISCSSAGSILGRSETKECIYYNANWEKDKTNSNGTEICYGDNDKRKH CFATWKNISGSIEIVKQGCWLDDINCYNKSKCTEKKDSPDVFFCCCEGNYCNEKFYHSPE MEVTQPTSNPVTTKPPLFNTLLYSLVPIMVVAVIVLFSFWMYRHHKLAYPPVLVPTQDPG PPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNETVAVKIFPVQDKLSWQNEYEIYSLP GMKHENILYFIGAEKRGTNLDTDLWLITAFHEKGSLTDYLKANVVSWNELCLIAETMARG LSHLHEDIPGLKDGHKPAVAHRDIKSKNVLLKNNLTACIADFGLALKFEAGKSAGDTHGQ VGTRRYMAPEVLEGAINFQRDAFLRIDMYAFGLVLWELASRCTASDGPVDEYMLPFEEEV GQHPSLEDMQEVVVHKKKRPILRECWQKHAGMAMLCETIEECWDHDAEARLSAGCVEERI IQMQKLTNIITTEDIVTVVTMVTNVDFPPKESSL >P22063; 30 AXONIN-1 PRECURSOR (AXONAL GLYCOPROTEIN TAG-1). MGTHARKKASLLLLVLATVALVSSPGWSFAQGTPATFGPIFEEQPIGLLFPEESAEDQVT LACRARASPPATYRWKMNGTDMNLEPGSRHQLMGGNLVIMSPTKTQDAGVYQCLASNPVG TVVSKEAVLRFGFLQEFSKEERDPVKTHEGWGVMLPCNPPAHYPGLSYRWLLNEFPNFIP TDGRHFVSQTTGNLYIARTNASDLGNYSCLATSHMDFSTKSVFSKFAQLNLAAEDPRLFA PSIKARFPPETYALVGQQVTLECFAFGNPVPRIKWRKVDGSLSPQWATAEPTLQIPSVSF EDEGTYECEAENSKGRDTVQGRIIVQAQPEWLKVISDTEADIGSNLRWGCAAAGKPRPMV RWLRNGEPLASQNRVEVLAGDLRFSKLSLEDSGMYQCVAENKHGTIYASAELAVQALAPD FRQNPVRRLIPAARGGEISILCQPRAAPKATILWSKGTEILGNSTRVTVTSDGTLIIRNI SRSDEGKYTCFAENFMGKANSTGILSVRDATKITLAPSSADINVGDNLTLQCHASHDPTM DLTFTWTLDDFPIDFDKPGGHYRRASAKETIGDLTILNAHVRHGGKYTCMAQTVVDGTSK EATVLVRGPPGPPGGVVVRDIGDTTVQLSWSRGFDNHSPIAKYTLQARTPPSGKWKQVRT NPVNIEGNAETAQVLGLMPWMDYEFRVSASNILGTGEPSGPSSKIRTKEAVPSVAPSGLS GGGGAPGELIINWTPVSREYQNGDGFGYLLSFRRQGSSSWQTARVPGADAQYFVYGNDSI QPYTPFEVKIRSYNRRGDGPESLTALVYSAEEEPRVAPAKVWAKGSSSSEMNVSWEPVLQ DMNGILLGYEIRYWKAGDNEAAADRVRTAGLDTSARVTGLNPNTKYHVTVRAYNRAGTGP ASPSADAMTVKPPPRRPPGNISWTFSSSSLSLKWDPVVPLRNESTVTGYKMLYQNDLHPT PTLHLTSKNWIEIPVPEDIGHALVQIRTTGPGGDGIPAEVHIVRNGGTSMMVESAAARPA HPGPAFSCMVILMLAGYQKL >P21611; 21 BETA-2-MICROGLOBULIN PRECURSOR. MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPASAGTKNVLNCFAAGFHPPKISITLM KDGVPMEGAQYSDMSFNDDWTFQRLVHADFTPSSGSTYACKVEHETLKEPQVYKWDPEF >P01884; 20 BETA-2-MICROGLOBULIN PRECURSOR. MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLL KNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM >P07882; 20 BILE-SALT-ACTIVATED LIPASE PRECURSOR (EC 3.1.1.3) (EC 3. MGRLEVLFLGLTCCLAAACAAKLGAVYTEGGFVEGVNKKLSLLGGDSVDIFKGIPFATAK TLENPQRHPGWQGTLKATDFKKRCLQATITQDDTYGQEDCLYLNIWVPQGRKQVSHDLPV MVWIYGGAFLMGSGQGANFLKNYLYDGEEIATRGNVIVVTFNYRVGPLGFLSTGDANLPG NFGLRDQHMAIAWVKRNIAAFGGDPDNITIFGESAGAASVSLQTLSPYNKGLIRRAISQS GVALSPWAIQENPLFWAKTIAKKVGCPTEDTAKMAGCLKITDPRALTLAYRLPLKSQEYP IVHYLAFIPVVDGDFIPDDPINLYDNAADIDYLAGINDMDGHLFATVDVPAIDKAKQDVT EEDFYRLVSGHTVAKGLKGTQATFDIYTESWAQDPSQENMKKTVVAFETDILFLIPTEMA LAQHRAHAKSAKTYSYLFSHPSRMPIYPKWMGADHADDLQYVFGKPFATPLGYRAQDRTV SKAMIAYWTNFAKSGDPNMGNSPVPTHWYPYTTENGNYLDINKKITSTSMKEHLREKFLK FWAVTFEMLPTVVGDHTPPEDDSEAAPVPPTDDSQGGPVPPTDDSQTTPVPPTDNSQAGD SVEAQMPGPIGF >P12630; 24 BARRIERPEPSIN PRECURSOR (EC 3.4.23.35) (EXTRACELLULAR "B MSAINHLCLKLILASFAIINTITALTNDGTGHLEFLLQHEEEMYYATTLDIGTPSQSLTV LFDTGSADFWVMDSSNPFCLPNSNTSSYSNATYNGEEVKPSIDCRSMSTYNEHRSSTYQY LENGRFYITYADGTFADGSWGTETVSINGIDIPNIQFGVAKYATTPVSGVLGIGFPRRES VKGYEGAPNEYYPNFPQILKSEKIIDVVAYSLFLNSPDSGTGSIVFGAIDESKFSGDLFT FPMVNEYPTIVDAPATLAMTIQGLGAQNKSSCEHETFTTTKYPVLLDSGTSLLNAPKVIA DKMASFVNASYSEEEGIYILDCPVSVGDVEYNFDFGDLQISVPLSSLILSPETEGSYCGF AVQPTNDSMVLGDVFLSSAYVVFDLDNYKISLAQANWNASEVSKKLVNIQTDGSISGAKI ATAEPWSTNEPFTVTSDIYSSTGCKSRPFLQSSTASSLIAETNVQSRNCSTKMPGTRSTT VLSKPTQNSAMHQSTGAVTQTSNETKLELSSTMANSGSVSLPTSNSIDKEFEHSKSQTTS DPSVAEHSTFNQTFVHETKYRPTHKTVITETVTKYSTVLINVCKPTY >P17790; 26 BASIGIN PRECURSOR (BLOOD-BRAIN BARRIER HT7 ANTIGEN) (NEU MAAGADVPCAVLALLVLGSLAAGGDATGPVITGQYSSSADKVVLSCNISAPPTLIKGHKW MLGDKVLKTDESDASSYISYTIEGKVEDHSGVYECIYNTNPVAKGNVSIEVEPQVVAYKK SEHGNEGDVGVLTCKSPSYPPVDHWAWYKSGQTVPLESSAGIYNISRTGNKTELRILKLN IEQDMGDYSCNGTNMKGSGSATVNLRVRSRLAALWPFLGIVAEVLVLVTIIFIYEKRRKP DEVLDDDDGGSAPLKSNATNHKDKNVRQRNAN >P09464; 15 BILIN-BINDING PROTEIN PRECURSOR (BBP). MQYLIVLALVAAASANVYHDGACPEVKPVDNFDWSNYHGKWWEVAKYPNSVEKYGKCGWA EYTPEGKSVKVSNYHVIHGKEYFIEGTAYPVGDSKIGKIYHKLTYGGVTKENVFNVLSTD NKNYIIGYYCKYDEDKKGHQDFVWVLSRSKVLTGEAKTAVENYLIGSPVVDSQKLVYSDF SEAACKVNN >Q02247; 20 BLASTOCYST PROTEIN 4 PRECURSOR. MGAVFAIIGGFALDSPILRLYLDQLSLNHFTDIVGATKVSSLNIPWPLRIPRRIRLPGRL YNMKYCFINRLIHFPNCRNSNNFYNSEKPSPQNEK >P46162; 22 BETA-DEFENSIN 4 PRECURSOR (BNDB-4). MRLHHLLLAVLFLVLSAGSGFTQRVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPC CRR >Q01742; 21 FIBROBLAST GROWTH FACTOR RECEPTOR BFR-2 PRECURSOR (EC 2. MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEGAPYWTNTEKMEKRLHAVPAANTV KFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVEN EYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVE KNGSKYGPDGLPYLKVLKHSGINSSNAEVLALFNVTEADAGEYICKVSNYIGQANQSAWL TVLPKQQAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPA VHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKW EFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSE MEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVP EEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNI DYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFK LLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEI >P23780; 24 BETA-GALACTOSIDASE PRECURSOR (EC 3.2.1.23) (LACTASE) (AC MLRVPLCTPLPLLALLQLLGAAHGIYNVTQRTFKLDYSRDRFLKDGQPFRYISGSIHYFR IPRFYWEDRLLKMKMAGLNAIQMYVPWNFHEPQPGQYEFSGDRDVEHFIQLAHELGLLVI LRPGPYICAEWDMGGLPAWLLEKQSIVLRSSDPDYLVAVDKWLAVLLPKMKPLLYQNGGP IITVQVENEYGSYFACDYDYLRFLVHRFRYHLGNDVILFTTDGASEKMLKCGTLQDLYAT VDFGTGNNITQAFLVQRKFEPKGPLINSEFYTGWLDHWGKPHSTVKTKTLATSLYNLLAR GANVNLYMFIGGTNFAYWNGANTPYEPQPTSYDYDAPLSEAGDLTKKYFALREVIQMFKE VPEGPIPPSTPKFAYGKVALRKFKTVAEALGILCPNGPVKSLYPLTFTQVKQYFGYVLYR TTLPQDCSNPKPIFSSPFNGVRDRAYVSVDGVPQGILDRNLMTALNIRGKAGATLDILVE NMGRVNYGRFINDFKGLISNMTINSTVLTNWTVFPLNTEAMVRNHLWGREASDEGHLDGR STSNSSDLILPTFYVGNFSIPSGIPDLPQDTFIQFPGWSKGQVWINGFNLGRYWPTMGPQ KTLFVPRNILTTSAPNNITVLELEFAPCSEGTPELCTVEFVDTPVIS >P15703; 23 GLUCAN 1,3-BETA-GLUCOSIDASE PRECURSOR (EC 3.2.1.58) (EXO MRFSTTLATAATALFFTASQVSAIGELAFNLGVKNNDGTCKSTSDYETELQALKSYTSTV KVYAASDCNTLQNLGPAAEAEGFTIFVGVWPTDDSHYAAEKAALQTYLPKIKESTVAGFL VGSEALYRNDLTASQLSDKINDVRSVVADISDSDGKSYSGKQVGTVDSWNVLVAGYNSAV IEASDFVMANAFSYWQGQTMQNASYSFFDDIMQALQVIQSTKGSTDITFWVGETGWPTDG TNFESSYPSVDNAKQFWKEGICSMRAWGVNVIVFEAFDEDWKPNTSGTSDVEKHWGVFTS SDNLKYSLDCDFS >P08236; 22 BETA-GLUCURONIDASE PRECURSOR (EC 3.2.1.31) (BETA-G1). MARGSAVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGLWSFRADFSDNRRRGFE EQWYRRPLWESGPTVDMPVPSSFNDISQDWRLRHFVGWVWYEREVILPERWTQDLRTRVV LRIGSAHSYAIVWVNGVDTLEHEGGYLPFEADISNLVQVGPLPSRLRITIAINNTLTPTT LPPGTIQYLTDTSKYPKGYFVQNTYFDFFNYAGLQRSVLLYTTPTTYIDDITVTTSVEQD SGLVNYQISVKGSNLFKLEVRLLDAENKVVANGTGTQGQLKVPGVSLWWPYLMHERPAYL YSLEVQLTAQTSLGPVSDFYTLPVGIRTVAVTKSQFLINGKPFYFHGVNKHEDADIRGKG FDWPLLVKDFNLLRWLGANAFRTSHYPYAEEVMQMCDRYGIVVIDECPGVGLALPQFFNN VSLHHHMQVMEEVVRRDKNHPAVVMWSVANEPASHLESAGYYLKMVIAHTKSLDPSRPVT FVSNSNYAADKGAPYVDVICLNSYYSWYHDYGHLELIQLQLATQFENWYKKYQKPIIQSE YGAETIAGFHQDPPLMFTEEYQKSLLEQYHLGLDQKRRKYVVGELIWNFADFMTEQSPTR VLGNKKGIFTRQRQPKSAAFLLRERYWKIANETRYPHSVAKSQCLENSPFT >P06651; 20 BINDIN PRECURSOR. MGFHQILVTVVALALASVRAEFPSRTDSPTDCPEADQGCWCRGSFAQCWRTYEEAGMTGE IGNRITKLDLLYQPSEEIVTYIRRSSAMRELRISEDGVSLDCSCDLIYALDDKHVTLVDQ AELTFSNCQQRGWPRDSMTARSFVNRCHVSRMQDGDLRKRRESEDVDDDDVSKRASPRKG DEPAGHTLKDLAPQNTNHLVSIDGADKHPADELVNFISGHSPTRRATDNDAAVSDDSKRG ARKKRYVNTMGYPQAMSPQMGGVNYGQPAQQGYGAQGMGGPVGGGPMGGPPQFGALPPGQ ADTDFGSSSSSVDGGDTTISARVMDDIKAVLGATKIDLPVDINDPYDLGLLLRHLRHHSN LLANIGDPAVREQVLSAMQEEEEEEEEDAATGAQQGVLNGNAPGQAGFGGGGGGGAMMSP QQMGGQPQGMIGQPQGMGFPHEGMGGPPQGMGMPHQGMGGPPQGMGMPPQGQPYGQGYLQ G >P20736; 19 GLYCOPROTEIN ANTIGEN BM86 PRECURSOR (PROTECTIVE ANTIGEN) MRGIALFVAAVSLIVEGTAESSICSDFGNEFCRNAECEVVPGAEDDFVCKCPRDNMYFNA AEKQCEYKDTCKTRECSYGRCVESNPSKASCVCEASDDLTLQCKIKNDYATDCRNRGGTA KLRTDGFIGATCDCGEWGAMNMTTRNCVPTTCLRPDLTCKDLCEKNLLQRDSRCCQGWNT ANCSAAPPADSYCSPGSPKGPDGQCINACKTKEAGFVCKHGCRSTGKAYECTCPSGSTVA EDGITCKSISHTVSCTAEQKQTCRPTEDCRVHKGTVLCECPWNQHLVGDTCISDCVDKKC HEEFMDCGVYMNRQSCYCPWKSRKPGPNVNINECLLNEYYYTVSFTPNISFDSDHCKWYE DRVLEAIRTSIGKEVFKVEILNCTQDIKARLIAEKPLSKHVLRKLQACEHPIGEWCMMYP KLLIKKNSATEIEEENLCDSLLKDQEAAYKGQNKCVKVDNLFWFQCADGYTTTYEMTRGR LRRSVCKAGVSCNENEQSECADKGQIFVYENGKANCQCPPDTKPGEIGCIERTTCNPKEI QECQDKKLECVYKNHKAECECPDDHECYREPAKDSCSEEDNGKCQSSGQRCVIENGKAVC KEKSEATTAATTTTKAKDKDPDPGKSSAAAVSATGLLLLLAATSVTAASL >P17213; 27 BACTERICIDAL PERMEABILITY-INCREASING PROTEIN PRECURSOR ( MARGPCNAPRWVSLMVLVAIGTAVTAAVNPGVVVRISQKGLDYASQQGTAALQKELKRIK IPDYSDSFKIKHLGKGHYSFYSMDIREFQLPSSQISMVPNVGLKFSISNANIKISGKWKA QKRFLKMSGNFDLSIEGMSISADLKLGSNPTSGKPTITCSSCSSHINSVHVHISKSKVGW LIQLFHKKIESALRNKMNSQVCEKVTNSVSSKLQPYFQTLPVMTKIDSVAGINYGLVAPP ATTAETLDVQMKGEFYSENHHNPPPFAPPVMEFPAAHDRMVYLGLSDYFFNTAGLVYQEA GVLKMTLRDDMIPKESKFRLTTKFFGTFLPEVAKKFPNMKIQIHVSASTPPHLSVQPTGL TFYPAVDVQAFAVLPNSSLASLFLIGMHTTGSMEVSAESNRLVGELKLDRLLLELKHSNI GPFPVELLQDIMNYIVPILVLPRVNEKLQKGFPLPTPARVQLYNVVLQPHQNFLLFGADV VYK >Q05928; 31 BETACELLULIN PRECURSOR (BTC). MDPTAPGSSVSSLPLLLVLALGLAILHCVVADGNTTRTPETNGSLCGAPGENCTGTTPRQ KVKTHFSRCPKQYKHYCIHGRCRFVVDEQTPSCICEKGYFGARCERVDLFYLQQDRGQIL VVCLIVVMVVFIILVIGVCTCCHPLRKHRKKKKEEKMETLDKDKTPISEDIQETNIA >P43251; 21 BIOTINIDASE PRECURSOR (EC 3.5.1.12). MSGARSKLALFLCGCYVVALGAHTGEESVADHHEAEYYVAAVYEHPSILSLNPLALISRQ EALELMNQNLDIYEQQVMTAAQKDVQIIVFPEDGIHGFNFTRTSIYPFLDFMPSPQVVRW NPCLEPHRFNDTEVLQRLSCMAIRGDMFLVANLGTKEPCHSSDPRCPKDGRYQFNTNVVF SNNGTLVDRYRKHNLYFEAAFDVPLKVDLITFDTPFAGRFGIFTCFDILFFDPAIRVLRD YKVKHVVYPTAWMNQLPLLAAIEIQKAFAVAFGINVLAANVHHPVLGMTGSGIHTPLESF WYHDMENPKSHLIIAQVAKNPVGLIGAENATGETDPSHSKFLKILSGDPYCEKDAQEVHC DEATKWNVNAPPTFHSEMMYDNFTLVPVWGKEGYLHVCSNGLCCYLLYERPTLSKELYAL GVFDGLHTVHGTYYIQVCALVRCGGLGFDTCGQEITEATGIFEFHLWGNFSTSYIFPLFL TSGMTLEVPDQLGWENDHYFLRKSRLSSGLVTAALYGRLYERD >P18892; 26 BUTYROPHILIN PRECURSOR (BT). MAVFPNSCLAGCLLIFILLQLPKLDSAPFDVIGPQEPILAVVGEDAELPCRLSPNVSAKG MELRWFREKVSPAVFVSREGQEQEGEEMAEYRGRVSLVEDHIAEGSVAVRIQEVKASDDG EYRCFFRQDENYEEAIVHLKVAALGSDPHISMKVQESGEIQLECTSVGWYPEPQVQWRTH RGEEFPSMSESRNPDEEGLFTVRASVIIRDSSMKNVSCCIRNLLLGQEKEVEVSIPASFF PRLTPWMVAVAVILVVLGLLTIGSIFFTWRLYKERSRQRRNEFSSKEKLLEELKWKRATL HAVDVTLDPDTAHPHLFLYEDSKSVRLEDSRQKLPEKPERFDSWPCVMGREAFTSGRHYW EVEVGDRTDWAIGVCRENVMKKGFDPMTPENGFWAVELYGNGYWALTPLRTPLPLAGPPR RVGVFLDYESGDIFFYNMTDGSHIYTFSKASFSGPLRPFFCLWSCGKKPLTICPVTDGLE GVMVVADAKDISKEIPLSPMGEDSASGDIETLHSKLIPLQPSQGVP >P00736; 17 COMPLEMENT C1R COMPONENT PRECURSOR (EC 3.4.21.41). MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED >P36222; 21 CARTILAGE GLYCOPROTEIN-39 PRECURSOR (GP-39) (39 KD SYNOV MGVKASQTGFVVLVLLQCCSAYKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFAN ISNDHIDTWEWNDVTLYGMLNTLKNRNPNLKTLLSVGGWNFGSQRFSKIASNTQSRRTFI KSVPPFLRTHGFDGLDLAWLYPGRRDKQHFTTLIKEMKAEFIKEAQPGKKQLLLSAALSA GKVTIDSSYDIAKISQHLDFISIMTYDFHGAWRGTTGHHSPLFRGQEDASPDRFSNTDYA VGYMLRLGAPASKLVMGIPTFGRSFTLASSETGVGAPISGPGIPGRFTKEAGTLAYYEIC DFLRGATVHRTLGQQVPYATKGNQWVGYDDQESVKSKVQYLKDRQLAGAMVWALDLDDFQ GSFCGQDLRFPLTNAIKDALAAT >P20851; 17 C4B-BINDING PROTEIN BETA CHAIN PRECURSOR. MFFWCACCLMVAWRVSASDAEHCPELPPVDNSIFVAKEVEGQILGTYVCIKGYHLVGKKT LFCNASKEWDNTTTECRLGHCPDPVLVNGEFSSSGPVNVSDKITFMCNDHYILKGSNRSQ CLEDHTWAPPFPICKSRDCDPPGNPVHGYFEGNNFTLGSTISYYCEDRYYLVGVQEQQCV DGEWSSALPVCKLIQEAPKPECEKALLAFQESKNLCEAMENFMQQLKESGMTMEELKYSL ELKKAELKAKLL >P04003; 48 C4B-BINDING PROTEIN ALPHA CHAIN PRECURSOR (PROLINE-RICH MHPPKTPSGALHRKRKMAAWPFSRLWKVSDPILFQMTLIAALLPAVLGNCGPPPTLSFAA PMDITLTETRFKTGTTLKYTCLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELR NGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRGVGWSHPLPQCEIVKCKPPPD IRNGRHSGEENFYAYGFSVTYSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCR KPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIHCDADSKWNPSPPACEPNSCI NLPDIPHASWETYPRPTKEDVYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQGC EALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCHETSRFSAICQGDGTWSPRTP SCGDICNFPPKIAHGHYKQSSSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQC KALCRKPELVNGRLSVDKDQYVEPENVTIQCDSGYGVVGPQSITCSGNRTWYPEVPKCEW ETPEGCEQVLTGKRLMQCLPNPEDVKMALEVYKLSLEIEQLELQRDSARQSTLDKEL >P11912; 32 B-CELL ANTIGEN RECEPTOR COMPLEX ASSOCIATED PROTEIN ALPHA MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGEDAHFQCPHNSSN NANVTWWRVLHGNYTWPPEFLGPGEDPNGTLIIQNVNKSHGGIYVCRVQEGNESYQQSCG TYLRVRQPPPRPFLDMGEGTKNRIITAEGIILLFCAVVPGTLLLFRKRWQNEKLGLDAGD EYEDENLYEGLNLDDCSMYEDISRGLQGTYQDVGSLNIGDVQLEKP >P10966; 21 T-CELL SURFACE GLYCOPROTEIN CD8 BETA.1 CHAIN PRECURSOR ( MRPRLWLLLAAQLTVLHGNSVLQQTPAYIKVQTNKMVMLSCEAKISLSNMRIYWLRQRQA PSSDSHHEFLALWDSAKGTIHGEEVEQEKIAVFRDASRFILNLTSVKPEDSGIYFCMIVG SPELTFGKGTQLSVVDFLPTTAQPTKKSTLKKRVCRLPRPETQKGPLCSPITLGLLVAGV LVLLVSLGVAIHLCCRRRRARLRFMKQFYK >P02457; 22 PROCOLLAGEN ALPHA 1(I) CHAIN PRECURSOR. MFSFVDSRLLLLIAATVLLTRGEGEEDIQTGSCVQDGLTYNDKDVWKPEPCQICVCDSGN ILCDEVICEDTSDCPNAEIPFGECCPICPDVDASPVYPESAGVEGPKGDTGPRGDRGLPG PPGRDGIPGQPGLPGPPGPPGPPGLGGNFAPQMSYGYDEKSAGVAVPGPMGPAGPRGLPG PPGAPGPQGFQGPPGEPGEPGASGPMGPRGPAGPPGKNGDDGEAGKPGRPGQRGPPGPQG ARGLPGTAGLPGMKGHRGFSGLDGAKGQPGPAGPKGEPGSPGENGAPGQMGPRGLPGERG RPGPSGPAGARGNDGAPGAAGPPGPTGPAGPPGFPGAAGAKGETGPQGARGSEGPQGSRG EPGPPGPAGAAGPAGNPGADGQPGAKGATGAPGIAGAPGFPGARGPSGPQGPSGAPGPKG NSGEPGAPGNKGDTGAKGEPGPAGVQGPPGPAGEEGKRGARGEPGPAGLPGPAGERGAPG SRGFPGADGIAGPKGPPGERGSPGAVGPKGSPGEAGRPGEAGLPGAKGLTGSPGSPGPDG KTGPPGPAGQDGRPGPAGPPGARGQAGVMGFPGPKGAAGEPGKPGERGAPGPPGAVGAAG KDGEAGAQGPPGPTGPAGERGEQGPAGAPGFQGLPGPAGPPGEAGKPGEQGVPGNAGAPG PAGARGERGFPGERGVQGPPGPQGPRGANGAPGNDGAKGDAGAPGAPGNEGPPGLEGMPG ERGAAGLPGAKGDRGDPGPKGADGAPGKDGLRGLTGPIGPPGPAGAPGDKGEAGPPGPAG PTGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGETGDAGAKGDAGPPGPAGPTGAPG PAGZVGAPGPKGARGSAGPPGATGFPGAAGRVGPPGPSGNIGLPGPPGPAGKZGSKGPRG ETGPAGRPGEPGPAGPPGPPGEKGSPGADGPIGAPGTPGPQGIAGQRGVVGLPGQRGERG FPGLPGPSGEPGKQGPSGASGERGPPGPMGPPGLAGPPGEAGREGAPGAEGAPGRDGAAG PKGDRGETGPAGPPGAPGAPGAPGPVGPAGKNGDRGETGPAGPAGPPGPAGARGPAGPQG PRGDKGETGEQGDRGMKGHRGFSGLQGPPGPPGAPGEQGPSGASGPAGPRGPPGSAGAAG KDGLNGLPGPIGPPGPRGRTGEVGPVGPPGPPGPPGPPGPPSGGFDFSFLPQPPQEKAHD GGRYYRADDANVMRDRDLEVDTTLKSLSQQIENIRSPEGTRKNPARTCRDLKMCHGDWKS GEYWIDPNQGCNLDAIKVYCNMETGETCVYPTQATIAQKNWYLSKNPKEKKHVWFGETMS DGFQFEYGGEGSNPADVAIQLTFLRLMSTEATQNVTYHCKNSVAYMDHDTGNLKKALLLQ GANEIEIRAEGNSRFTYGVTEDGCTSHTGAWGKTVIEYKTTKTSRLPIIDLAPMDVGAPD QEFGIDIGPVCFL >P14282; 20 COLLAGEN ALPHA 1(VIII) CHAIN PRECURSOR (ENDOTHELIAL COLL MAVPPGPPQLLQVLLTISLGSIRLIQAGAYYGIKPLPPQIPPQMPPQIPQYQPLGQQVPH MPLAKDGLTMGKEMPHAQYGKEYPHLPQYMKEVQPVPRMGKEAVPKKGKEIPLASLRGEQ GPRGEPGPRGPPGPPGLPGQGIPGIKGKPGPQGYPGVGKPGMPGMPGKPGAMGMPGAKGE IGPKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGAKGDRGPKGPPGPPGLQGPK GEKGFGMPGLPGLKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGPPGEPGPQGP IGVPGVQGPPGLPGVGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGVGKPGFPGPKG DRGIGGVPGALGPRGEKGPVGAPGMGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGIVG PQGPPGPKGEPGLQGFPGKPGFLGEVGPPGIRGLPGPIGPKGEAGHKGLPGLPGVPGLLG PKGEPGIPGDQGLQGPPGIPGITGPSGPIGPPGIPGPKGEPGLPGPPGFPGVGKPGVAGL HGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMPPTPAPQGEYLPDMGLGIDGVKTPHA YAAKKGKNGGPAYEMPAFTAELTAPFPPVGAPIKFDRLLYNGRQNYNPQTGIFTCEVPGV YYFAYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFLQMPS EQAAGLYAGQYVHSSFSGYLLYPM >P08122; 25 PROCOLLAGEN ALPHA 2(IV) CHAIN PRECURSOR. MDRVRFKASGPPLRGWLLLATVTVGLLAQSVLGGVKKLDVPCGGRDCSGGCQCYPEKGAR GQPGAVGPQGYNGPPGLQGFPGLQGRKGDKGERGVPGPTGPKGDVGARGVSGFPGADGIP GHPGQGGPRGRPGYDGCNGTRGDAGPQGPSGSGGFPGLPGPQGPKGQKGEPYALSKEDRD KYRGEPGEPGLVGYQGPPGRPGPIGQMGPMGAPGRPGPPGPPGPKGQPGNRGLGFYGQKG EKGDIGQPGPNGIPSDITLVGPTTSTIHPDLYKGEKGDEGEQGIPGVISKGEEGIMGFPG IRGFPGLDGEKGVVGQKGSRGLDGFQGPSGPRGPKGERGEQGPPGPSVYSPHPSLAKGAR GDPGFQGAHGEPGSRGEPGEPGTAGPPGPSVGDEDSMRGLPGEMGPKGFSGEPGSPARYL GPPGADGRPGPQGVPGPAGPPGPDGFLFGLKGSEGRVGYPGPSGFPGTRGQKGWKGEAGD CQCGQVIGGLPGLPGPKGFPGVNGELGKKGDQGDPGLHGIPGFPGFKGAPGVAGAPGPKG IKGDSRTITTKGERGQPGIPGVHGMKGDDGVPGRDGLDGFPGLPGPPGDGIKGPPGDAGL PGVPGTKGFPGDIGPPGQGLPGPKGRRGFPGDAGLPGPPGFPGPPGPPGTPGQRDCDTGV KRPIGGGQQVVVQPGCIEGPTGSPGQPGPPGPTGAKGVRGMPGFPGASGEQGLKGFPGDP GREGFPGPPGFMGPRGSKGTTGLPGPDGPPGPIGLPGPAGPPGDRGIPGEVLGAQPGTRG DAGLPGQPGLKGLPGETGAPGFRGSQGMPGMPGLKGQPGFPGPSGQPGQSGPPGQHAFPG TPGREGPLGQPGSPGLGGLPGDRGEPGDPGVPGPVGMKGLSGDRGDAGMSGERGHPGSPG FKGMAGMPGIPGQKGDRGSPGMDGFQGMLGLKGRQGFPGTKGEAGFFGVPGLKGLPGEPG VKGNRGDRGPPGPPPLILPGMKDIKGEKGDEGPMGLKGYLGLKGIQGMPGVPGVSGFPGL PGRPGFIKGVKGDIGVPGTPGLPGFPGVSGPPGITGFPGFTGSRGEKGTPGVAGVFGETG PTGDFGDIGDTVDLPGSPGLKGERGITGIPGLKGFFGEKGAAGDIGFPGITGMAGAQGSP GLKGQTGFPGLTGLQGPQGEPGRIGIPGDKGDFGWPGVPGLPGFPGIRGISGLHGLPGTK GFPGSPGVDAHGDPGFPGPTGDRGDRGEANTLPGPVGVPGQKGERGTPGERGPAGSPGLQ GFPGISPPSNISGSPGDVGAPGIFGLQGYQGPPGPPGPNALPGIKGDEGSSGAAGFPGQK GWVGDPGPQGQPGVLGLPGEKGPKGEQGFMGNTGPSGAVGDRGPKGPKGDQGFPGAPGSM GSPGIPGIPQKIAVQPGTLGPQGRRGLPGALGEIGPQGPPGDPGFRGAPGKAGPQGRGGV SAVPGFRGDQGPMGHQGPVGQEGEPGRPGSPGLPGMPGRSVSIGYLLVKHSQTDQEPMCP VGMNKLWSGYSLLYFEGQEKAHNQDLGLAGSCLARFSTMPFLYCNPGDVCYYASRNDKSY WLSTTAPLPMMPVAEEEIKPYISRCSVCEAPAVAIAVHSQDTSIPHCPAGWRSLWIGYSF LMYTAAGDEGGGQSLVSPGSCLEDFRATPFIECNGGRGTCHYFANKYSFWLTTIPEQNFQ STPSADTLKAGLIRTHISRCQVCMKNL >P05997; 26 PROCOLLAGEN ALPHA 2(V) CHAIN PRECURSOR. MMANWAEARPLLILIVLLGQFVSIKAQEEDEDEGYGEEIACTQNGQMYLNRDIWKPAPCQ ICVCDNGAILCDKIECQDVLDCADPVTPPGECCPVCSQTPGGGNTNFGRGRKGQKGEPGL VPVVTGIRGRPGPAGPPGSQGPRGERGPKGRPGPRGPQGIDGEPGVPGQPGAPGPPGHPS HPGPDGLSRPFSAQMAGLDEKSGLGSQVGLMPGSVGPVGPRGPQGLQGQQGGAGPTGPPG EPGDPGPMGPIGSRGPEGPPGKPGEDGEPGRNGNPGEVGFAGSPGARGFPGAPGLPGLKG HRGHKGLEGPKGEVGAPGSKGEAGPTGPMGAMGPLGPRGMPGERGRLGPQGAPGQRGAHG MPGKPGPMGPLGIPGSSGFPGNPGMKGEAGPTGARGPEGPQGQRGETGPPGPVGSPGLPG AIGTDGTPGPKGPTGSPGTSGPPGSAGPPGSPGPQGSTGPQGNSGLPGDPGFKGEAGPKG EPGPHGIQGPIGPPGEEGKRGPRGDPGTLGPPGPVGERGAPGNRGFPGSDGLPGPKGAQG ERGPVGSSGPKGSQGDPGRPGEPGLPGARGLTGNPGVQGPEGKLGPLGAPGEDGRPGPPG SIGIKGQPGTMGLPGPKGSNGDPGKPGEAGNPGVPGQRGAPGKDGKVGPYGPPGPPGLRG ERGEQGPPGPTGFQGHPGPPGPPGEGGKPGDQGVPGGPGAVGPLGPRGERGNPGERGEPG ITGLPGEKGMAGGHGPDGPKGSPGPSGTPGDTGPPGLQGMPGERGIAGTPGPKGDRGGIG EKGAEGTAGNDGAGGLPGPLGPPGPAGLLGEKGEPGPRGLVGPPGSRGNPGSRGENGPTG AVGFAGPQGSDGQPGVKGEPGEPGQKGDAGSPGPQGLAGSPGPHGPNGVPGLKGGRGTQG PPGATGFPGSAGRVGPPGPAGAPGPAGPLGEPGKEGPPGPRGDPGSHGRVGVRGPAGPPG GPGDKGDPGEDGQPGPDGPPGPAGTTGQRGIVGMPGQRGERGMPGLPGPAGTPGKVGPTG ATGDKGPPGPVGPPGSNGPVGEPGPEGPAGNDGTPGRDGAVGERGDRGDPGPAGLPGSQG APGTPGPVGAPGDAGQRGDPGSRGPIGHLGRAGKRGLPGPQGPRGDKGDHGDRGDRGQKG HRGFTGLQGLPGPPGPNGEQGSAGIPGPFGPRGPPGPVGPSGKEGNPGPLGPLGPPGVRG SVGEAGPEGPPGEPGPPGPPGPPGHLTAALGDIMGHYDESMPDPLPEFTEDQAAPDDKNK TDPGVHATLKSLSSQIETMRSPDGSKKHPARTCDDLKLCHSAKQSGEYWIDPNQGSVEDA IKVYCNMETGETCISANPSSVPRKTWWASKSPDNKPVWYGLDMNRGSQFAYGDHQSPNTA ITQMTFLRLLSKEASQNITYICKNSVGYMDDQAKNLKKAVVLKGANDLDIKAEGNIRFRY IVLQDTCSKRNGNVGKTVFEYRTQNVARLPIIDLAPVDVGGTDQEFGVEIGPVCFV >P15988; 27 COLLAGEN ALPHA 2(VI) CHAIN PRECURSOR. MSRRTAEMFQQAFLSTLLCVALVPLHAQFDDEPVTSCTEKTDCPISVYFVIDTSESIALQ TVPIQSLVDQIKQFIPRFIEKLENEVYQNQVSITWMFGGLHYSDVVEIYSPLTRSKDTYL TKLRAIRYLGRGTFTDCAISNMTQQFQSQTARDVKFAVVITDGHVTGSPCGGMKMQAERA RDMGIKLFAVAPSEDVYEQGLREIASPPHDLYRSNYTITPKDALHIDENTIERIIKAMKH EAYAECYKMTCLEIAGPAGPKGYRGQKGAKGNMGEPGSPGLKGRQGDPGIEGPIGYPGPK GVPGLKGEKGEIGSDGRRGAAGLAGRNGTDGQKGKLGRIGPPGCKGDRGDKGPDGYPGDA GDQGERGDEGMKGDPGRPGRSGPPGPPGEKGSPGIPGNPGAQGPGGTKGRKGETGPPGPK GEPGRRGDPGTKGSKGGPGAKGERGDPGPEGPRGLPGEVGNKGARGDQGLPGPRGPTGAV GEPGNIGSRGDPGDLGPRGDAGPPGPKGDRGRPGFSYPGPRGPQGDKGEKGQPGPKGGRG ELGPKGTQGTKGEKGEPGDPGPRGEPGTRGPPGEAGPEGTPGPPGDPGLTDCDVMTYVRE TCGCCDCEKRCGALDIMFVIDSSESIGYTNFTLEKNFVVNVVSRLGSIAKDPKSETGARV GVVQYSHEGTFEAIKLDDERINSLSSFKEAVKRLEWIAGGTWTPSALQFAYNKLIKESRR EKAQVFAVVITDGRYDPRDDDKNLGALCGRDVLVNTIGIGDIFDQPEQSETLVSIACNEP QRVQKMRLFSDLVAEEFIDKMEDMLCPDPQIVCPELPCQTELAVAQCTQRPVDIVFLLDG SERIGEQNFHRAHHFVEQVAQQLTLARRNDDNMNARIALLQYGSEREQNVVFPLTYNLTE ISNALAQIKYLDSSSNIGSAIIHAINNIVLSPGNGQRVARRNAELSFVFITDGITGSKNL EEAINSMKKQDVMPTVVALGSDVDMDVLLKLGLGDRAAIFREKDYESLSQPSFFDRFIRW IC >P22748; 18 CARBONIC ANHYDRASE IV PRECURSOR (EC 4.2.1.1) (CARBONATE MRMLLALLALSAARPSASAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTK AKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSD LPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGF QPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFRE PIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKSGAPGRPLPWALPALLG PMLACLLAGFLR >P01257; 25 CALCITONIN PRECURSOR. MGFLKFSPFLVVSILLLYQACGLQAVPLRSTLESSPGMATLSEEEARLLAALVQNYMQMK VRELEQEEEQEAEGSSLDSPRSKRCGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAPGKKR DMAKDLETNHHPYFGN >P01263; 25 CALCITONIN 1 PRECURSOR. MVMMKLSALLIAYFLVICQMYSSHAAPARTGLESMTDQVTLTDYEARRLLNAIVKEFVQM TSEELEQQANEGNSLDRPMSKRCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTPGKKRSL PESNRYASYGDSYDGI >P11627; 19 NEURAL CELL ADHESION MOLECULE L1 PRECURSOR (N-CAM L1). MVVMLRYVWPLLLCSPCLLIQIPDEYKGHHVLEPPVITEQSPRRLVVFPTDDISLKCEAR GRPQVEFRWTKDGIHFKPKEELGVVVHEAPYSGSFTIEGNNSFAQRFQGIYRCYASNKLG TAMSHEIQLVAEGAPKWPKETVKPVEVEEGESVVLPCNPPPSAAPPRIYWMNSKIFDIKQ DERVSMGQNGDLYFANVLTSDNHSDYICNAHFPGTRTIIQKEPIDLRVKPTNSMIDRKPR LLFPTNSSSRLVALQGQSLILECIAEGFPTPTIKWLHPSDPMPTDRVIYQNHNKTLQLLN VGEEDDGEYTCLAENSLGSARHAYYVTVEAAPYWLQKPQSHLYGPGETARLDCQVQGRPQ PEITWRINGMSMETVNKDQKYRIEQGSLILSNVQPTDTMVTQCEARNQHGLLLANAYIYV VQLPARILTKDNQTYMAVEGSTAYLLCKAFGAPVPSVQWLDEEGTTVLQDERFFPYANGT LSIRDLQANDTGRYFCQAANDQNNVTILANLQVKEATQITQGPRSAIEKKGARVTFTCQA SFDPSLQASITWRGDGRDLQERGDSDKYFIEDGKLVIQSLDYSDQGNYSCVASTELDEVE SRAQLLVVGSPGPVPHLELSDRHLLKQSQVHLSWSPAEDHNSPIEKYDIEFEDKEMAPEK WFSLGKVPGNQTSTTLKLSPYVHYTFRVTAINKYGPGEPSPVSESVVTPEAAPEKNPVDV RGEGNETNNMVITWKPLRWMDWNAPQIQYRVQWRPQGKQETWRKQTVSDPFLVVSNTSTF VPYEIKVQAVNNQGKGPEPQVTIGYSGEDYPQVSPELEDITIFNSSTVLVRWRPVDLAQV KGHLKGYNVTYWWKGSQRKHSKRHIHKSHIVVPANTTSAILSGLRPYSSYHVEVQAFNGR GLGPASEWTFSTPEGVPGHPEALHLECQSDTSLLLHWQPPLSHNGVLTGYLLSYHPVEGE SKEQLFFNLSDPELRTHNLTNLNPDLQYRFQLQATTQQGGPGEAIVREGGTMALFGKPDF GNISATAGENYSVVSWVPRKGQCNFRFHILFKALPEGKVSPDHQPQPQYVSYNQSSYTQW NLQPDTKYEIHLIKEKVLLHHLDVKTNGTGPVRVSTTGSFASEGWFIAFVSAIILLLLIL LILCFIKRSKGGKYSVKDKEDTQVDSEARPMKDETFGEYRSLESDNEEKAFGSSQPSLNG DIKPLGSDDSLADYGGSVDVQFNEDGSFIGQYSGKKEKEAAGGNDSSGATSPINPAVALE >P20160; 26 AZUROCIDIN PRECURSOR (CATIONIC ANTIMICROBIAL PROTEIN CAP MTRLTVLALLAGLLASSRAGSSPLLDIVGGRKARPRQFPFLASIQNQGRHFCGGALIHAR FVMTAASCFQSQNPGVSTVVLGAYDLRRRERQSRQTFSISSMSENGYDPQQNLNDLMLLQ LDREANLTSSVTILPLPLQNATVEAGTRCQVAGWGSQRSGGRLSRFPRFVNVTVTPEDQC RPNNVCTGVLTRRGGICNGDGGTPLVCEGLAHGVASFSLGPCGRGPDFFTRVALFRDWID GVLNNPGPGPA >P12637; 19 CALSEQUESTRIN, CARDIAC MUSCLE ISOFORM PRECURSOR. MKRTHLFIAGLYLLASCRAEEGLNFPTYDGKDRVVSLTEKNFKQVLKKYDVLCLYYHESV SSDKVAQKQFQLKEIVLELVAQVLEHKDIGFVMVDAKKEAKLAKKLGFDEEGSLYVLKGD RTIEFDGEFAADVLVEFLLDLIEDPVEIINSKLEVQAFERIEDQIKLIGFFKSEESEYYK AFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDFYEPFMDEPIAIPDKPYTEEELVEF VKEHQRPTLRRLRPEDMFETWEDDLNGIHIVAFAERSDPDGYEFLEILKQVARDNTDNPD LSIVWIDPDDFPLLVAYWEKTFKIDLFKPQIGVVNVTDADSVWMEIPDDDDLPTAEELED WIEDVLSGKINTEDDDNEEGDDGDDDEDDDDDDGNNSDEESNDDSDDDDE >P07221; 28 CALSEQUESTRIN, SKELETAL MUSCLE ISOFORM PRECURSOR (ASPART MNAADRMGARVALLLLLVLGSPQSGVHGEEGLDFPEYDGVDRVINVNAKNYKNVFKKYEV LALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEE DSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYF KNKDSEHYKAFKEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKP NSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGYEFLEILKSV AQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEED LPSAEELEDWLEDVLEGEINTEDDDDEDDDDDDDD >P09177; 22 MUCOROPEPSIN PRECURSOR (EC 3.4.23.23) (MUCOR RENNIN). MLFSKISSAILLTAASFALTSARPVSKQSDADDKLLALPLTSVNRKYSQTKHGQQAAEKL GGIKAFAEGDGSVDTPGLYDFDLEEYAIPVSIGTPGQDFYLLFDTGSSDTWVPHKGCDNS EGCVGKRFFDPSSSSTFKETDYNLNITYGTGGANGIYFRDSITVGGATVKQQTLAYVDNV SGPTAEQSPDSELFLDGMFGAAYPDNTAMEAEYGDTYNTVHVNLYKQGLISSPVFSVYMN TNDGGGQVVFGGANNTLLGGDIQYTDVLKSRGGYFFWDAPVTGVKIDGADAVSFDGAQAF TIDTGTNFFIAPSSFAEKVVKAALPDATESQQGYTVPCSKYQDSKTTFSLVLQKSGSSSD TIDVSVPISKMLLPVDKSGETCMFIVLPDGGNQFIVGNLFLRFFVNVYDFGKNRIGFAPL ASGYENN >P04656; 15 CASEIN B PRECURSOR (ALPHA-S1 CASEIN). MKLLILTCLVASAVAMPKFPFRHTELFQTQRGGSSSSSSSEERLKEENIFKFDQQKELQR KQSEKIKEIISESTEQREASSISSSEEVVPKNTEQKHIPQEDALYQQALEQLSRLIKYHQ LQMEVVHAQEQFHRINEHNQAQVKEPMRVFNQLDAYPFAAWYYGPEVQYMSFLPFSSIPQ PIFPEDAQNTEVMPEWVM >P02669; 21 KAPPA CASEIN PRECURSOR. MMKSFFLVVTILALTLPFLGAQEQNQEQRICCEKDERFFDDKIAKYIPIQYVLSRYPSYG LNYYQQRPVALINNQFLPYPYYAKPVAVRSPAQTLQWQVLPNAVPAKSCQDQPTAMARHP HPHLSFMAIPPKKDQDKTEIPAINTIASAEPTVHSTPTTEAVVNAVDNPEASSESIASAP ETNTAQVTSTEV >P15156; 21 CALCIUM-DEPENDENT SERINE PROTEINASE PRECURSOR (EC 3.4.21 MGKSSEAWCIVLFSVFASFSAEPTMHGEILSPNYPQAYPNEMEKTWDIEVPEGFGVRLYF THLDMELSENCEYDSVQIISGGVEEGRLCGQRTSKNANSPIVEEFQIPYNKLQVIFRSDF SNEERFTGFAAYYAAIDVNECTDFTDVPCSHFCNNFIGGYFCSCPPEYFLHDDMRNCGVN CSGNVFTALIGEISSPNYPNPYPENSRCEYQILLEEGFQVVVTIQREDFDVEPADSQGNC QDSLLFAAKNRQFGPFCGNGFPGPLTIETHSNTLDIVFQTDLTEQKKGWKLRYHGDPIPC PKEITANSVWAPEKAKYVFKDVVKISCVDGFEAVEGNVGSTFFYSTCQSNGQWSNSRLRC QPVDCGIPEPIQNGKVDDPENTLFGSVIHYSCEEPYYYMEHAEHGGEYRCAANGSWVNDE LGIELPKCVPVCGVPTEPFRIQQRIFGGFPAKIQSFPWQVFFEFPRAGGALIGEHWVLTA AHVVEGNSDPSMYVGSTSVRMENLANVQKLTTDRVIIHPGWKPGDDLSTRTNFDNDIALV RLKDPVKMGPTVSPICLPGTSSEYEPSEGDLGLISGWGRTERRNIVIQLRGAKLPVTSLE KCRQVKEENPKARADDYVFTSNMICAGEKGVDSCQGDSGGAFALPVPNVRDPKFYVAGLV SWGKKCGTYGIYTKVKNYKDWILQTMQENSVPSQD >P09668; 22 CATHEPSIN H PRECURSOR (EC 3.4.22.16). MWATLPLLCAGAWLLGVPVCGAAELSVNSLEKFHFKSWMSKHRKTYSTEEYHHRLQTFAS NWRKINAHNNGNHTFKMALNQFSDMSFAEIKHKYLWSEPQNCSATKSNYLRGTGPYPPSV DWRKKGNFVSPVKNQGACGSCWTFSTTGALESAIAIATGKMLSLAEQQLVDCAQDFNNYG CQGGLPSQAFEYILYNKGIMGEDTYPYQGKDGYCKFQPGKAIGFVKDVANITIYDEEAMV EAVALYNPVSFAFEVTQDFMMYRTGIYSSTSCHKTPDKVNHAVLAVGYGEKNGIPYWIVK NSWGPQWGMNGYFLIERGKNMCGLAACASYPIPLV >P08185; 22 CORTICOSTEROID-BINDING GLOBULIN PRECURSOR (CBG) (TRANSCO MPLLLYTCLLWLPTSGLWTVQAMDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPK KNIFISPVSISMALAMLSLGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSD TSLEMTMGNALFLDGSLELLESFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQG KIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENFYVDETTVVKVPMMLQSSTI SYLHDSELPCQLVQMNYVGNGTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLY IPKVTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGVDT AGSTGVTLNLTSKPIILRFNQPFIIMIFDHFTWSSLFLARVMNPV >P15086; 15 CARBOXYPEPTIDASE B PRECURSOR (EC 3.4.17.2) (PANCREAS-SPE MLALLVLVTVALASAHHGGEHFEGEKVFRVNVEDENHINIIRELASTTQIDFWKPDSVTQ IKPHSTVDFRVKAEDTVTVENVLKQNELQYKVLISNLRNVVEAQFDSRVRATGHSYEKYN KWETIEAWTQQVATENPALISRSVIGTTFEGRAIYLLKVGKAGQNKPAIFMDCGFHAREW ISPAFCQWFVREAVRTYGREIQVTELLNKLDFYVLPVLNIDGYIYTWTKSRFWRKTRSTH TGSSCIGTDPNRNFDAGWCEIGASRNPCDETYCGPAAESEKETKALADFIRNKLSSIKAY LTIHSYSQMMIYPYSYAYKLGENNAELNALAKATVKELASLHGTKYTYGPGATTIYPAAG GSDDWAYDQGIRYSFTFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVLEHLY >P15088; 15 MAST CELL CARBOXYPEPTIDASE A PRECURSOR (EC 3.4.17.1) (MC MRLILPVGLIATTLAIAPVRFDREKVFRVKPQDEKQADIIKDLAKTNELDFWYPGATHHV AANMMVDFRVSEKESQAIQSALDQNKMHYEILIHDLQEEIEKQFDVKEDIPGRHSYAKYN NWEKIVAWTEKMMDKYPEMVSRIKIGSTVEDNPLYVLKIGEKNERRKAIFMDCGIHAREW VSPAFCQWFVYQATKTYGRNKIMTKLLDRMNFYILPVFNVDGYIWSWTKNRMWRKNRSKN QNSKCIGTDLNRNFNASWNSIPNTNDPCADNYRGSAPESEKETKAVTNFIRSHLNEIKVY ITFHSYSQMLLFPYGYTSKLPPNHEDLAKVAKIGTDVLSTRYETRYIYGPIESTIYPISG SSLDWAYDLGIKHTFAFELRDKGKFGFLLPESRIKPTCRETMLAVKFIAKYILKHTS >P15169; 20 CARBOXYPEPTIDASE N CATALYTIC CHAIN PRECURSOR (EC 3.4.17. MSDLLSVFLHLLLLFKLVAPVTFRHHRYDDLVRTLYKVQNECPGITRVYSIGRSVEGRHL YVLEFSDHPGIHEPLEPEVKYVGNMHGNEALGRELMLQLSEFLCEEFRNRNQRIVQLIQD TRIHILPSMNPDGYEVAAAQGPNKPGYLVGRNNANGVDLNRNFPDLNTYIYYNEKYGGPN HHLPLPDNWKSQVEPETRAVIRWMHSFNFVLSANLHGGAVVANYPYDKSFEHRVRGVRRT ASTPTPDDKLFQKLAKVYSYAHGWMFQGWNCGDYFPDGITNGASWYSLSKGMQDFNYLHT NCFEITLELSCDKFPPEEELQREWLGNREALIQFLEQVHQGIKGMVLDENYNNLANAVIS VSGINHDVTSGDHGDYFRLLLPGIYTVSATAPGYDPETVTVTVGPAEPTLVNFHLKRSIP QVSPVRRAPSRRHGVRAKVQPQARKKEMEMRQLQRGPA >P17559; 19 CLARA CELL PHOSPHOLIPID-BINDING PROTEIN PRECURSOR (CCPBP MKIAITITVLMLSICCSSASSDICPGFLQVLEALLLGSESNYEAALKPFNPASDLQNAGT QLKRLVDTLPQETRINIVKLTEKILTSPLCEQDLRV >Q16627; 19 CHEMOKINE CC-1 PRECURSOR (HCC-1) (NCC-2). MKISVAAIPFFLLITIALGTKTESSSRGPYHPSECCFTYTTYKIPRQRIMDYYETNSQCS KPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN >P06731; 34 CARCINOEMBRYONIC ANTIGEN PRECURSOR (CEA) (MECONIUM ANTIG MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQ HLFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFY TLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWV NNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQNPVSARRSDSVILNVLYGPDAP TISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQSTQELFIPNITVNNSGSYTCQ AHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQNTTYLWWVNN QSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNELSVDHSDPVILNVLYGPDDPTI SPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQAN NSASGHSRTTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQS LPVSPRLQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISP PDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNL ATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVALI >P06307; 20 PROCHOLECYSTOKININ PRECURSOR (CCK). MNSGVCLCVLMAVLAAGALTQPVPPADPAGSGLQRAEEAPRRQLRVSQRTDGESRAHLGA LLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS >P47000; 18 COVALENTLY-LINKED CELL WALL PROTEIN 7 PRECURSOR. MQYKKTLVASALAATTLAAYAPSEPWSTLTPTATYSGGVTDYASTFGIAVQPISTTSSAS SAATTASSKAKRAASQIGDGQVQAATTTASVSTKSTAAAVSQIGDGQIQATTKTTAAAVS RDGQIQATTKTTSAKTTAAAVSQISDGQIQATTTTLAPKSTAAAVSQIGDGQVQATTKTT AAAVSQIGDGQVQATTKTTAAAVSQIGDGQVQATTKTTAAAVSQIGDGQVQATTKTTAAA VSQITDGQVQATTKTTQAASQVSDGQVQATTAWLLVTMMSSTNVCPVLSTTCTTNTLVVN VLQSTWKLSI >P10810; 15 MONOCYTE DIFFERENTIATION ANTIGEN CD14 PRECURSOR (LPS REC MERVLGLLLLLLVHASPAPPEPCELDEESCSCNFSDPKPDWSSAFNCLGAADVELYGGGR SLEYLLKRVDTEADLGQFTDIIKSLSLKRLTVRAARIPSRILFGALRVLGISGLQELTLE NLEVTGTAPPPLLEATGPDLNILNLRNVSWATRDAWLAELQQWLKPGLKVLSIAQAHSLN FSCEQVRVFPALSTLDLSDNPELGERGLISALCPLKFPTLQVLALRNAGMETPSGVCSAL AAARVQLQGLDLSHNSLRDAAGAPSCDWPSQLNSLNLSFTGLKQVPKGLPAKLSVLDLSY NRLDRNPSPDELPQVGNLSLKGNPFLDSESHSEKFNSGVVTAGAPSSQAVALSGTLALLL GDRLFV >P25918; 16 B-LYMPHOCYTE ANTIGEN CD19 PRECURSOR (B-LYMPHOCYTE SURFAC MPSPLPVSFLLFLTLVGGRPQKSLLVEVEEGGNVVLPCLPDSSPVSSEKLAWYRGNQSTP FLELSPGSPGLGLHVGSLGILLVIVNVSDHMGGFYLCQKRPPFKDIWQPAWTVNVEDSGE MFRWNASDVRDLDCDLRNRSSGSHRSTSGSQLYVWAKDHPKVWGTKPVCAPRGSSLNQSL INQDLTVAPGSTLWLSCGVPPVPVAKASISWTHVHPRRPNVSLLSLSLGGEHPVREMWVW GSLLLLPQATALDEGTYYCLRGNLTIERHVKVIARSAVWLWLLRTGGWIVPVVTLVYVIF CMVSLVAFLYCQRAFILRRKRKRMTDPARRFFKVTPPSGNGTQNQYGNVLSLPTSTSGQA HAQRWAAGLGSVPGSYGNPRIQVQDTGAQSHETGLEEEGEAYEEPDSEEGSEFYENDSNL GQDQVSQDGSGYENPEDEPMGPEEEDSFSNAESYENADEELAQPVGRMMDFLSPHGSAWD PSREASSLGSQSYEDMRGILYAAPQLHSIQSGPSHEEDADSYENMDKSDDLEPAWEGEGH MGTWGTT >P10747; 18 T-CELL-SPECIFIC SURFACE GLYCOPROTEIN CD28 PRECURSOR (TP4 MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLD SAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPP PYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVR SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS >P06729; 24 T-CELL SURFACE ANTIGEN CD2 PRECURSOR (T-CELL SURFACE ANT MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWE KTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEK IFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSL SAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQ RSRRNDEELETRAHRVATEERGRKPQQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPP GHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN >Q28270; 33 HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34 PRECURSOR. MLAGRGARAGGGLPRGWTALCLLSLLPFGFTNTETVITPTTVPTSTEIMSAVSENTSKRE AITLTPSGTTTLYSVSQDSSGTTATISETTVHVTSTSEITLTPGTMNSSVQSQTSLAITV SFTPTNFSTSSVTLEPSLLPGNGSDPPYNSTSLVTSPTEYYTSLSPTPSRNDTPSTIKGE IKCSGVKEVKLNQGICLELNETSSCEDFKKDNEEKLTQVLCEKEPAEAGAGVCSLLLAQS EVRPHCLLLVLANKTELFSKLQLLRKHQSDLKKLGIRDFTEQDVGSHQSYSRKTLIALVT SGILLAVLGTTGYFLMNRRSWSPTGERLGEDPYYTENGGGQGYSSGPGVSPEAQGKASVN RGPQENGTGQATSRNGHSARQHMVADTEL >P04234; 21 T-CELL SURFACE GLYCOPROTEIN CD3 DELTA CHAIN PRECURSOR (T MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDL GKRILDPRGIYRCNGTDIYKDKESTVQVHYRMCQSCVELDPATVAGIIVTDVIATLLLAL GVFCFAGHETGRLSGAADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK >P09693; 22 T-CELL SURFACE GLYCOPROTEIN CD3 GAMMA CHAIN PRECURSOR (T MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGK MIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLF AEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLR RN >P20963; 21 T-CELL SURFACE GLYCOPROTEIN CD3 ZETA CHAIN PRECURSOR (T- MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSAE PPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR >P06800; 23 LYMPHOCYTE COMMON ANTIGEN LY-5 PRECURSOR (EC 3.1.3.48) ( MGLWLKLLAFGFALLDTEVFVTGQTPTPSDGASLTTLTPSTLGLASTDPPSTTIATTTKQ TCAAMFGNITVNYTYESSNQTFKADLKDVQNAKCGNEDCENVLNNLEECSQIKNISVSND SCAPATTIDLYVPPGTDKFSLHDCTPKEKANTSICLEWKTKNLDFRKCNSDNISYVLHCE PENNTKCIRRNTFIPERCQLDNLRAQTNYTCVAEILYRGVKLVKNVINVQTDLGIPETPK PSCGDPAARKTLVSWPEPVSKPESASKPHGYVLCYKNNSEKCKSLPNNVTSFEVESLKPY KYYEVSLLAYVNGKIQRNGTAEKCNFHTKADRPDKVNGMKTSRPTDNSINVTCGPPYETN GPKTFYILVVRSGGSFVTNTTKTNCQFYGDNLYYSTDYEFLVSFHNGVYEGDSVIRSEST NFNAKALIIFLVFLIIVTSIALLVVLYKSYDLRKKRSSNLDEQQELVERDDEKQLMDVEP IHSDILLETYKRKIADEGRLFLAEFQSIPRVFSKFPIKDARKPHNQNKNRYVDILPYDYN RVELSEINGDAGSTYINASYIDGFKEPRKYIAAQGPRDETVDDFWRMIWEQKATVIVMVT RCEEGNRNKCAEYWPSMEEGTRAFKDIVVTINDHKRCPDYIIQKLNVAHKKEKATGREVT HIQFTSWPDHGVPEDPHLLLKLRRRVNAFSNFFSGPIVVHCSAGVGRTGTYIGIDAMLEG LEAEGKVDVYGYVVKLRRQRCLMVQVEAQYILIHQALVEYNQFGETQVNLSELHSCLHNM KKRDPPSDPSPREAEYQRLPSYRSWRTQHIGNQGENKKKKRNSNVVPYDFNRVPLKHELE MSKESEPESDESSDDDSDSEETSKYINASFVMSYWKPEMMIAAQGPLKETIGDFWQMIFQ RKVKVIVMLTELVNGDQEVCAQYWGEGKQTYGDMEVEMKDTNRASAYTLRTFELRHSKRK EPRTVYQYQCTTWKGEELPAEPKDLVSMIQDLKQKLPKASPEGMKYHKHASILVHCRDGS QQTGLFCALFNLLESAETEDVVDVFQVVKSLRKARPGVVCSYEQYQFLYDIIASIYPAQN GQVKKTNSQDKIEFHNEVDGGKQDANCVRPDGPLNKAQEDSRGVGTPEPTNSAEEPEHAA NGSASPAPTQSS >P10252; 22 MRC OX-45 SURFACE ANTIGEN PRECURSOR (BCM1 SURFACE ANTIGE MYFKKRRWFLILESLLLSLVTGFQDQSVPNVNAITGSNVTLTILKHPLASYQRLTWLHTT NQKILEYFPNGKKTVFESVFKDRVDLDKTNGALRIYNVSKEDRGDYYMRMLHETEDQWKI TMEVYDLVSKPAIKIEKTKNLTDSCHLRLSCKVEDQGVDYTWYEDSGPFPQRNPGYVLEI TITPHNKSTFYTCQVSNPVSSENDTLYFIPPCTLARSSGVHWIAAWLVVTLSIIPSILLA >P05540; 27 T-CELL SURFACE GLYCOPROTEIN CD4 PRECURSOR (T-CELL SURFAC MCRGFSFRHLLPLLLLQLSKLLVVTQGKTVVLGKEGGSAELPCESTSRRSASFAWKSSDQ KTILGYKNKLLIKGSLELYSRFDSRKNAWERGSFPLIINKLRMEDSQTYVCELENKKEEV ELWVFRVTFNPGTRLLQGQSLTLILDSNPKVSDPPIECKHKSSNIVKDSKAFSTHSLRIQ DSGIWNCTVTLNQKKHSFDMKLSVLGFASTSITAYKSEGESAEFSFPLNLGEESLQGELR WKAEKAPSSQSWITFSLKNQKVSVQKSTSNPKFQLSETLPLTLQIPQVSLQFAGSGNLTL TLDRGILYQEVNLVVMKVTQPDSNTLTCEVMGPTSPKMRLILKQENQEARVSRQEKVIQV QAPEAGVWQCLLSEGEEVKMDSKIQVLSKGLNQTMFLAVVLGSAFSFLVFTGLCILFCVR CRHQQRQAARMSQIKRLLSEKKTCQCSHRMQKSHNLI >P31358; 24 CAMPATH-1 ANTIGEN PRECURSOR (CD52 ANTIGEN) (CDW52) (CAMB MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSASSNISGGIFLFFVANAIIHLFCF S >P13379; 23 T-CELL SURFACE GLYCOPROTEIN CD5 PRECURSOR (LYMPHOCYTE GL MDSHEVLLAATYLLGTLAAFCLGQSGRGGLDIQVMLSGSNSKCQGQVEIQMENKWKTVCS SSWRLSQDHSKNAQQASAVCKQLRCGDPLALGPFPSLNRPQNQVFCQGSPWSISNCNNTS SQDQCLPLSLICLEPQRTTPPPTTTPPTTVPEPTAPPRLQLVPGHEGLRCTGVVEFYNGS WGGTILYKAKDRPLGLGNLICKSLQCGSFLTHLSGTEAAGTPAPAELRDPRPLPIRWEAP NGSCVSLQQCFQKTTAQEGGQALTVICSDFQPKVQSRLVGGSSVCEGIAEVRQRSQWEAL CDSSAARGRGRWEELCREQQCGDLISFHTVDADKTSPGFLCAQEKLSQCYHLQKKKHCNK RVFVTCQDPNPAGLAPGTVASIILTLVLLVVLLAMCGPLVYKKLVKKFRQKKQRQWIGPT GVNQNMSFHRSHTATVRSQVENPTASHVDNEYSQPPRNSHLSAYPALEGALHRSSTQPDN SSDSDYDLQVAQRL >P33681; 34 T LYMPHOCYTE ACTIVATION ANTIGEN CD80 PRECURSOR (ACTIVATI MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELA QTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLK YEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGE ELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFP DNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV >P01732; 21 T-CELL SURFACE GLYCOPROTEIN CD8 ALPHA CHAIN PRECURSOR (T MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN SIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFA CDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV >P01731; 27 T-CELL SURFACE GLYCOPROTEIN CD8 ALPHA CHAIN PRECURSOR (T MASPLTRFLSLNLLLLGESIILGSGEAKPQAPELRIFPKKMDAELGQKVDLVCEVLGSVS QGCSWLFQNSSSKLPQPTFVVYMASSHNKITWDEKLNSSKLFSAMRDTNNKYVLTLNKFS KENEGYYFCSVISNSVMYFSSVVPVLQKVNSTTTKPVLRTPSPVHPTGTSQPQRPEDCRP RGSVKGTGLDFACDIYIWAPLAGICVALLLSLIITLICYHRSRKRVCKCPRPLVRQEGKP RPSEKIV >P19336; 22 CEF-10 PROTEIN PRECURSOR. MGSAGARPALAAALLCLARLALGSPCPAVCQCPAAAPQCAPGVGLVPDGCGCCKVCAKQL NEDCSRTQPCDHTKGLECNFGASPAATNGICRAQSEGRPCEYNSKIYQNGESFQPNCKHQ CTCIDGAVGCIPLCPQELSLPNLGCPSPRLVKVPGQCCEEWVCDESKDALEELEGFFSKE FGLDASEGELTRNNELIAIVKGGLKMLPVFGSEPQSRAFENPKCIVQTTSWSQCSKTCGT GISTRVTNDNPDCKLIKETRICEVRPCGQPSYASLKKGKKCTKTKKSPSPVRFTYAGCSS VKKYRPKYCGSCVDGRCCTPQQTRTVKIRFRCDDGETFTKSVMMIQSCRCNYNCPHANEA YPFYRLVNDIHKFRD >P01507; 22 CECROPIN A AND C PRECURSOR. MNFSRIFFFVFACLTALAMVNAAPEPKWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQ IAKG >P11597; 17 CHOLESTERYL ESTER TRANSFER PROTEIN PRECURSOR (LIPID TRAN MLAATVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQTAFQRASYPDI TGEKAMMLLGQVKYGLHNIQISHLSIASSQVELVEAKSIDVSIQNVSVVFKGTLKYGYTT AWWLGIDQSIDFEIDSAIDLQINTQLTCDSGRVRTDAPDCYLSFHKLLLHLQGEREPGWI KQLFTNFISFTLKLVLKGQICKEINVISNIMADFVQTRAASILSDGDIGVDISLTGDPVI TASYLESHHKGHFIYKNVSEDLPLPTFSPTLLGDSRMLYFWFSERVFHSLAKVAFQDGRL MLSLMGDEFKAVLETWGFNTNQEIFQEVVGGFPSQAQVTVHCLKMPKISCQNKGVVVNSS VMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKLFLSLLDFQITPKTVSNLTESSSE SIQSFLQSMITAVGIPEVMSRLEVVFTALMNSKGVSLFDIINPEIITRDGFLLLQMDFGF PEHLLVDFLQSLS >Q06153; 25 CERATO-ULMIN PRECURSOR (DUTCH ELM DISEASE TOXIN) (CU). MQFSIATIALFLSSAMAAPYSGNSNSDSYDPCTGLLQKSPQCCNTDILGVANLDCHGPPS VPTSPSQFQASCVADGGRSARCCTLSLLGLALVCTDPVGI >P00751; 25 COMPLEMENT FACTOR B PRECURSOR (EC 3.4.21.47) (C3/C5 CONV MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEY VCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPY YNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQ YRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTE TIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKV ASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQ AVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPRE DYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGM VWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVS VGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCT EGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDA QYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWG VVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL >P08825; 21 CHORION CLASS A PROTEIN L12 PRECURSOR. MSTFAFLLFCAQACLIQNVCGLYLGGLGGCGCGGGWNGWNGLGGGWNGLGVGWNGIDGGY GAGCGSYGGEGIGNVGVAGELPVGGVTAVGGRVPIIGGVEYGGPACAAGAVSICGHCAPT CGCGRAGLGGYY >P08827; 21 CHORION CLASS B PROTEIN L11 PRECURSOR. MAAKLILFVCATALVAQSALGIGCGCGCGGRGYGGLGYGGLGYGGLGYGGYGGGCGRGFS GGGLPVATASAAPTGLGIASENRYEGTVGVCGNLPFLGTADVAGEFPTAGIGEILYGCGN GAVGITREGGLGFGAGYGGGYGLGYGGYGGGYGLGYGGYGGCGCGCGY >P08830; 20 CHORION CLASS CB PROTEIN M5H4 PRECURSOR. MTTIVVLICASALFVQLAFSQCLGRDPVIGFGGAYGSGWGGYDAISPYDGLGYGVPYSAG FIGLSPSNLAASCGGALAVNSLSPTTPTGLTVASENTIEGNLGIFGQLPFLGAVATDGAF STGGIGAVLYGCGDGAIGIVSEAPIVAPASIGYGQWPVNAGYKGIGPCGCGGLY >Q25588; 26 CRUSTACEAN HYPOGLYCEMIC HORMONE A* PRECURSOR (CHH A*). MVSFRTMWSVVVVVVVASLASSGVQGRSVEGSSRMERLLSSGSSSSEPLSFLSQDQSVNK RQVFDQACKGIYDRAIFKKLDRVCEDCYNLYRKPYVATTCRQNCYANSVFRQCLDDLLLI DVLDEYISGVQTVGK >P29025; 20 CHITINASE 1 PRECURSOR (EC 3.2.1.14). MISCNILGITIAAFITSTLAAYSSNGVNVMYYWGQNSAGGSNTQGSLVSYCQSGQVDVII LSFLNKFNMGGLPEINLASACEQTFFPNTNLLHCPTVGSDIKTCQSNGVKVLLSLGGAAG SYGFSSDSEGQTFAETIWNLFGGGTSDTRPFDDAVIDGIDLDIEGGSSTGYAAFVTALRS KGHFLIGAAPQCPFPDAILGSVIDAVGLDFVNVQFYNNVCSVASGSSFNFDVWNDWAKNK SPNKNIKVMLTVPGSSTAAGSGYASIAELGPIVSSVISQYSSFGGVSVWDASQAWNNNGF HSELYSIVHGSSAALGQAARKTPFPNTSSITTTSLATASSALFPLLYAGRSCSSQSKVSC TSTGSYTICNYGKWVTAPCPPGVICLSSAQSNNTDLTVSAQFFITSFAGGSFKAIINARR TTLTPFEKMKTIEFTVPDHVRLSQCNLGKIEQVGRSVRIRLKDHPNMAFVLNLSGNVSSD AFVAPDPSSWRFS >P29027; 22 CHITINASE 2 PRECURSOR (EC 3.2.1.14). MLTRTFLGMAISAFLASTGVQAAWSSHGPNVMYYWGQNSAGGSNTQASLGTYCESGQVDA VLLSFLHVFNVGGIPEINLSSACAGTYFPNTQLLSCPAVGADIKKCQDKGVKVILSLGGA AGVYGFTSDAQGQQFAQTIWNLFGGGNSDTRPFGDAVIDGVDLDIEGGSSTGYVAFVNAL RQKFSSNFLIGAAPQCPFPDAILGSVLNSASFDYVNVQFYNNYCSATGSSFNFDTWDNWA KTTSPNKNVKIMFTVPGSSTAAGSGYVPMSTLQTIVPSLASKYSSYGGVSVWDASQAWNN GGFNSQLYSLVHSGGSTPPPPSSSSATKTTTKTTATSTKTTTTTAPTATSTPGSCPVANQ PCSTQNQYACTADGKYAVCDHGKWVASSCPSNTVCIPTTDGASIYCGYATGSGSTCPSVS ALEITAASLGSKNGPVPRPYKASKVAAQLAVTSTDKNSFEAVINARRTTLTPFEKSVTIE FTTPSNIKFTESDMGPVRQVGNKVRIQAKNDYNESMTLVVKVKGSINSGVFVAPSTSAWN FK >P29030; 22 ENDOCHITINASE PRECURSOR (EC 3.2.1.14) (MF1 ANTIGEN). MNRTTLILFFIILSNTITVIHGYVRGCYYTNWAQYRDGEGKFLPGNIPNGLCTHILYAFA KVDELGDSKPFEWNDEDTEWSKGMYSAVTKLRETNPGLKVLLSYGGYNFGSAIFTGIAKS AQKTERFIKSAIAFLRKNNFDGFDLDWEYPVGVAEEHAKLVEAMKTAFVEEAKTSGKQRL LLTAAVSAGKGTIDGSYNVESLGKNFDLLFLMSYDLHGSWEKNVDLHGKLHPTKGEVSGI GIFNTEFAADYWASKGMPKEKIIIGIPMYAQGWTLDNPSETAIGAAASRPSSASKTNPAG GTASYWEICKYLKEGGKETVHQEGVGAYMVKGDQWYGYDNEETIRIKMKWLKEKGYGGAF IWALDFDDFTGKSCGKGPYPLLNAISSELEGESENPEITTEEPSITETEAYETDETEETS ETEAYDTDETEETSETEATTYDTDETEGQECPERDGLFPHPTDCHLFIQCANNIAYVMQC PATTFFNDAIKVCDHMTNAPDTCI >P00794; 16 PROCHYMOSIN A/B PRECURSOR (EC 3.4.23.4) (PREPRORENNIN). MRCLVVLLAVFALSQGTEITRIPLYKGKSLRKALKEHGLLEDFLQKQQYGISSKYSGFGE VASVPLTNYLDSQYFGKIYLGTPPQEFTVLFDTGSSDFWVPSIYCKSNACKNHQRFDPRK SSTFQNLGKPLSIHYGTGSMQGILGYDTVTVSNIVDIQQTVGLSTQEPGDVFTYAEFDGI LGMAYPSLASEYSIPVFDNMMNRHLVAQDLFSVYMDRNGQESMLTLGAIDPSYYTGSLHW VPVTVQQYWQFTVDSVTISGVVVACEGGCQAILDTGTSKLVGPSSDILNIQQAIGATQNQ YGEFDIDCDNLSYMPTVVFEINGKMYPLTPSAYTSQDQGFCTSGFQSENHSQKWILGDVF IREYYSVFDRANNLVGLAKAI >Q00954; 18 SODIUM CHANNEL BETA-1 SUBUNIT PRECURSOR. MGTLLALVVGAVLVSSAWGGCVEVDSETEAVYGMTFKILCISCKRRSETTAETFTEWTFR QKGTEEFVKILRYENEVLQLEEDERFEGRVVWNGSRGTKDLQDLSIFITNVTYNHSGDYE CHVYRLLFFDNYEHNTSVVKKIHLEVVDKANRDMASIVSEIMMYVLIVVLTIWLVAEMVY CYKKIAAATEAAAQENASEYLAITSESKENCTGVQVAE >P54900; 29 SODIUM CHANNEL BETA-2 SUBUNIT PRECURSOR. MHRDAWLPRPAFSLTGLSLFFSLVPSGRSMEVTVPTTLSVLNGSDTRLPCTFNSCYTVNH KQFSLNWTYQECSNCSEEMFLQFRMKIINLKLERFGDRVEFSGNPSKYDVSVTLKNVQLE DEGIYNCYITNPPDRHRGHGKIYLQVLLEVPPERDSTVAVIVGASVGGFLAVVILVLMVV KCVRRKKEQKLSTDDLKTEEEGKTDGEGNAEDGAK >P07187; 16 LARVAL CUTICLE PROTEIN II PRECURSOR. MFKFVMILAVVGVATALAPVSRSDDVHADVLSRSDDVRADGFDSSLHTSNGIEQAASGDA HGNIHGNFGWISPEGEHVEVKYVANENGYQPSGAWIPTPPPIPEAIARAVAWLESHPPAP EHPRHH >P07188; 16 LARVAL CUTICLE PROTEIN III PRECURSOR. MFKILLVCSLAALVAANANVEVKELVNDVQPDGFVSKLVLDDGSASSATGDIHGNIDGVF EWISPEGVHVRVSYKADENGYQPQSDLLPTPPPIPAAILKAIAYIEANPSKN >P10354; 18 CHROMOGRANIN A PRECURSOR (CGA) [CONTAINS: PANCREASTATIN; MRSSAALALLLCAGQVFALPVNSPMTKGDTKVMKCVLEVISDSLSKPSPMPVSPECLETL QGDERVLSILRHQNLLKELQDLALQGAKERAQQQQQQQQQQQQQQQQQQQQHSSFEDELS EVFENQSPAAKHGDAASEAPSKDTVEKREDSDKGQQDAFEGTTEGPRPQAFPEPKQESSM MGNSQSPGEDTANNTQSPTSLPSQEHGIPQTTEGSERGPSAQQQARKAKQEEKEEEEEEK EEEEEEKEEKAIAREKAGPKEVPTAASSSHFYSGYKKIQKDDDGQSESQAVNGKTGASEA VPSEGKGELEHSQQEEDGEEAMAGPPQGLFPGGKGQELERKQQEEEEEEERLSREWEDKR WSRMDQLAKELTAEKRLEGEDDPDRSMKLSFRARAYGFRDPGPQLRRGWRPSSREDSVEA RGDFEEKKEEEGSANRRAEDQELESLSAIEAELEKVAHQLQALRRG >P12387; 29 COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]. MGPAAGPSLLLLLLASVSLALGDPMYSIITPNILRLENEETVVLEAHEVQGDIPVTVTVH DFPAKKNVLSSEKTVLTSATGYLGTVTIKIPASKEFKSDKGRKLVVVQAAFGGTQLEKVV LVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVDSDLLPVGRTIIVTIETPDGIPIKRDTLS SNNQHGILPLSWNIPELVNMGQWKIQAFYENSPKQVFSAEFEVKEYVLPSFEVLVEPTEK FYYIDDPKGLEVNIIARFLYGKNVDGTAFVIFGVQDGDQRISLAQSLTRVVIEDGSGEVV LSRQVLLDGVQPSRPEALVGKSLYVSVTVILHSGSDMVEAERSGIPIVTSPYQIHFTKTP KYFKPAMPFEIMVLVTNPDGSPAPHVPVVTQGSNVQSLTQADGVARLSINTPNTRQPLSV TVQTKKGGIPDARQAINTMQALPYTTMYNSNNYLHLSMPRTELKPGETINVNFHLRSDPN QEAKIRYYTYLIMNKGKLLKVGRQPREPGQALVVLPMPITKELIPSFRLVAYYTLIGASA QREVVADSVWADVRDSCVGTLVVKGGSGKDGQDKRQQHLPRQQMTLRIEGNQGARVGLVA VDKGVFVLNKKHKLTQSKIWDVVEKADIGCTPGSGKDYAGVFTDAGLSFKSSKAGLQTAQ REGLDCPKPAARRRRSVQLMERRMDKAGKYKSKELRRCCEDGMRENPMQFSCQRRARYVS LGEACVKAFLDCCTYMAQLRQQHRREQNLGLARSDMDEDIIPEEDIISRSQFPESWLWTI EELKEPERNGISTKTMNIFLKDSITTWEILAVSLSDKKGICVADPFEVTVMQDFFIDLRL PYSVVRNEQVEIRAVLYNYREAQSLKVRVELLHNPAFCSLATAKKRHTQTVTIGPKSSVA VPYVLVPLKIGLQEVEVKAAVYNYFISDGVKKTLKVVPEGMRVNKTVAIRTLNPEQLGQG GVQREEIPAADLSDQVPDTDSETKILLQGTPVAQMAEDAVDAERLKHLIITPSGCGEQNM IGMTPTVIAVHYLDQTEQWEKFGLEKRQEALNLINRGYTQQLAFKQPNWAYAAFKNRASS TWLTAYVVKVFSLAANLIGIDSEVLCGAVKWLILEKQKPDGVFQEDGPVIHQEMIGGVRT AQEADVSLTAFVLIALQEAKDICRAQVNNLEANINKAGDYIESRYADVRRPYTLAIAGYA LALLERLNGATLQKFLNAATEKNRWEEARQKLYSVEATSYALLALLLLKDFDAVPPVVRW LNEQRYYGRGYGSTQATFMVFQALAQYQTDVPDHKDLNMEVALQLPSRSSPSKFRLVWEA GSLLRSEATKQNEGFKLTAKGKGQGTLSVVAVYYAKTKRKVVCKNFDLRVTLKPAPDTVK KPQEAKSTMILGICTRYLGDQDATMSILDISMMTGFIPDTDDLKLLATGVDRYISKYEMN KDFSKNTLIIYLDKVSHSEEECLSFKIHQFFNVGLIQPGSVKVYSYYNLDETCTQFYHPE KEDGMLNKLCHKDLCRCAEENCFIQLPEKITLDERLEKACEPGVDYVYKTKLLKMELSDD FDEYIMTIEQVIKSGSDEVQAGKERRFISHIKCRDALHLKEGKHYLMWGLSSDLWGERPN MSYIIGKDTWVEAWPEAEECQDEENQQQCQDLGTFTENMVVFGCPN >Q01833; 22 COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]. MEGMALYLVAALLIGFPGSSHGALYTLITPAVLRTDTEEQILVEAHGDSTPKSLDIFVHD FPRKQKTLFQSRVDMNQAGSMFVTPTIKVPAKELNKDSKQNQYVVVKVTGPQVALEKVVL LSYQSGFVFIQTDKGIYTPGSPVRYRVFSVDHNMHRMDKTVIVEFQTPEGIVVSSKPVNP SGSIRPYNLPELVSFGTWKAVAKYEHSPEESYTAYFDVREYVLPSFEVRLQPSDKFLYID GNKNFHVSITARYLYGKKVEGVAFVVFGVKIDDAKKSIPDSLTRIPIIDGDGEATLKRDT LRSRFQDLNQLVGHTLYVSVTVITESGSDMVVTEQGGIHIVTSPYQIYFTKTPKYFKPGM PYELTVYVTNPDGSPAAHVPVVSEAIHSEGTTLSDGTAKLILNTPLNIQSLPITVRTNHG DLPRERQAIKSMTATAYQTQGGSENYLHVAITSTEIKPGDNLPVNFNVRGNANSLNQIKY FTYLILNKGKIFKVGRQPRRDGQNLVTMNLHITPDLIPSFRFVAYYQVGNNEIVADSVWV DVKDTCMGTLVVKGASSRDDRIQKPGAAMKIKLEGDPGARVGLVAVDKAVYVLNDKYKIS QAKIWDTIEKSDFGCTAGSGQNNLGVFEDAGLALTTSTNLNTKQRSAAKCPQPANRRRRS SVLLLDSKASKAAQFQDQGLRKCCEDGMHENPMGYTCEKRAKYIQEGDACKAAFLECCHY IKGIRDENQRESELFLARSDFEDELFGDDNIISRSDFPESWLWLTEELTGEPNNQGISSK TVPFYLRDSITTWELLAVGLSPTKGICVAEPYEITVMKDFFIDLRLPYSVVKNEQVEIRA ILYNYADEDIYVRVELIYNPAFCSASTEGQRYRQQFPIKALSSRAVPFVIVPLEQGLHDV EVIASVRGELASDGVRKKLKVVPEGERKNIVTIIELDPSVKGVGGTQELTVIANKLDDKV PDTEVETRISVLGDPVAQIIENSIDGSKLNHLIITPSGCGEQNMITMTPSVIATYYLDAT GQWENLGVDRRTEAIKQIMTGYAQQMVYKKADHSYAAFTNRASSSWLTAYVVKVLAMASN MVKDISHEIICGGVKWLILNRQQPDGVFKENAPVIHGEMLGGTKGAEPEASLTAFIVTAL LESRSVCKEQINILDSSINKATDYLLKKYEKLQRPYTTALTAYALAAADRLNDDRVLMAA STGRNRWEEYNARTHNIEGTSYALLALLKMKKFAEVGPVVRWLIDQKYYGGTYGQTQATV MVFQALAEYEIQMPTHQDLNLDISIKLPEREVPERYSINDRNAVQARTVETKLNEDFTVS ASGDGKATMTILTVYNAQLREDANVCNKFHLDVSVENVELNLKQAKGGKAALRLKICTRY LGEVDSTMTIIDISMLTGFFPDAEDLKRLSNGVDRYISKFEIDNNMAQKGTVVIYLDKVS HSEDECLHFKIHKHFEVGFIQPGSVKVYSYYNLDEQCTKFYHPDKETGLLNKICHGNICR CAEETCSLLNQQKKIDLQLRIQKACAQNVDYVYKTKLLRIEEKDGNDIYFMDVLEVIKGG TDRNAQAKARQYVSQRKCQEALNLKLDNDYLIWGLSSDLWPMKDDISYLITKNTWIERWP NEDECQDEEFQNLCDDFAQLSNTLTIFGCPT >P01029; 19 COMPLEMENT C4 PRECURSOR [CONTAINS: C4A ANAPHYLATOXIN]. MRLLWGLAWVFSFCASSLQKPRLLLFSPSVVNLGTPLSVGVQLLDAPPGQEVKGSVFLRN PKGGSCSPKKDFKLSSGDDFVLLSLEVPLEDVRSCGLFDLRRAPHIQLVAQSPWLRNTAF KATETQGVNLLFSSRRGHIFVQTDQPIYNPGQRVRYRVFALDQKMRPSTDFLTITVENSH GLRVLKKEIFTSTSIFQDAFTIPDISEPGTWKISARFSDGLESNRSTHFEVKKYVLPNFE VKITPWKPYILMVPSNSDEIQLDIQARYIYGKPVQGVAYTRFALMDEQGKRTFLRGLETQ AKLVEGRTHISISKDQFQAALDKINIGVRDLEGLRLYAATAVIESPGGEMEEAELTSWRF VSSAFSLDLSRTKRHLVPGAHFLLQALVQEMSGSEASNVPVKVSATLVSGSDSQVLDIQQ STNGIGQVSISFPIPPTVTELRLLVSAGSLYPAIARLTVQAPPSRGTGFLSIEPLDPRSP SVGDTFILNLQPVGIPAPTFSHYYYMIISRGQIMAMGREPRKTVTSVSVLVDHQLAPSFY FVAYFYHQGHPVANSLLINIQSRDCEGKLQLKVDGAKEYRNADMMKLRIQTDSKALVALG AVDTALYAVGGRSHKPLDMSKVFEVINSYNVGCGPGGGDDALQVFQDAGLAFSDGDRLTQ TREDLSCPKEKKSRQKRNVNFQKAVSEKLGQYSSPDAKRCCQDGMTKLPMKRTCEQRAAR VPQQACREPFLSCCKFAEDLRRNQTRSQAHLARNNHNMLQEEDLIDEDDILVRTSFPENW LWRVEPVDSSKLLTVWLPDSMTTWEIHGVSLSKSKGLCVAKPTRVRVFRKFHLHLRLPIS IRRFEQFELRPVLYNYLNDDVAVSVHVTPVEGLCLAGGGMMAQQVTVPAGSARPVAFSVV PTAAANVPLKVVARGVFDLGDAVSKILQIEKEGAIHREELVYNLDPLNNLGRTLEIPGSS DPNIVPDGDFSSLVRVTASEPLETMGSEGALSPGGVASLLRLPQGCAEQTMIYLAPTLTA SNYLDRTEQWSKLSPETKDHAVDLIQKGYMRIQQFRKNDGSFGAWLHRDSSTWLTAFVLK ILSLAQEQVGNSPEKLQETASWLLAQQLGDGSFHDPCPVIHRAMQGGLVGSDETVALTAF VVIALHHGLDVFQDDDAKQLKNRVEASITKANSFLGQKASAGLLGAHAAAITAYALTLTK ASEDLRNVAHNSLMAMAEETGEHLYWGLVLGSQDKVVLRPTAPRSPTEPVPQAPALWIET TAYALLHLLLREGKGKMADKAASWLTHQGSFHGAFRSTQDTVVTLDALSAYWIASHTTEE KALKVTLSSMGRNGLKTHGLHLNNHQVKGLEEELKFSLGSTISVKVEGNSKGTLKILRTY NVLDMKNTTCQDLQIEVKVTGAVEYAWDANEDYEDYYDMPAADDPSVPLQPVTPLQLFEG RRSRRRREAPKVAEEQESRVQYTVCIWRNGKLGLSGMAIADITLLSGFHALRADLEKLTS LSDRYVSHFETDGPHVLLYFDSVPTTRECVGFGASQEVVVGLVQPSSAVLYDYYSPDHKC SVFYAAPTKSQLLATLCSGDVCQCAEGKCPRLLRSLERRVEDKDGYRMRFACYYPRVEYG FTVKVLREDGRAAFRLFESKITQVLHFRKDTMASIGQTRNFLSRASCRLRLEPNKEYLIM GMDGETSDNKGDPQYLLDSNTWIEEMPSEQMCKSTRHRAACFQLKDFLMEFSSRGCQV >P13671; 21 COMPLEMENT COMPONENT C6 PRECURSOR. MARRSVLYFILLNALINKGQACFCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQENF CEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCIEKQSKVRSVLRPSQFGGQPCTEP LVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAVC TRKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVKSSRTSNPYRVPANLENVG FEVQTAEDDLKTDFYKDLTSLGHNENQQGSFSSQGGSSFSVPIFYSSKRSENINHNSAFK QAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDVFLKALNHLPLEYNSALYSRIFDD FGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFAKKTKVEHRC TTNKLSEKHEGSFIQGAEKSISLIRGGRSEYGAALAWEKGSSGLEEKTFSEWLESVKENP AVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGRPTLSGTECL CVCQSGTYGENCEKQSPDYKSNAVDGQWGCWSSWSTCDATYKRSRTRECNNPAPQRGGKR CEGEKRQEEDCTFSIMENNGQPCINDDEEMKEVDLPEIEADSGCPQPVPPENGFIRNEKQ LYLVGEDVEISCLTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQEVLTITPFQR LYRIGESIELTCPKGFVVAGPSRYTCQGNSWTPPISNSLTCEKDTLTKLKGHCQLGQKQS GSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQLHFLHIGSCQDG RQLEWGLERTRLSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQCFKGGNQLYCVKM GSSTSEKTLNICEVGTIRCANRKMEILHPGKCLA >P10643; 22 COMPLEMENT COMPONENT C7 PRECURSOR. MKVISLFILVGFIGEFQSFSSASSPVNCQWDFYAPWSECNGCTKTQTRRRSVAVYGQYGG QPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCDEDSADEDRCE DSERRPSCDIDKPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRKVFSGDGKDFYRLS GNVLSYTFQVKINNDFNYEFYNSTWSYVKHTSTEHTSSSRKRSFFRSSSSSSRSYTSHTN EIHKGKSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYSAYRRLIDQYG THYLQSGSLGGEYRVLFYVDSEKLKQNDFNSVEEKKCKSSGWHFVVKFSSHGCKELENAL KAASGTQNNVLRGEPFIRGGGAGFISGLSYLELDNPAGNKRRYSAWAESVTNLPQVIKQK LTPLYELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQNGGLATVEGTHCLCHCKPY TFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRECNNPPPSGGGRSCVGETT ESTQCEDEELEHLRLLEPHCFPLSLVPTEFCPSPPALKDGFVQDEGPMFPVGKNVVYTCN EGYSLIGNPVARCGEDLRWLVGEMHCQKIACVLPVLMDGIQSHPQKPFYTVGEKVTVSCS GGMSLEGPSAFLCGSSLKWSPEMKNARCVQKENPLTQAVPKCQRWEKLQNSRCVCKMPYE CGPSLDVCAQDERSKRILPLTVCKMHVLHCQGRNYTLTGRDSCTLPASAEKACGACPLWG KCDAESSKCVCREASECEEEGFSICVEVNGKEQTMSECEAGALRCRGQSISVTSIRPCAA ETQ >P48747; 21 COMPLEMENT COMPONENT C9 PRECURSOR. MAASHSFAFVVCVLEIGALTAGPTPSYVHEPIQRSDPLQPIDCRMSPWSEWSHCDPCLRQ MFRSRSIEVFGQFHGKSCVDALGDRRACIPTEACEDAEEDCEKDEFHCGTGRCIKRRLLC NGDNDCGDFSDEDDCETEPRLTCRNREVQESELARTAGYGINILGMDPLATPFDNEYYHG LCDRVWDGNTLTHYRKPWNVAVLAYETKIDKNFRTEYYEEQMQAFKSIIEEETSNFNANL ALKFTPTEAKASKAEEASPKNKSLDDNDKGFSSKFQFSYSKNETYQLFLSYSSQKEKMFL LVKGIIQLGRFVMKNRGVMLTNTFLDDIKSLPTTYEKGEYFAFLETYGTHYSSSGSLGGR YELIYVLDKASMKEKGIELNDIKKCLGFDLDLSLNIPGKSAGLSLTGQANKNNCLKSGHG NAVNITRANLIDDVISLIRGGTQKFAFELKEKLLTKAKMVDVTDFINWASSLSDAPVLIN QKLSPIYNLIPVKIKDAHQKRQNLERGIEDYINEFSTKKCSPCQNGGTALLMDGQCLCTC PFMFEGIACEISKRKLA >P03998; 20 COAGULOGEN PRECURSOR [CONTAINS: COAGULIN; PEPTIDE C]. MEKKLLGIAILFVTVVSVLAGDPNVPTCLCEEPTLLGRKVIVSQETKDKIEEAVQAITDK DEISGRGFSIFGGHPAFKECGKYECRTVTSEDSRCYNFFPFHHFPSECPVSVSACEPTFG YTTSNELRIIVQAPKAGFRQCVWQHKCRAYGSNFCQRTGRCTQQRSVVRLVTYDLEKGVF FCENVRTCCGCPCRS >Q90611; 26 72 KD TYPE IV COLLAGENASE PRECURSOR (EC 3.4.24.24) (72 K MKTHSVFGFFFKVLLIQVYLFNKTLAAPSPIIKFPGDSTPKTDKELAVQYLNKYYGCPKD NCNLFVLKDTLKKMQKFFGLPETGDLDQNTIETMKKPRCGNPDVANYNFFPRKPKWEKNH ITYRIIGYTPDLDPETVDDAFARAFKVWSDVTPLRFNRINDGEADIMINFGRWEHGDGYP FDGKDGLLAHAFAPGPGIGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFWFNGKE YNSCTDAGRNDGFLWCSTTKDFDADGKYGFCPHESLFTMGGNGDGQPCKFPFKFQGQSYD QCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFIFLGNKYDSC TSAGRNDGKLWCASTSSYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSEDPGALMAP IYTYTKNFRLSQDDIKGIQELYEVSPDVEPGPGPGPGPGPRPTLGPVTPELCKHDIVFDG VAQIRGEIFFFKDRFMWRTVNPRGKPTGPLLVATFWPDLPEKIDAVYESPQDEKAVFFAG NEYWVYTASNLDRGYPKKLTSLGLPPDVQRIDAAFNWGRNKKTYIFSGDRYWKYNEEKKK MELATPKFIADSWNGVPDNLDAVLGLTDSGYTYFFKDQYYLQMEDKSLKIVKIGKISSDW LGC >P09237; 17 MATRILYSIN PRECURSOR (EC 3.4.24.23) (PUMP-1 PROTEASE) (U MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLK EMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDL PHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAF APGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGD PQNFKLSQDDIKGIQKLYGKRSNSRKK >P22894; 20 NEUTROPHIL COLLAGENASE PRECURSOR (EC 3.4.24.34) (MATRIX MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIV EKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNY TPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGIL AHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYA FRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKD RYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQG YPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGI ESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG >P17084; 17 COLIPASE PRECURSOR. MKVLVVLLVTLVAVAYAVPGPRGLFINLEDGEICVNSMQCKSRCCQHDTILGIARCTHKA MENSECSPKTLYGIYYRCPCERGLTCEGDRSIIGAITNTNYGVCLDSTRSKQ >Q00945; 26 LYS-CONOPRESSIN G-NEUROPHYSIN PRECURSOR. MMSSLCGMPLTYLLTAAVLSLSLTDACFIRNCPKGGKRSLDTGMVTSRECMKCGPGGTGQ CVGPSICCGQDFGCHVGTAEAAVCQQENDSSTPCLVKGEACGSRDAGNCVADGICCDSES CAVNDRCRDLDGNAQANRGDLIQLIHKLLKVRDYD >Q12860; 20 CONTACTIN PRECURSOR (GLYCOPROTEIN GP135). MKMWLLVSHLVIISITTCLAEFTWYRRYGHGVSEEDKGFGPIFEEQPINTIYPEESLEGK VSLNCRARASPFPVYKWRMNNGDVDLTSDRYSMVGGNLVINNPDKQKDAGIYYCLASNNY GMVRSTEATLSFGYLDPFPPEERPEVRVKEGKGMVLLCDPPYHFPDDLSYRWLLNEFPVF ITMDKRRFVSQTNGNLYIANVEASDKGNYSCFVSSPSITKSVFSKFIPLIPIPERTTKPY PADIVVQFKDVYALMGQNVTLECFALGNPVPDIRWRKVLEPMPSTAEISTSGAVLKIFNI QLEDEGIYECEAENIRGKDKHQARIYVQAFPEWVEHINDTEVDIGSDLYWPCVATGKPIP TIRWLKNGYAYHKGELRLYDVTFENAGMYQCIAENTYGAIYANAELKILALAPTFEMNPM KKKILAAKGGRVIIECKPKAAPKPKFSWSKGTEWLVNSSRILIWEDGSLEINNITRNDGG IYTCFAENNRGKANSTGTLVITDPTRIILAPINADITVGENATMQCAASFDPALDLTFVW SFNGYVIDFNKENIHYQRNFMLDSNGELLIRNAQLKHAGRYTCTAQTIVDNSSASADLVV RGPPGPPGGLRIEDIRATSVALTWSRGSDNHSPISKYTIQTKTILSDDWKDAKTDPPIIE GNMEAARAVDLIPWMEYEFRVVATNTLGRGEPSIPSNRIKTDGAAPNVAPSDVGGGGGRN RELTITWAPLSREYHYGNNFGYIVAFKPFDGEEWKKVTVTNPDTGRYVHKDETMSPSTAF QVKVKAFNNKGDGPYSLVAVINSAQDAPSEAPTEVGVKVLSSSEISVHWEHVLEKIVESY QIRYWAAHDKEEAANRVQVTSQEYSARLENLLPDTQYFIEVGACNSAGCGPPSDMIEAFT KKAPPSQPPRIISSVRSGSRYIITWDHVVALSNESTVTGYKVLYRPDGQHDGKLYSTHKH SIEVPIPRDGEYVVEVRAHSDGGDGVVSQVKISGAPTLSPSLLGLLLPAFGILVYLEF >P22323; 24 CONTRAPSIN PRECURSOR (CP). MPSAISRGLLLLAGLCYLVFGIMAEDIQVAQVPSQHMPSHKVPRSLAHFAHSMHRVLTQQ SNTSNIFFSPVSIATALAMVSLGAKGDTHTQILRSLEFNLTEIAEADIHDGFQNLLHTLN RPHSEHQLTTGNGLFLDQNLKLKEKFSGDVKTLYHAEAFPTNFSNPKEAEKQINAYVEKG TQGKIVDLVKDLGADTVLALVNYIFFRGKWEKPFDVKHTTQEDFHVDANTTVKVPMMKQQ GMHKAFHCSTIQSWVLLLDYEGNVTALFLLPDEGKMQHLEETLTPELVFKFLRKTETMPA YVSLPKLSISGTYDLKEVLRDLGITNVFSGAADLSGITEDMPLKISKGLHKALLTIDEEG TEAAAATVLEATRTARPPRLSFNKPFFFLIIDHSTDTPLFVGKVMDPTKK >P00410; 15 CYTOCHROME C OXIDASE POLYPEPTIDE II PRECURSOR (EC 1.9.3. MLDLLRLQLTTFIMNDVPTPYACYFQDSATPNQEGILELHDNIMFYLLVILGLVSWMLYT IVMTYSKNPIAYKYIKHGQTIEVIWTIFPAVILLIIAFPSFILLYLCDEVISPAMTIKAI GYQWYWKYEYSDFINDSGETVEFESYVIPDELLEEGQLRLLDTDTSMVVPVDTHIRFVVT AADVIHDFAIPSLGIKVDATPGRLNQVSALIQREGVFYGACSELCGTGHANMPIKIEAVS LPKFLEWLNEQ >P05545; 28 CONTRAPSIN-LIKE PROTEASE INHIBITOR PRECURSOR (CPI-21) (K MAFIAALGLLMAGICPAVLCDGILGRDTLPHEDQGKGRQLHSLTLASINTDFTLSLYKKL ALRNPDKNVVFSPLSISAALAILSLGAKDSTMEEILEVLKFNLTEITEEEIHQGFGHLLQ RLSQPEDQAEINTGSALFIDKEQPILSEFQEKTRALYQAEAFVADFKQCNEAKKFINDYV SNQTQGKIAELFSELDERTSMVLVNYLLFKGKWKVPFNPNDTFESEFYLDEKRSVKVPMM KIKDLTTPYIRDEELSCSVLELKYTGNASALFILPDQGKMQQVESSLQPETLKKWKDSLR PRIISELRMPKFSISTDYNLEEVLPELGIRKIFSQQADLSRITGTKNLHVSQVVHKAVLD VDETGTEGAAATAVTAALKSLPQTIPLLNFNRPFMLVITDNNGQSVFFMGKVTNPM >P17927; 41 COMPLEMENT RECEPTOR TYPE 1 PRECURSOR (C3B/C4B RECEPTOR) MGASSPRSPEPVGPPAPGLPFCCGGSLLAVVVLLALPVAWGQCNAPEWLPFARPTNLTDE FEFPIGTYLNYECRPGYSGRPFSIICLKNSVWTGAKDRCRRKSCRNPPDPVNGMVHVIKG IQFGSQIKYSCTKGYRLIGSSSATCIISGDTVIWDNETPICDRIPCGLPPTITNGDFIST NRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTP PNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPP PDVLHAERTQRDKDNFSPGQEVFYSCEPGYDLRGAASMRCTPQGDWSPAAPTCEVKSCDD FMGQLLNGRVLFPVNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCEQIF CPSPPVIPNGRHTGKPLEVFPFGKAVNYTCDPHPDRGTSFDLIGESTIRCTSDPQGNGVW SSPAPRCGILGHCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNL VWSSPKDVCKRKSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGN AAHWSTKPPICQRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGE PSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGF VMKGPRRVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNFSPGQEVFYSCEPGY DLRGAASMRCTPQGDWSPAAPTCEVKSCDDFMGQLLNGRVLFPVNLQLGAKVDFVCDEGF QLKGSSASYCVLAGMESLWNSSVPVCEQIFCPSPPVIPNGRHTGKPLEVFPFGKAVNYTC DPHPDRGTSFDLIGESTIRCTSDPQGNGVWSSPAPRCGILGHCQAPDHFLFAKLKTQTNA SDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITD IQVGSRINYSCTTGHRLIGHSSAECILSGNTAHWSTKPPICQRIPCGLPPTIANGDFIST NRENFHYGSVVTYRCNLGSRGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTP PNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPP PEILHGEHTPSHQDNFSPGQEVFYSCEPGYDLRGAASLHCTPQGDWSPEAPRCAVKSCDD FLGQLPHGRVLFPLNLQLGAKVSFVCDEGFRLKGSSVSHCVLVGMRSLWNNSVPVCEHIF CPNPPAILNGRHTGTPSGDIPYGKEISYTCDPHPDRGMTFNLIGESTIRCTSDPHGNGVW SSPAPRCELSVRAGHCKTPEQFPFASPTIPINDFEFPVGTSLNYECRPGYFGKMFSISCL ENLVWSSVEDNCRRKSCGPPPEPFNGMVHINTDTQFGSTVNYSCNEGFRLIGSPSTTCLV SGNNVTWDKKAPICEIISCEPPPTISNGDFYSNNRTSFHNGTVVTYQCHTGPDGEQLFEL VGERSIYCTSKDDQVGVWSSPPPRCISTNKCTAPEVENAIRVPGNRSFFSLTEIIRFRCQ PGFVMVGSHTVQCQTNGRWGPKLPHCSRVCQPPPEILHGEHTLSHQDNFSPGQEVFYSCE PSYDLRGAASLHCTPQGDWSPEAPRCTVKSCDDFLGQLPHGRVLLPLNLQLGAKVSFVCD EGFRLKGRSASHCVLAGMKALWNSSVPVCEQIFCPNPPAILNGRHTGTPFGDIPYGKEIS YACDTHPDRGMTFNLIGESSIRCTSDPQGNGVWSSPAPRCELSVPAACPHPPKIQNGHYI GGHVSLYLPGMTISYTCDPGYLLVGKGFIFCTDQGIWSQLDHYCKEVNCSFPLFMNGISK ELEMKKVYHYGDYVTLKCEDGYTLEGSPWSQCQADDRWDPPLAKCTSRAHDALIVGTLSG TIFFILLIIFLSWIILKHRKGNNAHENPKEVAIHLHSQGGSSVHPRTLQTNEENSRVLP >P20023; 20 COMPLEMENT RECEPTOR TYPE 2 PRECURSOR (CR2) (COMPLEMENT C MGAAGLLGVFLALVAPGVLGISCGSPPPILNGRISYYSTPIAVGTVIRYSCSGTFRLIGE KSLLCITKDKVDGTWDKPAPKCEYFNKYSSCPEPIVPGGYKIRGSTPYRHGDSVTFACKT NFSMNGNKSVWCQANNMWGPTRLPTCVSVFPLECPALPMIHNGHHTSENVGSIAPGLSVT YSCESGYLLVGEKIINCLSSGKWSAVPPTCEEARCKSLGRFPNGKVKEPPILRVGVTANF FCDEGYRLQGPPSSRCVIAGQGVAWTKMPVCEEIFCPSPPPILNGRHIGNSLANVSYGSI VTYTCDPDPEEGVNFILIGESTLRCTVDSQKTGTWSGPAPRCELSTSAVQCPHPQILRGR MVSGQKDRYTYNDTVIFACMFGFTLKGSKQIRCNAQGTWEPSAPVCEKECQAPPNILNGQ KEDRHMVRFDPGTSIKYSCNPGYVLVGEESIQCTSEGVWTPPVPQCKVAACEATGRQLLT KPQHQFVRPDVNSSCGEGYKLSGSVYQECQGTIPWFMEIRLCKEITCPPPPVIYNGAHTG SSLEDFPYGTTVTYTCNPGPERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSLLAV QCSHVHIANGYKISGKEAPYFYNDTVTFKCYSGFTLKGSSQIRCKADNTWDPEIPVCEKE TCQHVRQSLQELPAGSRVELVNTSCQDGYQLTGHAYQMCQDAENGIWFKKIPLCKVIHCH PPPVIVNGKHTGMMAENFLYGNEVSYECDQGFYLLGEKKLQCRSDSKGHGSWSGPSPQCL RSPPVTRCPNPEVKHGYKLNKTHSAYSHNDIVYVDCNPGFIMNGSRVIRCHTDNTWVPGV PTCIKKAFIGCPPPPKTPNGNHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTW SQPAPHCKEVNCSSPADMDGIQKGLEPRKMYQYGAVVTLECEDGYMLEGSPQSQCQSDHQ WNPPLAVCRSRSLAPVLCGIAAGLILLTFLIVITLYVISKHRERNYYTDTSQKEAFHLEA REVYSVDPYNPAS >P10040; 90 CRUMBS PROTEIN PRECURSOR (95F). MAKIANASLSQQQKQRQAETATTTTTTVAASGRNSNNNSKKSRPHEKRHVKLRSHLLKRR PFQFIRRPQWIPLFILIYLATDVASVAVPTKEAYFNGSTYLRLTTPMPIWDHSAISFRSC RGGEILAQQYNKNSIVISVLNDFLQISLAGPAVHGPNNRLDVKLPYQLLDNRWHTLQFKY EYGNLYLHVDRAASIFANSTYNSQFLTNQDIGYKDAILILGNSFSGCLLDGPGLQFVNNS TVQNVVFGHCPLTPGPCSDHDLFTRLPDNFCLNDPCMGHGTCSSSPEGYECRCTARYSGK NCQKDNGSPCAKNPCENGGSCLENSEGNYQCFCDPNHSGQHCETEVNIHPLCQTNPCLNN GACVVIGGSGALTCECPKGYAGARCEVDTDECASQPCQNNGSCIDRINGFSCDCSGTGYT GAFCQTNVDECDKNPCLNGGRCLHTYGWYTCQCLDGWGGEICDRPMTCQTQQCFNGGTCL DKPIGFQCLCPPEYTGELCQIAPSCAQQCPIDSECVGGKCVCKPGSSGYNCQTSTGDGAS ALALTPINCNATNGKCLNGGTCSMNGTHCYCAVGYSGDRCEKAENCSPLNCQEPMVCVQN QCLCPENKVCNQCATQPCQNGGECVDLPNGDYECKCTRGWTGRTCGNDVDECTLHPKICG NGICKNEKGSYKCYCTPGFTGVHCDSDVDECLSFPCLNGATCHNKINAYECVCQPGYEGE NCEVDIDECGSNPCSNGSTCIDRINNFTCNCIPGMRGRICDIDIDDCVGDPCLNGGQCID QLGGFRCDCSGTGYEGENCELNIDECLSNPCTNGAKCLDRVKDYFCDCHNGYKGKNCEQD INECESNPCQYNGNCLERSNITLYQMSRITDLPKVFSQPFSFENASGYECVCVPGIIGKN CEININECDSNPCSKHGNCNDGIGTYTCECEPGFEGTHCEINIDECDRYNPCQRGTCYDQ IDDYDCDCDANYGGKNCSVLLKGCDQNPCLNGGACLPYLINEVTHLYTCTCENGFQGDKC EKTTTLSMVATSLISVTTEREEGYDINLQFRTTLPNGVLAFGTTGEKNEPVSYILELING RLNLHSSLLNKWEGVFIGSKLNDSNWHKVFVAINTSHLVLSANDEQAIFPVGSYETANNS QPSFPRTYLGGTIPNLKSYLRHLTHQPSAFVGCMQDIMVNGKWIFPDEQDANISYTKLEN VQSGCPRTEQCKPNPCHSNVECTDLWHTFACHCPRPFFGHTCQHNMTAATFGHENTTHSA VIVETTDVARRAIRSILDISMFIRTREPTGQVFYLGTDPRKAPTKNIGDSYVAAKLHGGE LLVKMQFSGTPEAYTVGGQKLDNGYNHLIEVVRNQTLVQVKLNGTEYFRKTLSTTGLLDA QLLYLGGPAPTRESLLGATTEPGIIPVPGAGIPIEDTTVPKEADDSRDYFKGIIQDVKVS NGSLNLIVEMYSLNVTDVQVNAKPLGAVTIDRASVLPGEVSDDLCRKNACLHNAECRNTW NDYTCKCPNGYKGKKCARRSEFCQHVTCPGQSLCQNLDDGYECVTNTTFTGQERSPLAFF YFQEQQSDDIVSEASPKQTLKPVIDIAFRLVLEVLCLYIDNVDGFFEIGVNGGRVTITWK LSALHFGESARFEKENTDGEWSRIYLRAHNSKLEGGWKGWESMVDPTPAFSTDIDQAAFQ SLIATSTQVYLGGMPESRQARGSTLSAQQGSQFKGCVGEARLGDLLLPYFSMAELYSRTN VSVQQKAQFRLNATRPEEGCILCFQSDCKNDGFCQSPSDEYACTCQPGFEGDDCGTDIDE CLNTECLNNGTCINQVAAFFCQCQPGFEGQHCEQNIDECADQPCHNGGNCTDLIASYVCD CPEDYMGPQCDVLKQMTCENEPCRNGSTCQNGFNASTGNNFTCTCVPGFEGPLCDIPFCE ITPCDNGGLCLTTGAVPMCKCSLGYTGRLCEQDINECESNPCQNGGQCKDLVGRYECDCR ARIRGIRCENDIDECNMEGDYCGGLGRCFNKPGSFQCICQKPYCGAYCNFTDPCNATDLC LNGGRCVESCGAKPDYYCECPEGFAGKNCTAPITAKEDGPSTTDIAIIVIPVVVVLLLIA GALLGTFLVMARNKRATRGTYSPSVVKSTATHGWKWTTY >P25308; 24 CORTICOLIBERIN 2 PRECURSOR (CORTICOTROPIN-RELEASING FACT MRLNFLVTTMALLVAFPPPYECRAIDSSSNQPVTDPDEERQSPAVLARMGEEYFIRLGNR NKNSPRSPPDTYPEASQYSKRALQLQLTQRVLEGKVGNVGRWDGNYALRALDSEERERRS EEPPISLDLTFHLLREVLEMARAEQLVQQAHSNRKMMEIFGK >P24387; 24 CORTICOTROPIN-RELEASING FACTOR BINDING PROTEIN PRECURSOR MSPNFKLQCHFILIFLTALRGESRYLELREAADYDPFLLFSANLKRELAGEQPYRRALRC LDMLSLQGQFTFTADRPQLHCAAFFISEPEEFITIHYDQVSIDCQGGDFLKVFDGWILKG EKFPSSQDHPLPSAERYIDFCESGLSRRSIRSSQNVAMIFFRVHEPGNGFTLTIKTDPNL FPCNVISQTPNGKFTLVVPHQHRNCSFSIIYPVVIKISDLTLGHVNGLQLKKSSAGCEGI GDFVELLGGTGLDPSKMTPLADLCYPFHGPAQMKVGCDNTVVRMVSSGKHVNRVTFEYRQ LEPYELENPNGNSIGEFCLSGL >P06205; 24 C-REACTIVE PROTEIN 1.1 PRECURSOR. MKTFHGPTCGTAVSLCLLLFLTSALEEGEITSKVKFPPSSSPSFPRLVMVGTLPDLQEIT LCYWFKVNRLKGTLHMFSYATAKKDNELLTLIDEQGDFLFNVHGAPQLKVQCPNKIHIGK WHHVCHTWSSWEGEATIAVDGFHCKGNATGIAVGRTLSQGGLVVLGQDQDSVGGKFDATQ SLEGELSELNLWNTVLNHEQIKYLSKCAHPSERHIYGNIIQWDKTQFKAYDGVVLSPNEI CA >P02741; 18 C-REACTIVE PROTEIN PRECURSOR. MEKLLCFLVLTSLSHAFGQTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTE LSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWES ASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMW DFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWP >Q07203; 16 C-REACTIVE PROTEIN PRECURSOR (CRP). MERFALWFIFLAGSLAQEDLVGNVFLFPKPSVTTYAILKPEVEKPLKNLTVCLRSYTTLT RFHSLLSLATSNPLQDNAFLLFSKPPNQCSIYINQEENVFKVDPTAVEWKHTCVSWDSVS GVVELWIDGKLYPRTVSKKASSIGFPSSIIQGQEQDSFGGGFNIDQSFVGEISDVHMWDY VLTPDHIQKVLFANMDFNGNIISWRSLQYELRGQATTQPKRQCKTLEHHYGLFAKCYK >P79845; 21 CYSTEINE-RICH VENOM PROTEIN PRECURSOR (CRVP). MEWYPEAAANAERWAYRCIESHSSRDSRVIGGIKCGENIYMSPYPAKWTDIIHAWHGEYK DFKYGVGAVPSNAATGHYTQIVWYKSYRGGCAAAYCPSSKYRYFYVCQYCPAGNMIGKTA TPYTSGPPCGDCPSDCDNGLCTNPCTQENTYSNCNSLVQQSSCQDNNMKTKCPASCFCQN KII >P08796; 19 CONTACT SITE A PROTEIN PRECURSOR (CSA) (MEMBRANE-ASSOCIA MKFLLVLIILYNILNSAHSAPTITAVSNGKFGVPTYITITGTGFTGTPVVTIGGQTCDPV IVANTASLQCQFSAQLAPGNSNFDVIVKVGGVPSTGGNGLFKYTPPTLSTIFPNNGRIGM ILVDGPSNISGYKLNVNDSINSAMLSVTADSVSPTIYFLVPNTIAGGLLNLELIQPFGFS TIVTSKSVFSPTITSITPLAFDLTPTNVTVTGKYFVTTASVTMGSHIYTGLTVQDDGTNC HVIFTTRSVYESSNTITAKASTGVDMIYLDNQGNQQPITFTYNPPTITSTKQVNDSVEIS TTNTGTDFTQISLTMGTSSPTNLVITGTNEKIVITLPHALPEGEIQFNLKAGISNVVTST LLVTPVINSVTQAPHNGGSITISGIFLNNAHVSIVVDQNTTDIVCAPDSNGESIICPVEA GSGTINLVVTNYKNFASDPTIKTEATTSTTYTIPDTPTPTDTATPSPTPTETATPSPTPK PTSTPEETEAPSSATTLISPLSLIVIFISFVLLI >P09603; 32 MACROPHAGE COLONY STIMULATING FACTOR-1 PRECURSOR (CSF-1) MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQME TSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLK SCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSS QDVVTKPDCNCLYPKAIPSSDPASVSPHQPLAPSMAPVAGLTWEDSEGTEGSSLLPGEQP LHTVDPGSAKQRPPRSTCQSFEPPETPVVKDSTIGGSPQPRPSVGAFNPGMEDILDSAMG TNWVPEEASGEASEIPVPQGTELSPSRPGGGSMQTEPARPSNFLSASSPLPASAKGQQPA DVTGTALPRVGPVRPTGQDWNHTPQKTDHPSALLRDPPEPGSPRISSLRPQGLSNPSTLS AQPQLSRSHSSGSVLPLGELEGRRSTRDRRSPAEPEGGPASEGAARPLPRFNSVPLTDTG HERQSEGSSSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEG SPLTQDDRQVELPV >P01587; 17 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR PRECURS MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALNLLDDMPVTLNEEVEVVSNE FSFKKLTCVQTRLKIFEQGLRGNFTKLKGALNMTASYYQTYCPPTPETDCETQVTTYADF IDSLKTFLTDIPFECKKPGQK >P09920; 30 GRANULOCYTE COLONY-STIMULATING FACTOR PRECURSOR (G-CSF). MAQLSAQRRMKLMALQLLLWQSALWSGREAVPLVTVSALPPSLPLPRSFLLKSLEQVRKI QASGSVLLEQLCATYKLCHPEELVLLGHSLGIPKASLSGCSSQALQQTQCLSQLHSGLCL YQGLLQALSGISPALAPTLDLLQLDVANFATTIWQQMENLGVAPTVQPTQSAMPAFTSAF QRRAGGVLAISYLQGFLETARLALHHLA >P08307; 16 CIRCUMSPOROZOITE PROTEIN PRECURSOR (CS). MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE NWYSLKKNSRSLGENDDGDNDNGNNNNGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKH KKLKQPGDGNPDPNANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNAN PNANPNANPNANPNANPNANPNANPNANPNVDPNANPNANPNANPNANPNANPNANPNAN PNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNAN PNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKH IEQYLKKIQNSLSTEWSPCSVTCGNGIQVRIKPGSADKPKDQLDYENDIEKKICKMEKCS SVFNVVNSSIGLIMVLSFLFLN >P06914; 19 CIRCUMSPOROZOITE PROTEIN PRECURSOR (CS). MKKCTILVVASLLLVDSLLPGYGQNKSVQAQRNLNELCYNEENDNKLYHVLNSKNGKIYN RNIVNRLLGDALNGKPEEKKDDPPKDGNKDDLPKEEKKDDLPKEEKKDDPPKDPKKDDPP KEAQNKLNQPVVADENVDQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAP QGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQEPPQQPPQQPP QQPPQQPPQQPPQQPPQQPRPQPDGNNNNNNNNGNNNEDSYVPSAEQILEFVKQISSQLT EEWSQCSVTCGSGVRVRKRKNVNKQPENLTLEDIDTEICKMDKCSSIFNIVSNSLGFVIL LVLVFFN >P47796; 18 CHYMOTRYPSIN A PRECURSOR (EC 3.4.21.1). MGHEVDSVLPGLFRRTYGCGRPAISPVITGYSRIVNGEEAVPHSWSWQVSLQDQTGFHFC GGSLINENWVVTAAHCNVKNYHRVVLGEHDRSSNSEGVQVMTVGQVFKHPRYNGFTINND ILLVKLATPATLNMRVSPVCLAETDDVFEGGMKCVTSGWGLTRYNAADTPALLQQAALPL LTNEQCKKFWGNKISDLMICAGAAGASSCMGDSGGPLVCQKAGSWTLVGIVSWGSGTCTP TMPGVYARVTELRAWVDQTIAAN >P07338; 18 CHYMOTRYPSINOGEN B PRECURSOR (EC 3.4.21.1). MAFLWLVSCFALVGATFGCGVPTIQPVLTGLSRIVNGEDAIPGSWPWQVSLQDKTGFHFC GGSLISEDWVVTAAHCGVKTSDVVVAGEFDQGSDEENIQVLKIAQVFKNPKFNMFTVRND ITLLKLATPAQFSETVSAVCLPNVDDDFPPGTVCATTGWGKTKYNALKTPEKLQQAALPI VSEADCKKSWGSKITDVMTCAGASGVSSCMGDSGGPLVCQKDGVWTLAGIVSWGSGVCST STPAVYSRVTALMPWVQQILEAN >Q08738; 16 LARVAL CUTICLE PROTEIN LCP-30 PRECURSOR. MRVFLAICLSLTVALAAETGKYTPFQYNRVYSTVSPFVYKPGRYVADPGRYDPSRDNSGR YIPDNSGAYNGDRGDRGAAGGFYTGSGTAGGPGGAYVGTKEDLSKYLGDAYKGSSIVPLP VVKPTIPVPVTPTYVASKVVPPSGAGYDYKYGIIRYDNDVAPEATTTCTRPRTRFSLKKP ARSRTLAPKTKASRSRDSTNTLAPTVSPTE >P45590; 17 LARVAL/PUPAL RIGID CUTICLE PROTEIN 66 PRECURSOR (HCCP66) MLVKFVACFVFVAVASASDFSSFSYGVADPSTGDFKSQIESRLGDNVQGQYSLLESDGTQ RTVDYAAGSEGFNAVVRKDPALIAAAPYITAPYGYAVPYAYTSPYGISNLANYRALKFAS ALPYSRVFF >P80686; 16 LARVAL/PUPAL CUTICLE PROTEIN H1C PRECURSOR (TM-H1C) (TM- MYKFVVFAAALAYANAGLIGAPAVAAYSAAPAVSSAYIHQAAPVAVAHAAPLAVAHAPVA VAHAAPYAIHAPAVGASHQSVVRSLGGNQAVSHYSKAVDSAFSSVRKFDTRVTNDALAVA HAPVVSTYAHAAPVVSTYAHAAPVVSSYAAHAPVAAYAAHAPVATYAAHAPVATYAAHAP VVATRTSAVAYSPAAVVSHASFSGLGASYAW >P00590; 16 CUTINASE PRECURSOR (EC 3.1.1.-). MKFFALTTLLAATASALPTSNPAQELEARQLGRTTRDDLINGNSASCRDVIFIYARGSTE TGNLGTLGPSIASNLESAFGKDGVWIQGVGGAYRATLGDNALPRGTSSAAIREMLGLFQQ ANTKCPDATLIAGGYSQGAALAAASIEDLDSAIRDKIAGTVLFGYTKNLQNRGRIPNYPA DRTKVFCNTGDLVCTGSLIVAAPHLAYGPDARGPAPEFLIEKVRAVRGSA >P43497; 20 CELL WALL PROTEIN CWP2 PRECURSOR (LOW PH RESISTANCE PROT MQFSTVASVAFVALANFVAAESAAAISQITDGQIQATTTATTEATTTAAPSSTVETVSPS STETISQQTENGAAKAAVGMGAGALAAAAMLL >P80311; 25 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE B PRECURSOR (EC 5.2. MKILFVAALVVGSVFFLLLPGPSAADEKKKGPKVTVKVYFDLRIGDEDIGRVVIGLFGKT VPKTVDNFVALATGEKGFGYKDSKFHRVIKDFMIQGGDFTRGDGTGGKSIYGERFPDENF KLKHYGPGWVSMANAGKDTNGSQFFITTVKTAWLDGKHVGFGKVLEGMDVVRKVESTKTD GRDKPLKDVTIADCGKIEVEKPFAIAKE >P19313; 27 CYSTATIN S PRECURSOR (LM PROTEIN). MAYLLHAQLFLLTTFILVLNMRLCPVLGHFLGGIEKSSMEEEGASEALNYAVNEYNEKNS DLYLSRVVEVKDVQKQVVAGTKFFFDVILGKTICLKTQGDLTNCPLNEEADQQEHEFCSF VVHDIPWENYIVLLSSSCHSI >Q98967; 19 CYSTATIN PRECURSOR. MEWKIVVPLLAVAFTVANAGLVGGPMDANMNDQGTRDALQFAVVEHNKKTNDMFVRQVAK VVNAQKQVVSGMKYIFTVQMGRTPCRKGGVEKICSVHKDPQMAVPYKCTFEVWSRPWMSD IQMVKNQCES >P18169; 23 DEFECTIVE CHORION-1 FC125 PROTEIN PRECURSOR. MRLFSLLPLLALLVVQVAGQSEVTSDDPATDAGSTTNSTTDTKPRIPSQDEILGQMPSIN PIRTGNPQMDAFYMMFPALGSLLKWGSLFPAYSILGAIPDNLQPTAAASKVVLVLADDAT AKTRVARQNPPPNPLGQLMNWPALPQDFQLPSMDLGPQVGSFLAQLPAMPTVPGLLGAAA PVPAPAPAPAAAPPPAPAPAADPPAAPVPDAPQPAILGEAALQNAFTFFNPANFDASSLL GQSVPTFAPPNLDFVAQMQRQFFPGMTPAQPAAAGTDAQASDISEVRVRPEDPYSQEAQM KIKSALEMEQERQQQAQVKDQEQVPLLWFRMPTTQNQDATEEKTLEHLRVEAKLRAFERQ VIAELRMLQKIELMAKQMRSSTAAQNGDSPYRISYPLSRTPIHKITRADIEQALRDDYVR RLVNKEAQRRARNSGINTQKANALKRQAKSQDQTLSKEDIVQIMAYAYRMANEQMESEKG KQDKVYAAYRTEQNPMMMQQRQWSEEQAKIQQNQQQIQQNPMMMQQRQWSEEQAKIQQNQ QQIQQNPMMMQQRQWSEEQAKIQQNQQQIQQNPMMMQQRQWSEEQAKIQQNQQQIQQNPM MVQQRQWSEEQAKIQQNQQQIQQNPMMMQQRQWSEEQAKIQHDQQMAQQMAQQGLMMTEQ RQRQWSEDQAKIQQAQQMAQQTPMMMPQMQQRQWTEDPQMVQQMQQRQWAEDQTRMQMAQ QNPMMQQQRQMAENPQMMQQRQWSEEQTKIEQAQQMAQQNQMMMQQMQQRQWSEDQAQIQ QQQRQMMQQTPMMMKERQWAEENPQSVQQQGPMMMQQQMPSMMQREVEDEDNKAEDDLVG EAGPQMAGERRHRQAQSRCPGSWRQQAQEVQVQVGAATVINYYYAAPSVRWFRVTEQATA EGGYGSNAYGVPRPVNSYQSQGYRAAVGNDEVDEMLRQHQTMARTINPKQPGEVGGSESQ KSNSNPPTTLTPAPQEQPQEHRVHKSPSSAPSETEIENAPSSDPQVGSIFTYGEGLLHPF MGLLPVERPDDPWNQKPYDPHHPLYTGGGSYDAYLRDGRHRRDTHIMGQGTQHGILTPGM LERLLRIKMDFQRRFPPFIQGYAESPYESYPCRGTASGSGQDF >P11479; 19 NEUTROPHIL DEFENSINS 1, 2 AND 3 PRECURSOR (HNP) (DEFENSI MRTLAILAAILLVALQAQAEPLQARADEVAAAPEQIAADIPEVVVSLAWDESLAPKHPGS RKNMACYCRIPACIAGERRYGTCIYQGRLWAFCC >P49278; 17 MITE ALLERGEN DER P 2 PRECURSOR (DER P II) (DPX). MMYKILCLSLLVAAVARDQVDVKDCANHEIKKVLVPGCHGSEPCIIHRGKPFQLEAVFEA NQNTKTAKIEIKASIDGLEVDVPGIDPNACHYMKCPLVKGQQYDIKYTWNVPKIAPKSEN VVVTVKVMGDDGVLACAIATHAKIRD >P18173; 42 GLUCOSE DEHYDROGENASE [ACCEPTOR] PRECURSOR (EC 1.1.99.10 MSASASACDCLVGVPTGPTLASTCGGSAFMLFMGLLEVFIRSQCDLEDPCGRASSRFRSE PDYEYDFIVIGGGSAGSVVASRLSEVPQWKVLLIEAGGDEPVGAQIPSMFLNFIGSDIDY RYNTEPEPMACLSSMEQRCYWPRGKVLGGTSVLNGMMYVRGNREDYDDWAADGNPGWAYN DVLPFFKKSEDNLDLDEVGTEYHAKGGLLPVGKFPYNPPLSYAILKAGEELGFSVHDLNG QNSTGFMIAQMTARNGIRYSSARAFLRPARMRNNLHILLNTTATKILIHPHTKNVLGVEV SDQFGSTRKILVKKEVVLSAGAVNSPHILLLSGVGPKDELQQVNVRTVHNLPGVGKNLHN HVTYFTNFFIDDADTAPLNWATAMEYLLFRDGLMSGTGISDVTAKLATRYADSPERPDLQ LYFGGYLASCARTGQVGELLSNNSRSIQIFPAVLNPRSRGFIGLRSADPLEPPRIVANYL THERDVKTLVEGIKFVIRLSQTTPLKQYGMRLDKTVVKGCEAHAFGSDAYWECAVRQNTG PENHQAGSCKMGPSHDPMAVVNHELRVHGIRGLRVMDTSIMPKVSSGNTHAPAVMIAEKG AYLLKRAWGAKV >P15101; 32 DOPAMINE-BETA-MONOOXYGENASE PRECURSOR (EC 1.14.17.1) (DO MQVPSPSVREAASMYGTAVAVFLVILVAALQGSAPAESPFPFHIPLDPEGTLELSWNISY AQETIYFQLLVRELKAGVLFGMSDRGELENADLVVLWTDRDGAYFGDAWSDQKGQVHLDS QQDYQLLRAQRTPEGLYLLFKRPFGTCDPNDYLIEDGTVHLVYGFLEEPLRSLESINTSG LHTGLQRVQLLKPSIPKPALPADTCTMEIRAPDVLIPGQQTTYWCYVTELPDGFPRHHIV MYEPIVTEGNEALVHHMEVFQCAAEFRDHPHFSGPCDSKMKPQRLNFCRHVLAAWALGAK AFYYPEEAGLAFGGPGSSRFLRLEVHYHNPLVITGRRDSSGIRLYYTAALRRFDAGIMEL GLAYTPVMAIPPQETAFVLTGYCTDKCTQLALPASGIHIFASQLHTHLTGRKVVTVLARD GRETEIVNRDNHYSPHFQEIRMLKKVVSVQPGDVLITSCTYNTEDRRLATVGGFGILEEM CVNYVHYYPQTQLELCKSAVDPGFLHKYFRLVNRFNSEEVCTCPQASVPEQFASVPWNSF NREVLKALYGFAPISMHCNRSSAVRFQGEWNRQPLPEIVSRLEEPTPQCPASQAQSPAGP TVLNISGGKG >O18998; 21 DEOXYRIBONUCLEASE I PRECURSOR (EC 3.1.21.1) (DNASE I). MRSEMLTALLTLAVLLQVAGSLKIAAFNIRSFGETKMSNATLTSYIVRILQRYDIALIQE VRDSHLTAVGKLLDKLNEKAADTYRFVASEPLGRRTYKERYLFVYRPDQVSVLDSYYYDD GCEPCGTDTFSREPAVVRFSSPSTKVREFAIVPLHSAPEDAVAEIDALYDVYLDVQKKWG LQDVMLMGDFNADYSYVTSSQWSSIRLRTNPAFKWLIPDTADTTATSTNCAYDRIVVAGP LLQDAVVPNSAAPFNFQAAYGLSNQLAQAISDHYPVEVTLA >P11919; 26 ECLOSION HORMONE PRECURSOR (ECDYSIS ACTIVATOR) (EH). MAGKVTVAFFMFAMIAFLANFGYVECNPAIATGYDPMEICIENCAQCKKMLGAWFEGPLC AESCIKFKGKLIPECEDFASIAPFLNKL >Q61508; 19 EXTRACELLULAR MATRIX PROTEIN 1 PRECURSOR (SECRETORY COMP MGTVSRAALILACLALASAASEGAFKASDQREMTPERLFQHLHEVGYAAPPSLPQTRRLR VDHSVTSLHDPPLFEEQREVQPPSSPEDIPVYEEDWPTFLNPNVDKAGPAVPQEAIPLQK EQPPPQVHIEQKEIDPPAQPQEEIVQKEVKPHTLAGQLPPEPRTWNPARHCQQGRRGVWG HRLDGFPPGRPSPDNLKQICLPERQHVIYGPWNLPQTGYSHLSRQGETLNVLETGYSRCC PCRSDTNRLDCLKLVWEDAMTQFCEAEFSVKTRPHLCCRLRGEERFSCFQKEAPRPDYLL RPCPVHQNGMSSGPQLPFPPGLPTPDNVKNICLLRRFRAVPRNLPATDAIQRQLQALTRL ETEFQRCCRQGHNHTCTWKAWEGTLDGYCERELAIKTHPHSCCHYPPSPARDECFAHLAP YPNYDRDILTLDLSRVTPNLMGQLCGSGRVLSKHKQIPGLIQNMTVRCCELPYPEQACCG EEEKLAFIENLCGPRRNSWKDPALCCDLSPEDKQINCFNTNYLRNVALVAGDTGNATGLG EQGPTRGTDANPAPGSKEE >P13387; 30 EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112 MGVRSPLSASGPRGAAVLVLLLLGVALCSAVEEKKVCQGTNNKLTQLGHVEDHFTSLQRM YNNCEVVLSNLEITYVEHNRDLTFLKTIQEVAGYVLIALNMVDVIPLENLQIIRGNVLYD NSFALAVLSNYHMNKTQGLRELPMKRLSEILNGGVKISNNPKLCNMDTVLWNDIIDTSRK PLTVLDFASNLSSCPKCHPNCTEDHCWGAGEQNCQTLTKVICAQQCSGRCRGKVPSDCCH NQCAAGCTGPRESDCLACRKFRDDATCKDTCPPLVLYNPTTYQMDVNPEGKYSFGATCVR ECPHNYVVTDHGSCVRSCNTDTYEVEENGVRKCKKCDGLCSKVCNGIGIGELKGILSINA TNIDSFKNCTKINGDVSILPVAFLGDAFTKTLPLDPKKLDVFRTVKEISGFLLIQAWPDN ATDLYAFENLEIIRGRTKQHGQYSLAVVNLKIQSLGLRSLKEISDGDIAIMKNKNLCYAD TMNWRSLFATQSQKTKIIQNRNKNDCTADRHVCDPLCSDVGCWGPGPFHCFSCRFFSRQK ECVKQCNILQGEPREFERDSKCLPCHSECLVQNSTAYNTTCSGPGPDHCMKCAHFIDGPH CVKACPAGVLGENDTLVWKYADANAVCQLCHPNCTRGCKGPGLEGCPNGSKTPSIAAGVV GGLLCLVVVGLGIGLYLRRRHIVRKRTLRRLLQERELVEPLTP >P00533; 24 EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112 MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV APQSSEFIGA >P12796; 18 EGGSHELL PROTEIN PRECURSOR (CHORION PROTEIN). MKQSLTLVFLVAIGYATAHTTSHDYSGGYGGGCYGSDCDSGYGDSGYGGGCTGGDCGGGY GGGYGGGCSGGDCGNYGGGYGGDCNGGDCGNYGGGYGGGNGGGCSGGNCGGGFDEAFPAP YGGDYGNGGNGFGKGGSKGNNYGKGYGGGSGKGKGGGKGGKGGKGGTYKPSHYGGGY >P07915; 17 PUTATIVE EGGSHELL PROTEIN PRECURSOR. MKFHLVLLLAIVPLTLARHPHGKFNRHASYDDREKHRGYRKENDYLNYDLKGKFSRTRQA YLHGSFDKYGNENERGRYDDQGKYSLAGKSAHDGKYGMYGNMYAKGDFKAYGNEDEGAKF EEVTTFRRGGGYDSYGKKKSYDDYDTKGHLKKFANKGRQSKFDMYGNVKADGQAISNGNM NATVCLTPMANTISMAK >P17813; 25 ENDOGLIN PRECURSOR (CD105 ANTIGEN). MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNA ILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAY NSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLS FCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVEL SCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLL GEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQ TKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASM ISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVS PSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVP IPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAF LIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA >P00772; 16 ELASTASE 1 PRECURSOR (EC 3.4.21.36). MLRLLVVASLVLYGHSTQDFPETNARVVGGTEAQRNSWPSQISLQYRSGSSWAHTCGGTL IRQNWVMTAAHCVDRELTFRVVVGEHNLNQNDGTEQYVGVQKIVVHPYWNTDDVAAGYDI ALLRLAQSVTLNSYVQLGVLPRAGTILANNSPCYITGWGLTRTNGQLAQTLQQAYLPTVD YAICSSSSYWGSTVKNSMVCAGGDGVRSGCQGDSGGPLHCLVNGQYAVHGVTSFVSRLGC NVTRKPTVFTRVSAYISWINNVIASN >P05208; 16 ELASTASE 2 PRECURSOR (EC 3.4.21.71). MIRTLLLSALVAGALSCGYPTYEVEDDVSRVVGGQEATPNTWPWQVSLQVLSSGRWRHNC GGSLVANNWVLTAAHCLSNYQTYRVLLGAHSLSNPGAGSAAVQVSKLVVHQRWNSQNVGN GYDIALIKLASPVTLSKNIQTACLPPAGTILPRNYVCYVTGWGLLQTNGNSPDTLRQGRL LVVDYATCSSASWWGSSVKSSMVCAGGDGVTSSCNGDSGGPLNCRASNGQWQVHGIVSFG SSLGCNYPRKPSVFTRVSNYIDWINSVMARN >P41801; 20 ELICITIN PRECURSOR. MNFRALFAATVAALVGSTSATTCTTTQQTAAYVALVSILSDTSFNQCSTDSGYSMLTATS LPTTEQYKLMCASTACKTMINKIVTLNPPDCELTVPTSGLVLNVFTYANGFSSTCASL >P04985; 26 ELASTINS A/B/C PRECURSOR (TROPOELASTIN). MRSLTAAARRPEVLLLLLCILQPSQPGGVPGAVPGGVPGGVFFPGAGLGGLGVGGLGPGV KPAKPGVGGLVGPGLGAEGSALPGAFPGGFFGAGGGAAGAAAAYKAAAKAGAAGLGVGGI GGVGGLGVSTGAVVPQLGAGVGAGVKPGKVPGVGLPGVYPGGVLPGAGARFPGIGVLPGV PTGAGVKPKAQVGAGAFAGIPGVGPFGGQQPGLPLGYPIKAPKLPAGYGLPYKTGKLPYG FGPGGVAGSAGKAGYPTGTGVGPQAAAAAAKAAAKLGAGGAGVLPGVGVGGPGIPGAPGA IPGIGGIAGVGAPDAAAAAAAAAKAAKFGAAGGLPGVGVPGVGVPGVGVPGVGVPGVGVP GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGALSPAATAKAAAKAAKFGARGAVGIGGIP TFGLGPGGFPGIGDAAAAPAAAAAKAAKIGAGGVGALGGVVPGAPGAIPGLPGVGGVPGV GIPAAAAAKAAAKAAQFGLGPGVGVAPGVGVVPGVGVVPGVGVAPGIGLGPGGVIGAGVP AAAKSAAKAAAKAQFRAAAGLPAGVPGLGVGAGVPGLGVGAGVPGLGVGAGVPGPGAVPG TLAAAKAAKFGPGGVGALGGVGDLGGAGIPGGVAGVVPAAAAAAKAAAKAAQFGLGGVGG LGVGGLGAVPGAVGLGGVSPAAAAKAAKFGAAGLGGVLGAGQPFPIGGGAGGLGVGGKPP KPFGGALGALGFPGGACLGKSCGRKRK >P04552; 18 EGG-LYSIN PRECURSOR (SPERM-LYSIN). MKLLVLCIFAMMATLAMSRSWHYVEPKFLNKAFEVALKVQIIAGFDRGLVKWLRVHGRTL STVQKKALYFVNRRYMQTHWANYMLWINKKIDALGRTPVVGDYTRLGAEIGRRIDMAYFY DFLKDKNMIPKYLPYMEEINRMRPADVPVKYMGK >P32803; 20 ENDOSOMAL P24B PROTEIN PRECURSOR (24 KD ENDOMEMBRANE PRO MASFATKFVIACFLFFSASAHNVLLPAYGRRCFFEDLSKGDELSISFQFGDRNPQSSSQL TGDFIIYGPERHEVLKTVRDTSHGEITLSAPYKGHFQYCFLNENTGIETKDVTFNIHGVV YVDLDDPNTNTLDSAVRKLSKLTREVKDEQSYIVIRERTHRNTAESTNDRVKWWSIFQLG VVIANSLFQIYYLRRFFEVTSLV >P43555; 28 47 KD ENDOMEMBRANE PROTEIN PRECURSOR (ENDOSOMAL P44 PROT MMMLITMKSTVLLSVFTVLATWAGLLEAHPLGDTSDASKLSSDYSLPDLINARKVPNNWQ TGEQASLEEGRIVLTSKQNSKGSLWLKQGFDLKDSFTMEWTFRSVGYSGQTDGGISFWFV QDSNVPRDKQLYNGPVNYDGLQLLVDNNGPLGPTLRGQLNDGQKPVDKTKIYDQSFASCL MGYQDSSVPSTIRVTYDLEDDNLLKVQVDNKVCFQTRKVRFPSGSYRIGVTAQNGAVNNN AESFEIFKMQFFNGVIEDSLIPNVNAMGQPKLITKYIDQQTGKEKLIEKTAFDADKDKIT NYELYKKLDRVEGKILANDINALETKLNDVIKVQQELLSFMTTITKQLSSKPPANNEKGT STDDAIAEDKENFKDFLSINQKLEKVLVEQEKYREATKRHGQDGPQVDEIARKLMIWLLP LIFIMLVMAYYTFRIRQEIIKTKLL >P79345; 19 SECRETORY PROTEIN E1 PRECURSOR (EPV20). MRFLTVAFLFLALSASALAEPVKFKDCGSWVGVIKEVNVSPCPTQPCKLHRGQSYSVNVT FTSNTQSQSSKAVVHGIVMGIPVPFPIPESDGCKSGIRCPIEKDKTYNYVNKLPVKNEYP SIKVVVEWELTDDKNQRFFCWQIPIEVEA >P28770; 21 EPENDYMIN I PRECURSOR (EPD-I). MQAFAVAALSIWLCLGATTLAESHGPQHCTSPNMTGVLTVLALTGGEIKATGHYSYDSTD KKIRFTESEMHLNKTEHLEDYLMLFEEGVFYDIDMKNQSCKKMSLHSHAHALELPAGAAH QVELFLGSDTVQEEDIKVNIWTGSVPETKGQYFLSTTVGECLPLSTFYSTDSITLLFSNS EVVTEVKAPEVFNLPSFCEGVELEEAPEGQKNDFFSLFNSV >P12958; 20 EPENDYMIN II PRECURSOR (EPD-II). MHTVKLLCVVFSCLCAVAWASSDRQPCHSPPLISGTMKVVSTGGHDLASGEFSYDSKANK FRFVEDAAHANKTSHTDVLVHFEEGTLYEIDSKNESCKKETLQFRKHLMEIPPDATHESE IYMGSPSITEQGLRVRVWSGKLPELHAHYSLSITSCGCLPVSGSYYGDKKDLLFSFFGVE TEVDDLQVFVPPAYCEGVAFEEAPDDHSFFDLFHD >P14753; 24 ERYTHROPOIETIN RECEPTOR PRECURSOR (EPO-R). MDKLRVPLWPRVGPLCLLLAGAAWAPSPSLPDPKFESKAALLASRGSEELLCFTQRLEDL VCFWEEAASSGMDFNYSFSYQLEGESRKSCSLHQAPTVRGSVRFWCSLPTADTSSFVPLE LQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYE VDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPAS LLTASDLDPLILTLSLILVLISLLLTVLALLSHRRTLQQKIWPGIPSPESEFEGLFTTHK GNFQLWLLQRDGCLWWSPGSSFPEDPPAHLEVLSEPRWAVTQAGDPGADDEGPLLEPVGS EHAQDTYLVLDKWLLPRTPCSENLSGPGGSVDPVTMDEASETSSCPSDLASKPRPEGTSP SSFEYTILDPSSQLLCPRALPPELPPTPPHLKYLYLVVSDSGISTDYSSGGSQGVHGDSS DGPYSHPYENSLVPDSEPLHPGYVACS >P30040; 32 ENDOPLASMIC RETICULUM PROTEIN ERP29 PRECURSOR (ERP31) (E MAAAVPRAAFLSPLLPLLLGFLLLSAPHGGSGLHTKGALPLDTVTFYKVIPKSKFVLVKF DTQYPYGEKQDEFKRLAENSASSDDLLVAEVGISDYGDKLNMELSEKYKLDKESYPVFYL FRDGDFENPVPYTGAVKVGAIQRWLKGQGVYLGMPGCLPVYDALAGEFIRASGVEARQAL LKQGQDNLSSVKETQKKWAEQYLKIMGKILDQGEDFPASEMTRIARLIEKNKMSDGKKEE LQKSLNILTAFQKKGAEKEEL >P49257; 30 ERGIC-53 PROTEIN PRECURSOR (ER-GOLGI INTERMEDIATE COMPAR MAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS DGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA DGLAIWYAENQGLEGPVFGSADLWNGVGIFFDTFDNDGKKNNPAIVIIGNNGQIHYDHQN DGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA QGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL DKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR RYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM QHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH FIIFVVVQTVLFIGYIMYRSQQEAAAKKFF >P30101; 24 PROBABLE PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR (EC MRLRRLALFPGVALLLAAARLAAASDVLELTDDNFESRISDTGSAGLMLVEFFAPWCGHC KRLAPEYEAAATRLKGIVPLAKVDCTANTNTCNKYGVSGYPTLKIFRDGEEAGAYDGPRT ADGIVSHLKKQAGPASVPLRTEEEFKKFISDKDASIVGFFDDSFSEAHSEFLKAASNLRD NYRFAHTNVESLVNEYDDNGEGIILFRPSHLTNKFEDKTVAYTEQKMTSGKIKKFIQENI FGICPHMTEDNKDLIQGKDLLIAYYDVDYEKNAKGSNYWRNRVMMVAKKFLDAGHKLNFA VASRKTFSHELSDFGLESTAGEIPVVAIRTAKGEKFVMQEEFSRDGKALERFLQDYFDGN LKRYLKSEPIPESNDGPVKVVVAENFDEIVNNENKDVLIEFYAPWCGHCKNLEPKYKELG EKLSKDPNIVIAKMDATANDVPSPYEVRGFPTIYFSPANKKLNPKKYEGGRELSDFISYL QREATNPPVIQEEKPKKKKKAQEDL >P06911; 22 EPIDIDYMAL-RETINOIC ACID BINDING PROTEIN PRECURSOR (E-RA MENIMPFALLGLCVGLAAGTEGAVVKDFDISKFLGFWYEIAFASKMGTPGLAHKEEKMGA MVVELKENLLALTTTYYSEDHCVLEKVTATEGDGPAKFQVTRLSGKKEVVVEATDYLTYA IIDITSLVAGAVHRTMKLYSRSLDDNGEALYNFRKITSDHGFSETDLYILKHDLTCVKVL QSAAESRP >P38660; 19 PROBABLE PROTEIN DISULFIDE ISOMERASE P5 PRECURSOR (EC 5. MARLGFGLVSCTFFLAASGLYSSSDDVIELTPSNFNREVIQSNSLWLVEFYAPWCGHCQR LTPEWKKAATALKDVVKVGAVDADKHQSLGGQYGVQGFPTIKIFGANKNKPEDYQGGRTG EAIVDAALSALRQLVKDRLSGRSGGYSSGKQGRGDSSSKKDVIELTDDTFDKNVLDSDDV WMVEFYAPWCGHCKNLEPEWATAATEVKEQTKGKVKLAAVDATVNQVLANRYGIRGFPTI KIFQKGEAPVDYDGGRTRSDIVSRALDLFSDNAPPPELLEIINEDVAKKMCEEHQLCVVA VLPHILDTGAARNSYLEILLKLADKYKKKMWGWLWTEAGAQSELENALGIGGFGYPAMAR INARKMKFALLKGSFSEQGINEFLRELSFGRASTAPVGGGSFPAITAREPWDGRDGELPV EDDIDLSDVELDDLEKDEL >P16303; 18 LIVER CARBOXYLESTERASE 10 PRECURSOR (EC 3.1.1.1) (CARBOX MRLYPLVWLFLAACTAWGYPSSPPVVNTVKGKVLGKYVNLEGFAQPVAVFLGIPFAKPPL GSLRFAPPQPAEPWNFVKNTTSYPPMCSQDAVGGQVLSELFTNRKENIPLQFSEDCLYLN VYTPADLTKNSRLPVMVWIHGGGLVVGGASTYDGQVLSAHENVVVVTIQYRLGIWGFFST GDEHSRGNWGHLDQVAALHWVQDNIANFGGNPGSVTIFGESAGGFSVSALVLSPLAKNLF HRAISESGVVLTSALITTDSKPIAKLIATLSGCKTTTSAVMVHCLRQKTEDELLETSLKL NLFKLDLLGNPKESYPFLPTVIDGVVLPKTPEEILAEKSFNTVPYIVGINKQEFGWIIPT LMGYPLSEGKLDQKTAKSLLWKSYPTLKISEKMIPVVAEKYFGGTDDPAKRKDLFQDLVA DVIFGVPSVMVSRSHRDAGAPTFMYEFEYRPSFVSAMRPKTVIGDHGDELFSVFGSPFLK DGASEEETNLSKMVMKYWANFARNGSPNGGGLPHWPEYDQKEGYLKIGASTQAAQRLKDK EVAFWSELRAKEAAEEPSHWKHVEL >P04477; 23 VSG EXPRESSION SITE-ASSOCIATED PROTEIN 117A PRECURSOR (E MKVTIVELVVWLFSVNFFVVVAEESRWTLVDDHYGKNLHESVCYLRCLSNALNKLYSEGE RRLFVNEEVYANASRILDDMEGKTGESTTYLSVVSSEMGGENNKLEKLISYGNAMGDLVA KVGGLFAEVNESVRAVREEIPSALIRANKYYTAIAEITRTVWDDVNRPLQQDKATCGDQK VTGVGELKTECGAHTCPLSDGVNESALQKYKGGCLEINVMSGSVSECFNLPRNKLYRSVA LSSSHGFLKWYQDEAKRFQLGLRVKNIFGPLIASFGVGQPPSVLAEMINNITSLQSRFNE VHSNFTSILLADNLTADVDNTDSTI >P35578; 21 EPIDIDYMAL SECRETORY PROTEIN IV PRECURSOR (LESP IV) (C73 MIAVLLLVFGMTPDYIFPVSADIPVVPNFDAQKTVGKWHPIGMASKLPEVPEYEQKISPM DHMVELTDGDMKLTANYMDGVCKEATAMLKHTDKPGVFKFTGGEIRMMDIDYEKYLIMYM KKSTFEAMYLSARGSDVGDDIKEKFKKLVLEQNFPEAHIKYFNAEQCTPTAA >P35501; 23 ESTERASE E4 PRECURSOR (EC 3.1.1.1) (CARBOXYLIC-ESTER HYD MKNTCGILLNLFLFIGCFLTCSASNTPKVQVHSGEIAGGFEYTYNGRKIYSFLGIPYASP PVQNNRFKEPQPVQPWLGVWNATVPGSACLGIEFGSGSKIIGQEDCLFLNVYTPKLPQEN SAGDLMNVIVHIHGGGYYFGEGILYGPHYLLDNNDFVYVSINYRLGVLGFASTGDGVLTG NNGLKDQVAALKWIQQNIVAFGGDPNSVTITGMSAGASSVHNHLISPMSKGLFNRAIIQS GSAFCHWSTAENVAQKTKYIANLMGCPTNNSVEIVECLRSRPAKAIAKSYLNFMPWRNFP FTPFGPTVEVAGYEKFLPDIPEKLVPHDIPVLISIAQDEGLIFSTFLGLENGFNELNNNW NEHLPHILDYNYTISNENLRFKTAQDIKEFYFGDKPISKETKSNLSKMISDRSFGYGTSK AAQHIAAKNTAPVYFYEFGYSGNYSYVAFFDPKSYSRGSSPTHGDETSYVLKMDGFYVYD NEEDRKMIKTMVNIWATFIKSGVPDTENSEIWLPVSKNLADPFRFTKITQQQTFEAREQS TTGIMNFGVAYH >P28088; 26 ENDOTHELIN B RECEPTOR PRECURSOR (ET-B) (ENDOTHELIN RECEP MQPLPSLCGRALVALILACGVAGIQAEEREFPPAGATQPLPGTGEMMETPTETSWPGRSN ASDPRSSATPQIPRGGRMAGIPPRTPPPCDGPIEIKETFKYINTVVSCLVFVLGIIGNST LLRIIYKNKCMRNGPNILIASLALGDLLHIIIDIPINTYKLLAKDWPFGVEMCKLVPFIQ KASVGITVLSLCALSIDRYRAVASWSRIKGIGVPKWTAVEIVLIWVVSVVLAVPEAVGFD IITSDHIGNKLRICLLHPTQKTAFMQFYKTAKDWWLFSFYFCLPLAITALFYTLMTCEML RKKSGMQIALNDHLKQRREVAKTVFCLVLVFALCWLPLHLSRILKLTLYDQHDPRRCEFL SFLLVLDYIGINMASLNSCINPIALYLVSKRFKNCFKSCLCCWCQSFEEKQSLEEKQSCL KFKANDHGYDNFRSSNKYSSS >P49426; 42 GLUCAN 1,3-BETA-GLUCOSIDASE PRECURSOR (EC 3.2.1.58) (EXO MRFSSLLACLGAVGIQAAAIPFQRRVDNTTDSGSLDAAQAAAAIVDGYWLNDLSGKGRAP FNSNPNYKVFRNVKDYGAKGDGVTDDSDAFNRAISDGSRCGPWVCDSSTDSPAVVYVPSG TYLINKPIIFYYMTALIGNPRELPVLKAASSLQALALIDGSPYSNQNGEPGWISTNLFLR QIRNLIIDGTAVAPTSGFQAIHWPASQATTIQNVKIRMTQASNSVHAGIFVENGSGGHMA DLDITGGLYGMNIGNQQFTMRNVKISKAVVGISQIWNWGWLYSGLQISDCGTAFSMVNGG SAGKQEVGSAVIIDSEITNCQKFVDSAWSQTSNPTGSGQLVIENIKLTNVPAAVVSNGAT VLAGGSLTIQTWGQGNKYAPNASGPSKFQGAISGATRPTGLLQNGKFYSKSKPQYETLST SSFISARGAGATGDGVTDDTRAVQAAVTQAASQNKVLFFEHGVYKVTNTIYVPPGSRMVG EIFSAIMGSGSTFGDQANPVPIIQIGKPGESGSIEWSDMIVQTQGATPGAIVIQYNLNTA LGSGLWDVHTRIGGAKGTNLQVAQCPAVLGQVKPECFSAHTNVHVTKGANGAYFENNWFW TADHDLDDADSTRINIYTGRGFHVEANNVWIWANGAEHHTMYQYQFNAAQDIFAGYIQTE TPYFQPTPIAPLPYVSSSKYSDPVYSSSQTSAWGLRLLDAKNVLIYGGGLYSFFDNYDVG CSSPTAPNGFRDCQTRILSIEGSTSVQAFGFSEVGVEWMVTAAGQDKANWKDNLSVYPTT IGYLSYGF >P05160; 20 COAGULATION FACTOR XIII B CHAIN PRECURSOR (EC 2.3.2.13) MRLKNLTFIIILIISGELYAEEKPCGFPHVENGRIAQYYYTFKSFYFPMSIDKKLSFFCL AGYTTESGRQEEQTTCTTEGWSPEPRCFKKCTKPDLSNGYISDVKLLYKIQENMHYGCAS GYKTTGGKDEEVVQCLSDGWSSQPTCRKEHETCLAPELYNGNYSTTQKTFKVKDKVQYEC ATGYYTAGGKKTEEVECLTYGWSLTPKCTKLKCSSLRLIENGYFHPVKQTYEEGDVVQFF CHENYYLSGSDLIQCYNFGWYPESPVCEGRRNRCPPPPLPINSKIQTHSTTYRHGEIVHI ECELNFEIHGSAEIRCEDGKWTEPPKCIEGQEKVACEEPPFIENGAANLHSKIYYNGDKV TYACKSGYLLHGSNEITCNRGKWTLPPECVENNENCKHPPVVMNGAVADGILASYATGSS VEYRCNEYYLLRGSKISRCEQGKWSSPPVCLEPCTVNVDYMNRNNIEMKWKYEGKVLHGD LIDFVCKQGYDLSPLTPLSELSVQCNRGEVKYPLCTRKESKGMCTSPPLIKHGVIISSTV DTYENGSSVEYRCFDHHFLEGSREAYCLDGMWTTPPLCLEPCTLSFTEMEKNNLLLKWDF DNRPHILHGEYIEFICRGDTYPAELYITGSILRMQCDRGQLKYPRCIPRQSTLSYQEPLR T >P03951; 18 COAGULATION FACTOR XI PRECURSOR (EC 3.4.21.27) (PLASMA T MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFT FTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDM KGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITK LDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFT FFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTD FLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKIL HGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSI IGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYD IALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLV TNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCA QRERPGVYTNVVEYVDWILEKTQAV >P00451; 19 COAGULATION FACTOR VIII PRECURSOR (PROCOAGULANT COMPONEN MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN TSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV GVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH VDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD AASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH RQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE EAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA PDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL LIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP TKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE NRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS IGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG MTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI PENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS PGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN KTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL NHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG QGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN LHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD GAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT SQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE KGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY RKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP KPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP GKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL NACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE IDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR PYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV DLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA PCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN PPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA TWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL ISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM EVLGCEAQDLY >Q20224; 19 FATTY ACID-BINDING PROTEIN HOMOLOG 1 PRECURSOR. MSSKFLILLAFCGATLVAAEQLPEKFYGTFDLDHSENFDEYLTAKGYGWFTRKLVTFATF KKVFAKNANKNLFDYSNLTSKKDVFYKNVQIGSKFEGEGLDNTKHEVTFTLKDGHLFEHH KPLEEGESKEETYEYYFDGDFLIQKMSFNNIEGRRFYKRLP >P37889; 26 FIBULIN-2 PRECURSOR. MLLQESAGVWLALALVTALTPSPSMAVPWQDCTGAECPLLENCIEEALEPGACCATCVQQ GCACEGYQYYDCVQGGFVDGRVPAGQSYFVDFGSTECSCPPGGGKISCQFMLCPELPPNC IEAVVVADSCPQCGQVGCVHSGRKYAAGHTVHLSSCRACHCPDAGGELICYQLPGCHGNF SDAEEGDSERQYEDPYSYDQEVAEAEATTAIVNEVQAGAEGPPAALGGGNLPPSSIRVTP WPVALPRPTAAAALGPPAPVQAKARRVTLDTEEDEEEEEEETLVTEPPTAGSPGRLDSLP TRSPARPGFPVQEKEAEAKAGPEENLIPDAQVTPRSVMQEGAAPVPRSGLAALSPSLATD SSSEDPVKPSDHPTLSTLPPDRAQVSPSPETPEEIPQHPQLLPRFRAEEDIDPNSVHSVP RGDLDGSTKDLIETCCAAGQQWAIDNDECQEIPENGAQSDICRIAQRQCCISYLKEKSCV AGVMGAKEGETCGAEDNDTCGVSLYKQCCDCCGLGLRVRAEGQSCESNPNLGYPCNHVML SCCEGEEPLIVPEVRRPPEPEAAPRRVSEMEMASREALSLGTEAELPNSLPGDDQDECLM LPGELCQHLCINTVGSYRCACFPGFELQGDGRTCRPDRGAPQLDTARESAPRSESAQVSP NTIPLPVPQPNTCKDNGPCRQVCRVVGDTAMCSCFPGYAIMADGVSCEDQDECLMGTHDC SWKQFCVNTLGSFYCVNHTVLCAEGYILNAHRKCVDINECVTDLHTCTRAEHCVNTPGSF QCYKALTCEPGYVLTDGECTDVDECVTGTHNCQAGFSCQNTKGSFYCQARQRCMDGFLQD PEGNCVDINECTSLLEPCRSGFSCINTVGSYTCQRNPLVCGRGYHANEEGSECVDVNECE TGVHRCGEGQLCYNLPGSYRCDCKPGFQRDAFGRTCIDVNECWVSPGRLCQHTCENTPGS YRCSCAAGFLLAADGKHCEDVNECETRRCSQECANIYGSYQCYCRQGYQLAEDGHTCTDI DECAQGAGILCTFRCVNVPGSYQCACPEQGYTMMANGRSCKDLDECALGTHNCSEAETCH NIQGSFRCLRFDCPPNYVRVSQTKCERTTCQDITECQTSPARITHYQLNFQTGLLVPAHI FRIGPAPAFAGDTISLTITKGNEEGYFVTRRLNAYTGVVSLQRSVLEPRDFALDVEMKLW RQGSVTTFLAKMYIFFTTFAP >P12319; 25 HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR ALPHA-SUBU MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR KGFRLLNPHPKPNPKNN >P08101; 29 LOW AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR II PRECURS MESNWTVHVFSRTLCHMLLWTAVLNLAAGTHDLPKAVVKLEPPWIQVLKEDTVTLTCEGT HNPGNSSTQWFHNGRSIRSQVQASYTFKATVNDSGEYRCQMEQTRLSDPVDLGVISDWLL LQTPQLVFLEGETITLRCHSWRNKLLNRISFFHNEKSVRYHHYSSNFSIPKANHSHSGDY YCKGSLGRTLHQSKPVTITVQGPKSSRSLPVLTIVAAVTGIAVAAIVIILVSLVYLKKKQ VPALPGNPDHREMGETLPEEVGEYRQPSGGSVPVSPGPPSGLEPTSSSPYNPPDLEEAAK TEAENTITYSLLKHPEALDEETEHDYQNHI >P12318; 36 LOW AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR II-A PRECU MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD KNIYLTLPPNDHVNSNN >P30440; 17 MAJOR ALLERGEN I POLYPEPTIDE CHAIN 2 PRECURSOR (ALLERGEN MRGALLVLALLVTQALGVKMAETCPIFYDVFFAVANGNELLLDLSLTKVNATEPERTAMK KIQDCYVENGLISRVLDGLVMTTISSSKDCMGEAVQNTVEDLKLNTLGR >P30439; 18 MAJOR ALLERGEN I POLYPEPTIDE CHAIN 1 MINOR FORM PRECURSO MLDAALPPCPTVAATADCEICPAVKRDVDLFLTGTPDEYVEQVAQYKALPVVLENARILK NCVDAKMTEEDKENALSVLDKIYTSPLC >P21781; 31 KERATINOCYTE GROWTH FACTOR PRECURSOR (KGF) (FIBROBLAST G MHKWILTWILPTLLYRSCFHIICLVGTISLACNDMTPEQMATNVNCSSPERHTRSYDYME GGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLA MNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTK KEQKTAHFLPMAIT >Q03364; 14 FIBROBLAST GROWTH FACTOR RECEPTOR 2 PRECURSOR (EC 2.7.1. MLLLALLAFLLVSRTIARPSYSMVDDTTPEPEEPPAKYQISKADVFPVLPGEPLDLRCPL ADGPLVTWTKDGAKLEVNNRTLIVRTYLQIKESTTRDSGLYACSVLKNSHFFHVNVTEAS SSGDDEDDNDGSEDFTNDNNNIRAPYWTNTEKMEKKLHAVSAANTVKLRCPAREPHPSNE WLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGIYTCIVENEHGSINHTYHLDVIE RSSHRPILQAGLPANTTAVVGGDAEFVCKVYSDAQPHIRWVRYIEKNGSRFGVDGLPYFK VLKAAGVNVTDEEIEVLYVRNVSFEDAGEYTCIAGNSIGISQHSAWLTVHPAPVNPLEDN PVPYYMEIGIYSTGIFIIFCMVVVCVVCRMRQGAKKKKNFTGPPVHKLTKRIPLHRQVTV SADSSSSMNSTTPLVRITTRLLNSTDAMPLANVSEYELPHDPMWEFSRDKLTLGKPLGEG CFGQVVMAEALGIDKERPKESVTVAVKMLKDNATEKDLADLVSEMEMMKMIGKHKNIINL LGACTQGGTLYVIVEYAAKGNLRQYLRARRPLEMEYSFDVTRVPDEQMTFKDLVSCTYQI ARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDVNNIDYYKKTSNGRLPVKWM APEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTN ELYMMMRDCWHAIPSHRPTFKQLVEDLDRILTLTTNEEYLDLSAPLEQYSPSFPDSSCSA SSSSGDDSVFSPDPMPHDPCLPKFQHVNGVVKT >P22607; 22 FIBROBLAST GROWTH FACTOR RECEPTOR 3 PRECURSOR (FGFR-3) ( MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE EELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK RQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE GCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN LLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW MAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT HDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS SSSGDDSVFAHDLLPPAPPSSGGSRT >P19477; 24 FIBRINOGEN-LIKE PROTEIN A PRECURSOR (FREP-A). MFSFIMKAAILLILVGCISFCISSEPLNESEITFEREERSLADPAGRQKRQSGLSCPKRI SHSPEYPRDCYDILQSCSGQSPPSGQYYIQPDGGNLIKVYCDMETDEGGWTVFQRRIDGT INFYRSWSYYQTGFGNLNTEFWLGNDNIHYLTSQGDYELRVELNNTLGNHYYAKYNKFRI GDSFSEYLLVLGAYSGTAGDSLAYHNTMRFSTYDNDNDVYSINCASHSSYGRGAWWYKSC LLSNLNGQYYDYSGAPSIYWSYLPGDNDQIPFAEMKLRNRSI >P06399; 19 FIBRINOGEN ALPHA/ALPHA-E CHAIN PRECURSOR. MLSLRVACLILSLASTVWTADTGTTSEFIEAGGDIRGPRIVERQPSQCKETDWPFCSDED WNHKCPSGCRMKGLIDEANQDFTNRINKLKNSLFDFQKNNKDSNSLTRNIMEYLRGDFAN ANNFDNTFGQVSEDLRRRIQILKRKVIEKAQQIQVLQKDVRDQLIDMKRLEVDIDIKIRS CKGSCSRSVSREINLKDYEGQQKQLEQVIAKDLLPAKDRQYLPAIKMSPVPDLVPGSFKS QLQEGPPEWKALTEMRQMRMELERPGKDGASRGDLPGDSRGDSATRGPGSKIENPMTPGH GGSGYWRPGSSGSGSDGNWGSGTTGSDDTGTWGAGSSRPSSGSGNLKPSNPDWGEFSEFG GSSSPATRKEYHTGKLVTSKGDKELLIGNEKVTSTGTSTTRRSCSKTITKTVLGNDGHRE VVKEVVTSDDGSDCGDGMDLGLTHSFSGRLDELSRMHPELGSFYDSRFGSLTSNFKEFGS KTSDSDIFTDIENPSSHVPEFSSSSKTSTVRKQVTKSYKMADEAASEAHQEGDTRTTKRG RARTMRDCDDVLQTHPSGAQNGIFSIKLPGSSKIFSVYCDQETSLGGWLLIQQRMDGSLN FNRTWQDYKRGFGSLNDKGEGEFWLGNDYLHLLTLRGSVLRVELEDWAGKEAYAEYHFRV GSEAEGYALQVSSYQGTAGDALMEGSVEEGTEYTSHSNMQFSTFDRDADQWEENCAEVYG GGWWYNSCQAANLNGIYYPGGTYDPRNNSPYEIENGVLWVPFRGADYSLWAVRMKIRPLV GQ >P02679; 26 FIBRINOGEN GAMMA-A CHAIN PRECURSOR. MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRIMLEEIM KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI GEGQQHHLGGAKQAGDV >P17634; 25 FIBRINOGEN GAMMA-CHAIN PRECURSOR. MTRLPKQGLLLLQSLALLSSAFGNIIPNTDNCCILDGRFGEYCPTTCGISDFLNRYQENV DTDLQYLENLLTQISNSTSGTTIIVEHLIDSGKKPATSPQTAIDPMTQKSKTCWMKLTDM KNYYQYEENILYLQEVYSSNQNKIFLLKQKIANLELQCQQPCRDTVQIQEFTGKDCQEVA NKGARLSGLYYIKPLKAKQQFLVYCEIEPSGSAWTVIQRRLDGSVNFHKNWVQYREGFGY LSPNDKTEFWLGNEKIHLLSTQSTIPYVMRIELEDWSNQKSTADYSTFRLGSEKDNYRFT YAYFIGGDAGDAFDGFDFGDDPSDKFYTSHNGMQFSTFDKDNDKFDGNCAEQDGSGWWMN RCHAAHLNGKYYQGGTYSEADSGPSGYDNGIIWATWRRRWYSMKSVTMKIMPLNRYGAEG QQTLGGSKKSDFENRGDF >P04937; 32 FIBRONECTIN PRECURSOR (FN). MLRGPGPGRLLLLAVLCLGTSVRCTETGKSKRQAQQIVQPPSPVAVSQSKPGCFDNGKHY QINQQWERTYLGNALVCTCYGGSRGFNCESKPEPEETCFDKYTGNTYKVGDTYERPKDSM IWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDKWRRPHETGGYMLECLCLGNGKGEWTC KPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGNGRITCTSRNRCNDQDTRTS YRIGDTWSKKDNRGNLLQCVCTGNGRGEWKCERHVLQSASAGSGSFTDVRTAIYQPQTHP QPAPYGHCVTDSGVVYSVGMQWLKSQGDKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPC VLPFHYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHAVLVQTRGGNSNGALC HFPFLYSNRNYSDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRI GDQWDKQHDLGHMMRCTCVGNGRGQWACIPYSQLRDQCIVDDITYNVNDTFHKRHEEGHM LNCTCFGQGRGRWKCDPIDRCQDSETRTFYQIGDSWEKFVHGVRYQCYCYGRGIGEWHCQ PLQTYPGTTGPVQVIITETPSQPNSHPIQWNAPEPSHITKYILRWRPKTSTGRWKEATIP GHLNSYTIKGLTPGVIYEGQLISIQQYGHQEVTRFDFTTSASTPVTSNTVTGETAPFSPV VATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLL PGRKYIVNVYQISEEGKQSLILSTSQTTAPDAPPDPTVDQVDDTSIVVRWSRPQAPITGY RIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVFIQQETTGV PRSDDVPAPKDLQFVEVTDVKVTIMWTPPNSAVTGYRVDVLPVNLPGEHGQRLPVNRNTF AEVTGLSPGVTYLFKVFAVHQGRESKPLTAQQTTKLDAPTNLQFVNETDRTVLVTWTPPR ARIAGYRLTVGLTRGGQPKQYNVGPMASKYPLRNLQPGSEYTVTLMAVKGNQQSPKATGV FTTLQPLRSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVS GLTPGVEYTYTIQVLRDGQERDAPIVNRVVTPLSPPTNLHLEANPDTGVLTVSWERSTTP DITGYRITTTPTNGQQGTALEEVVHADQSSCTFENRNPGLEYNVSVYTVKDDKESAPISD TVIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVG YYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPP PSIELTNLLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYLVSVSSVYEQHESIPL RGRQKTGLDSPTGFDSSDVTANSFTVHWVAPRAPITGYIIRHHAEHSAGRPRQDRVPPSR NSITLTNLNPGTEYIVTIIAVNGREESPPLIGQQSTVSDVPRDLEVIASTPTSLLISWEP PAVSVRYYRITYGETGGNSPVQEFTVPGSKSTATINNIKPGADYTITLYAVTGRGDSPAS SKPVSINYQTEIDKPSQMQVTDVQDNSISVRWLPSTSPVTGYRVTTAPKNGLGPTKSQTV SPDQTEMTIEGLQPTVEYVVSVYAQNRNGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKI AWESPQGQVSRYRVTYSSPEDGIHELFPAPDGDEDTAELHGLRPGSEYTVSVVALHGGME SQPLIGVQSTAIPAPTNLKFTQVSPTTLTAQWTAPSVKLTGYRVRVTPKEKTGPMKEINL SPDSTSVIVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTI TISWRTKTETITGFQVDAIPANGQTPVQRTISPDVRSYTITGLQPGTDYKIHLYTLNDNA RSSPVVIDASTAIDAPSNLRFLTTTPNSLLVSWQAPRARITGYIIKYEKPGSPPREVVPR PRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEI LDVPSTVQKTPFVTNPGYDTENGIQLPGTSHQQPSVGQQMIFEEHGFRRTTPPTAATPVR LRPRPYLPNVDEEVQIGHVPRGDVDYHLYPHVPGLNPNASTGQEALSQTTISWTPFQESS EYIISCQPVGTDEEPLQFQVPGTSTSATLTGLTRGVTYNIIVEALHNQRRHKVREEVVTV GNTVNEGLNQPTDDSCFDPYTVSHYAVGEEWERLSDSGFKLTCQCLGFGSGHFRCDSSKW CHDNGVNYKIGEKWDRQGENGQRMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQK EYLGAICSCTCFGGQRGWRCDNCRRPGAAEPSPDGTTGHTYNQYTQRYHQRTNTNVNCPI ECFMPLDVQADRDDSRE >P26885; 21 FK506-BINDING PROTEIN PRECURSOR (FKBP-13) (PEPTIDYL-PROL MRLSWFRVLTVLSICLSAVASTGTEGKRKLQIGVKKRVDHCPIKSRKGDVLHMHYTGKLE DGTEFDSSLPQNQPFVFSLGTGQVIKGWDQGLLGMYEGEKRKLVIPSELGYGERGAPPKI PGGATLVFEVELLKIERRTEL >P05620; 24 FLAVOXOBIN PRECURSOR (EC 3.4.21.-). MVLIRVLANLLILQLSYAQKSSELVIGGDECNINEHPFLVALYDAWSGRFLCGGTLINPE WVLTAAHCDSKNFKMKLGAHSKKVLNEDEQIRNPKEKFICPNKKNDEVLDKDIMLIKLDS PVSYSEHIAPLSLPSSPPSVGSVCRIMGWGSITPVEETFPDVPHCANINLLDDVECKPGY PELLPEYRTLCAGVLQGGIDTCGFDSGTPLICNGQFQGIVSYGGHPCGQSRKPGIYTKVF DYNAWIQSIIAGNTAATCLP >P15697; 19 FEMALE PROTEIN PRECURSOR (FP) (SERUM AMYLOID P-COMPONENT MDKMLLLLGVSILLSEVFAQTDLTGKVFVFPRESESDYVKLIPRLEKPLENFTLCFRTYT DLSRPHSLFSYNTKNKDNELLIYKERMGEYGLYIENLGAIVRGVEEFASPVHFCTSWESS SGIAEFWVNGIPWVKKGLKKGYTVKTQPSIILGQEQDNYGGGFDKSQSFVGEMGDLNMWD SVLTPEEIKSVYEGSWLEANILDWRTLNYEMSGYAVIRPRCVALSSYNKIS >P42578; 18 YOLK FERRITIN PRECURSOR. MNSVLFLTLAVCSSLAYGKEFVATVRQNYKENINQLLEQQIQKELAASYIYQAYASYFQR ADVSLPGIKKFFSDASSEERDDAQSLIDYINQRGGHVQYDKIDLKDACETVMKFVTSDTS GLEEFRDRRMCICGFVATKTINDNCGERSDWKEGLIAFEDTLAIERYVNAQLLDIHKKAD DEKDAHLTHILEHEFLEEQVSSINKIAHAITRLRSFEQGSGNNYKLGRVYLRPTPQISH >P41822; 27 FERRITIN SUBUNIT PRECURSOR. MMKSVFFGVVAITVAILSIYQETAQAQEQTVGATDNYQWDSVDDQCLAALHRQINKEFDA SIIYLKYAAYFAQEKINLPGFEKFFFHAAAEEREHGIKLIEYALMRGKAPVDKHFKLNYD HEVPTVTTGESALETALQKEVEVTRSIRGVIKACEDGSNDFHLADYLTGEYLDEQHKGQR ELAEKIATLKKMKKSAPKLGEFLFDKNHM >P01227; 19 FOLLITROPIN BETA CHAIN PRECURSOR (FOLLICLE-STIMULATING H MKSVQFCFLFCCWRAICCRSCELTNITITVEKEECSFCISINTTWCAGYCYTRDLVYKDP ARPNIQKACTFKELVYETVKVPGCAHHADSLYTYPVATECHCGKCDRDSTDCTVRGLGPS YCSFSDIRE >P27869; 17 GLYCOPROTEIN 25L PRECURSOR (GP25L). MPMLAFALSFYFSLSTAFYFHVGEREEKCIIEDIPSDTLVTGTFKTQQWDFRRQDFLESA PGLGMFVTVTTYNDEVLLSKLYGPQGRFYFTSHSPGEHIICLESNSTRLVSFGGSKLRIH LEIRVGQHDLDAAIAQAKDKVNEVSFKLEHLIEQIEQIVKEQNYQRDREENFRMISEDTN SNVLWWAFAQTLIFIAIGIFQMKSLKNFFIAKKLV >P34059; 26 N-ACETYLGALACTOSAMINE-6-SULFATASE PRECURSOR (EC 3.1.6.4) MAAVVAATRWWQLLLVLSAAGMGASGAPQPPNILLLLMDDMGWGDLGVYGEPSRETPNLD RMAAEGLLFPNFYSANPLCSPSRAALLTGRLPIRNGFYTTNAHARNAYTPQEIVGGIPDS EQLLPELLKKAGYVSKIVGKWHLGHRPQFHPLKHGFDEWFGSPNCHFGPYDNKARPNIPV YRDWEMVGRYYEEFPINLKTGEANLTQIYLQEALDFIKRQARHHPFFLYWAVDATHAPVY ASKPFLGTSQRGRYGDAVREIDDSIGKILELLQDLHVADNTFVFFTSDNGAALISAPEQG GSNGPFLCGKQTTFEGGMREPALAWWPGHVTAGQVSHQLGSIMDLFTTSLALAGLTPPSD RAIDGLNLLPTLLQGRLMDRPIFYYRGDTLMAATLGQHKAHFWTWTNSWENFRQGIDFCP GQNVSGVTTHNLEDHTKLPLIFHLGRDPGERFPLSFASAEYQEALSRITSVVQQHQEALV PAQPQLNVCNWAVMNWAPPGCEKLGKCLTPPESIPKKCLWSH >P19969; 31 GAMMA-AMINOBUTYRIC-ACID RECEPTOR ALPHA-5 SUBUNIT PRECURS MDNGMLSRFIMTKTLLVFCISMTLSSHFGFSQMPTSSVQDETNDNITIFTRILDGLLDGY DNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPL NNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDF PMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTS TGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTM TTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAA KIKKKERELILNKSTNAFTTGKLTHPPNIPKEQLPGGTGNAVGTASIRASEEKTSESKKT YNSISKIDKMSRIVFPILFGTFNLVYWATYLNREPVIKGATSPK >P24045; 25 GAMMA-AMINOBUTYRIC-ACID RECEPTOR BETA-4 SUBUNIT PRECURSO MWTFQADRLSGIVSALAALCVACCAQSPSTGNISVVKEIVDKLLKGYDVRLRPDFGGNPV TVGMSIHISSIDQISEVNMDYTITMYFQQSWRDKRLAYNDLPLNLTLDNRVADQLWLPDT YFLNDKKSFLHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDQQNCTLEIES YGYTVDDIVFFWQGNDSAVTGMEVLELPQFTIIEQRLVSREVVFTTGSYLRLSLSFRIKR NIGYFILQTYMPSILITILSWVSFWINYDASAARVALGVTTVLTMTTINTHLRETLPKIP YVKAIDVYLMGCFVFVFLALLEYAFVNYIFFGRGPRQQKKQSERISKANNERHRYEEKRV REQVDPYGNILLSTLDMNNELLATDMMSSVGDSRNSVMSFEGSGIQFRKPLASRDGFGHH PTLDRHVPLTHHAAARNRANCRLRRRSSKLKLKIPDLTDVSTIDKWSRIIFPITFGFFNL VYWLYYVN >P48842; 16 ARABINOGALACTAN ENDO-1,4-BETA-GALACTOSIDASE PRECURSOR (E MFASLLLAALPLLTHAALTYRGADISSLLLLEDEGYSYKNLNGQTQALETILADAGINSI RQRVWVNPSDGSYDLDYNLELAKRVKAAGMSLYLDLHLSDTWADPSDQTTPSGWSTTDLG TLKWQLYNYTLEVCNTFAENDIDIEIISIGNEIRAGLLWPLGETSSYSNIGALLHSGAWG VKDSNLATTPKIMIHLDDGWSWDQQNYFYETVLATGELLSTDFDYFGVSYYPFYSASATL ASLKTSLANLQSTYDKPVVVVETNWPVSCPNPAYAFPSDLSSIPFSVAGQQEFLEKLAAV VEATTDGLGVYYWEPAWIGNAGLGSSCADNLMVDYTTDEVYESIETLGEL >Q01745; 41 GALACTOSE OXIDASE PRECURSOR (EC 1.1.3.9). MKHLLTLALCFSSINAVAVTVPHKAVGTGIPEGSLQFLSLRASAPIGSAISRNNWAVTCD SAQSGNECNKAIDGNKDTFWHTFYGANGDPKPPHTYTIDMKTTQNVNGLSMLPRQDGNQN GWIGRHEVYLSSDGTNWGSPVASGSWFADSTTKYSNFETRPARYVRLVAITEANGQPWTS IAEINVFQASSYTAPQPGLGRWGPTIDLPIVPAAAAIEPTSGRVLMWSSYRNDAFGGSPG GITLTSSWDPSTGIVSDRTVTVTKHDMFCPGISMDGNGQIVVTGGNDAKKTSLYDSSSDS WIPGPDMQVARGYQSSATMSDGRVFTIGGSWSGGVFEKNGEVYSPSSKTWTSLPNAKVNP MLTADKQGLYRSDNHAWLFGWKKGSVFQAGPSTAMNWYYTSGSGDVKSAGKRQSNRGVAP DAMCGNAVMYDAVKGKILTFGGSPDYQDSDATTNAHIITLGEPGTSPNTVFASNGLYFAR TFHTSVVLPDGSTFITGGQRRGIPFEDSTPVFTPEIYVPEQDTFYKQNPNSIVRVYHSIS LLLPDGRVFNGGGGLCGDCTTNHFDAQIFTPNYLYNSNGNLATRPKITRTSTQSVKVGGR ITISTDSSISKASLIRYGTATHTVNTDQRRIPLTLTNNGGNSYSFQVPSDSGVALPGYWM LFVMNSAGVPSVASTIRVTQ >P22146; 22 GLYCOLIPID ANCHORED SURFACE PROTEIN PRECURSOR (GLYCOPROT MLFKSLSKLATAAAFFAGVATADDVPAIEVVGNKFFYSNNGSQFYIRGVAYQADTANETS GSTVNDPLANYESCSRDIPYLKKLNTNVIRVYAINTTLDHSECMKALNDADIYVIADLAA PATSINRDDPTWTVDLFNSYKTVVDTFANYTNVLGFFAGNEVTNNYTNTDASAFVKAAIR DVRQYISDKNYRKIPVGYSSNDDEDTRVKMTDYFACGDDDVKADFYGINMYEWCGKSDFK TSGYADRTAEFKNLSIPVFFSEYGCNEVTPRLFTEVEALYGSNMTDVWSGGIVYMYFEET NKYGLVSIDGNDVKTLDDFNNYSSEINKISPTSANTKSYSATTSDVACPATGKYWSAATE LPPTPNGGLCSCMNAANSCVVSDDVDSDDYETLFNWICNEVDCSGISANGTAGKYGAYSF CTPKEQLSFVMNLYYEKSGGSKSDCSFSGSATLQTATTQASCSSALKEIGSMGTNSASGS VDLGSGTESSTASSNASGSSSKSNSGSSGSSSSSSSSSASSSSSSKKNAATNVKANLAQV VFTSIISLSIAAGVGFALV >P01350; 21 GASTRIN PRECURSOR. MQRLCVYVLIFALALAAFSEASWKPRSQQPDAPLGTGANRDLELPWLEQQGPASHHRRQL GPQGPPHLVADPSKKQGPWLEEEEEAYGWMDFGRRSAEDEN >P06396; 27 GELSOLIN PRECURSOR, PLASMA (ACTIN-DEPOLYMERIZING FACTOR) MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQGRVPEARPNSMVVEHPEFL KAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNEC SQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVV PNEVVVQRLFQVKGRRVVRATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNRYERLKA TQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAANRKLAKL YKVSNGAGTMSVSLVADENPFAQGALKSEDCFILDHGKDGKIFVWKGKQANTEERKAALK TASDFITKMDYPKQTQVSVLPEGGETPLFKQFFKNWRDPDQTDGLGLSYLSSHIANVERV PFDAATLHTSTAMAAQHGMDDDGTGQKQIWRIEGSNKVPVDPATYGQFYGGDSYIILYNY RHGGRQGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSRVVQGKEPAHLMSLFG GKPMIIYKGGTSREGGQTAPASTRLFQVRANSAGATRAVEVLPKAGALNSNDAFVLKTPS AAYLWVGTGASEAEKTGAQELLRVLRAQPVQVAEGSEPDGFWEALGGKAAYRTSPRLKDK KMDAHPPRLFACSNKIGRFVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGKDSQEEEK TEALTSAKRYIETDPANRDRRTPITVVKQGFEPPSFVGWFLGWDDDYWSVDPLDRAMAEL AA >P16882; 24 HIGH MOLECULAR WEIGHT GROWTH HORMONE RECEPTOR/BINDING PR MDLCQVFLTLALAVTSSTFSGSEATPATLGKASPVLQRINPSLGTSSSGKPRFTKCRSPE LETFSCYWTEGDNPDLKTPGSIQLYYAKRESQRQAARIAHEWTQEWKECPDYVSAGKNSC YFNSSYTSIWIPYCIKLTTNGDLLDQKCFTVDEIVQPDPPIGLNWTLLNISLTGIRGDIQ VSWQPPPNADVLKGWIILEYEIQYKEVNESKWKVMGPIWLTYCPVYSLRMDKEHEVRVRS RQRSFEKYSEFSEVLRVIFPQTNILEACEEDIQFPWFLIIIFGIFGVAVMLFVVIFSKQQ RIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILGIHDNYKPDFYNDDSWVEFIELDID EADVDEKTEGSDTDRLLSNDHEKSAGILGAKDDDSGRTSCYDPDILDTDFHTSDMCDGTL KFRQSQKLNMEADLLCLDQKNLKNLPYDASLGSLHPSITQTVEENKPQPLLSSETEATHQ LASTPMSNPTSLANIDFYAQVSDITPAGGDVLSPGQKIKAGIAQGNTQREVATPCQENYS MNSAYFCESDAKKCIAVARRMEATSCIKPSFNQEDIYITTESLTTTAQMSETADIAPDAE MSVPDYTTVHTVQSPRGLILNATALPLPDKKNFPSSCGYVSTDQLNKIMQ >P55320; 31 GONAD-INHIBITING HORMONE PRECURSOR (GIH) (VITELLOGENESIS MVTRVGSGFSVQRVWLLLVIVVVLCGSVTQQASAWFTNDECPGVMGNRDLYEKVAWVCND CANIFRNNDVGVMCKKDCFHTMDFLWCVYATERHGEIDQFRKWVSILRAGRK >Q03077; 13 GALACTOSE-INHIBITABLE LECTIN 35 KD SUBUNIT PRECURSOR. MIILVLLISYSFGKTQDGKDQLSPNYPYGKMNKDVNFNKPFTSAVDSYQIQQYAENGVFS ANQENYVRAKCKTCCRVIFASDYNYKTNTQFTDEDDKKGDERYVMDMEFDDKRSVRFRNG GYEQNILLRPLKQGNELQFFEFAPYRMYTSYAIPKRVHDIRGGANEEATLIIWPKNPPLS DAPGTRNQRFVYVHPYPTEWYPEYNSTTKYTQNGKTVIKTLKWPTYKRHFYLPYRLDVDL CYQARKATDGRSTWTGNKNLNTTSKSYQIIASRCSATEARQIFIPVFA >P11583; 16 GLOBIN CTT-VIIB-5/CTT-VIIB-9 PRECURSOR. MKFFAVLALCIVGAIASPLTADEASLVQSSWKAVSHNEVEILAAVFAAYPDIQNKFSQFA GKDLASIKDTGAFATHATRIVSFLSEVIALSGNTSNAAAVNSLVSKLGDDHKARGVSAAQ FGEFRTALVAYLQANVSWGDNVAAAWNKALDNTFAIVVPRL >P27613; 15 GLOBIN-LIKE HOST-PROTECTIVE ANTIGEN PRECURSOR. MRFLLLAAFVAYAYAKSDEEIRKDALSALDVVPLGSTPEKLENGREFYKYFFTNHQDLRK YFKGAETFTADDIAKSDRFKKLGNQLLLSVHLAADTYDNEMIFRAFVRDTIDRHVDRGLD PKLWKEFWSIYQKFLESKGKTLSADQKAAFDAIGTRFNDEAQKQLAHHGLPHT >P28316; 18 EXTRACELLULAR GLOBIN PRECURSOR. MRSLLLLSIVFFVVTVSANKTRELCMKSLEHAKVDTSNEARQDGIDLYKHMFENYPPLRK YFKNREEYTAEDVQNDPFFAKQGQKILLACHVLCATYDDRETFNAYTRELLDRHARDHVH MPPEVWTDFWKLFEEYLGKKTTLDEPTKQAWHEIGREFAKEINKHGRHAVRHQCMRSLQH IDIGHSETAKQNGIDLYKHMFENYPSMREAFKDRENYTAEDVQKDPFFVKQGQRILLACH LLCASYDDEETFHMYVHELMERHERLGVQLPDQHWTDFWKLFEEFLEKKSHLCEHTKHAW AVIGKEFAYEATRHGKEHHEHKEEHKEEHKEEHKEEQH >P17439; 19 GLUCOSYLCERAMIDASE PRECURSOR (EC 3.2.1.45) (BETA-GLUCOCE MAARLIGFFLFQAVSWAYGAQPCIPKSFGYSSVVCVCNASYCDSLDPVTLPALGTFSRYE STRRGRRMELSVGAIQANRTGTGLLLTLQPEKKFQKVKGFGGAMTDATALNILALSPPTQ KLLLRSYFSTNGIEYNIIRVPMASCDFSIRVYTYADTPNDFQLSNFSLPEEDTKLKIPLI HQALKMSSRPISLFASPWTSPTWLKTNGRVNGKGSLKGQPGDIFHQTWANYFVKFLDAYA KYGLRFWAVTAENEPTAGLFTGYPFQCLGFTPEHQRDFISRDLGPALANSSHDVKLLMLD DQRLLLPRWAEVVLSDPEAAKYVHGIAVHWYMDFLAPAKATLGETHRLFPNTMLFASEAC VGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVTGWTDWNLALNPEGGPNWVRNFVDSPI IVDIPKDAFYKQPMFYHLGHFSKFIPEGSQRVALVASESTDLETVALLRPDGSAVVVVLN RSSEDVPLTISDPDLGFLETVSPGYSIHTYLWRRQ >P18857; 23 GLYCOPROTEIN HORMONES ALPHA CHAIN 2 PRECURSOR (GONADOTRO MFWTRYAGASVLLFLMLIHLGQLYPRNYMNNFGCEECKLKENNIFSKPGAPVYQCMGCCF SRAYPTPLRSKKTMLVPKNITSEATCCVAKEFKQVLVNDIKLVNHTDCHCSTCYYHKS >P13153; 22 GLYCOPROTEIN HORMONES ALPHA CHAIN 2 PRECURSOR (GONADOTRO MCLLKSTGLSLILSALLVIADSYPNSDKTNMGCEECTLKPNTIFPNIMQCTGCCFSRAYP TPLRSKQTMLVPKNITSEATCCVAKEGERVTTKDGFPVTNHTECHCSTCYYHKS >P01216; 24 GLYCOPROTEIN HORMONES ALPHA CHAIN PRECURSOR. MDYYRKYAAVILVMLSMFLHILHSLPDGDFIIQGCPECKLKENKYFSKLGAPIYQCMGCC FSRAYPTPARSKKTMLVPKNITSEATCCVAKAFTKATVMGNARVENHTECHCSTCYYHKS >P06028; 19 GLYCOPHORIN B PRECURSOR (PAS-3) (SIALOGLYCOPROTEIN DELTA MYGKIIFVLLLSEIVSISALSTTEVAMHTSTSSSVTKSYISSQTNGETGQLVHRFTVPAP VVIILIILCVMAGIIGTILLISYTIRRLIKA >P19439; 23 PROBABLE GLUTAMATE RECEPTOR PRECURSOR (KAINATE-BINDING P MDKGLHFIFCVVTAVLLLRESSQTGAMRNDDAMIKPNDLRGPEENLPSLTVTTILEDPYV MVRSAELEGYCIDLLKALASMLHFSYKVKVVGDGKYGAISPSGNWTGMIGEILRQEADIA VAPLTVTSAREEVVSFTTPFLQTGIGILLRKETISQEMSFFHFLAPFSKETWTGLLFAYV LTCVCLFLVARLSPCEWNEPKNEENHFTFLNSLWFGAGALTLQGVTPRPKAFSVRVIAAI WWLFTIALLAAYIANFTALLSSGSEQLSIQTFEDLVKQRKLEFGTLDGSSTFYFFKNSKN PIHRMVYEYMDKRRDHVLVKTYQEAVQRVMESNYAFIGESISQDLAAARHCNLIRAPEVI GARGFGIATAQASPWTKKLSVAVLKLRETGDLDYLRNKWWESSCLHKSREGWSPLQPQAL GGLFLTLAIGLALGVIAAMVELSNKSRHAAGHIKKSCCSIFTEEMCTRLRIKENTRQTQE TSGRANA >P01273; 20 GLUCAGON PRECURSOR. MKNIYIVAGFFVVLVQGSWQHSLQDTEEKSRSFPASQTDPLEDPDQINEDKRHSQGTFTS DYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLEGQAAKEFI AWLVKGRGRRDFPEEVTIVEELGRRHADGSFSDEMNTILDSLATRDFINWLIQTKITDKK >P35052; 23 GLYPICAN-1 PRECURSOR. MELRARGWWLLCAAAALVACARGDPASKSRSCGEVRQIYGAKGFSLSDVPQAEISGEHLR ICPQGYTCCTSEMEENLANRSHAELETALRDSSRVLQAMLATQLRSFDDHFQHLLNDSER TLQATFPGAFGELYTQNARAFRDLYSELRLYYRGANLHLEETLAEFWARLLERLFKQLHP QLLLPDDYLDCLGKQAEALRPFGEAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQV PLGPECSRAVMKLVYCAHCLGVPGARPCPDYCRNVLKGCLANQADLDAEWRNLLDSMVLI TDKFWGTSGVESVIGSVHTWLAEAINALQDNRDTLTAKVIQGCGNPKVNPQGPGPEEKRR RGKLAPRERPPSGTLEKLVSEAKAQLRDVQDFWISLPGTLCSEKMALSTASDDRCWNGMA RGRYLPEVMGDGLANQINNPEVEVDITKPDMTIRQQIMQLKIMTNRLRSAYNGNDVDFQD ASDDGSGSGSGDGCLDDLCGRKVSRKSSSSRTPLTHALPGLSEQEGQKTSAASCPQPPTF LLPLLLFLALTVARPRWR >P15509; 22 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTO MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC FLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA AQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL DNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP RTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD VRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP QIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT >P51918; 22 GONADOLIBERIN I PRECURSOR (GONADOTROPIN-RELEASING HORMON MAAKILALWLLLAGTVFPQGCCQHWSYGLSPGGKRDLDNFSDTLGNMVEEFPRVEAPCSV FGCAEESPFAKMYRVKGLLASVAERKMDTGHSRNERFL >P07490; 23 GONADOLIBERIN I PRECURSOR (LHRH I) (LUTEINIZING HORMONE METIPKLMAAVVLLTVCLEGCSSQHWSYGLRPGGKRNTEHLVDSFQEMGKEEDQMAEPQN FECTVHWPRSPLRDLRGALERLIEEEAGQKKM >P30973; 23 GONADOLIBERIN III PRECURSOR (GONADOTROPIN-RELEASING HORM MDLSSKTVVQVVMLALIAQVTFSQHWSYGWLPGGKRSVGELEATIRMMDTGGVMALPEET GAHIPERLRPYDVMSKKRMPHK >P11654; 25 INTEGRAL MEMBRANE GLYCOPROTEIN GP210 PRECURSOR. MARASLIQPGLWALLLLQAVGPAVAAKLNIPKVLLPFTRATRVNFTLEASEGCYRWSSTR PEVASIEPLGSSEQQCSQKAVVQARLTQPARLTSIIFAEDITTGQVLRCDAIVDLIHGIQ IVSTTRELYLEDSPLELKIQALDSEGNTFSTLAGLVFDWTIVKDTEANGFSDSHNALRIL TFLESTYIPPSYISEMEKAAKQGDTILVSGMKTGSSKLKARIQEAVYKNVRPAEVRLLIL ENILLNPAYDVYLLVGTSIHYKVQKIRQGKITELSMPSDQYELQLQNSIPDPQGDPARPV AVLTQDTSRVTAMQMGQSNLVLGHRSIRMQGASRLPNSTIYVVEAGYLGFTVHPGDRWVL ETGHLYAVTIEVFDRSSNKVYPSDNIRIEAVFPAEFFEVLSSSQNGSYHHVRAIQSGQTT ISASLTSVVDQDGGVHVLQVPVWNQQEVDIHIPITLYPSILTFPWQPKTGAYQYTIKAHG GSGNFTWSSSSYMVATVTVKGVMTTGGDTGLSVIRAHDVQNPLHFGEMKVYVIEPSSMEF APCQVEARVGHTLELPLTISGLMPGGSSEVVTLSDCSHFDLVVEVENQGVFQPLPGRLPP GPEHCSGVKVRADAQGSTTLLVSYTHGHVHLGAKITLAAYLPLKAVDPSSVAVVTLGSSK EMLFEGGPRPWVLEPSKFFRNVTSEDTGSISLSLLGPPASRNYQQHRVLVTCQALGEQVI ALSVGNRPSLSNPFPAVEPTVVKSVCAPPSRLTLMPVYALPQLDLSCPLLQQNKQVVPVS SHRNPLLDLGAYDQQGRRFDNFSSLSIQWESFRPLLASIEVDQPMQLVSQDDGNGQKKLH GLQTVSVHEASGTTAISATATGYQQSHLSAAGVKQLRDPLVPVSASIELILVEDVRVSPE EVTIYNHPGVQVELHITEGSGYFFLNTSTQDIINVAYQDTRGVAMVHPLFPGSSTVMVHD LCLTFPAPAKATIHVSDIQELYVRVVDKVEIGKAVKAYVRVLDFYKKPFLAKYFTFMDLK LRAASQIITLVTLDEALDNYTATFLVHGVAIGQTSLSASVTDKSGQRVSSTAQQIEVFPP FRLIPRKVTLIIGAMIQITSEGGPQPQSNILFSINNESVAAVSSAGLVRGLMVGNGSVLG VVQAVDAETGKVIIVSQDHVEVEVLQLQAVRIRAPITRMRTGTQMPVYVTGITSNQSPFS FGNAVPGLTFHWSVTKRDVLDLRGRHHEVSIRLSPQYNFAMNVHGRVKGRTGLRVVVKAL DPTAGQLHGLGKELSDEIQIQVFEKLRLLNPEVEAEQILMSPNSFIKLQTNRDGAAILSY RVLDGPEKAPIVHIDEKGFLVSGSGIGVSTLEVIAQEPFGTNQTVLVAVKVSPISYLRIS MSPVLHTQHKEVLTALPLGMTVTFTVHFHDSSGDIFHAHNSDLNFATNRDDFVQIGKGAT NNTCIIRTVSVGLTLLHVWDVEHLGLSDFVPLPVLQAITPELSGAVVVGDILCLASVLIS LGGVSGTWSSSAGNVLYVDPKTGVAIARDAGPVTVYYEIAGHLKTFKEIVVVTPQKIVAR RLHATQTSIQEATASKVTVSVGDRSSNLLGECSSAQREAIEALHPESLISCQLQFKQDVF DFPARDIFSVEPGFDTALGQYLCSVTMHRLTDKQLKHLNMKKTSLAVTASMPSSRTSVEK VGAEVPFSPGLYANQAEILLSNHYPSSEVKIFGAVEILENLEVRSGSPAVLASVKEKSFG LPSFITYTVGVLDPTAGSQGPLSTALTFSSPATNQAITIPVTVAFVLDRRGPGPYGASLL SHFLDSYQVMFFTFFALLAGTAVTIIAYHTVCAPRELASPLALTPHASPQHSPHYLASSP TAFNTLPSDRKASPPSGLWSPAYASH >Q01493; 18 MAJOR MICROFILARIAL SHEATH PROTEIN PRECURSOR. MCCKAILSFCILSSLGNALYFGSHRPQYLREVGQRQYPFEPQAFGMLPVPQQPMGPQPMG PQPMEPQPLPMGPQSPQMQVPDRSCSGCVININCGGRECLPTRPTQTQPTQPSWTVETPP TPTPGASQGCRVCACYVPPPCQICQPCQ >P25291; 21 PANCREATIC SECRETORY GRANULE MEMBRANE MAJOR GLYCOPROTEIN MVGSYVLWLALASCILTLASPEQQGNRNLINTRSYDPCQNYTLLDEPSRSTENTEGSQVC DKDKHGWYRFVGDGGVRMPETCVPMYRCQTDAPLWLNGTHPTLAEGIVNRTACAHWSGNC CLWKTVVQVKACPGEFHVYRLEGTPKCSLRYCTDASTATDKCKNLCRPEEACSFLNGTWD CFCRSDLNSSDVHSLQPRLNCGAKEIQVSLDKCQLGGLGFGDEVIAYLRDWNCSNMMQRE ERNWISVTSPTQARACGNILERNGTHAIYKNTLSLANEFIIRDTILNINFQCAYPLDMKV SLQTALHPIVSSLNISVDGEGEFTVRMALFQDQSYISPYEGAAAVLAVESMLYVGAILEK GDTSRFNLLLRNCYATPTKDKTDPVKYFIIRNSCPNQYDSTIHVEENGVSSESRFSVQMF MFAGNYDLVFLHCEIHLCDSLNEQCQPCCSRSQQRSEIVALNPARVLDLGPITRRSSASV DITDGTPSTAGFLLAWPMLLLPILLAELF >P21978; 32 SURFACE MEMBRANE GLYCOPROTEIN GP46/M-2 PRECURSOR. MAQCVRRLVLAAPLAAVVALLLCTSSAPVARAAGTSDFTGAQQKNTLTVLQAFARAIPAL GDTWTGSDFCSWEHIICYSSGVGVWMHNVDYTGTLPEMPASVDYKDVMILALDFGAMGQG LSGTLPPSWSSMKHLIVLDLEGTKVSGTLPPEWSEMTSAEALQLENCGLSGSLPTSWSSM PKLRIVSLSGNHFCGCVPDSWREKDRLDVTIEEWHMGEDCKLANACRPTAAPGTTTTNPP TTTGTPAASSTPSPGSGCEVDGCEVCEGDSAARCARCREGYSLTDEKTCLGEPRWRRGGG VERTAGCRCCVGGCAVERGAGGVRVRRAPLLCGAPGACPRPRHGVVAALSPPPADGETDS HTRTRTRRRASRVLSAVVAPARMHGHAEACMRVRVPALVCLSVWPAVGTRRRSNVRAAAV CRLGQRRCGARPSPCASVCVSWPRERRTECACPALFDGARLRCCALVVCAGAAPAG >Q00689; 37 LEISHMANOLYSIN PRECURSOR (EC 3.4.24.36) (CELL SURFACE PR MSRDRSSTHRRRSVAARLIGFAAAGLVMAVGAAAVWAQAAGHHCIHDRLQARVLQSVAQQ RSVPAAFSALGLPYVSTGTISSAHTVDWALADSTSPSVARAADWGTLRIAVSTADLTDPG YHCTRVGQRVNNHNGEIVTCTAEDVLTEEKRDILVSYLIPQALQLHAERLKVRQVQGSWK VTGMTGSICGDFSVPTAHLTAGVTNADFVLYVASVPSEPGVLAWATTCQVFSDDHPAVGV INIPAANIVSRYDQGATRVVTHEVAHALGFSSTFFKSAGIVKSVTNLRGKPFAAPVINSS TVVAKAREQYGCPTLEYLEVEDQGGSGSAGSHIKMRNAKDELMAPASAAGYYTALTMAVF EDLGFYKADFTKAEVMPWGRNASCDFLTKKCMENNITQWPEMFCNTTERRYRCPTDRLRL GTCGIRTYSTPMPPYFEYFNDTFLAGYSAFLDYCPFTLGYSNGACNQDPSTAPALLKEFS VFSDASRCLDGAFQPTTAREVLMYNALCANVMCDTAARTYSVQVRGSSGYVACTPGQRVE LATLSAAFVNGSYITCPPYVEVCQANIKGVIDFEGDAADTAAMRRWRERMTALATVTAAL LGIVLAAMAILVVWLLLITIP >P21995; 24 TERATOCARCINOMA GLYCOPROTEIN GP-70 PRECURSOR. MRSHTGLRALVAPGYPLLLLCLLAATRPDPAEGDPTDPTFTSLPVREEMMAKYSNLSLKS CNISVTEKSNVSVEENVILEKPSHVELKCVYTATKDLNLMNVTWKKDDEPLETTGDFNTT KMGNTLTSQYRFIVFNSKQLGKYSCVFGEKELRGTFNIHVPQSSWEKKSLIAYVGDSTVL KCVCQDCLPLNWTWYMGNETAQVPIDAHSNEKYIINGSHANETRLKIKHLLEEDGGSYWC RATFQLGESEEQNELVVLSFLVPLKPFLAILAEVILLVAIILLCEVYTHKKKNGPDAGKE FEQIEQLKSDDSNGIENNVPRYRKTDSADQ >Q03877; 24 85 KD SURFACE ANTIGEN PRECURSOR. MSRRVFTSAALHLLVVMWMCCGPCEAAAASTGENSVNARQPQRFDLFVPQKTVLLPRGGG NSEKKWDSFASPSLVSAGGVIAAFAEGHLSSKNKDNKSTEPSSDAVAWYIDSAWEWSTLV GEVNKSTWQAHTVLGKVDGKERFDVVLRPTTTTKDNKVFLLAGSSVASNVNGSWSHGGLK LKLVVGDVRKPTDSEQSGRINWGEVQSPLNENSGAVQERKLTAFVASGGAGVLMEDGTIV FSLMARNEEEDVYSMIIYSKDDGSTWALSNSVSSAKCVNPRITEWEGSLLMIVDCEDEQK VYVSRDMGTTWTEAVGKLLGVWVNSGSGASQDSSLHVDALITATIEGRRVMLYTQRGNSL GENANPLYLWVTDNNRSFHVGPVGMDNAEKEELESALLYSDGKLHLLQRRVSGEGSVISL SRLTEELKEIESVLSTWAQKDIFFSSLSIPTAGLVAVLSDAAGDGRWNDEYLCLNATVKN AVKVKDGFQLTESNSRVLWSVNTRDNNLRHVFLSHDFTVVATVIIQNVPSGKTSLLTATL ANTESNYTMGLSYTADNKWETIFKGDKKPTTESRPWEPKKEYQVALMLQGKKASVYIDGR SLGEGEALLTDEKSLEFVHFCFGACVQESSPTAAQKTKVTVTNVFLYNRPLNSTEMRAIK DRIPIPKRGPGSQVEGGTERRHIPRIEGVRANAPVGSGLLPLLLLLGLWVFAAL >P14770; 16 PLATELET GLYCOPROTEIN IX PRECURSOR (GPIX) (CD42A). MPAWGALFLLWATAEATKDCPSPCTCRALETMGLWVDCRGHGLTALPALPARTRHLLLAN NSLQSVPPGAFDHLPQLQTLDVTQNPWHCDCSLTYLRLWLEDRTPEALLQVRCASPSLAA HGPLGRLTGYQLGSCGWQLQASWVRPGVLWDVALVAVAALGLALLAGLLCATTEALD >P07823; 18 78 KD GLUCOSE REGULATED PROTEIN PRECURSOR (GRP 78) (IMMU MKFPMVAAALLLLCAVRAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR ITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV EKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ RQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG VFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS SQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV LVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC PLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG TFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER MVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE KIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTSEKDEL >P16474; 42 78 KD GLUCOSE REGULATED PROTEIN HOMOLOG PRECURSOR (GRP 7 MFFNRLSAGKLLVPLSVVLYALFVVILPLQNSFHSSNVLVRGADDVENYGTVIGIDLGTT YSCVAVMKNGKTEILANEQGNRITPSYVAFTDDERLIGDAAKNQVAANPQNTIFDIKRLI GLKYNDRSVQKDIKHLPFNVVNKDGKPAVEVSVKGEKKVFTPEEISGMILGKMKQIAEDY LGTKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVLRIVNEPTAAAIAYGLDKSDKEHQI IVYDLGGGTFDVSLLSIENGVFEVQATSGDTHLGGEDFDYKIVRQLIKAFKKKHGIDVSD NNKALAKLKREAEKAKRALSSQMSTRIEIDSFVDGIDLSETLTRAKFEELNLDLFKKTLK PVEKVLQDSGLEKKDVDDIVLVGGSTRIPKVQQLLESYFDGKKASKGINPDEAVAYGAAV QAGVLSGEEGVEDIVLLDVNALTLGIETTGGVMTPLIKRNTAIPTKKSQIFSTAVDNQPT VMIKVYEGERAMSKDNNLLGKFELTGIPPAPRGVPQIEVTFALDANGILKVSATDKGTGK SESITITNDKGRLTQEEIDRMVEEAEKFASEDASIKAKVESRNKLENYAHSLKNQVNGDL GEKLEEEDKETLLDAANDVLEWLDDNFETAIAEDFDEKFESLSKVAYPITSKLYGGADGS GAADYDDEDEDDDGDYFEHDEL >P07727; 28 GLYCINE RECEPTOR ALPHA-1 CHAIN PRECURSOR (48 KD) (STRYCH MYSFNTLRFYLWETIVFFSLAASKEADAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNF KGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDS IWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTC IMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEA RFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRA SLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKDDEGGEG RFNFSAYGMGPACLQAKDGISVKGANNNNTTNPAPAPSKSPEEMRKLFIQRAKKIDKISR IGFPMAFLIFNMFYWIIYKIVRREDVHNK >P12544; 26 GRANZYME A PRECURSOR (EC 3.4.21.78) (CYTOTOXIC T-LYMPHOC MRNSYRFLASSLSVVVSLLLIPEDVCEKIIGGNEVTPHSRPYMVLLSLDRKTICAGALIA KDWVLTAAHCNLNKRSQVILGAHSITREEPTKQIMLVKKEFPYPCYDPATREGDLKLLQL TEKAKINKYVTILHLPKKGDDVKPGTMCQVAGWGRTHNSASWSDTLREVNITIIDRKVCN DRNHYNFNPVIGMNMVCAGSLRGGRDSCNGDSGSPLLCEGVFRGVTSFGLENKCGDPRGP GVYILLSKKHLNWIIMTIKGAV >P04187; 18 GRANZYME B(G,H) PRECURSOR (EC 3.4.21.79) (CYTOTOXIC CELL MKILLLLLTLSLASRTKAGEIIGGHEVKPHSRPYMALLSIKDQQPEAICGGFLIREDFVL TAAHCEGSIINVTLGAHNIKEQEKTQQVIPMVKCIPHPDYNPKTFSNDIMLLKLKSKAKR TRAVRPLNLPRRNVNVKPGDVCYVAGWGRMAPMGKYSNTLQEVELTVQKDRECESYFKNR YNKTNQICAGDPKTKRASFRGDSGGPLVCKKVAAGIVSYGYKDGSPPRAFTKVSSFLSWI KKTMKSS >P14095; 24 GROWTH REGULATED PROTEIN PRECURSOR (CYTOKINE-INDUCED NEU MVSATRSLLCAALPVLATSRQATGAPVANELRCQCLQTVAGIHFKNIQSLKVMPPGPHCT QTEVIATLKNGREACLDPEAPMVQKIVQKMLKGVPK >P10257; 24 GONADOTROPIN BETA-I CHAIN PRECURSOR (GTH-I). MYCTHLMTLQLVVMAMLWVTPVRAGTECRYGCRLNNMTIIVEREDCHGSITITTCAGLCE TTDLNYQSTWLPRSQGVCNFKEWSYEKVYLEGCPSGVEPFFIPVAKSCDCIKCKTDNTDC DRISMATPSCIVNPLEM >P01235; 27 GONADOTROPIN BETA CHAIN PRECURSOR. MGTPVKILVVRNHILFSVVVLLAVAQSSYLPPCEPVNETVAVEKEGCPKCLVLQTTICSG HCLTKEPVYKSPFSTVYQHVCTYRDVRYETVRLPDCPPGVDPHITYPVALSCDCSLCTMD TSDCTIESLQPDFCMSQREDFLVY >P07981; 22 ENDOGLUCANASE EG-1 PRECURSOR (EC 3.2.1.4) (ENDO-1,4-BETA MAPSVTLPLTTAILAIARLVAAQQPGTSTPEVHPKLTTYKCTKSGGCVAQDTSVVLDWNY RWMHDANYNSCTVNGGVNTTLCPDEATCGKNCFIEGVDYAASGVTTSGSSLTMNQYMPSS SGGYSSVSPRLYLLDSDGEYVMLKLNGQELSFDVDLSALPCGENGSLYLSQMDENGGANQ YNTAGANYGSGYCDAQCPVQTWRNGTLNTSHQGFCCNEMDILEGNSRANALTPHSCTATA CDSAGCGFNPYGSGYKSYYGPGDTVDTSKTFTIITQFNTDNGSPSGNLVSITRKYQQNGV DIPSAQPGGDTISSCPSASAYGGLATMGKALSSGMVLVFSIWNDNSQYMNWLDSGNAGPC SSTEGNPSNILANNPNTHVVFSNIRWGDIGSTTNSTAPPPPPASSTTFSTTRRSSTTSSS PSCTQTHWGQCGGIGYSGCKTCTSGTTCQYSNDYYSQCL >P07982; 21 ENDOGLUCANASE EG-II PRECURSOR (EC 3.2.1.4) (ENDO-1,4-BET MNKSVAPLLLAASILYGGAVAQQTVWGQCGGIGWSGPTNCAPGSACSTLNPYYAQCIPGA TTITTSTRPPSGPTTTTRATSTSSSTPPTSSGVRFAGVNIAGFDFGCTTDGTCVTSKVYP PLKNFTGSNNYPDGIGQMQHFVNEDGMTIFRLPVGWQYLVNNNLGGNLDSTSISKYDQLV QGCLSLGAYCIVDIHNYARWNGGIIGQGGPTNAQFTSLWSQLASKYASQSRVWFGIMNEP HDVNINTWAATVQEVVTAIRNAGATSQFISLPGNDWQSAGAFISDGSAAALSQVTNPDGS TTNLIFDVHKYLDSDNSGTHAECTTNNIDGAFSPLATWLRQNNRQAILTETGGGNVQSCI QDMCQQIQYLNQNSDVYLGYVGWGAGSFDSTYVLTETPTSSGNSWTDTSLVSSCLARK >P46237; 18 ENDOGLUCANASE TYPE C PRECURSOR (EC 3.2.1.4) (ENDO-1,4-BE MKSLSLILSALAVQVAVAQTPDKAKEQHPKLETYRCTKASGCKKQTNYIVADAGIHGIRQ KNGAGCGDWGQKPNATACPDEASCAKNCILSGMDSNAYKNAGITTSGNKLRLQQLINNQL VSPRVYLLEENKKKYEMLHLTGTEFSFDVEMEKLPCGMNGALYLSEMPQDGGKSTSRNSK AGAYYGAGYCDAQCYVTPFINGVGNIKGQGVCCNELDIWEANSRATHIAPHPCSKPGLYG CTGDECGSSGICDKAGCGWNHNRINVTDFYGRGKQYKVDSTRKFTVTSQFVANKQGDLIE LHRHYIQDNKVIESAVVNISGPPKINFINDKYCAATGANEYMRLGGTKQMGDAMSRGMVL AMSVWWSEGDFMAWLDQGVAGPCDATEGDPKNIVKVQPNPEVTFSNIRIGEIGSTSSVKA PAYPGPHRL >P19355; 17 EXOGLUCANASE I PRECURSOR (EC 3.2.1.91) (EXOCELLOBIOHYDRO MYQKLALISAFLATARAQSACTLQAETHPPLTWQKCSSGGTCTQQTGSVVIDANWRWTHA TNSSTNCYDGNTWSSTLCPDNETCAKNCCLDGAAYASTYGVTTSADSLSIGFVTQSAQKN VGARLYLMASDTTYQEFTLLGNEFSFDVDVSQLPCGLNGALYFVSMDADGGVTKYPTNTA GAKYGTGYCDSQCPRDLKFINGQANVEGWEPSSNNANTGIGGHGSCCSEMDIWEANSISE ALTPHPCTTVGQEICEGDSCGGTYSGDRYGGTCDPDGCDWNPYRLGNTSFYGPGSSFTLD TTKKLTVVTQFETSGAINRYYVQNGVTFQQPNAELGDYSGNSLDDDYCAAEEAEFGGSSF SDKGGLTQFKKATSGGMVLVMSLWDDYYANMLWLDSTYPTDETSSTPGAVRGSSSTSSGV PAQLESNSPNAKVVYSNIKFGPIGSTGNPSGGNPPGGNPPGTTTPRPATSTGSSPGPTQT HYGQCGGIGYIGPTVCASGSTCQVLNPYYSQCL >P07987; 24 EXOGLUCANASE II PRECURSOR (EC 3.2.1.91) (EXOCELLOBIOHYDR MIVGILTTLATLATLAASVPLEERQACSSVWGQCGGQNWSGPTCCASGSTCVYSNDYYSQ CLPGAASSSSSTRAASTTSRVSPTTSRSSSATPPPGSTTTRVPPVGSGTATYSGNPFVGV TPWANAYYASEVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTAN KNGGNYAGQFVVYDLPDRDCAALASNGEYSIADGGVAKYKNYIDTIRQIVVEYSDIRTLL VIEPDSLANLVTNLGTPKCANAQSAYLECINYAVTQLNLPNVAMYLDAGHAGWLGWPANQ DPAAQLFANVYKNASSPRALRGLATNVANYNGWNITSPPSYTQGNAVYNEKLYIHAIGPL LANHGWSNAFFITDQGRSGKQPTGQQQWGDWCNVIGTGFGIRPSANTGDSLLDSFVWVKP GGECDGTSDSSAPRFDSHCALPDALQPAPQAGAWFQAYFVQLLTNANPSFL >P06339; 20 H-2 CLASS I HISTOCOMPATIBILITY ANTIGEN, D-37 ALPHA CHAIN MLLFAHLLQLLVSATVPTQSSPHSLRYFTTAVSRPGLGEPRFIIVGYVDDTQFVRFDSDA ENPRMEPRARWIEQEGPEYWERETWKARDMGRNFRVNLRTLLGYYNQSNDESHTLQWMYG CDVGPDGRLLRGYCQEAYDGQDYISLNEDLRSWTANDIASQISKHKSEAVDEAHQQRAYL QGPCVEWLHRYLRLGNETLQRSDPPKAHVTHHPRSEDEVTLRCWALGFYPADITLTWQLN GEELTQDMELVETRPAGDGTFQKWAAVVVPLGKEQYYTCHVYHEGLPEPLTLRWEPPPST VSNMVIIAVLVVLGAVIILGAVVAFVMKRRRHIGVKGCYAHVLGSKSFQTSDWPQKA >P15979; 22 CLASS I HISTOCOMPATIBILITY ANTIGEN, F10 ALPHA CHAIN PREC MGPCGALGLGLLLAAVCGAAAPELHTLRYIQTAMTDPGPGQPWFVTVGYVDGELFVHYNS TARRYVPRTEWIAAKADQQYWDGQTQIGQGNEQIDRENLGILQRRYNQTGGSHTVQWMYG CDILEGGPIRGYYQMAYDGRDFTAFDKGTMTFTAAVPEAVPTKRKWEEESEPERWKNYLE ETCVEWLRRYVEYGKAELGRRERPEVRVWGKEADGILTLSCRAHGFYPRPIVVSWLKDGA VRGQDAHSGGIVPNGDGTYHTWVTIDAQPGDGDKYQCRVEHASLPQPGLYSWEPPQPNLV PIVAGVAVAIVAIAIMVGVGFIIYRRHAGKKGKGYNIAPGSNPAI >P14432; 26 H-2 CLASS I HISTOCOMPATIBILITY ANTIGEN, TLA(B) ALPHA CHA MRMGTPVPGTLLILLAASQGQTQTCPGSHSLRYFYTALSRPAISEPWYIAVGYLDDTQFV RFNSSGETATYKLSAPWVEQEGPEYWARETEIVTSNAQFFRENLQTMLDYYNLSQNGSHT IQVMYGCEVEFFGSLFRAYEQHGYDGPDYIALNEDLKTWTAADTAAEITRSKWEQAGYTE LRRTYLEGPCKDSLLRYLENRKKTQECTDPPKTHVTHHPRPEGYVTLRCWALRFYPADIT LTWQLNGEELIQDTELVETRPAGDGTFQKWAAVVVPLGKEQKYTCHVYHEGLPEPLTLRW EPPQTSMPNRTTVRALLGAMIILGFMSGSVMMWMRKNNGGNGDDNTAAYQNEREHLSLDP RAESEALGVEAGMKDLPSAPPLVS >P01904; 25 H-2 CLASS II HISTOCOMPATIBILITY ANTIGEN, E-D ALPHA CHAIN MATIGALVLRFFFIAVLMSSQKSWAIKEEHTIIQAEFYLLPDKRGEFMFDFDGDEIFHVD IEKSETIWRLEEFAKFASFEAQGALANIAVDKANLDVMKERSNNTPDANVAPEVTVLSRS PVNLGEPNILICFIDKFSPPVVNVTWLRNGRPVTEGVSETVFLPRDDHLFRKFHYLTFLP STDDFYDCEVDHWGLEEPLRKTWEFEEKTLLPETKENVMCALGLFVGLVGIVVGIILIMK GIKKRNVVERRQGAL >P01907; 23 HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DQ(5) ALPHA CHA MILNKALLLGALALTTVMSPCGGEDIVADHVASCGVNLYQFYGPSGQYTHEFDGDEQFYV DLERKETAWRWPEFSKFGGFDPQGALRNMAVAKHNLNIMIKRYNSTAATNEVPEVTVFSK SPVTLGQPNTLICLVDNIFPPVVNITWLSNGQSVTEDVSETSFLSKSDHSFFKISYLTFL PSADEIYDCKVEHWGLDQPLLKHWEPEIPAPMSELTETVVCALGLSVGLMGIVVGTVFII QGLRSVGASRHQGPL >P20036; 28 HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DP ALPHA CHAIN MRPEDRMFHIRAVILRALSLAFLLSLRGAGAIKADHVSTYAAFVQTHRPTGEFMFEFDED EMFYVDLDKKETVWHLEEFGQAFSFEAQGGLANIAILNNNLNTLIQRSNHTQATNDPPEV TVFPKEPVELGQPNTLICHIDKFFPPVLNVTWLCNGELVTEGVAESLFLPRTDYSFHKFH YLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQEPIQMPETTETVLCALGLVLGLVGIIVG TVLIIKSLRSGHDPRAQGTL >Q01528; 19 HEMAGGLUTININ/AMEBOCYTE AGGREGATION FACTOR PRECURSOR (18 MNSPAIVIIIFSTLTFSEAWVNDWDGALNFQCQLKDSIKTISSIHSNHHEDRRWNFGCER TLRDPSCYFTNYVNDWDKLLHFTCKSGEAIAGFNSYHDNRREDRRWKIYCCKDKNKCTDY RTCAWTGYVNSWDGDLHYTVPKDYVLTGVISEHDNHREDRRWKFQHCRLKNC >P01918; 32 HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DQ(1) BETA CHAI MSWKKALRIPGGLRAATVTLMLSMLSTPVAEGRDSPEDFVYQFKGMCYFTNGTERVRLVS RSIYNREEIVRFDSDVGEFRAVTLLGLPAAEYWNSQKDILERKRAAVDRVCRHNYQLELR TTLQRRVEPTVTISPSRTEALNHHNLLVCSVTDFYPAQIKVRWFRNDQEETAGVVSTPLI RNGDWTFQILVMLEMTPQRGDVYTCHVEHPSLQSPITVEWRAQSESAQSKMLSGIGGFVL GLIFLGLGLIIHHRSQKGLLH >P01915; 31 H-2 CLASS II HISTOCOMPATIBILITY ANTIGEN, E-D BETA CHAIN MVWLPRVPCVAAVILLLTVLSPPVALVRDTRPRFLEYVTSECHFYNGTQHVRFLERFIYN REENLRFDSDVGEYRAVTELGRPDAENWNSQPEILEDARASVDTYCRHNYEISDKFLVRR RVEPTVTVYPTKTQPLEHHNLLVCSVSDFYPGNIEVRWFRNGKEEETGIVSTGLVRNGDW TFQTLVMLETVPQSGEVYTCQVEHPSLTDPVTVEWKAQSTSAQNKMLSGVGGFVLGLLFL GAGLFIYFRNQKGQSGLQPTGLLS >P01913; 29 HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DR-1 BETA CHAIN MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELLKSECHFFNGTERVRFLERHF HNQEEYARFDSDVGEYRAVRELGRPDAEYWNSQKDLLEQKRGQVDNYCRHNYGVVESFTV QRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNG DWTFQTLVMLETFPRSGEVYTCQVEHPSVTSPLTVEWSARSESAQSKMLSGVGGFVLGLL FLGAGLFIYFRNQKGHSGLQPTGFLS >P01921; 27 H-2 CLASS II HISTOCOMPATIBILITY ANTIGEN, A-D BETA CHAIN MALQIPSLLLSAAVVVLMVLSSPRTEGGNSERHFVVQFKGECYYTNGTQRIRLVTRYIYN REEYVRYDSDVGEYRAVTELGRPDAEYWNSQPEILERTRAEVDTACRHNYEGPETSTSLR RLEQPNVAISLSRTEALNHHNTLVCSVTDFYPAKIKVRWFRNGQEETVGVSSTQLIRNGD WTFQVLVMLEMTPHQGEVYTCHVEHPSLKSPITVEWRAQSESARSKMLSGIGGCVLGVIF LGLGLFIRHRSQKGPRGPPPAGLLQ >P13765; 26 HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DO BETA CHAIN P MGSGWVPWVVALLVNLTRLDSSMTQGTDSPEDFVIQAKADCYFTNGTEKVQFVVRFIFNL EEYVRFDSDVGMFVALTKLGQPDAEQWNSRLDLLERSRQAVDGVCRHNYRLGAPFTVGRK VQPEVTVYPERTPLLHQHNLLHCSVTGFYPGDIKIKWFLNGQEERAGVMSTGPIRNGDWT FQTVVMLEMTPELGHVYTCLVDHSSLLSPVSVEWRAQSEYSWRKMLSGIAAFLLGLIFLL VGIVIQLRAQKGYVRTQMSGNEVSRAVLLPQSC >P25033; 19 HEMOLIN PRECURSOR (P4 PROTEIN) (HEMOCYTE AGGREGATION INH MAFKSIAVLSACIIVGSALPVDKYPVLKDQPAEVLFRENNPTVLECIIEGNDQGVKYSWK KDGKSYNWQEHNAALRKDEGSLVFLRPQASDEGHYQCFAETPAGVASSRVISFRKTYLIA SPAKTHEKTPIEGRPFQLDCVLPNAYPKPLITWKKRLSGADPNADVTDFDRRITAGPDGN LYFTIVTKEDVSDIYKYVCTAKNAAVDEEVVLVEYEIKGVTKDNSGYKGEPVPQYVSKDM MAKAGDVTMIYCMYGSNPMGYPNYFKNGKDVNGNPEDRITRHNRTSGKRLLFKTTLPEDE GVYTCEVDNGVGKPQKHSLKLTVVSAPKYEQKPEKVIVVKQGQDVTIPCKVTGLPAPNVV WSHNAKPLSGGRATVTDSGLVIKGVKNGDKGYYGCRATNEHGDKYFETLVQVN >P50828; 28 HEMOPEXIN PRECURSOR (HYALURONIDASE) (EC 3.2.1.35). MARALGTVEAPWLLGLCCSLAIAHPLSLTAGPKHGAEGRNESKPDPDVTERCSDGWGFDA STLDEHGAMLFFKGPSVWAGQNWTRGLISERWKNAPSSVDAAFRRGHDRVFLIQGDKVWV YPPEKEKENPRSLQEEFPGVPSPLDAAVECHRGECQDEGVLFFQGTHTWFWDSTTKTTKE RLWPAVGNCSSAMRWISRYYCFRGNQFLRFDPVTGHVDPKYPRDVRDYFMSCPGRGHAHR NATHRGDDRCSPDLVLTALLSDNHGATYAFRGTHYWRLDTSRDGWHSWPIDHQWSHGPSA VDAAFSWDDKLYLIQGTQVYIFLTKAGYTLVDNYPKQLEKELGSPHGISLDAVDATFVCP GTSRLHVMAGRKLWWLDLSLGAQGPWTELPWPHEKVDAALCTEKSLGPNSCSASGLGLYI VHGPHVYCYKDVEKLVSAKALPQPQSVNSLLGCHRSRGS >P20058; 25 HEMOPEXIN PRECURSOR. MVKASGIPIALGVWGLCWSLATVNSVPLTSAHGNVTEGESGTKPEADVIEQCSDGWSFDA TTLDDNGTMLFFKDEFVWKSHRGIRELISERWKNFIGPVDAAFRHGHTSVYLIKGDKVWV YTSEKNEKVYPKSLQDEFPGIPFPLDAAVECHRGECQDEGILFFQGNRKWFWDLTTGTKK ERSWPAVGNCTSALRWLGRYYCFQGNQFLRFNPVSGEVPPGYPLDVRDYFLSCPGRGHRS SHRNSTQHGHESTRCDPDLVLSAMVSDNHGATYVFSGSHYWRLDTNRDGWHSWPIAHQWP QGPSTVDAAFSWEDKLYLIQDTKVYVFLTKGGYTLVNGYPKRLEKELGSPPVISLEAVDA AFVCPGSSRLHIMAGRRLWWLDLKSGAQATWTELPWPHEKVDGALCMEKPLGPNSCSTSG PNLYLIHGPNLYCYRHVDKLNAAKNLPQPQRVSRLLGCTH >P05546; 19 HEPARIN COFACTOR II PRECURSOR (HC-II) (PROTEASE INHIBITO MKHSLNALLIFLIITSAWGGSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFH KENTVTNDWIPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHGK SRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGLKGETHEQVHSI LHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLRSVNDLYIQKQFPILLDFKTKV REYYFAEAQIADFSDPAFISKTNNHIMKLTKGLIKDALENIDPATQMMILNCIYFKGSWV NKFPVEMTHNHNFRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVP HKMSGMKTLEAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFDK NGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRFTVDRPFLFLIY EHRTSCLLFMGRVANPSRS >P06865; 22 BETA-HEXOSAMINIDASE ALPHA CHAIN PRECURSOR (EC 3.2.1.52) MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSV LDEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTI NDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHY LPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVK EVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEF MSTFFLEVSSVFPDFYLHLGGDEVDFTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLL DIVSSYGKGYVVWQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSAPW YLNRISYGPDWKDFYVVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAV AERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLNVGFCEQEFEQT >P14210; 31 HEPATOCYTE GROWTH FACTOR PRECURSOR (SCATTER FACTOR) (SF) MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIK TKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYE NKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNP RGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTP HRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPL ETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGS ESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNME DLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNL DHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRD LKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLP NYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAG AEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKII LTYKVPQS >P15515; 19 HISTATIN 1 PRECURSOR (HISTIDINE-RICH PROTEIN 1) (POST-PB MKFFVFALVLALMISMISADSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN >P13747; 21 HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, E E*0101/E*0102 MVDGTLLLLSSEALALTQTWAGSHSLKYFHTSVSRPGRGEPRFISVGYVDDTQFVRFDND AASPRMVPRAPWMEQEGSEYWDRETRSARDTAQIFRVNLRTLRGYYNQSEAGSHTLQWMH GCELGPDRRFLRGYEQFAYDGKDYLTLNEDLRSWTAVDTAAQISEQKSNDASEAEHQRAY LEDTCVEWLHKYLEKGKETLLHLEPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQQ DGEGHTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPVTLRWKPASQ PTIPIVGIIAGLVLLGSVVSGAVVAAVIWRKKSSGGKGGSYSKAEWSDSAQGSESHSL >Q02592; 27 HEAVY METAL TOLERANCE PROTEIN PRECURSOR. MVLRYNSPRLNILELVLLYVGFFSIGSLNLLQKRKATSDPYRRKNRFGKEPIGIISWWIL GIALTYVVDISNLVIYALRVPNWWPCKTTVVCLILFLLFWIIVLISCADSKALPKNADSI LKAYRLSVLYVWAIDIVFETIFIVYSPHPNETFQGIVLADHVARLVLCVFATAIYLTYRR KRHTHDPLDFEERQLTEESNVNENAISQNPSTVQLGVSASTSNFGTLKSTSKKPSDKSWA EYFRSFSTLLPYLWPTKDYRLQFQIFICIVLLFLGRAVNILAPRQLGVLTEKLTKHSEKI PWSDVILFVIYRFLQGNMGVIGSLRSFLWVPVSQYAYRAISTKALRHVLNLSYDFHLNKR AGEVLTALTKGSSLNTFAEQVVFQIGPVLLDLGVAMVYFFIKFDIYFTLIVLIMTLCYCY VTVKITSWRTEARRKMVNSWRESYAVQNDAIMNFETVKNFDADDFENERYGHAVDIYLKQ ERKVLFSLNFLNIVQGGIFTFSLAIACLLSAYRVTFGFNTVGDFVILLTYMIQLQQPLNF FGTLYRSLQNSIIDTERLLEIFEEKPTVVEKPNAPDLKVTQGKVIFSHVSFAYDPRKPVL SDINFVAQPGKVIALVGESGGGKSTIMRILLRFFDVNSGSITIDDQDIRNVTLSSLRSSI GVVPQDSTLFNDTILYNIKYAKPSATNEEIYAAAKAAQIHDRILQFPDGYNSRVGERGLK LSGGEKQRVAVARAILKDPSIILLDEATSALDTNTERQIQAALNRLASGRTAIVIAHRLS TITNADLILCISNGRIVETGTHEELIKRDGGAYKKMWFQQAMGKTSAETH >Q25055; 20 HOLOTRICIN 3 PRECURSOR. MNKLIILGLACIIAVASAMPYGPGDGHGGGHGGGHGGGHGNGQGGGHGHGPGGGFGGGHG GGHGGGGRGGGGSGGGGSPGHGAGGGYPGGHGGGHHGGYQTHGY >Q06575; 23 HIBERNATION-ASSOCIATED PLASMA PROTEIN HP-20 PRECURSOR (H MTDVWRLAIFVLMVNVLNDQVSCSGPPGPVGYPGVPGVPGPRGPPGQPGAAGRPGDPGPK GPSVKCPCRERSAFTVKFSGRLPPPSEPVVFTEVLYNTQRDLKESTGVFNCVEPGNYHFS FDVELYHCKVKIGLMKNHIQVMEKHQLSKNEYENASGAMIMPLRQGDKVWLEADVETEEP DQAKVVIYFSGFLISS >Q06576; 28 HIBERNATION-ASSOCIATED PLASMA PROTEIN HP-25 PRECURSOR (H MPAQRGGALSMGAAGFWILVLSITSALADSNNQGNSEPCGPPGPPGPPGIPGFPGAPGAL GPPGPPGVPGIPGPQGPPGDVEKCSSRPKSAFAVKLSERPPEPFQPIVFKEALYNQEGHF NMATGEFSCVLPGVYNFGFDIRLFQSSVKIRLMRDGIQVREKEAQANDSYKHAMGSVIMA LGKGDKVWLESKLKGTESEKGITHIVFFGYLLYGK >P00738; 18 HAPTOGLOBIN-2 PRECURSOR. MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRT EGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTE GDGVYTLNNEKQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMV SHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHP NYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFA VHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN >P04196; 18 HISTIDINE-RICH GLYCOPROTEIN PRECURSOR (HISTIDINE-PROLINE MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDR VENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLR VIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRI ERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVIN CEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPP PDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQH PHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPP PHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSF PLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK >P04929; 23 HISTIDINE-RICH GLYCOPROTEIN PRECURSOR. MFTSLKKVATFSFLVWISQYSGSNSCSSSLVKHIPQTGSNLTFDRVLVEDTVHPEHLHEE HHHHHPEEHHEPHHEEHHHHHPEEHHEPHHEEHHHHHPHPHHHHHHHPPHHHHHLGHHHH HHHAAHHHHHEEHHHHHHAAHHHHHEEHHHHHHAAHHHPWFHHHHLGYHHHHAPHHHHHH HHAPHHHHHHHHAPHHHHHHHHAPHHHHHHHHAPHHHHHHHHGHHHHHHHHHGHHHHHHH HHGHHHHHHHHHDAHHHHHHHHDAHHHHHHHHDAHHHHHHHHDAHHHHHHHHDAHHHHHH HHDAHHHHHHHDAHHHHHHHHDAHHHHHHHHDAHHHHHHHHDAHHHHHHHH >P04930; 21 SMALL HISTIDINE-ALANINE-RICH PROTEIN PRECURSOR (SHARP) ( MVSFSKNKILSAAVFASVLLLDNNNSEFNNNLFSKNAKGLNSNKRLLHESQAHAGDAHHA HHVADAHHAHHAANAHHAANAHHAANAHHAANAHHAANAHHAANAHHAANAHHAANAHHA ANAHHAANAHHAANAHHAANAHHAADANHGFHFNLHDNNSHTLHHAKANACFDDSHHDDA HHDGAHHDDAHHDGAHHDGAHHDGAHHDGAHHNATTHHLHH >P29844; 18 HEAT SHOCK 70 KD PROTEIN COGNATE 3 PRECURSOR (78 KD GLUC MKLCILLAVVAFVGLSLGEEKKEKDKELGTVIGIDLGTTYSCVGVYKNGRVEIIANDQGN RITPSYVAFTADGERLIGDAAKNQLTTNPENTVFDAKRLIGREWSDTNVQHDIKFFPFKV VEKNSKPHISVDTSQGAKVFAPEEISAMVLGKMKETAEAYLGKKVTHAVVTVPAYFNDAQ RQATKDAGVIAGLQVMRIINEPTAAAIAYGLDKKEGEKNVLVFDLGGGTFDVSLLTIDNG VFEVVATNGDTHLGGEDFDQRVMDHFIKLYKKKKGKDIRKDNRAVQKLRREVEKAKRALS GSHQVRIEIESFFEGDDFSETLTRAKFEELNLDLFRSTLKPVQKVLEDADMNKKDVHEIV LVGGSTRIPKVQQLVKDFFGGKEPSRGINPDEAVAYGAAVQAGVLSGEQDTDAIVLLDVN PLTMGIETVGGVMTKLIPRNTVIPTKKSQVFSTASDNQHTVTIQVYEGERPMTKDNHLLG KFDLTGIPPAPRGIPQIEVSFEIDANAILTVSAEDKGTGNKEKIVITNDQNRLTPEDIDR MIRDAEKFADEDKKLKERVESRNELESYAYSLKNQIGDKDKLGAKLSDDEKTKLESAIDE SIKWLEQNPDADPEEYKKQKKDLEAIVQPVIAKLYQGAGGAPPPEGGDDADLKDEL >Q17128; 21 HYPERTREHALOSAEMIC HORMONE PRECURSOR (HTH) (HYPERTREHALO MNHLVKVLIVVVAIALVLCEAQVNFSPGWGTGKRSAVQDSPCKGSAESLMYIYKLVQNEA QKILECEKFSSN >P01813; 19 IG HEAVY CHAIN PRECURSOR V REGION. MGLGLHLLVLAAALQGAWSQVQLVESGGDVRKPGNSLRLSCKASGFTFGGYGMFWVRQAP GKGLDWVATINTDGSSQWYSPAVQGKFTISRGNSQNMLYLQMSSLTPEDTATYYCAR >P03983; 19 IG HEAVY CHAIN PRECURSOR V REGION. MRSAISLSLLLVFLSRVQSDIVLTQPEADTGKPEGSLRLTCKTSGFSLGSYYMTWVRQVP GQGLEWLVSYHSSSYQYYAPEIKDRFTASKDTSNNIFALDMKSLKTEDTAMYYCAR >P01805; 19 IG HEAVY CHAIN PRECURSOR V REGION (IR2). MDLRLTYVFIVAILKGVLCEVKLEESGGGLVQPGMSVKLSCATSGFTFSDYWMEWVRQAP GKGLEWVAEIRNKANNYVAYYGKSLKGRFTLSRDDSKSIVYLQMNNIRSEDTGIYYCSRG YGGYSENWFVYWGQGTLVTVSS >P03982; 19 IG HEAVY CHAIN PRECURSOR V REGION. MTHWLCFTLALVAVRGVLSEIQLVESGGAIRKPGDSLRLSCKASGFTFSDTWMAWARQPP GKGLQWVGEINGNSETIRYAPEVKGRLTISRDNTQNLLFLQISSLKPEDTATYYCAR >P01751; 19 IG HEAVY CHAIN PRECURSOR V REGION (B1-8 / 186-2). MGWSCIMLFLAATATGVHSQVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRP GRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYDY YGSSYFDYWGQGTTLTVSS >P01744; 15 IG HEAVY CHAIN PRECURSOR V-I REGION (ND) (FRAGMENTS). MDWTFLVAAATRVHSQTQLVQSGAEVRKPGASVRVSCKASGYTFIDSYIHWIRQAPGHGL EWVGWINPNSGGTNYAPRFQGRVTMTRDASFSTAYMDLRSLRSDDSAVFYCAKSDPFWSD YYNFDYSYTLDVWGQGTTVTVSS >P04438; 19 IG HEAVY CHAIN PRECURSOR V-II REGION (SESS). MDILCSTLLLLTVPSGVLSQVNLRESGPALVKATHTLTLTCTFSGLSVNTRGMSVSWIRQ PPGKALEWLARIDWDDDKYYGTSLETRLTISKDTSKNQVVLKVTNMDPADTATYYCARMQ VTMVREVMITSNAFDIWGQGTWSPSLQ >P06331; 19 IG HEAVY CHAIN PRECURSOR V-II REGION (ARH-77). MKHLWFLLLWCQLPDVGVLSQVQLQQWGAGLVKPSETLSLTCAVFGGSFSGYYWSWIRQP PGRGLEWIGEINHSGSTNYKTSLKSRVTISLDTSKNLFSLKLSSVTAADTAVYYCARGLL RGGWNDVDYYYGMDVWGQGTTVTVSS >P01822; 18 IG HEAVY CHAIN PRECURSOR V REGION (MOPC 315). MKVLSLLYLLTAIPGIMSDVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYFWNWIRQFP GNKLEWLGFIKYDGSNGYNPSLKNRVSITRDTSENQFFLKLNSVTTEDTATYYCAGDNDH LYYFDYWGQGTTLTVSS >P29459; 22 INTERLEUKIN-12 ALPHA CHAIN PRECURSOR (IL-12A) (CYTOTOXIC MCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLE FYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMM ALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQK SSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVTSYLNAS >P29460; 22 INTERLEUKIN-12 BETA CHAIN PRECURSOR (IL-12B) (CYTOTOXIC MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC RKNASISVRAQDRYYSSSWSEWASVPCS >P22362; 23 T LYMPHOCYTE-SECRETED PROTEIN I-309 PRECURSOR (SMALL IND MQIITTALVCLLLAGMWPEDVDSKSMQVPFSRCCFSFAEQEIPLRAILCYRNTSSICSNE GLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK >P20155; 23 ACROSIN-TRYPSIN INHIBITOR II PRECURSOR (HUSI-II). MALSVLRLALLLLAVTFAASLIPQFGLFSKYRTPNCSQYRLPGCPRHFNPVCGSDMSTYA NECTLCMKIREGGHNIKIIRNGPC >P24591; 25 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PRECURSOR ( MPEVLAVRAWPLLLSLAVQLGATVGAPQPWRCAPCSAERMALCPPVPASCPELTRSAGCG CCPMCALPLGAACGVATARCARGLSCRALPGEPRPLHALTRGQGACMTSPCDEATDTKDT TSPENVSPESSEITQEQLLDNFHLMAESSEDLPILWNAISNYESLRALEISDVKKWKEPC QRELYKVLDRLAREQQKAGDKLYKFYLPNCNKNGFYHSKQCETSLEGEPGLCWCVYPWSG KRILGSVAVRGDPKCQQYFNLQN >P22692; 21 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 PRECURSOR ( MLPLCLVAALLLAAGPGPSLGDEAIHCPPCSEEKLARCRPPVGCEELVREPGCGCCATCA LGLGMPCGVYTPRCGSGLRCYPPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDE GDHPNNSFSPCSAHDRRCLQKHFAKIRDRSTSGGKMKVNGAPREDARPVPQGSCQSELHR ALERLAASQSRTHEDLYIIPIPNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGG LEPKGELDCHQLADSFRE >P05362; 25 INTERCELLULAR ADHESION MOLECULE-1 PRECURSOR (ICAM-1) (MA MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGI ETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAP LPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHH GANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLD GLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKA TPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQ AWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTREVTVNVLSPRYE IVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP >Q00630; 17 INSECTICYANIN B FORM PRECURSOR (BLUE BILIPROTEIN) (INS-B MQRFLVFTIVAVATAAAGDIFYPGYCPDVKPVDDFDLSAFAGAWHEIAKLPLENENQGKC TIAEYKYDGKKASVYNSFVVNGVKEYMEGDLEIAPDAKYTKQGKYVMTFKFGQRVVNLVP WVLATDYKNYAINYNCNYHPDKKAHSIHAWILSKSKVLEGNTKEVVDNVLKTFSHLIDAS KFISNDFSEAACQYSTTYSLTGPDRH >P01346; 24 INSULIN-LIKE GROWTH FACTOR II PRECURSOR (MULTIPLICATION MGIPVGKSMLVLLISLAFALCCIAAYRPSETLCGGELVDTLQFVCSDRGFYFSRPSSRAN RRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTSQAVLPDDFPRYPVGKFFKFDTWR QSAGRLRRGLPALLRARRGRMLAKELEAFREAKRHRPLIVLPPKDPAHGGASSEMSSNHQ >P01592; 21 IMMUNOGLOBULIN J CHAIN PRECURSOR. MKTHLLLWGVLAIFVKVVLVTGDDEATILADNKCMCTRVTSKIIPSTEDPNEDIVERNIR IVVPLNNRENISDPTSPLRRNFVYHLSDVCKKCDPVEVELEDQVVTATQSNICNEDDGVP ETCYMYDRNKCYTTMVPLRYHGETKMVQAALTPDSCYPD >Q06323; 24 INTERFERON GAMMA UP-REGULATED I-5111 PROTEIN PRECURSOR ( MAMLRVQPEAQAKVDVFREDLCTKTENLLGSYFPKKISELDAFLKEPALNEANLSNLKAP LDIPVPDPVKEKEKEERKKQQEKEDKDEKKKGEDEDKGPPCGPVNCNEKIVVLLQRLKPE IKDVIEQLNLVTTWLQLQIPRIEDGNNFGVAVQEKVFELMTSLHTKLEGFHTQISKYFSE RGDAVTKAAKQPHVGDYRQLVHELDEAEYRDIRLMVMEIRNAYAVLYDIILKNFEKLKKP RGETKGMIY >P35225; 20 INTERLEUKIN-13 PRECURSOR (IL-13). MALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTA GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLL HLKKLFREGRFN >P40222; 15 INTERLEUKIN-14 PRECURSOR (IL-14) (HIGH MOLECULAR WEIGHT MIRLLRSIIGLVLALPKGRGSDAKGLLTSTSSHAKTFSRSLVSRQEIPSSERPARLCLGT PFLRSREVKVSLPEQLGGPELDLSKPCSSRQMQFNDLGVLLVLSSEGQGGVIEPQSQTEK CSSHFCQLTVMAATDDSPSQDSSAHRQATDFICTHPHPQCKLHCTLTGINAFARPCKMPY VRKTDPQKCQNCKCQMPARSEHAWLQQWAAQHGSLLWARLAGLPLPSQHDPTPGSLGPGG GGLLRPVWPDASVLGCSWVARRFCDPGGAGCLMPQCPSGLLSGPLSVREPWPPALRSCTL LFRSLRSVCSARHSFSSRWIFTCRPSSSLSRTVFSSAISSRALLLLSHRDRYMVVSFSSF LIFLVIFSISCLNVVNTSLLLESVFWNSSNFSVYRASCCFRWVSCCFISSHILWDSTASF RRKSFSRWCRSSASFSISWACWSLASTSCCCRSLCLKTLSICSSRSSYCSISFLSLSASS MFSWRSLELRSLCCSICS >P12342; 21 INTERLEUKIN-2 RECEPTOR ALPHA CHAIN PRECURSOR (IL-2 RECEP MEPSLLMWRFFVFIVVPGCVTEACHDDPPSLRNAMFKVFRYEVGTMINCDCKTGFRRVSA VMRCVGDSSHSAWENRCFCNSTSPAKNQVKQVTPAPEEHREKKHTDAQNQTQPPEEADLP GHCEEPPPWEHEREPLKRVYHFTLGQTVHYQCAQGFRALQTSPAESTCMMINGELRWTRP RLKCIREGEHGQASDDAEPQESTEAPPGSGTFLPTRMAGTTNFQKPTDEIATLDTFIFTT EYQIAVAGCTLLLASILLLSCLTWQRKWKKNRRTI >P04351; 20 INTERLEUKIN-2 PRECURSOR (IL-2) (T-CELL GROWTH FACTOR) (T MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLS RMENYRNLKLPRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENF ISNIRVTVVKLKGSDNTFECQFDDESATVVDFLRRWIAFCQSIISTSPQ >P16382; 25 INTERLEUKIN-4 RECEPTOR ALPHA CHAIN PRECURSOR (IL-4R-ALPH MGRLCTKFLTSVGCLILLLVTGSGSIKVLGEPTCFSDYIRTSTCEWFLDSAVDCSSQLCL HYRLMFFEFSENLTCIPRNSASTVCVCHMEMNRPVQSDRYQMELWAEHRQLWQGSFSPSG NVKPLAPDNLTLHTNVSDEWLLTWNNLYPSNNLLYKDLISMVNISREDNPAEFIVYNVTY KEPRLSFPINILMSGVYYTARVRVRSQILTGTWSEWSPSITWYNHFQLPLIQRLPLGVTI SCLCIPLFCLFCYFSITKIKKIWWDQIPTPARSPLVAIIIQDAQVPLWDKQTRSQESTKY PHWKTCLDKLLPCLLKHRVKKKTDFPKAAPTKSLQSPGKAGWCPMEVSRTVLWPENVSVS VVRCMELFEAPVQNVEEEEDEIVKEDLSMSPENSGGCGFQESQADIMARLTENLFSDLLE AENGGLGQSALAESCSPLPSGSGQASVSWACLPMGPSEEATCQVTEQPSHPGPLSGSPAQ SAPTLACTQVPLVLADNPAYRSFSDCCSPAPNPGELAPEQQQADHLEEEEPPSPADPHSS GPPMQPVESWEQILHMSVLQHGAAAGSTPAPAGGYQEFVQAVKQGAAQDPGVPGVRPSGD PGYKAFSSLLSSNGIRGDTAAAGTDDGHGGYKPFQNPVPNQSPSSVPLFTFGLDTELSPS PLNSDPPKSPPECLGLELGLKGGDWVKAPPPADQVPKPFGDDLGFGIVYSSLTCHLCGHL KQHHSQEEGGQSPIVASPGCGCCYDDRSPSLGSLSGALESCPEGIPPEANLMSAPKTPSN LSGEGKGPGHSPVPSQTTEVPVGALGIAVS >P07750; 20 INTERLEUKIN-4 PRECURSOR (IL-4) (B-CELL STIMULATORY FACTO MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATK NTTESELVCRASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESK STSLKDFLESLKSIMQMDYS >P21183; 17 INTERLEUKIN-5 RECEPTOR ALPHA CHAIN PRECURSOR (IL-5R-ALPH MVPVLLILVGALATLQADLLNHKKFLLLPPVNFTIKATGLAQVLLHWDPNPDQEQRHVDL EYHVKINAPQEDEYDTRKTESKCVTPLHEGFAASVRTILKSSHTTLASSWVSAELKAPPG SPGTSVTNLTCTTHTVVSSHTHLRPYQVSLRCTWLVGKDAPEDTQYFLYYRFGVLTEKCQ EYSRDALNRNTACWFPRTFINSKGFEQLAVHINGSSKRAAIKPFDQLFSPLAIDQVNPPR NVTVEIESNSLYIQWEKPLSAFPDHCFNYELKIYNTKNGHIQKEKLIANKFISKIDDVST YSIQVRAAVSSPCRMPGRWGEWSQPIYVGKERKSLVEWHLIVLPTAACFVLLIFSLICRV CHLWTRLFPPVPAPKSNIKDLPVVTEYEKPSNETKIEVVHCVEEVGFEVMGNSTF >P22272; 19 INTERLEUKIN-6 RECEPTOR ALPHA CHAIN PRECURSOR (IL-6R-ALPH MLTVGCTLLVALLAAPAVALVLGSCRALEVANGTVTSLPGATVTLICPGKEAAGNVTIHW VYSGSQNREWTTTGNTLVLRDVQLSDTGDYLCSLNDHLVGTVPLLVDVPPEEPKLSCFRK NPLVNAICEWRPSSTPSPTTKAVLFAKKINTTNGKSDFQVPCQYSQQLKSFSCQVEILEG DKVYHIVSLCVANSVGSKSSHNEAFHSLKMVQPDPPANLVVSAIPGRPRWLKVSWQHPET WDPSYYLLQFQLRYRPVWSKEFTVLLLPVAQYQCVIHDALRGVKHVVQVRGKEELDLGQW SEWSPEVTGTPWIAEPRTTPAGILWNPTQVSVEDSANHEDQYESSTEATSVLAPVQESSS MSLPTFLVAGGSLAFGLLLCVFIILRLKQKWKSEAEKESKTTSPPPPPYSLGPLKPTFLL VPLLTPHSSGSDNTVNHSCLGVRDAQSPYDNSNRDYLFPR >P05231; 29 INTERLEUKIN-6 PRECURSOR (IL-6) (B-CELL STIMULATORY FACTO MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYI LDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLL EFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQ AQNQWLQDMTTHLILRSFKEFLQSSLRALRQM >P16871; 20 INTERLEUKIN-7 RECEPTOR ALPHA CHAIN PRECURSOR (IL-7R-ALPH MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFE DPDVNTTNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKK IDLTTIVKPEAPFDLSVIYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTH VNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDP ILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNP ESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVVTPES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFS LQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ >P13232; 25 INTERLEUKIN-7 PRECURSOR (IL-7). MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCL NNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQ VKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH >P10145; 22 INTERLEUKIN-8 PRECURSOR (IL-8) (MONOCYTE-DERIVED NEUTROP MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPH CANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS >P15247; 18 INTERLEUKIN-9 PRECURSOR (IL-9) (T-CELL GROWTH FACTOR P40 MLVTYILASVLLFSSVLGQRCSTTWGIRDTNYLIENLKDDPPSKCSCSGNVTSCLCLSVP TDDCTTPCYREGLLQLTNATQKSRLLPVFHRVKRIVEVLKNITCPSFSCEKPCNQTMAGN TLSFLKSLLGTFQKTEMQRQKSRP >P01562; 23 INTERFERON ALPHA-1/13 PRECURSOR (INTERFERON ALPHA-D) (LE MASPFALLMVLVVLSCKSSCSLGCDLPETHSLDNRRTLMLLAQMSRISPSSCLMDRHDFG FPQEEFDGNQFQKAPAISVLHELIQQIFNLFTTKDSSAAWDEDLLDKFCTELYQQLNDLE ACVMQEERVGETPLMNADSILAVKKYFRRITLYLTEKKYSPCAWEVVRAEIMRSLSLSTN LQERLRRKE >P01574; 21 INTERFERON BETA PRECURSOR (IFN-BETA) (FIBROBLAST INTERFE MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFD IPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLK TVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINR LTGYLRN >P15261; 22 INTERFERON-GAMMA RECEPTOR ALPHA CHAIN PRECURSOR. MGPQAAAGRMILLVVLMLSAKVGSGALTSTEDPEPPSVPVPTNVLIKSYNLNPVVCWEYQ NMSQTPIFTVQVKVYSGSWTDSCTNISDHCCNIYGQIMYPDVSAWARVKAKVGQKESDYA RSKEFLMCLKGKVGPPGLEIRRKKEEQLSVLVFHPEVVVNGESQGTMFGDGSTCYTFDYT VYVEHNRSGEILHTKHTVEKEECNETLCELNISVSTLDSRYCISVDGISSFWQVRTEKSK DVCIPPFHDDRKDSIWILVVAPLTVFTVVILVFAYWYTKKNSFKRKSIMLPKSLLSVVKS ATLETKPESKYSLVTPHQPAVLESETVICEEPLSTVTAPDSPEAAEQEELSKETKALEAG GSTSAMTPDSPPTPTQRRSFSLLSSNQSGPCSLTAYHSRNGSDSGLVGSGSSISDLESLP NNNSETKMAEHDPPPVRKAPMASGYDKPHMLVDVLVDVGGKESLMGYRLTGEAQELS >P01579; 20 INTERFERON GAMMA PRECURSOR (IFN-GAMMA) (IMMUNE INTERFERO MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWK EESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTN YSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ >P02778; 21 INTERFERON-GAMMA INDUCED PROTEIN PRECURSOR (GAMMA-IP10). MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRV EIIATMKKKGEKRCLNPESKAIKNLLKAVSKEMSKRSP >P05002; 23 INTERFERON OMEGA-2 PRECURSOR (INTERFERON ALPHA-II-2). MALLPSLLTALVVYELWPCGALGCDLPQNHILVSRKNFVLLGQMSRISSAICLKDRKDFR FPQDMADGRQFPEAQAASVLHEMLQQIFSLFHTERSSAAWNTTLLDELCTGLLRQLEDLD TCLEQEMGEEESALGTVRPTLAVKRYFRGIHLYLKEKKYSDCAWEIVRMEIMRSFSSSAN LQGRLRMKDGDLGSP >P06213; 27 INSULIN RECEPTOR PRECURSOR (EC 2.7.1.112) (IR). MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNHIVLNKDDNE ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN PS >P15127; 26 INSULIN RECEPTOR PRECURSOR (EC 2.7.1.112) (IR). MGSGRGCETTAVPLLMAVAVAGGTAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQ ILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALV IFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDYVEDNYIVLNKDDNEE CGDVCPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHKECLG NCSEPDDPTKCVACRNFYLDGQCVETCPPPYYHFQDWRCVNFSFCQDLHYKCRNSRKPGC HQYVIHNNKCIPECPSGYTMNSSNLMCTPCLGPCPKVCQILEGEKTIDSVTSAQELRGCT VINGSLIINIRGGNNLAAELEANLGLIEEISGFLKIRRSYALVSLSFFRKLHLIRGETLE IGNYSFYALDNQNLRQLWDWNKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQER NDIALKTNGDQASCENELLKFSFIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQN VTEFDGQDACGSNSWTVVDIDPPQRSNDPKSQTPSHPGWLMRGLKPWTQYAIFVKTLVTF SDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVYW ERQAEDSELFELDYCLKGLKLPSRTWSPPFESDDSQKHNQSEYDDSASECCSCPKTDSQI LKELEESSFRKTFEDYLHNVVFVPRKTSSGNGAEDTRPSRKRRSLEEVGNVTATTPTLPD FPNISSTIAPTSHEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDSPEERSGVAAY VSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLC VSRKHFALERGCRLRGLSPGNYSVRVRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIII GPLIFVFLFSVVIGSIYLFLRKRQPDGPMGPLYASSNPEYLSASDVFPSSVYVPDEWEVP REKITLLRELGQGSFGMVYEGNAKDIIKGEVETRVAVKTVNESASLRERIEFLNEASVMK GFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSHLRSLRPDAENNPGRPPPTLQEMIQM TAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLP VRWMSPESLKDGVFTASSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDPPD NCPERLTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFYSEENKAPESEELEM EFEDMENVPLDRSSHCQREEAGCREGGSSLSIKRTYDEHIPYTHMNGGKKNGRVLTLPRS NPS >P01335; 21 INSULIN PRECURSOR. MAVWIQAGALLFLLAVSSVNANAGAPQHLCGSHLVDALYLVCGPTGFFYNPKRDVDPPLG FLPPKSAQETEVADFAFKDHAEVIRKRGIVEQCCHKPCSIFELQNYCN >P01342; 26 INSULIN PRECURSOR. MALSPFLAAVIPLVLLLSRAPPSADTRTTGHLCGKDLVNALYIACGVRGFFYDPTKMKRD TGALAAFLPLAYAEDNESQDDESIGINEVLKSKRGIVEQCCHKRCSIYDLENYCN >P07635; 19 INVERTASE 7 PRECURSOR (EC 3.2.1.26) (BETA-FRUCTOFURANOSI MLLQAFIFLLAGFAAKISALMTNETSDRPLVHFTPNKGWMNDPNGLWYDAKEGKWHLYFQ YNPNDTVWGLPLFWVNMTTGVDNLFYIDKFQVREVK >P24133; 22 INVERTASE PRECURSOR (EC 3.2.1.26) (BETA-FRUCTOFURANOSIDA MVQVLSVLVIPLLTLFFGYVASSSIDLSVDTSEYNRPLIHFTPEKGWMNDPNGLFYDKTA KLWHLYFQYNPNATAWGQPLYWGHATSNDLVHWDEHEIAIGPEHDNEGIFSGSIVVDHNN TSGFFNSSIDPNQRIVAIYTNNIPDLQTQDIAFSLDGGYTFTKYENNPVIDVSSNQFRDP KVFWHERFKSMDHGCSEIARVKIQIFGSANLKNWVLNSNFSSGYYGNQYGMSRLIEVPIE NSDKSKWVMFLAINPGSPLGGSINQYFVGDFDGFQFVPDDSQTRFVDIGKDFYAFQTFSE VEHGVLGLAWASNWQYADQVPTNPWRSSTSLARNYTLRYVIQMLKLTANIDKSVLPDSIN VVDKLKKKNVKLTNKKPIKTNFKGSTGLFDFNITFKVLNLNVSPGKTHFDILINSQELNS SVDSIKIGFDSSQSLFYIDRHIPNVEFPRKQFFTDKLAAYLEPLDYDQDLRVFSLYGIVD KNIIELYFNDGTVAMTNTFFMGEGKYPHDIQIVTDTEEPLFELESVIIRELNK >P10184; 23 OVOINHIBITOR PRECURSOR. MRTARQFVQVALALCCFADIAFGIEVNCSLYASGIGKDGTSWVACPRNLKPVCGTDGSTY SNECGICLYNREHGANVEKEYDGECRPKHVMIDCSPYLQVVRDGNTMVACPRILKPVCGS DSFTYDNECGICAYNAEHHTNISKLHDGECKLEIGSVDCSKYPSTVSKDGRTLVACPRIL SPVCGTDGFTYDNECGICAHNAEQRTHVSKKHDGKCRQEIPEIDCDQYPTRKTTGGKLLV RCPRILLPVCGTDGFTYDNECGICAHNAQHGTEVKKSHDGRCKERSTPLDCTQYLSNTQN GEAITACPFILQEVCGTDGVTYSNDCSLCAHNIELGTSVAKKHDGRCREEVPELDCSKYK TSTLKDGRQVVACTMIYDPVCATNGVTYASECTLCAHNLEQRTNLGKRKNGRCEEDITKE HCREFQKVSPICTMEYVPHCGSDGVTYSNRCFFCNAYVQSNRTLNLVSMAAC >P01005; 24 OVOMUCOID PRECURSOR (ALLERGEN GAL D 1) (GAL D I). MAMAGVFVLFSFVLCGFLPDAAFGAEVDCSRFPNATDKEGKDVLVCNKDLRPICGTDGVT YTNDCLLCAYSIEFGTNISKEHDGECKETVPMNCSSYANTTSEDGKVMVLCNRAFNPVCG TDGVTYDNECLLCAHKVEQGASVDKRHDGGCRKELAAVSVDCSEYPKPDCTAEDRPLCGS DNKTYGNKCNFCNAVVESNGTLTLSHFGKC >P00995; 23 PANCREATIC SECRETORY TRYPSIN INHIBITOR PRECURSOR (TUMOR- MKVTGIFLLSALALLSLSGNTGADSLGREAKCYNELNGCTKIYDPVCGTDGNTYPNECVL CFENRKRQTSILIQKSGPC >P18614; 28 INTEGRIN ALPHA-1 PRECURSOR (LAMININ AND COLLAGEN RECEPTO MVPRRPASLEVTVACIWLLTVILGFCVSFNVDVKNSMSFSGPVEDMFGYTVQQYENEEGK WVLIGSPLVGQPKARTGDVYKCPVGRERAMPCVKLDLPVNTSIPNVTEIKENMTFGSTLV TNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSFAPVQECSTQLDIVIVLDGS NSIYPWESVIAFLNDLLKRMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAANKI GRQGGLQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNYRLKQVIQDCEDE NIQRFSIAILGHYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKALGERIF ALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKANQMVIPHNTT FQTEPAKMNEPLASYLGYTVNSATIPGDVLYIAGQPRYNHTGQVVIYKMEDGNINILQTL GGEQIGSYFGSVLTTIDIDKDSYTDLLLVGAPMYMGTEKEEQGKVYVYAVNQTRFEYQMS LEPIRQTCCSSLKDNSCTKENKNEPCGARFGTAIAAVKDLNVDGFNDVVIGAPLEDDHAG AVYIYHGSGKTIREAYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAAL FWARDVAVVKVTMNFEPNKVNIQKKNCRVEGKETVCINATMCFHVKLKSKEDSIYEADLQ YRVTLDSLRQISRSFFSGTQERKIQRNITVRESECIRHSFYMLDKHDFQDSVRVTLDFNL TDPENGPVLDDALPNSVHEHIPFAKDCGNKERCISDLTLNVSTTEKSLLIVKSQHDKFNV SLTVKNKGDSAYNTRTVVQHSPNLIFSGIEEIQKDSCESNQNITCRVGYPFLRAGETVTF KIIFQFNTSHLSENAIIHLSATSDSEEPLESLNDNEVNISIPVKYEVGLQFYSSASEHHI SVAANETIPEFINSTEDIGNEINVFYTIRKRGHFPMPELQLSISFPNLTADGYPVLYPIG WSSSDNVNCRPRSLEDPFGINSGKKMTISKSEVLKRGTIQDCSSTCGVATITCSLLPSDL SQVNVSLLLWKPTFIRAHFSSLNLTLRGELKSENSSLTLSSSNRKRELAIQISKDGLPGR VPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK >P17852; 32 INTEGRIN ALPHA-3 PRECURSOR (GALACTOPROTEIN B3) (GAPB3) ( MGPGPRCAPGDPGWMLGALALMVAASGRFAFAFNLDTRFLVVKEAVNPGSLFGYSVALHR QTERQQRYLLLAGAPRDLSVADGYTNRTGAVYLCPLTALKDDCERMDISEKSDPDHHIIE DMWLGVTVASQGPAGRVLVCAHRYTQVLWSGMEDQRRMVGKCYVRGNDLQLDPGDDWQTY HNEMCNSNTDYLQTGMCQLGTSGGFTQNTVYFGAPGAYNWKGNSYMIQRKDWDLSEYSYK GSEDQGNLYIGYTVQVGSAVLHPTYITVVAGAPRHQHMGAVFLLSQESGGDLKRKQVLEG TQVGAYFGSAIALADLNNDGWQDLLVGAPYYFERKEEVGGAVYVFMNQAGTSFPDQPSLL LHGPSRSAFGISIASIGDINQDGFQDIAVGAPFEGLGKVYIYHSSSGGLLRQPQQIVHGD KLGLPGLSTFGYSLSGKMDVDDNSYPDLLVGSLSDHIVLLRARPVINILQRTLVARPAVL DPSLCTPTSCVQVELCFAYNQSAGNPSYRRNITLAYTLEADRDRRPPRLRFARSQSAVFH GFLSMPETHCQTLELLLMDNVRDKLRPIVIAMNYSLPLRMPDRLKLGMRSLDAYPVLNQA QALENHTEVHFQKECGPDNKCDSNLQMRAAFVSEQLQPLSRLQYSRDTKKLFLSINVTNT PSRERAGEDAHEALLTLEVPPALLLSSVRPSGTCQANETILCELGNPFKRNQRMELLIAF EVIGVTLHTRDLKAQLQLSTSSHQDNLQPMTLILQVDYTLQASLSLMTHRLQSFFGGTVM GEAGMKTVEDVGSPLKYEFQVSPVGDGLAALGTLVLGLEWPYEVTNGKWLLYPTEIIIHS NESWPCQPPGNLVNPLNLILSDPGDKPHSPQRRRRQLDPGGDQGSPPVTLAAAKKAKSET VLTCASGRARCVWLECPIPDTSNVTNVTVKARVWNSTFIEDYRDFDRVRVDGWATLFLRT SIPTINMENKTTWFSVDIDSELVEELPAEIELWLVLVAVSAGLLLLGLIIILLWKCGFFK RARTRALYEAKRQKAEMKSQPSETERLTDDY >P13612; 39 INTEGRIN ALPHA-4 SUBUNIT PRECURSOR (INTEGRIN ALPHA-IV) ( MFPTESAWLGKRGANPGPEAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGY SVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPC GKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRT ELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNK YKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNIL HEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAM ETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTF SQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLS HPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFY FSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTE EFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSM KTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIG YIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEV KLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSP QTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKAD PHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELN KDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQ EENRRDSWSYINSKSNDD >P08648; 41 FIBRONECTIN RECEPTOR ALPHA SUBUNIT PRECURSOR (INTEGRIN A MGSRTPESPLHAVQLRWGPRRRPPLVPLLLLLVPPPPRVGGFNLDAEAPAVLSGPPGSFF GFSVEFYRPGTDGVSVLVGAPKANTSQPGVLQGGAVYLCPWGASPTQCTPIEFDSKGSRL LESSLSSSEGEEPVEYKSLQWFGATVRAHGSSILACAPLYSWRTEKEPLSDPVGTCYLST DNFTRILEYAPCRSDFSWAAGQGYCQGGFSAEFTKTGRVVLGGPGSYFWQGQILSATQEQ IAESYYPEYLINLVQGQLQTRQASSIYDDSYLGYSVAVGEFSGDDTEDFVAGVPKGNLTY GYVTILNGSDIRSLYNFSGEQMASYFGYAVAATDVNGDGLDDLLVGAPLLMDRTPDGRPQ EVGRVYVYLQHPAGIEPTPTLTLTGHDEFGRFGSSLTPLGDLDQDGYNDVAIGAPFGGET QQGVVFVFPGGPGGLGSKPSQVLQPLWAASHTPDFFGSALRGGRDLDGNGYPDLIVGSFG VDKAVVYRGRPIVSASASLTIFPAMFNPEERSCSLEGNPVACINLSFCLNASGKHVADSI GFTVELQLDWQKQKGGVRRALFLASRQATLTQTLLIQNGAREDCREMKIYLRNESEFRDK LSPIHIALNFSLDPQAPVDSHGLRPALHYQSKSRIEDKAQILLDCGEDNICVPDLQLEVF GEQNHVYLGDKNALNLTFHAQNVGEGGAYEAELRVTAPPEAEYSGLVRHPGNFSSLSCDY FAVNQSRLLVCDLGNPMKAGASLWGGLRFTVPHLRDTKKTIQFDFQILSKNLNNSQSDVV SFRLSVEAQAQVTLNGVSKPEAVLFPVSDWHPRDQPQKEEDLGPAVHHVYELINQGPSSI SQGVLELSCPQALEGQQLLYVTRVTGLNCTTNHPINPKGLELDPEGSLHHQQKREAPSRS SASSGPQILKCPEAECFRLRCELGPLHQQESQSLQLHFRVWAKTFLQREHQPFSLQCEAV YKALKMPYRILPRQLPQKERQVATAVQWTKAEGSYGVPLWIIILAILFGLLLLGLLIYIL YKLGFFKRSLPYGTAMEKAQLKPPATSDA >P23229; 23 INTEGRIN ALPHA-6 PRECURSOR (VLA-6) (CD49F). MAAAGQLCLLYLSAGLLSRLGAAFNLDTREDNVIRKYGDPGSLFGFSLAMHWQLQPEDKR LLLVGAPRGEALPLQRANRTGGLYSCDITARGPCTRIEFDNDADPTSESKEDQWMGVTVQ SQGPGGKVVTCAHRYEKRQHVNTKQESRDIFGRCYVLSQNLRIEDDMDGGDWSFCDGRLR GHEKFGSCQQGVAATFTKDFHYIVFGAPGTYNWKGIVRVEQKNNTFFDMNIFEDGPYEVG GETEHDESLVPVPANSYLGFSLDSGKGIVSKDEITFVSGAPRANHSGAVVLLKRDMKSAH LLPEHIFDGEGLASSFGYDVAVVDLNKDGWQDIVIGAPQYFDRDGEVGGAVYVYMNQQGR WNNVKPIRLNGTKDSMFGIAVKNIGDINQDGYPDIAVGAPYDDLGKVFIYHGSANGINTK PTQVLKGISPYFGYSIAGNMDLDRNSYPDVAVGSLSDSVTIFRSRPVINIQKTITVTPNR IDLRQKTACGAPSGICLQVKSCFEYTANPAGYNPSISIVGTLEAEKERRKSGLSSRVQFR NQGSEPKYTQELTLKRQKQKVCMEETLWLQDNIRDKLRPIPITASVEIQEPSSRRRVNSL PEVLPILNSDEPKTAHIDVHFLKEGCGDDNVCNSNLKLEYKFCTREGNQDKFSYLPIQKG VPELVLKDQKDIALEITVTNSPSNPRNPTKDGDDAHEAKLIATFPDTLTYSAYRELRAFP EKQLSCVANQNGSQADCELGNPFKRNSNVTFYLVLSTTEVTFDTPDLDINLKLETTSNQD NLAPITAKAKVVIELLLSVSGVAKPSQVYFGGTVVGEQAMKSEDEVGSLIEYEFRVINLG KPLTNLGTATLNIQWPKEISNGKWLLYLVKVESKGLEKVTCEPQKEINSLNLTESHNSRK KREITEKQIDDNRKFSLFAERKYQTLNCSVNVNCVNIRCPLRGLDSKASLILRSRLWNST FLEEYSKLNYLDILMRAFIDVTAAAENIRLPNAGTQVRVTVFPSKTVAQYSGVPWWIILV AILAGILMLALLVFILWKCGFFKRNKKDHYDATYHKAEIHAQPSDKERLTSDA >P20701; 25 LEUKOCYTE ADHESION GLYCOPROTEIN LFA-1 ALPHA CHAIN PRECUR MKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGA PGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCD QNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMK DVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYV ATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLH KFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSR GHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLL ASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLI GAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVA VGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVA VGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLY PQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQD LISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEAN LRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQ IPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTC NNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPS IHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFR CPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMK VDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDS EQLASGQEAGDPGCLKPLHEKDSESGGGKD >P05555; 16 CELL SURFACE GLYCOPROTEIN MAC-1 ALPHA SUBUNIT PRECURSOR MTLKALLVTALALCHGFNLDTEHPMTFQENAKGFGQNVVQLGGTSVVVAAPQEAKAVNQT GALYQCDYSTSRCHPIPLQVPPEAVNMSLGLSLAVSTVPQQLLACGPTVHQNCKENTYVN GLCYLFGSNLLRPPQQFPEALRECPQQESDIVFLIDGSGSINNIDFQKMKEFVSTVMEQF KKSKTLFSLMQYSDEFRIHFTFNDFKRNPSPRSHVSPIKQLNGRTKTASGIRKVVRELFH KTNGARENAAKILVVITDGEKFGDPLDYKDVIPEADRAGVIRYVIGVGNAFNKPQSRREL DTIASKPAGEHVFQVDNFEALNTIQNQLQEKIFAIEGTQTGSTSSFEHEMSQEGFSASIT SNGPLLGSVGSFDWAGGAFLYTSKDKVTFINTTRVDSDMNDAYLGYASAVILRNRVQSLV LGAPRYQHIGLVVMFRENFGTWEPHTSIKGSQIGSYFGASLCSVDMDADGNTNLILIGAP HYYEKTRGGQVSVCPLPRGRARWQCEALLHGDQGHPWGRFGAALTVLGDVNGDKLTDVAI GAPGEQENQGAVYIFYGASIASLSASHSHRIIGAHFSPGLQYFGQSLSGGKDLTMDGLMD LAVGAQGHLLLLRAQPVLRLEATMEFSPKKVARSVFACQEQVLKNKDAGEVRVCLRVRKN TKDRLREGDIQSTVTYDLALDPVRSRIRAFFDETKNNTRRRTQVFGLMQKCETLKLILPD CVDDSVSPIILRLNYTLVGEPLRSFGNLRPVLAMDAQRFFTAMFPFEKNCGNDSICQDDL SITMSAMGLDTLVVGGPQDFNMSVTLRNDGEDSYGTQVTVYYPSGLSYRKDSASQNPLTK KPWFVKPAESSSSSEGHGALKSTTWNINHPIFPANSEVTFNVTFDVDSHASFGNKLLLKA IVASENNMSRTHKTKFQLELPVKYAIYMIVTSDESSIRYLNFTASEMTSKVIQHQYQFNN LGQRSLPVSVVFWIPVQINNVTVWDHPQVIFSQNLSSACHTEQKSPPHSNFRDQLERTPV LNCSVAVCKRIQCDLPSFNTQEIFNVTLKGNLSFDWYIKTSHGHLLLVSSTEILFNDSAF ALLPGQESYVRSKTETKVEPYEVHNPVPLIVGSSIGGLVLLALITAGLYKLGFFKRQYKD MMNEAAPQDAPPQ >P06756; 30 VITRONECTIN RECEPTOR ALPHA SUBUNIT PRECURSOR (INTEGRIN A MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSA SSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS HQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDAD GQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLAT RTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTK LNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI LEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY PSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRR ALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVK AQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG TQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP DHIFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLY ILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIH TLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIE FPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGF FKRVRPPQEEQEREQLQPHENGEGNSET >P20702; 19 LEUKOCYTE ADHESION GLYCOPROTEIN P150,95 ALPHA CHAIN PREC MTRTRAALLLFTALATSLGFNLDTEELTAFRVDSAGFGDSVVQYANSWVVVGAPQKITAA NQTGGLYQCGYSTGACEPIGLQVPPEAVNMSLGLSLASTTSPSQLLACGPTVHHECGRNM YLTGLCFLLGPTQLTQRLPVSRQECPRQEQDIVFLIDGSGSISSRNFATMMNFVRAVISQ FQRPSTQFSLMQFSNKFQTHFTFEEFRRTSNPLSLLASVHQLQGFTYTATAIQNVVHRLF HASYGARRDATKILIVITDGKKEGDSLDYKDVIPMADAAGIIRYAIGVGLAFQNRNSWKE LNDIASKPSQEHIFKVEDFDALKDIQNQLKEKIFAIEGTETTSSSSFELEMAQEGFSAVF TPDGPVLGAVGSFTWSGGAFLYPPNMSPTFINMSQENVDMRDSYLGYSTELALWKGVQSL VLGAPRYQHTGKAVIFTQVSRQWRMKAEVTGTQIGSYFGASLCSVDVDTDGSTDLVLIGA PHYYEQTRGGQVSVCPLPRGWRRWWCDAVLYGEQGHPWGRFGAALTVLGDVNGDKLTDVV IGAPGEEENRGAVYLFHGVLGPSISPSHSQRIAGSQLSSRLQYFGQALSGGQDLTQDGLV DLAVGARGQVLLLRTRPVLWVGVSMQFIPAEIPRSAFECREQVVSEQTLVQSNICLYIDK RSKNLLGSRDLQSSVTLDLALDPGRLSPRATFQETKNRSLSRVRVLGLKAHCENFNLLLP SCVEDSVTPITLRLNFTLVGKPLLAFRNLRPMLAALAQRYFTASLPFEKNCGADHICQDN LGISFSFPGLKSLLVGSNLELNAEVMVWNDGEDSYGTTITFSHPAGLSYRYVAEGQKQGQ LRSLHLTCDSAPVGSQGTWSTSCRINHLIFRGGAQITFLATFDVSPKAVLGDRLLLTANV SSENNTPRTSKTTFQLELPVKYAVYTVVSSHEQFTKYLNFSESEEKESHVAMHRYQVNNL GQRDLPVSINFWVPVELNQEAVWMDVEVSHPQNPSLRCSSEKIAPPASDFLAHIQKNPVL DCSIAGCLRFRCDVPSFSVQEELDFTLKGNLSFGWVRQILQKKVSVVSVAEITFDTSVYS QLPGQEAFMRAQTTTVLEKYKVHNPTPLIVGSSIGGLLLLALITAVLYKVGFFKRQYKEM MEEANGQIAPENGTQTPSPPSEK >P09055; 20 FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BE MNLQLVSWIGLISLICSVFGQTDKNRCLKANAKSCGECIQAGPNCGWCTNTTFLQEGMPT SARCDDLEALKKKGCQPSDIENPRGSQTIKKNKNVTNRSKGMAEKLRPEDITQIQPQQLL LKLRSGEPQKFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDF RIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTDRGEFFNELVGQQR ISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQ CHLENNVYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTL SGNSSNVIQLIIDAYNSLSSEVILENSKLPDGVTINYKSYCKNGVNGTGENGRKCSNISI GDEVQFEISITANKCPNKESETIKIKPLGFTEEVEVVLQFICKCNCQSHGIPASPKCHEG NGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRK RDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCRCRVCECYPNYTGSACDCSLDTGPCL ASNGQICNGRGICECGACKCTDPKFQGPTCETCQTCLGVCAEHKECVQCRAFNKGEKKDT CAQECSHFNLTKVESREKLPQPVQVDPVTHCKEKDIDDCWFYFTYSVNGNNEAIVHVVET PDCPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGEN PIYKSAVTTVVNPKYEGK >P12606; 21 INTEGRIN BETA-1 SUBUNIT PRECURSOR. MAHYPVFTVGLLTCLVLCINAQQGGTECLKANAKSCGECIQAGPNCGWCTKVDFLQEGEP TSARCDDLAALKSKGCPEDDIQNPRGRKQKLKDIPITSKGKGERMDPANITQLRPQQMVF ELRSGEPQTFNLTFRRAEDYPIDLYYLMDLSFSMKDDLENVKSLGTALMTEMEKITSDFR IGFGSFVEKTVMPYISTTPAKLINPCTSDQNCTSPFSYKNVLNLTKDGKLFNDLVGKQQI SGNLDSPEGGFDAIMQVAVCGEQIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGKC HLHENMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEDFQPVYQELKNLIPKSAVGTLS SNSSNVIQLIIDSYNSLSSELILENSKLPEGVTISYKSFCKNGVKGTGEDGRKCSNISIG DQVEFEISVTAHKCPKKGQAESIKIKPLGFNEEVEIILQFLCECDCQDKGTPNSPECHFG NGTFECGACRCNDGRIGKECECSTDEVNSEDMDAYCRRENSSEICSNNGDCICGQCVCKK RDNPNEVYSGKYCECDNFNCDRSNGLICGGKGICKCRVCECFPNYSGSACDCSEDTSTCM AKNGQICNGRGICDCGRCKCTDPKFQGPTCELCQTCVGVCAEHKECVQCRAFQKGEKQDV CMEQCMHFNISLVDSREELPQPGQAEALTHCKEKDAEDCWFYFTYSVDSKNEVMVHVVKE PECPSGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGEN PIYKSAVTTVVNPKYEGK >P16144; 27 INTEGRIN BETA-4 SUBUNIT PRECURSOR (GP150) (CD104). MAGPRPSPWARLLLAALISVSLSGTLANRCKKAPVKSCTECVRVDKDCAYCTDEMFRDRR CNTQAELLAAGCQRESIVVMESSFQITEETQIDTTLRRSQMSPQGLRVRLRPGEERHFEL EVFEPLESPVDLYILMDFSNSMSDDLDNLKKMGQNLARVLSQLTSDYTIGFGKFVDKVSV PQTDMRPEKLKEPWPNSDPPFSFKNVISLTEDVDEFRNKLQGERISGNLDAPEGGFDAIL QTAVCTRDIGWRPDSTHLLVFSTESAFHYEADGANVLAGIMSRNDERCHLDTTGTYTQYR TQDYPSVPTLVRLLAKHNIIPIFAVTNYSYSYYEKLHTYFPVSSLGVLQEDSSNIVELLE EAFNRIRSNLDIRALDSPRGLRTEVTSKMFQKTRTGSFHIRRGEVGIYQVQLRALEHVDG THVCQLPEDQKGNIHLKPSFSDGLKMDAGIICDVCTCELQKEVRSARCSFNGDFVCGQCV CSEGWSGQTCNCSTGSLSDIQPCLREGEDKPCSGRGECQCGHCVCYGEGRYEGQFCEYDN FQCPRTSGFLCNDRGRCSMGQCVCEPGWTGPSCDCPLSNATCIDSNGGICNGRGHCECGR CHCHQQSLYTDTICEINYSAIHPGLCEDLRSCVQCQAWGTGEKKGRTCEECNFKVKMVDE LKRAEEVVVRCSFRDEDDDCTYSYTMEGDGAPGPNSTVLVHKKKDCPPGSFWWLIPLLLL LLPLLALLLLLCWKYCACCKACLALLPCCNRGHMVGFKEDHYMLRENLMASDHLDTPMLR SGNLKGRDVVRWKVTNNMQRPGFATHAASINPTELVPYGLSLRLARLCTENLLKPDTREC AQLRQEVEENLNEVYRQISGVHKLQQTKFRQQPNAGKKQDHTIVDTVLMAPRSAKPALLK LTEKQVEQRAFHDLKVAPGYYTLTADQDARGMVEFQEGVELVDVRVPLFIRPEDDDEKQL LVEAIDVPAGTATLGRRLVNITIIKEQARDVVSFEQPEFSVSRGDQVARIPVIRRVLDGG KSQVSYRTQDGTAQGNRDYIPVEGELLFQPGEAWKELQVKLLELQEVDSLLRGRQVRRFH VQLSNPKFGAHLGQPHSTTIIIRDPDELDRSFTSQMLSSQPPPHGDLGAPQNPNAKAAGS RKIHFNWLPPSGKPMGYRVKYWIQGDSESEAHLLDSKVPSVELTNLYPYCDYEMKVCAYG AQGEGPYSSLVSCRTHQEVPSEPGRLAFNVVSSTVTQLSWAEPAETNGEITAYEVCYGLV NDDNRPIGPMKKVLVDNPKNRMLLIENLRESQPYRYTVKARNGAGWGPEREAIINLATQP KRPMSIPIIPDIPIVDAQSGEDYDSFLMYSDDVLRSPSGSQRPSVSDDTGCGWKFEPLLG EELDLRRVTWRLPPELIPRLSASSGRSSDAEAPTAPRTTAARAGRAAAVPRSATPGPPGE HLVNGRMDFAFPGSTNSLHRMTTTSAAAYGTHLSPHVPHRVLSTSSTLTRDYNSLTRSEH SHSTTLPRDYSTLTSVSSHGLPPIWEHGRSRLPLSWALGSRSRAQMKGFPPSRGPRDSII LAGRPAAPSWGPDSRLTAGVPDTPTRLVFSALGPTSLRVSWQEPRCERPLQGYSVEYQLL NGGELHRLNIPNPAQTSVVVEDLLPNHSYVFRVRAQSQEGWGREREGVITIESQVHPQSP LCPLPGSAFTLSTPSAPGPLVFTALSPDSLQLSWERPRRPNGDIVGYLVTCEMAQGGGPA TAFRVDGDSPESRLTVPGLSENVPYKFKVQARTTEGFGPEREGIITIESQDGGPFPQLGS RAGLFQHPLQSEYSSITTTHTSATEPFLVDGPTLGAQHLEAGGSLTRHVTQEFVSRTLTT SGTLSTHMDQQFFQT >P26011; 19 INTEGRIN BETA-7 SUBUNIT PRECURSOR (INTEGRIN BETA-P) (M29 MVDSSTVLIFLLVLGGGQSELDTKITSSGEAAEWEDPDLSLQGSCQPVPSCQKCILSHPS CAWCKQLNFTASGEAEARRCARREELLARGCPAQELEEPRGRQEVLQDKPLSQGDRGEGA TQLAPQRIRVTLRPGEPQKFRVRFLRAAGYPVDLYYLMDLSYSMKDDLERVRQLGHALLV RLQEVTHSVRIGFGSFVDKTVLPFVSTVPSKLHHPCPSRLERCQPPFSFHHVLSLTGDAQ AFEREVGRQNVSGNLDSPEGGFDAILQAALCQEQIGWRNVSRLLVFTSDDTFHTAGDGKL GGIFMPSDGRCHLDSNGVYTNSAEFDYPSVGQVAQALTAANIQPIFAVTGATLPVYQELR QLIPKSAVGELSEDSSNVVQLIMDAYDSLSSTVTLEHSPLPPGVSISFESHCKGPEKTEG EAGDRGQCNDVRVNQTVDFWVTLQATHCLPEAHVLRLWALGFSEELTVELHTVCDCNCGD AQPHAPYCSDGQGDLQCGICSCAPGRLGQLCECSEADLSSPDLESGCRAPNGTGPLCSGK GRCQCGRCSCSGQSSGRLCECDDASCERHEGILCGGFGHCQCGVCHCHANHTGRACECSK SVDSCVSPEGGLCSGHGYCKCNRCQCLDGYYGALCDQCLGCKSPCEQYRDCAECGAFGTG PLAANCSVVCADVNVTLTLAPNLDDGWCKERTIDNQLFFFLVEHAASGIVLRVRPQEKGV DHTRAIILGCTGGIVAVGLGLVLAYRLSVEIYDRREYRRFEKEQQQLNWKQDNNPLYKSA ITTTVNPRFQGTNGRSPSLSLTREAD >P23807; 23 COAGULATION FACTOR IX/FACTOR X-BINDING PROTEIN B CHAIN P MGRFIFMSFGFLVVFLSLSGTAADCPSDWSSYEGHCYKPFSEPKNWADAENFCTQQHAGG HLVSFQSSEEADFVVKLAFQTFGHSIFWMGLSNVWNQCNWQWSNAAMLRYKAWAEESYCV YFKSTNNKWRSRACRMMAQFVCEFQA >P14272; 19 PLASMA KALLIKREIN PRECURSOR (EC 3.4.21.34) (PLASMA PREKA MILFKQVGYFVSLFATVSCGCLSQLYANTFFRGGDLAAIYTPDAQHCQKMCTFHPRCLLF SFLAVSPTKETDKRFGCFMKESITGTLPRIHRTGAISGHSLKQCGHQLSACHQDIYEGLD MRGSNFNISKTDSIEECQKLCTNNIHCQFFTYATKAFHRPEYRKSCLLKRSSSGTPTSIK PVDNLVSGFSLKSCALSEIGCPMDIFQHFAFADLNVSQVVTPDAFVCRTVCTFHPNCLFF TFYTNEWETESQRNVCFLKTSKSGRPSPPIIQENAVSGYSLFTCRKARPEPCHFKIYSGV AFEGEELNATFVQGADACQETCTKTIRCQFFTYSLLPQDCKAEGCKCSLRLSTDGSPTRI TYEAQGSSGYSLRLCKVVESSDCTTKINARIVGGTNSSLGEWPWQVSLQVKLVSQNHMCG GSIIGRQWILTAAHCFDGIPYPDVWRIYGGILNLSEITNKTPFSSIKELIIHQKYKMSEG SYDIALIKLQTPLNYTEFQKPICLPSKADTNTIYTNCWVTGWGYTKERGETQNILQKATI PLVPNEECQKKYRDYVITKQMICAGYKEGGIDACKGDSGGPLVCKHSGRWQLVGITSWGE GCARKEQPGVYTKVAEYIDWILEKIQSSKERALETSPA >P09620; 22 CARBOXYPEPTIDASE KEX1 PRECURSOR (EC 3.4.16.6) (CARBOXYPE MFYNRWLGTWLAMSALIRISVSLPSSEEYKVAYELLPGLSEVPDPSNIPQMHAGHIPLRS EDADEQDSSDLEYFFWKFTNNDSNGNVDRPLIIWLNGGPGCSSMDGALVESGPFRVNSDG KLYLNEGSWISKGDLLFIDQPTGTGFSVEQNKDEGKIDKNKFDEDLEDVTKHFMDFLENY FKIFPEDLTRKIILSGESYAGQYIPFFANAILNHNKFSKIDGDTYDLKALLIGNGWIDPN TQSLSYLPFAMEKKLIDESNPNFKHLTNAHENCQNLINSASTDEAAHFSYQECENILNLL LSYTRESSQKGTADCLNMYNFNLKDSYPSCGMNWPKDISFVSKFFSTPGVIDSLHLDSDK IDHWKECTNSVGTKLSNPISKPSIHLLPGLLESGIEIVLFNGDKDLICNNKGVLDTIDNL KWGGIKGFSDDAVSFDWIHKSKSTDDSEEFSGYVKYDRNLTFVSVYNASHMVPFDKSLVS RGIVDIYSNDVMIIDNNGKNVMITTDDDSDQDATTESGDKPKENLEEEEQEAQNEEGKEK EGNKDKDGDDDNDNDDDDEDDHNSEGDDDDDDDDDEDDNNEKQSNQGLEDSRHKSSEYEQ EEEEVEEFAEEISMYKHKAVVVTIVTFLIVVLGVYAYDRRVRRKARHTILVDPNNRQHDS PNKTVSWADDLESGLGAEDDLEQDEQLEGGAPISSTSNKAGSKLKTKKKKKYTSLPNTEI DESFEMTDF >P05532; 22 MAST/STEM CELL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7. MRGARGAWDLLCVLLVLLRGQTATSQPSASPGEPSPPSIHPAQSELIVEAGDTLSLTCID PDFVRWTFKTYFNEMVENKKNEWIQEKAEATRTGTYTCSNSNGLTSSIYVFVRDPAKLFL VGLPLFGKEDSDALVRCPLTDPQVSNYSLIECDGKSLPTDLTFVPNPKAGITIKNVKRAY HRLCVRCAAQRDGTWLHSDKFTLKVREAIKAIPVVSVPETSHLLKKGDTFTVVCTIKDVS TSVNSMWLKMNPQPQHIAQVKHNSWHRGDFNYERQETLTISSARVDDSGVFMCYANNTFG SANVTTTLKVVEKGFINISPVKNTTVFVTDGENVDLVVEYEAYPKPEHQQWIYMNRTSAN KGKDYVKSDNKSNIRYVNQLRLTRLKGTEGGTYTFLVSNSDASASVTFNVYVNTKPEILT YDRLINGMLQCVAEGFPEPTIDWYFCTGAEQRCTTPVSPVDVQVQNVSVSPFGKLVVQSS IDSSVFRHNGTVECKASNDVGKSSAFFNFAFKEQIQAHTLFTPLLIGFVVAAGAMGIIVM VLTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFG KVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACT VGGPTLVITEYCCYGDLLNFLRRKRDSFIFSKQEEQAEAALYKNLLHSTEPSCDSSNEYM DMKPGVSYVVPTKTDKRRSARIDSYIERDVTPAIMEDDELALDLDDLLSFSYQVAKAMAF LASKNCIHRDLAARNILLTHGRITKICDFGLARDIRNDSNYVVKGNARLPVKWMAPESIF SCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMVSPEHAPAEMYDV MKTCWDADPLKRPTFKQVVQLIEKQISDSTKHIYSNLANCNPNPENPVVVDHSVRVNSVG SSASSTQPLLVHEDA >P00759; 18 TONIN PRECURSOR (EC 3.4.21.35) (ESTERASE 1) (S2 KALLIKRE MWLQILSLVLSVGRIDAAPPGQSRIVGGYKCEKNSQPWQVAVINEYLCGGVLIDPSWVIT AAHCYSNNYQVLLGRNNLFKDEPFAQRRLVRQSFRHPDYIPLIVTNDTEQPVHDHSNDLM LLHLSEPADITGGVKVIDLPTKEPKVGSTCLASGWGSTNPSEMVVSHDLQCVNIHLLSNE KCIETYKDNVTDVMLCAGEMEGGKDTCAGDSGGPLICDGVLQGITSGGATPCAKPKTPAI YAKLIKFTSWIKKVMKENP >P01045; 18 KININOGEN, HMW II PRECURSOR (THIOL PROTEINASE INHIBITOR) MKLITILFLCSRLLPSLTQESSQEIDCNDQDVFKAVDAALTKYNSENKSGNQFVLYRITE VARMDNPDTFYSLKYQIKEGDCPFQSNKTWQDCDYKDSAQAATGQCTATVAKRGNMKFSV AIQTCLITPAEGPVVTAQYECLGCVHPISTKSPDLEPVLRYAIQYFNNNTSHSHLFDLKE VKRAQKQVVSGWNYEVNYSIAQTNCSKEEFSFLTPDCKSLSSGDTGECTDKAHVDVKLRI SSFSQKCDLYPGEDFLPPMVCVGCPKPIPVDSPDLEEALNHSIAKLNAEHDGTFYFKIDT VKKATVQVVGGLKYSIVFIARETTCSKGSNEELTKSCEINIHGQILHCDANVYVVPWEEK VYPTVNCQPLGQTSLMKRPPGFSPFRSVQVMKTEGSTTVSLPHSAMSPVQDEERDSGKEQ GPTHGHGWDHGKQIKLHGLGLGHKHKHDQGHGHHRSHGLGHGHQKQHGLGHGHKHGHGHG KHKNKGKNNGKHYDWRTPYLASSYEDSTTSSAQTQEKTEETTLSSLAQPGVAITFPDFQD SDLIATVMPNTLPPHTESDDDWIPDIQTEPNSLAFKLISDFPETTSPKCPSRPWKPVNGV NPTVEMKESHDFDLVDALL >P06312; 20 IG KAPPA CHAIN PRECURSOR V-IV REGION (FRAGMENT). MVLQTQVFISLLLWISGAYGDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYST P >P01634; 29 IG KAPPA CHAIN PRECURSOR V-V REGION (MOPC 21). MHQTSMGIKMESHTLVFISILLCLYGADGNIVMTQSPKSMSMSVGERVTLTCKASENVVT YVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQG YSYPYTFGGGTKLEIK >P01639; 22 IG KAPPA CHAIN PRECURSOR V-V REGION (MOPC 41). MDMRAPAQIFGFLLLLFQGTRCDIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQ EPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYASSPWTF GGGTKLEIKR >Q12541; 19 LACCASE I PRECURSOR (EC 1.10.3.2) (BENZENEDIOL:OXYGEN OX MRLSNALVLVAACISSVVAKTRTFDFDLVNTRLAPDGFERDTVVINGEFPGTLIQVNKGD SVRIPLHNKLTSPTMRRSVSIHWHGFFQARTSGQDGPSFVNQCPQPPNTTFTYEFSVAEQ SGTFWYHSHLSTQYCDGLRGAFIVYDPRDPLRHLYDVDDESTVITLAEWYHILAPDATNE FFSSGIIPVQDSGLINGKGRFNGGPLTPFAVVNVRRGKRYRLRVIAISCRPFFTFSVDNH SLVFMEADGVEHDPVEVQNVDIYAAQRVSVILHANQPIDNYWIRAPMTGGNPDRNPNLNI SLTLAILRYHGARHVEPTTVNVPGHKLLDQEMHPIRQEGPGKLGDGPPDKHITLNIAQPN APFFDINGISYISPTVPVLLQILSGAKRPEDVLPSEQIFFVPKNSLIEVNIPGEGAHPFH LHGHNFDVVLASNDDTFNFKNPPRRDVYPINGGNTTFRFFTDNPGAWFLHCHIDWHLEAG LAIVFAEAPEDNVSGPQSQITPQDWLDLCPEYNAIEPEFQ >Q01679; 21 LACCASE PRECURSOR (EC 1.10.3.2) (BENZENEDIOL:OXYGEN OXID MHTFLRSTALVVAGLSARALASIGPVTDFHIVNAAVSPDGFSRQAVLAEGVFPGPLIAGN KGDNFQINVIDELTNATMLKTTTIHWHGFFQHGTNWADGPAFINQCPIASGDSFLYNFQV PDQAGTFWYHSHLSTQYCDGLRGPFVVYDPADPYLDQYDVDDDSTVITLADWYHTAARLG SPFPAADTTLINGLGRCGEAGCPVSDLAVISVTKGKRYRFRLVSISCDSFFTFSIDGHSL NVIEVDATNHQPLTVDELTIYAGQRYSFILTADQDVDNYWIRANPGIGITTGFAGGINSA ILRYDGADVVEPTTTQATSPVVLSESNLAPLTNAAAPGLPEVGGVDLALNFNLTFDGPSL KFQINGVTFVPPTVPVLLQILSGAQSAADLLPSGSVYALPSNATIELSLPAGALGGPHPF HLHGHTFSVVRPAGSTTYNYVNPVQRDVVSIGNTGDNVTIRFDTNNPGPWFLHCHIDWHL EAALPLSSLRTSLTLRPLTLSPRTGPTCALSTTLWTHLITSGFASIIQWMMGGNGLFAPH ALSFLGSQ >Q12739; 23 LACCASE 2 PRECURSOR (EC 1.10.3.2) (BENZENEDIOL:OXYGEN OX MFPGARILATLTLALHLLHGAHAAIGPAGNMYIVNEDVSPDGFARSAVVARSVPATDPTP ATASIPGVLVQGNKGDNFQLNVVNQLSDTTMLKTTSIHWHGFFQAGSSWADGPAFVTQCP VASGDSFLYNFNVPDQAGTFWYHSHLSTQYCDGLRGPFVVYDPSDPHLSLYDIDNADTVI TLEDWYHIVAPQNAAIPTPDSTLINGKGRYAGGPTSPLAIINVESNKRYRFRLVSMSCDP NFTFSIDGHSLLVIEADAVNIVPITVDSIQIFAGQRYSFVLTANQAVDNYWIRANPNLGS TGFVGGINSAILRYAGATEDDPTTTSSTSTPLLETNLVPLENPGAPGPPVPGGADININL AMAFDFTTFELTINGVPFLPPTAPVLLQILSGASTAASLLPSGSIYELEANKVVEISMPA LAVGGPHPFHLHGHTFDVIRSAGSTTYNFDTPARRDVVNTGTGANDNVTIRFVTDNPGPW FLHCHIDWHLEIGLAVVFAEDVTSISAPPAAWDDLCPIYNALSDNDKGGIVPS >Q02081; 19 LACCASE 4 PRECURSOR (EC 1.10.3.2) (BENZENEDIOL:OXYGEN OX MLSSITLLPLLAAVSTPAFAAVRNYKFDIKNVNVAPDGFQRPIVSVNGLVPGTLITANKG DTLRINVTNQLTDPSMRRATTIHWHGLFQATTADEDGPAFVTQCPIAQNLSYTYEIPLHG QTGTMWYHAHLASQYVDGLRGPLVIYDPNDPHKSRYDVDDASTVVMLEDWYHTPAPVLEK QMFSTNNTALLSPVPDSGLINGKGRYVGGPAVPRSVINVKRGKRYRLRVINASAIGSFTF SIEGHRLTVIEADGIPHQPLPVDSFQIYAGQRYSVIVEANQTAANYWIRAPMTVAGAGTN ANLDPTNVFAVLHYEGAPNAEPTTEQGSAIGTALVEENLHALINPGAPGGSAPADVSLNL AIGRSTVDGILRFTFNNIKYEAPSLPTLLKILANNASNDADFTPNEHTIVLPHNKVIGAQ HHRGADHPIHLHGHVFDIVKSLGGTPNYVNPPRRDVVRVGGTGVVLRFKADNPGPWFVHC HIDCTWRLGSHLSLPRPPARFARVSSRSSPTMPGTSSAPSTRLFLPICSKW >P02754; 16 BETA-LACTOGLOBULIN PRECURSOR (BETA-LG). MKCLLLALALTCGAQALIVTQTMKGLDIQKVAGTWYSLAMAASDISLLDAQSAPLRVYVE ELKPTPEGDLEILLQKWENGECAQKKIIAEKTKIPAVFKIDALNENKVLVLDTDYKKYLL FCMENSAEPEQSLACQCLVRTPEVDDEALEKFDKALKALPMHIRLSFNPTQLEEQCHI >P33575; 19 LAMPRIN 0.9-12/10 PRECURSOR (CARTILAGE MATRIX PROTEIN). MAAAIQALLVLALLHLATATPVIGKQTVSTLSTGYLGHPVVGGLGYGGLGYGGLGVAGLG VAGLGYGGLGYPGAALGGVYTHHAAGLVHPYGGLGYHAAPYHHALGGLGYPLGIGAGVVA PHVVKGKIAAPLAPVVAAI >P16621; 32 PROTEIN-TYROSINE PHOSPHATASE DLAR PRECURSOR (EC 3.1.3.48 MGLQMTAARPIAALSLLVLSLLTWTHPTIVDAAHPPEIIRKPQNQGVRVGGVASFYCAAR GDPPPSIVWRKNGKKVSGTQSRYTVLEQPGGISILRIEPVRAGRDDAPYECVAENGVGDA VSADATLTIYEGDKTPAGFPVITQGPGTRVIEVGHTVLMTCKAIGNPTPNIYWIKNQTKV DMSNPRYSLKDGFLQIENSREEDQGKYECVAENSMGTEHSKATNLYVKVRRVPPTFSRPP ETISEVMLGSNLNLSCIAVGSPMPHVKWMKGSEDLTPENEMPIGRNVLQLINIQESANYT CIAASTLGQIDSVSVVKVQSLPTAPTDVQISEVTATSVRLEWSYKGPEDLQYYVIQYKPK NANQAFSEISGIITMYYVVRALSPYTEYEFYVIAVNNIGRGPPSAPATCTTGETKMESAP RNVQVRTLSSSTMVITWEPPETPNGQVTGYKVYYTTNSNQPEASWNSQMVDNSELTTVSD VTPHAIYTVRVQAYTSMGAGPMSTPVQVKAQQGVPSQPSNFRATDIGETAVTLQWTKPTH SSENIVHYELYWNDTYANQAHHKRISNSEAYTLDGLYPDTLYYIWLAARSQRGEGATTPP IPVRTKQYVPGAPPRNITAIATSSTTISLSWLPPPVERSNGRIIYYKVFFVEVGREDDEA TTMTLNMTSIVLDELKRWTEYKIWVLAGTSVGDGPRSHPIILRTQEDVPGDPQDVKATPL NSTSIHVSWKPPLEKDRNGIIRGYHIHAQELRDEGKGFLNEPFKFDVVDTLEFNVTGLQP DTKYSIQVAALTRKGDGDRSAAIVVKTPGGVPVRPTVSLKIMEREPIVSIELEWERPAQT YGELRGYRLRWGVKDQALKEEMLSGPQMTKKRFDNLERGVEYEFRVAGSNHIGIGQETVK IFQTPEGTPGGPPSNITIRFQTPDVLCVTWDPPTREHRNGIITRYDVQFHKKIDHGLGSE RNMTLRKAVFTNLEENTEYIFRVRAYTKQGAGPFSDKLIVETERDMGRAPMSLQAEATSE QTAEIWWEPVTSRGKLLGYKIFYTMTAVEDLDDWQTKTVGLTESADLVNLEKFAQYAVAI AARFKNGLGRLSEKVTVRIKPEDVPLNLRAHDVSTHSMTLSWSPPIRLTPVNYKISFDAM KVFVDSQGFSQTQIVPKREIILKHYVKTHTINELSPFTTYNVNVSAIPSDYSYRPPTKIT VTTQMAAPQPMVKPDFYGVVNGEEILVILPQASEEYGPISHYYLVVVPEDKSNLHKIPDQ FLTDDLLPGRNKPERPNAPYIAAKFPQRSIPFTFHLGSGDDYHNFTNRKLEREKRYRIFV RAVVDTPQKHLYTSSPFSEFLSLDMREAPPGERPHRPDPNWPAEPEVSVNRNKDEPEILW VVLPLMVSTFIVSTALIVLCVVKRRRQPCKTPDQAAVTRPLMAADLGAGPTPSDPVDMRR LNFQTPGMISHPPIPISEFANHIERLKSNDNQKFSQEYESIEPGQQFTWDNSNLEHNKSK NRYANVTAYDHSRVQLPAVEGVVGSDYINANYCDGYRKHNAYVATQGPLQETFVDFWRMC WELKTATIVMMTRLEERTRIKCDQYWPTRGTETYGQIFVTITETQELATYSIRTFQLCRQ GFNDRREIKQLQFTAWPDHGVPDHPAPFLQFLRRCRALTPPESGPVIVHCSAGVGRTGCY IVIDSMLERMKHEKIIDIYGHVTCLRAQRNYMVQTEDQYIFIHDAILEAIICGVTEVPAR NLHTHLQKLLITEPGETISGMEVEFKKLSNVKMDSSKFVTANLPCNKHKNRLVHILPYES SRVYLTPIHGIEGSDYVNASFIDGYRYRSAYIAAQGPVQDAAEDFWRMLWEHNSTIVVML TKLKEMGREKCFQYWPHERSVRYQYYVVDPIAEYNMPQYKLREFKVTDARDGSSRTVRQF QFIDWPEQGVPKSGEGFIDFIGQVHKTKEQFGQDGPITVHCSAGVGRSGVFITLSIVLER MQYEGVLDVFQTVRILRSQRPAMVQTEDQYHFCYRAALEYLGSFDNYTN >P23631; 20 ALPHA-LATROTOXIN PRECURSOR. MISVGEIMERANHSLVRMRREGEDLTLEEKAEICSELELQQKYVDIASNIIGDLSSLPIA GKIAGTIAAAAMTATHVASGRLDIEQTLLGCSDLPFDQIKEVLENRFNEIDRKLDSHSAA LEEITKLVEKSISVVEKTRKQMNKRFDEVMKSIQDAKVSPIISKINNFARYFDTEKERIR GLKLNDYILKLEEPNGILLHFKESRTPTDDSLQAPLFSIIEEGYAVPKSIDDELAFKVLY ALLYGTQTYVSVMFFLLEQYSFLANHYYEKGYLEKYDEYFNSLNNVFLDFKSSLVGTGTS NNEGLLDRVLQVLMTVKNSEFLGLEKNGVDEMLNEKINLFNKIKEEIEGKQKMTLSETPE NFAQISFDKDITTPIGDWRDGREVRYAVQYASETLFSKISHWSDPVSVREKACPTLRMPV DQTRRNVLVFRKFDSSKPQLVGEITPYLSNFIDIDRDLYNAASNPDSAVGFKEFTKLNYD GANIRATFDHGRTVFHAAAKSGNDKIMFGLTFLAKSTELNQPDKKGYTPIHVAADSGNAG IVNLLIQRGVSINSKTYHFLQTPLHLAAQRGFVTTFQRLMESPEININERDKDGFTPLHY AIRGGERILEAFLNQISIDVNAKSNTGLTPFHLAIIKNDWPVASTLLGSKKVDINAVDEN NITALHYAAILGYLETTKQLINLKEINANVVSSPGLLSALHYAILYKHDDVASFLMRSSN VNVNLKALGGITPLHLAVIQGRKQILSLMFDIGVNIEQKTDEKYTPLHLAAMSKYPELIQ ILLDQGSNFEAKTNSGATPLHLATFKGKSQAALILLNNEVNWRDTDENGQMPIHGAAMTG LLDVAQAIISIDATVVDIEDKNSDTPLNLAAQNSHIDVIKYFIDQGADINTRNKKGLAPL LAFSKKGNLDMVKYLFDKNANVYIADNDGMNFFYYAVQNGHLNIVKYAMSEKDKFEWSNT DNNRRDECPNEECAISHFAVCDAVQFDRIEIVKYFVGTLGNFAICGPLHQAARYGHLDIV KYLVEEEFLSVDGSKTDTPLCYASENGHFTVVQYLVSNGAKVNHDCGNGMTAIDKAITKN HLQVVQFLAANGVDFRRKNSRGTTPFLTAVAENALDIAEYLIREKRQDININEQNVDKDT ALHLAVYYKNLQMIKLLIKYGIDVTIRNAYDKTALDIAIDAKFSNIVEYLKTKSGKFRRE YKSSYGERSLLQTNQISNFIDRKNIEHDHPLFINADNESSELFSKTASNIDVIGTLLLID VLIRYFSKQGYISKESDSASDGITQAAALSITEKFEDVLNSLHNESAKEQVDLAEVHGKV YAALKSGRNSQIHQILCSSLNSISTLKPEDMEKLESVIMNSHSSVSLPEVTDSANEAYGE TLHLFGESCLHSDGILTKKLM >P17454; 26 LIPOPOLYSACCHARIDE-BINDING PROTEIN PRECURSOR (LBP). MGTWARALLGSTLLSLLLAAAPGALGTNPGLITRITDKGLEYAAREGLLALQRKLLEVTL PDSDGDFRIKHFGRAQYKFYSLKIPRFELLRGTLRPLPGQGLSLDISDAYIHVRGSWKVR KAFLRLKNSFDLYVKGLTISVHLVLGSESSGRPTVTTSSCSSDIQNVELDIEGDLEELLN LLQSQIDARLREVLESKICRQIEEAVTAHLQPYLQTLPVTTQIDSFAGIDYSLMEAPRAT AGMLDVMFKGEIFPLDHRSPVDFLAPAMNLPEAHSRMVYFSISDYVFNTASLAYHKSGYW NFSITDAMVPADLNIRRTTKSFRPFVPLLANLYPNMNLELQGTVNSEQLVNLSTENLLEE PEMDIEALVVLPSSAREPVFRLGVATNVSATLTLNTRKITGFLKPGRLQVELKESKVGGF NVELLEALLNYYILNNLYPKVNEKLAHRFPLPLLRHIQLYDLLLQTHENFLLVGANIQYR RV >P00711; 19 ALPHA-LACTALBUMIN PRECURSOR (LACTOSE SYNTHASE B PROTEIN MMSFVSLLLVGILFHATQAEQLTKCEVFRELKDLKGYGGVSLPEWVCTTFHTSGYDTQAI VQNNDSTEYGLFQINNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGI NYWLAHKALCSEKLDQWLCEKL >P31579; 20 LOW CHORIOLYTIC ENZYME PRECURSOR (EC 3.4.24.66) (HATCHIN MDLLAKASVLLLLLLSLSNAQTDNMEEAENGSSKEEIDESELEDVSSIIFRMNNNSMEEL LEGDLVLPKTRNAMKCFGAPDSCRWPKSSNGIVKVPYVVSDNYESDEKETIRNAMKEFAE KTCIHFVPRNNERAYLSLEPRFGCKSMMGYVGDKQVVVLQRFGCIKHAVIQHELLHALGF YHEHTRSDRDQHVKINWENIIKDFTHNFDKNDTDNLGTPYDYGSIMHYGRTAFGKDRKET ITPIPNPKAAIGQTERMSDIDILRVNKLYKC >P07439; 24 LECTIN BRA-3 PRECURSOR. MQRSEIVQAVTLLVVVFAITTAECTCPGNLDWQEYDGHCYWASTYQVRWNDAQLACQTVH PGAYLATIQSQLENAFISETVSNNRLWIGLNDIDLEGHYVWSNGEATDFTYWSSNNPNNW ENQDCGVVNYDTVTGQWDDDDCNKNKNFLCKMPIIGCPPCGI >Q02988; 20 LECTIN PRECURSOR. MVWCLADLRAYVLVLLVISGLYQGSDQLIPEKCGEDCTPGWDCHFNSYYKYIPNAKSWTD AEFYCQKLYPGAHLASIHSEDENDFLTEITFKNNSNYPVVWVGGSDCYKDRSFVWTDGSQ WDYQKWRQWEPSNTGGREPCIDFNFVTPGLWNDEHCDQKFPFICKYTTPCRY >P05047; 23 LECTIN, ALPHA SUBUNIT PRECURSOR. MSLTMKNVEGFVIFLVIFTSTAAVPQLQKALDGREYLIETELKYNWHQAWHECARHDQQL VTIESADKNNAIIDLVKRVVGKSHNLWLGGNDEYSSSRDYGRPFFWSPTGQAFSFAYWSE NNPDNYKHQEHCVHIWDTKPLYQWNDNDCNVKMGYICEPNHFRETYDQALKQKCEAIKIT NSKISTEFDQLHAKQSLEFDSITQNVAKVNEDWKIEIQKLQNATQIAIQQIMENHEKKIR DLSDNLLKQLQDSNEQLKQSTDHMNASFGEKLKGQQAENNEIC >P18337; 28 L-SELECTIN PRECURSOR (LYMPH NODE HOMING RECEPTOR) (LEUKO MVFPWRCEGTYWGSRNILKLWVWTLLCCDFLIHHGTHCWTYHYSEKPMNWENARKFCKQN YTDLVAIQNKREIEYLENTLPKSPYYYWIGIRKIGKMWTWVGTNKTLTKEAENWGAGEPN NKKSKEDCVEIYIKRERDSGKWNDDACHKRKAALCYTASCQPGSCNGRGECVETINNHTC ICDAGYYGPQCQYVVQCEPLEAPELGTMDCIHPLGNFSFQSKCAFNCSEGRELLGTAETQ CGASGNWSSPEPICQVVQCEPLEAPELGTMDCIHPLGNFSFQSKCAFNCSEGRELLGTAE TQCGASGNWSSPEPICQETNRSFSKIKEGDYNPLFIPVAVMVTAFSGLAFLIWLARRLKK GKKSQERMDDPY >P27113; 23 E-SELECTIN PRECURSOR (ENDOTHELIAL LEUKOCYTE ADHESION MOL MVASWLLSTLTFALVLLIKETSTWTYHFSAENMTYDEASAYCQQNYTHLVAIQNKEEIDY LNSILDYSPSYYWIGIRKVNNVWIWVGTHKPLTEGAKNWAPGEPNNKQNNEDCVEIYIKR PKDTGMWNDERCSKKKLALCYTAACTEASCSGHGECIETINNYSCKCYPGFSGLKCEQVV TCEAQVQPQHGSLNCTHPLGNFSYNSSCSVSCERGYLPSSTETTWCTSSGEWSAPPATCK VVECDTMGKPANGDVKCSPSQGSAPWNTTCTFDCEEGFTLLGARSLQCTSSGSWDNEKPT CKAVSCDTIHHPQNGSVSCSNSSEGKFTFRSSCNFTCEENFLLRGPAQVECTAQGQWTQQ APVCEAVKCDPVHTLEDGFVKCTHPHTGEFTYKSSCTFNCREGFELHGSAQLECTSQGQW AQELPSCQVVQCPSLAVLGKTNVSCSGEPVFGTVCNFACPEGWTLNGSAALMCGAEGQWS GMLPTCEEPIASNVPLAVGLSVSGTSFLTLTSFLLWFLKYFRKKAKKFVPASSRYVGLEA HGNCQVPSHLI >P16109; 41 P-SELECTIN PRECURSOR (GRANULE MEMBRANE PROTEIN 140) (GMP MANCQIAILYQRFQRVVFGISQLLCFSALISELTNQKEVAAWTYHYSTKAYSWNISRKYC QNRYTDLVAIQNKNEIDYLNKVLPYYSSYYWIGIRKNNKTWTWVGTKKALTNEAENWADN EPNNKRNNEDCVEIYIKSPSAPGKWNDEHCLKKKHALCYTASCQDMSCSKQGECLETIGN YTCSCYPGFYGPECEYVRECGELELPQHVLMNCSHPLGNFSFNSQCSFHCTDGYQVNGPS KLECLASGIWTNKPPQCLAAQCPPLKIPERGNMICLHSAKAFQHQSSCSFSCEEGFALVG PEVVQCTASGVWTAPAPVCKAVQCQHLEAPSEGTMDCVHPLTAFAYGSSCKFECQPGYRV RGLDMLRCIDSGHWSAPLPTCEAISCEPLESPVHGSMDCSPSLRAFQYDTNCSFRCAEGF MLRGADIVRCDNLGQWTAPAPVCQALQCQDLPVPNEARVNCSHPFGAFRYQSVCSFTCNE GLLLVGASVLQCLATGNWNSVPPECQAIPCTPLLSPQNGTMTCVQPLGSSSYKSTCQFIC DEGYSLSGPERLDCTRSGRWTDSPPMCEAIKCPELFAPEQGSLDCSDTRGEFNVGSTCHF SCNNGFKLEGPNNVECTTSGRWSATPPTCKGIASLPTPGLQCPALTTPGQGTMYCRHHPG TFGFNTTCYFGCNAGFTLIGDSTLSCRPSGQWTAVTPACRAVKCSELHVNKPIAMNCSNL WGNFSYGSICSFHCLEGQLLNGSAQTACQENGHWSTTVPTCQAGPLTIQEALTYFGGAVA STIGLIMGGTLLALLRKRFRQKDDGKCPLNPHSHLGTYGVFTNAAFDPSP >P19256; 28 LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3 PRECURSOR (ANTI MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQK DKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYV LESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMEND LPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKC DRKPDRTNSN >P28175; 25 LIMULUS CLOTTING FACTOR C PRECURSOR (EC 3.4.21.84). MVLASFLVSGLVLGILAQQMRPVQSRGVDLGLCDETRFECKCGDPGYVFNVPMKQCTYFY RWRPYCKPCDDLEAKDICPKYKRCQECKAGLDSCVTCPPNKYGTWCSGECQCKNGGICDQ RTGACTCRDRYEGAHCEILKGCPLLPSDSQVQEVRNPPDNPQTIDYSCSPGFKLKGVARI SCLPNGQWSSFPPKCIRECAKVSSPEHGKVNAPSGNMIEGATLRFSCDSPYYLIGQETLT CQGNGQWSGQIPQCKKLVFCPDLDPVNHAEHQVKIGVEQKYGQFPQGTEVTYTCSGNYFL MGFNTLKCNPDGSWSGSQPSCVKVADREVDCDSKAVDFLDDVGEPVRIHCPAGCSLTAGT VWGTAIYHELSSVCRAAIHAGKLPNSGGAVHVVNNGPYSDFLGSDLNGIKSEELKSLARS FRFDYVSSSTAGRSGCPDGWFEVEENCVYVTSKQRAWERAQGVCTNMAARLAVLDKDLIP SSLTETLRGKGLTTTWIGLHRLDAEKPFVWELMDRSNVVLNDNLTFWASGEPGNETNCVY LDIRDQLQPVWKTKSCFQPSSFACMMDLSDRNKAKCDDPGPLENGHATLHGQSIDGFYAG SSIRYSCEVLHYLSGTETVTCTTNGTWSAPKPRCIKVITCQNPPVPSYGSVEIKPPSRTN SISRVGSPFLRLPRLPLPLARAAKPPPKPRSSQPSTVDLASKVKLPEGHYRVGSRAIYTC ESRYYELLGSQGRRCDSNGNWSGRPASCIPVCGRSDSPRSPFIWNGNSTEIGQWPWQAGI SRWLADHNMWFLQCGGSLLNEKWIVTAAHCVTYSATAEIIDPSQFKIYLGKYYRDDSRDD DYVQVREALEIHVNPNYDPGNLNFDIALIQLKTPVTLTTRVQPICLPTDITTREHLKEGT LAVVTGWGLNENNTYSEMIQQAVLPVVAASTCEEGYKEADLPLTVTENMFCAGYKKGRYD ACSGDSGGPLVFADDSRTERRWVLEGIVSWGSPSGCGKANQYGGFTKVNVFLSWIRQFI >P09056; 23 LEUKEMIA INHIBITORY FACTOR PRECURSOR (LIF) (DIFFERENTIAT MKVLAAGIVPLLLLVLHWKHGAGSPLPITPVNATCAIRHPCHGNLMNQIKNQLAQLNGSA NALFISYYTAQGEPFPNNVEKLCAPNMTDFPSFHGNGTEKTKLVELYRMVAYLSASLTNI TRDQKVLNPTAVSLQVKLNATIDVMRGLLSNVLCRLCNKYRVGHVDVPPVPDHSDKEAFQ RKKLGCQLLGTYKQVISVVVQAF >P49012; 21 LIGNINASE LG2 PRECURSOR (EC 1.11.1.-) (LIGNIN PEROXIDASE MAFKQLFAAITVALSLTAANAAVVKEKRATCANGKTVGDASCCAWFDVLDDIQANMFHGG QCGAEAHESIRLVFHDSIAISPAMEAKGKFGGGGADGSIMIFDTIETAFHPNIGLDEVVA MQKPFVQKHGVTPGDFIAFAGAVALSNCPGAPQMNFFTGRKPATQPAPDGLVPEPFHTVD QIIARVNDAGEFDELELVWMLSAHSVAAVNDVDPTVQGLPFDSTPGIFDSQFFVETQFRG TLFPGSGGNQGEVESGMAGEIRIQTDHTLARDSRTACEWQSFVGNQSKLVDDFQFIFLAL TQLGQDPNAMTDCSDVIPLSKPIPGNGPFSFFPPGKSHSDIEQACAETPFPSLVTLPGPA TSVARIPPHKA >P20013; 26 LIGNINASE C PRECURSOR (EC 1.11.1.-) (LIGNIN PEROXIDASE). MAFKSLLSFVSVIGALQGANAALTRRVACPDGVNTATNAACCQLFAVREDLQQNLFHGGL CTAEAHESLRLTFHDAIAISPALEAQGIFGGGGADGSIAIFPEIETNFHPNIGLDEIIEL QKPFIARHNISVADFIQFAGAIGASNCAGAPQLAAFVGRKDATQPAPDGLVPEPFHTPDQ IFDRLADASQGEFDPILTVWLLTAHTVAAANDVDPTKSGLPFDSTPELWDTQFFLETQLR GTSFPGSGGNQGEVESPLAGEMRLQSDHTIARDSRTACEWQSFVDNQPKAQQMFQFVFHD LSIFGQDINTLVDCTEVVPIPADPQGHTHFPAGLSNADIEQACAETPFPTFPTDPGPKTA VAPVPKPPAARK >P32946; 14 LIPASE 2 PRECURSOR (EC 3.1.1.3). MKLCLLALGAAVAAAPTATLANGDTITGLNAIVNEKFLGIPFAEPPVGTLRFKPPVPYSA SLNGQQFTSYGPSCMQMNPMGSFEDTLPKNARHLVLQSKIFQVVLPNDEDCLTINVIRPP GTRASAGLPVMLWIFGGGFELGGSSLFPGDQMVAKSVLMGKPVIHVSMNYRVASWGFLAG PDIQNEGSGNAGLHDQRLAMQWVADNIAGFGGDPSKVTIYGESAGSMSTFVHLVWNDGDN TYNGKPLFRAAIMQSGCMVPSDPVDGTYGTEIYNQVVASAGCGSASDKLACLRGLSQDTL YQATSDTPGVLAYPSLRLSYLPRPDGTFITDDMYALVRDGKYAHVPVIIGDQNDEGTLFG LSSLNVTTDAQARAYFKQSFIHASDAEIDTLMAAYTSDITQGSPFDTGIFNAITPQFKRI SALLGDLAFTLARRYFLNYYQGGTKYSFLSKQLSGLPVLGTFHGNDIIWQDYLVGSGSVI YNNAFIAFANDLDPNKAGLWTNWPTYTSSSQSGNNLMQINGLGLYTGKDNFRPDAYSALF SNPPSFFV >P22394; 19 LIPASE 2 PRECURSOR (EC 3.1.1.3). MVSKSLFLAAAVNLAGVLAQAPRPSLNGNEVISGVLEGKVDTFKGIPFADPPLNDLRFKH PQPFTGSYQGLKANDFSPACMQLDPGNSLTLLDKALGLAKVIPEEFRGPLYDMAKGTVSM NEDCLYLNVFRPAGTKPDAKLPVMVWIYGGAFVYGSSAAYPGNSYVKESINMGQPVVFVS INYRTGPFGFLGGDAITAEGNTNAGLHDQRKGLEWVSDNIANFGGDPDKVMIFGESAGAM SVAHQLIAYGGDNTYNGKKLFHSAILQSGGPLPYHDSSSVGPDISYNRFAQYAGCDTSAS ANDTLECLRSKSSSVLHDAQNSYDLKDLFGLLPQFLGFGPRPDGNIIPDAAYELFRSGRY AKVPYISGNQEDEGTAFAPVALNATTTPHVKKWLQYIFYDASEASIDRVLSLYPQTLSVG SPFRTGILNALTPQFKRVAAILSDMLFQSPRRVMLSATKDVNRWTYLSTHLHNLVPFLGT FHGNELIFQFNVNIGPANSYLRYFISFANHHDPNVGTNLLQWDQYTDEGKEMLEIHMTDN VMRTDDYRIEGISNFETDVNLYG >Q64424; 18 PANCREATIC LIPASE RELATED PROTEIN 2 PRECURSOR (EC 3.1.1. MMLFVWTTGLLLLATARGNEVCYSHLGCFSDEKPWAGTLQRPVKSLPASPESINTRFLLY TNENPNNYQLITATDPATIKASNFNLHRKTRFVIHGFIDNGEKDWLTDICKRMFQVEKVN CICVDWQGGSLAIYSQAVQNIRVVGAEVAYLVQVLSDQLGYKPGNVHMIGHSLGAHTAAE AGRRLKGLVGRITGLDPAEPCFQDTPEEVRLDPSDAMFVDVIHTDIAPIIPSFGFGMSQK VGHMDFFPNGGKEMPGCEKNIISTIVDVNGFLEGITSLAACNHMRSYQYYSSSILNPDGF LGYPCASYEEFQKDGCFPCPAEGCPKMGHYADQFQGKANGVEKTYFLNTGDSDNFPRWRY KVSVTLSGEKELSGDIKIALFGRNGNSKQYEIFKGSLKPDARYTHDIDVDLNVGEIQKVK FLWHNNGINLLQPKLGASQITVQSGEYGTKYNFCSSNTVQEDVLQSLSPC >P32947; 15 LIPASE 3 PRECURSOR (EC 3.1.1.3) (CHOLESTEROL ESTERASE). MKLALALSLIASVAAAPTAKLANGDTITGLNAIINEAFLGIPFAEPPVGNLRFKDPVPYS GSLNGQKFTSYGPSCMQQNPEGTFEENLGKTALDLVMQSKVFQAVLPQSEDCLTINVVRP PGTKAGANLPVMLWIFGGGFEIGSPTIFPPAQMVTKSVLMGKPIIHVAVNYRVASWGFLA GDDIKAEGSGNAGLKDQRLGMQWVADNIAGFGGDPSKVTIFGESAGSMSVLCHLIWNDGD NTYKGKPLFRAGIMQSGAMVPSDPVDGTYGNEIYDLFVSSAGCGSASDKLACLRSASSDT LLDATNNTPGFLAYSSLRLSYLPRPDGKNITDDMYKLVRDGKYASVPVIIGDQNDEGTIF GLSSLNVTTNAQARAYFKQSFIHASDAEIDTLMAAYPQDITQGSPFDTGIFNAITPQFKR ISAVLGDLAFIHARRYFLNHFQGGTKYSFLSKQLSGLPIMGTFHANDIVWQDYLLGSGSV IYNNAFIAFATDLDPNTAGLLVNWPKYTSSSQSGNNLMMINALGLYTGKDNFRTAGYDAL MTNPSSFFV >P04634; 18 TRIACYLGLYCEROL LIPASE PRECURSOR (EC 3.1.1.3) (LIPASE, L MWLLLITSVISTFGGAHGLFGKLGPGNPEANMNISQMITYWGYPCQEYEVVTEDGYILGV YRIPHGKNNSENIGKRPVVYLQHGLIASATNWIANLPNNSLAFMLADAGYDVWLGNSRGN TWSRKNVYYSPDSVEFWAFSFDEMAKYDLPATINFIVQKTGQEKIHYVGHSQGTTIGFIA FSTNPTLAKKIKTFYALAPVATVKYTQSPLKKISFIPTFLFKLMFGKKMFLPHTYFDDFL GTEVCSREVLDLLCSNTLFIFCGFDKKNLNVSRFDVYLGHNPAGTSVQDFLHWAQLVRSG KFQAFNWGSPSQNMLHYNQKTPPEYDVSAMTVPVAVWNGGNDILADPQDVAMLLPKLSNL LFHKEILAYNHLDFIWAMDAPQEVYNEMISMMAED >P07867; 22 TRIACYLGLYCEROL LIPASE PRECURSOR (EC 3.1.1.3) (LIPASE, H MGNHLQISVSLVLCIFIQSSACGQGVGTEPFGRNLGATEERKPLQKPEIRFLLFKDESDR LGCQLRPQHPETLQECGFNSSHPLVMIIHGWSVDGLLETWIWKIVGALKSRQSQPVNVGL VDWISLAYQHYAIAVRNTRVVGQEVAALLLWLEESMKFSRSKVHLIGYSLGAHVSGFAGS SMGGKRKIGRITGLDPAGPMFEGTSPNERLSPDDANFVDAIHTFTREHMGLSVGIKQPIA HYDFYPNGGSFQPGCHFLELYKHIAEHGLNAITQTINCAHERSVHLFIDSLQHSNLQNTG FQCSNMDSFSQGLCLNCKKGRCNSLGYDIRRIGHVKSKTLFLITRAQSPFKVYHYQFKIQ FINQMEKPMEPTFTMTLLGTKEEIKKIPITLGEGITSNKTYSLLITLNKDIGELIMLKFK WENSAVWANVWNTVQTIMLWDTEPHYAGLIVKTIWVKAGETQQRMTFCPDNVDDLQLHPT QEKVFVKCDLKSKD >P06858; 27 LIPOPROTEIN LIPASE PRECURSOR (EC 3.1.1.34) (LPL). MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTAEDTCHLIPGV AESVATCHFNHSSKTFMVIHGWTVTGMYESWVPKLVAALYKREPDSNVIVVDWLSRAQEH YPVSAGYTKLVGQDVARFINWMEEEFNYPLDNVHLLGYSLGAHAAGIAGSLTNKKVNRIT GLDPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGHVDIYPNGGTFQ PGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFIDSLLNEENPSKAYRCSSKEAFEKG LCLSCRKNRCNNLGYEINKVRAKRSSKMYLKTRSQMPYKVFHYQVKIHFSGTESETHTNQ AFEISLYGTVAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMLKLKWKSDSYFSWSDW WSSPGFAIQKIRVKAGETQKKVIFCSREKVSHLQKGKAPAVFVKCHDKSLNKKSG >Q01584; 20 LIPOCALIN PRECURSOR. MKGLVLSFALVALSALCVYGDVPIQPDFQEDKILGKWYGIGLASNSNWFQSKKQQLKMCT TVITPTADGNLDVVATFPKLDRCEKKSMTYIKTEQPGRFLSKSPRYGSDHVIRVVESNYD EYTLMHTIKTKGNEVNTIVSLFGRRKTLSPELLDKFQQFAKEQGLTDDNILILPQTDSCM SEV >P11046; 25 LAMININ BETA-1 CHAIN PRECURSOR (LAMININ B1 CHAIN). MLELRLIVVIVLALALLSWQWDPVDSQRPPQHGRRDRPKYPPNKFIKTHPCERSSCYPAT GNLLIGRENRLTASSTCGLHSPERFCILSHLQDKKCFLCDTREETKHDPYKNHRIGQIIY KTKPGTNIPTWWQSENGKENATIQLDLEAEFHFTHLIITFTTFRPAAMYIERSFDFGQTW HIYRYFAYDCKESFPGVPTVLENITDVMCTSRYSNVEPSRNGEVIFRVLPPNINVTDPYA EHVQNQLKMTNLRIQMTKLHKLGDNLLDSRLENEEKYYYGISNMVVRGSCSCYGHASQCL PLDPAFSQADNEDGMVHGRCECTHNTKGMNCEECEDFFNDLPWKPAFGKKTNACKKCECN DHAVSCHFDEAVFTASGFVSGGVCDNCLHNTRGQHCEECMPYFYRDPEQDITSERVCQPC DCDPQGSSDDGICDSLNELEEGAVAGACHCKAFVTGRRCNQCKDGYWNLQSDNPEGCEPC TCNPLGTLNNSGCVMRTGECKCKKYVTGKDCNQCMPETYGLSESPEGCSLCNCDAGGSYD NYCDVISGQCRCRPHMTGRSCSQPKQNYFIPLLPEVHEAEVVDECISYGANGNCSLVAET PDGSFTGIGFTRVPENSELVFTVGDIPRSMPYDAVIRYQSTSRGDWENAFITLVRPDQVD PEGGCGEHAAATSSETRIPFSLPDRSRQVVALNEVCLEAGKVYKFRIYFERKRHDVDSPT ATILVDSLTLIPRIDVTPIFQGSVLADIRKKDYEKYNCKSSLYDMNYKSDPKCQNLDNIL SVFVHDGASMCNCNPTGSLSKVCESNGGYCQCKPNVVGRQCDQCAPGTYGFGPEGCKACD CNSIGSMDKYCDLITGQCQCVPNTYGRECNQCQPGYWNFPECRVCQCNGHAATCDPIQGT CIDCQDSTTGYSCDSCLDGYYGNPLFGSEIGCRPCRCPETVAGGLAHADGCSLDTRNNNM LCHCQEGYSGSRCEICADNFFGNPDNGGTCSKCECSNNVDLYDTGNCDRQTGACLKCLYQ TTGDHCELCKDGFFGDALQQNCQQCECDFLGTNNTIAHCDRFTGQCPCLPNVQGVRCDQC AENHWKIASGEGCESCNCDPIGALHEQCNSYTGQCQCKPGFGGRACNQCQAHYWGNPNEK CQPCECDQFGAADFQCDRETGNCVCHEGIGGYKCNECARGYIGQFPHCSPCGECFNNWDL ILSALEDATTATILRAKEIKQVGATGAYTSEFSELDKKLQHIRNLLQNTSVSLVDIEKLD YETQSLRDQLQASHGRLSETEQNLDDIYNSLSLSGVELESLQNHSRLVQQLSKELKENGI QLQESNIEGALNLTRHAYERVSNLSTLKDEANELASNSDRIAREWKICLIRFRPNADDLA NNNKLIEDYRAELTSLTSQIPELNNQVCGKPGDPCDSLCGGAGCGHCGGFLSCEHGAKTH SEEALKVAKDAETAITSKKDQADQTIRALTQAKLNASEAYEKAKRGFEQSERYLNQTNAN IKLAENLFIALNNFQENKTASPSESKELAQKTLDLDLKLEPEEIETLGDQINRAVSSLKN VEAIIYRTKPDLDRVNNLQSIANATKEKADKILDSANSVVERAAADESQGKAKDAIQQAN SNIELAGQDLEKIDEETYSAEAPANNTAQQVEKLAKKVQKLQNNIMKNDRDAKEITKEAG SVKLEAMRARGEANNLQSATSATNQTLTDRASRSENARERAKQLLQRASKLTVDTNAKLK DLNDLQTVYLNKNQQLLRLQAEIGPLNKELNEHLIHIKERGSHYRQCYT >P02469; 21 LAMININ BETA-1 CHAIN PRECURSOR (LAMININ B1 CHAIN). MGLLQVFAFGVLALWGTRVCAQEPEFSYGCAEGSCYPATGDLLIGRAQKLSVTSTCGLHK PEPYCIVSHLQEDKKCFICDSRDPYHETLNPDSHLIENVVTTFAPNRLKIWWQSENGVEN VTIQLDLEAEFHFTHLIMTFKTFRPAAMLIERSSDFGKTWGVYRYFAYDCESSFPGISTG PMKKVDDIICDSRYSDIEPSTEGEVIFRALDPAFKIEDPYSPRIQNLLKITNLRIKFVKL HTLGDNLLDSRMEIREKYYYAVYDMVVRGNCFCYGHASECAPVDGVNEEVEGMVHGHCMC RHNTKGLNCELCMDFYHDLPWRPAEGRNSNACKKCNCNEHSSSCHFDMAVFLATGNVSGG VCDNCQHNTMGRNCEQCKPFYFQHPERDIRDPNLCEPCTCDPAGSENGGICDGYTDFSVG LIAGQCRCKLHVEGERCDVCKEGFYDLSAEDPYGCKSCACNPLGTIPGGNPCDSETGYCY CKRLVTGQRCDQCLPQHWGLSNDLDGCRPCDCDLGGALNNSCSEDSGQCSCLPHMIGRQC NEVESGYYFTTLDHYIYEAEEANLGPGVVVVERQYIQDRIPSWTGPGFVRVPEGAYLEFF IDNIPYSMEYEILIRYEPQLPDHWEKAVITVQRPGKIPASSRCGNTVPDDDNQVVSLSPG SRYVVLPRPVCFEKGMNYTVRLELPQYTASGSDVESPYTFIDSLVLMPYCKSLDIFTVGG SGDGEVTNSAWETFQRYRCLENSRSVVKTPMTDVCRNIIFSISALIHQTGLACECDPQGS LSSVCDPNGGQCQCRPNVVGRTCNRCAPGTFGFGPNGCKPCDCHLQGSASAFCDAITGQC HCFQGIYARQCDRCLPGYWGFPSCQPCQCNGHALDCDTVTGECLSCQDYTTGHNCERCLA GYYGDPIIGSGDHCRPCPCPDGPDSGRQFARSCYQDPVTLQLACVCDPGYIGSRCDDCAS GFFGNPSDFGGSCQPCQCHHNIDTTDPEACDKDTGRCLKCLYHTEGDHCQLCQYGYYGDA LRQDCRKCVCNYLGTVKEHCNGSDCHCDKATGQCSCLPNVIGQNCDRCAPNTWQLASGTG CGPCNCNAAHSFGPSCNEFTGQCQCMPGFGGRTCSECQELFWGDPDVECRACDCDPRGIE TPQCDQSTGQCVCVEGVEGPRCDKCTRGYSGVFPDCTPCHQCFALWDAIIGELTNRTHKF LEKAKALKISGVIGPYRETVDSVEKKVNEIKDILAQSPAAEPLKNIGILFEEAEKLTKDV TEKMAQVEVKLTDTASQSNSTAGELGALQAEAESLDKTVKELAEQLEFIKNSDIQGALDS ITKYFQMSLEAEKRVNASTTDPNSTVEQSALTRDRVEDLMLERESPFKEQQEEQARLLDE LAGKLQSLDLSAAAQMTCGTPPGADCSESECGGPNCRTDEGEKKCGGPGCGGLVTVAHSA WQKAMDFDRDVLSALAEVEQLSKMVSEAKVRADEAKQNAQDVLLKTNATKEKVDKSNEDL RNLIKQIRNFLTEDSADLDSIEAVANEVLKSGNASTPQQLQNLTEDIRERVETLSQVEVI LQQSAADIARAELLLEEAKRASKSATDVKVTADMVKEALEEAEKAQVAAEKAIKQADEDI QGTQNLLTSIESETAASEETLTNASQRISKLERNVEELKRKAAQNSGEAEYIEKVVYSVK QNADDVKKTLDGELDEKYKKVESLIAQKTEESADARRKAELLQNEAKTLLAQANSKLQLL EDLERKYEDNQKYLEDKAQELVRLEGEVRSLLKDISEKVAVYSTCL >P15800; 35 LAMININ BETA-2 CHAIN PRECURSOR (S-LAMININ) (LAMININ CHAI MEWASGKPGRGRQGQPVPWELRLGLLLSVLAATLAQVPSLDVPGCSRGSCYPATGDLLVG RADRLTASSTCGLHSPQPYCIVSHLQDEKKCFLCDSRRPFSARDNPNSHRIQNVVTSFAP QRRTAWWQSENGVPMVTIQLDLEAEFHFTHLIMTFKTFRPAAMLVERSADFGRTWRVYRY FSYDCGADFPGIPLAPPRRWDDVVCESRYSEIEPSTEGEVIYRVLDPAIPIPDPYSSRIQ NLLKITNLRVNLTRLHTLGDNLLDPRREIREKYYYALYELVIRGNCFCYGHASQCAPAPG APAHAEGMVHGACICKHNTRGLNCEQCQDFYQDLPWHPAEDGHTHACRKCECNGHSHSCH FDMAVYLASGNVSGGVCDGCQHNTAGRHCELCRPFFYRDPTKDMRDPAACRPCDCDPMGS QDGGRCDSHDDPVLGLVSGQCRCKEHVVGTRCQQCRDGFFGLSASNPRGCQRCQCNSRGT VPGGTPCDSSSGTCFCKRLVTGDGCDRCLPGHWGLSHDLLGCRPCDCDVGGALDPQCDEA TGQCPCRPHMIGRRCEQVQPGYFRPFLDHLTWEAEGAHGQVLEVVERLVTNRETPSWTGV GFVRLREGQEVEFLVTSLPRAMDYDLLLRWEPQVPEQWAELELVVQRPGPVSAHSPCGHV LPRDDRIQGMLHPNTRVLVFPRPVCLEPGLSYKLKLKLTGTGGRAHPETPYSGSGILIDS LVLQPHVLMLEMFSGGDAAALERRTTFERYRCHEEGLMPSKTPLSEACVPLLISASSLVY NGALPCQCDPQGSLSSECNPHGGQCRCKPGVVGRRCDACATGYYGFGPAGCQACQCSPDG ALSALCEGTSGQCLCRTGAFGLRCDHCQRGQWGFPNCRPCVCNGRADECDAHTGACLGCR DYTGGEHCERCIAGFHGDPRLPYGGQCRPCPCPEGPGSQRHFATSCHRDGYSQQIVCHCR AGYTGLRCEACAPGHFGDPSKPGGRCQLCECSGNIDPTDPGACDPHTGQCLRCLHHTEGP HCGHCKPGFHGQAARQSCHRCTCNLLGTDPQRCPSTDLCHCDPSTGQCPCLPHVQGLSCD RCAPNFWNFTSGRGCQPCACHPSRARGPTCNEFTGQCHCHAGFGGRTCSECQELHWGDPG LQCRACDCDPRGIDKPQCHRSTGHCSCRPGVSGVRCDQCARGFSGVFPACHPCHACFGDW DRVVQDLAARTRRLEQWAQELQQTGVLGAFESSFLNLQGKLGMVQAIVAARNTSAASTAK LVEATEGLRHEIGKTTERLTQLEAELTDVQDENFNANHALSGLERDGLALNLTLRQLDQH LDILKHSNFLGAYDSIRHAHSQSTEAERRANASTFAIPSPVSNSADTRRRAEVLMGAQRE NFNRQHLANQQALGRLSTHTHTLSLTGVNELVCGAPGDAPCATSPCGGAGCRDEDGQPRC GGLGCSGAAATADLALGRARHTQAELQRALVEGGGILSRVSETRRQAEEAQQRAQAALDK ANASRGQVEQANQELRELIQNVKDFLSQEGADPDSIEMVATRVLDISIPASPEQIQRLAS EIAERVRSLADVDTILAHTMGDVRRAEQLLQDAQRARSRAEGERQKAETVQAALEEAQRA QGAAQGAIRGAVVDTKNTEQTLQQVQERMAGTEQSLNSASERARQLHALLEALKLKRAGN SLAASTAEETAGSAQSRAREAEKQLREQVGDQYQTVRALAERKAEGVLAAQARAEQLRDE ARGLLQAAQDKLQRLQELEGTYEENERELEVKAAQLDGLEARMRSVLQAINLQVQIYNTC Q >P11047; 33 LAMININ GAMMA-1 CHAIN PRECURSOR (LAMININ B2 CHAIN). MRGSHRAAPALRPRGRLWPVLAVLAAAAAAGCAQAAMDECTDEGGRPQRCMPEFVNAAFN VTVVATNTCGTPPEEYCVQTGVTGVTKSCHLCDAGQPHLQHGAAFLTDYNNQADTTWWQS QTMLAGVQYPSSINLTLHLGKAFDITYVRLKFHTSRPESFAIYKRTREDGPWIPYQYYSG SCENTYSKANRGFIRTGGDEQQALCTDEFSDFSPLTGGNVAFSTLEGRPSAYNFDNSPVL QEWVTATDIRVTLNRLNTFGDEVFNDPKVLKSYYYAISDFAVGGRCKCNGHASECMKNEF DKLVCNCKHNTYGVDCEKCLPFFNDRPWRRATAESASECLPCDCNGRSQECYFDPELYRS TGHGGHCTNCQDNTDGAHCERCRENFFRLGNNEACSSCHCSPVGSLSTQCDSYGRCSCKP GVMGDKCDRCQPGFHSLTEAGCRPCSCDPSGSIDECNVETGRCVCKDNVEGFNCERCKPG FFNLESSNPRGCTPCFCFGHSSVCTNAVGYSVYSISSTFQIDEDGWRAEQRDGSEASLEW SSERQDIAVISDSYFPRYFIAPAKFLGKQVLSYGQNLSFSFRVDRRDTRLSAEDLVLEGA GLRVSVPLIAQGNSYPSETTVKYVFRLHEATDYPWRPALTPFEFQKLLNNLTSIKIRGTY SERSAGYLDDVTLASARPGPGVPATWVESCTCPVGYGGQFCEMCLSGYRRETPNLGPYSP CVLCACNGHSETCDPETGVCNCRDNTAGPHCEKCSDGYYGDSTAGTSSDCQPCPCPGGSS CAVVPKTKEVVCTNCPTGTTGKRCELCDDGYFGDPLGRNGPVRLCRLCQCSDNIDPNAVG NCNRLTGECLKCIYNTAGFYCDRCKDGFFGNPLAPNPADKCKACNCNPYGTMKQQSSCNP VTGQCECLPHVTGQDCGACDPGFYNLQSGQGCERCDCHALGSTNGQCDIRTGQCECQPGI TGQHCERCEVNHFGFGPEGCKPCDCHPEGSLSLQCKDDGRCECREGFVGNRCDQCEENYF YNRSWPGCQECPACYRLVKDKVADHRVKLQELESLIANLGTGDEMVTDQAFEDRLKEAER EVMDLLREAQDVKDVDQNLMDRLQRVNNTLSSQISRLQNIRNTIEETGNLAEQARAHVEN TERLIEIASRELEKAKVAAANVSVTQPESTGDPNNMTLLAEEARKLAERHKQEADDIVRV AKTANDTSTEAYNLLLRTLAGENQTAFEIEELNRKYEQAKNISQDLEKQAARVHEEAKRA GDKAVEIYASVAQLSPLDSETLENEANNIKMEAENLEQLIDQKLKDYEDLREDMRGKELE VKNLLEKGKTEQQTADQLLARADAAKALAEEAAKKGRDTLQEANDILNNLKDFDRRVNDN KTAAEEALRKIPAINQTITEANEKTREAQQALGSAAADATEAKNKAHEAERIASAVQKNA TSTKAEAERTFAEVTDLDNEVNNMLKQLQEAEKELKRKQDDADQDMMMAGMASQAAQEAE INARKAKNSVTSLLSIINDLLEQLGQLDTVDLNKLNEIEGTLNKAKDEMKVSDLDRKVSD LENEAKKQEAAIMDYNRDIEEIMKDIRNLEDIRKTLPSGCFNTPSIEKP >P05300; 18 LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 1 PRECURSOR (L MGGAARAVLLGFLQASSSFDVRDSTGKVCIIANLTVAFSVEYKSSGQKQFAHFFLPQNAT SQSHSSCGEGNTSHPILALSFGAGHLISLNFSKTLDKYQVEELTFHYNLSDETLFPNATE GKVMVATQKSVIQARIGTEYRCINSKYVRMKHVNITFSNVTLEAYPTNDTFSANKTECRE DMVSTTTVAPTTPKHATSQVPTTSPAPTAAPSSPAVGKYNVTGANGTCVLASMGLQLNIT YVKKDEKMGLDLLNFIPHNTSASGMCESTSAFLNLAFEKTKITFHFVLNASSEKFFLQGV NVSTTLPSEAKAPTFEASNDSMSESRATVGNSYKCSAEENFQVTDKALVNVFNVQVQAFK VDGDKFGAMEECQLDENNMLIPIIVGAALAGLVLIVLIAYLIGRKRSHAGYQTI >P11279; 27 LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 1 PRECURSOR (L MAPRSARRPLLLLLPVAAARPHALSSAAMFMVKNGNGTACIMANFSAAFSVNYDTKSGPK NMTFDLPSDATVVLNRSSCGKENTSDPSLVIAFGRGHTLTLNFTRNATRYSVQLMSFVYN LSDTHLFPNASSKEIKTVESITDIRADIDKKYRCVSGTQVHMNNVTVTLHDATIQAYLSN SSFSRGETRCEQDRPSPTTAPPAPPSPSPSPVPKSPSVDKYNVSGTNGTCLLASMGLQLN LTYERKDNTTVTRLLNINPNKTSASGSCGAHLVTLELHSEGTTVLLFQFGMNASSSRFFL QGIQLNTILPDARDPAFKAANGSLRALQATVGNSYKCNAEEHVRVTKAFSVNIFKVWVQA FKVEGGQFGSVEECLLDENSTLIPIAVGGALAGLVLIVLIAYLVGRKRSHAGYQTI >P17046; 26 LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 2 PRECURSOR (L MRLPLSGYGSKLVLLFLFLGAVRSDALKLNLTDSKGTCLYAEWEMNFTITYEALKVNETV TITVPDKVTYNGSSCGDDKNGAKIMIQYGSTLSWAVNFTKEASQYFINNITLSYNTNDTK TFPGAVPKGILTVIIPVGSQLPLGVIFKCSSVLTFNLSPVVQHYWGIHLQAFVQNGTVSK HEQVCKEDKTATTVAPIIHTTVPSPTTTLTPTSIPVPTPTVGNYTISNGNATCLLATMGL QLNITEEKVPFIFNINPATTNFTGSCQPQTAQLRLNNSQIKYLDFIFAVKNEKRFYLKEV NVNMYLANGSAFHVSNNNLSFWDAPLGSSYMCNKEQVVSVSRTFQINTFNLKVQPFNVTK GEYSTAQDCSADEDNFLVPIAVGAALGGVLILVLLAYFIGLKRHHTGYEQF >P09334; 19 LOW MOLECULAR LIPOPROTEIN 30 KD PROTEIN PRECURSOR (CLONE MRLTLFAFVLAVCALASNATLAPRTDDVLAEQLYMSVVIGEYETAIAKCSEYLKEKKGEV IKEAVKRLIENGKRNTMDFAYQLWTKDGKEIVKSYFPIQFRVIFTEQTVKLINKRDHHAL KLIDQQNHNKIAFGDSKDKTSKKVSWKFTPVLENNRVYFKIMSTEDKQYLKLDNTKGSSD DRIIYGDSTADTFKHHWYLEPSMYESDVMFFVYNREYNSVMTLDEDMAANEDREALGHSG EVSGYPQLFAWYIVPY >P09336; 17 LOW MOLECULAR LIPOPROTEIN 30 KD PROTEIN PRECURSOR (CLONE MKPAIVILCLFVASLYAADSDVPNDILEEQLYNSVVVADYDSAVEKSKHLYEEKKSEVIT NVVNKLIRNNKMNCMEYAYQLWLQGSKDIVRDCFPVEFRLIFAENAIKLMYKRDGLALTL SNDVQGDDGRPAYGKDKTSPRVSWKLIALWENNKVYFKILNTERNQYLVLGVGTNWNGDH MAFGVNSVDSFRAQWYLQPAKYDNDVLFYIYNREYSKALTLSRTVEPSGHRMAWGYNGRV IGSPEHYAWGIKAF >P09848; 19 LACTASE-PHLORIZIN HYDROLASE PRECURSOR (EC 3.2.1.108) (EC MELSWHVVFIALLSFSCWGSDWESDRNFISTAGPLTNDLLHNLSGLLGDQSSNFVAGDKD MYVCHQPLPTFLPEYFSSLHASQITHYKVFLSWAQLLPAGSTQNPDEKTVQCYRRLLKAL KTARLQPMVILHHQTLPASTLRRTEAFADLFADYATFAFHSFGDLVGIWFTFSDLEEVIK ELPHQESRASQLQTLSDAHRKAYEIYHESYAFQGGKLSVVLRAEDIPELLLEPPISALAQ DTVDFLSLDLSYECQNEASLRQKLSKLQTIEPKVKVFIFNLKLPDCPSTMKNPASLLFSL FEAINKDQVLTIGFDINEFLSCSSSSKKSMSCSLTGSLALQPDQQQDHETTDSSPASAYQ RVWEAFANQSRAERDAFLQDTFPEGFLWGASTGAFNVEGGWAEGGRGVSIWDPRRPLNTT EGQATLEVASDSYHKVASDVALLCGLRAQVYKFSISWSRIFPMGHGSSPSLPGVAYYNKL IDRLQDAGIEPMATLFHWDLPQALQDHGGWQNESVVDAFLDYAAFCFSTFGDRVKLWVTF HEPWVMSYAGYGTGQHPPGISDPGVASFKVAHLVLKAHARTWHHYNSHHRPQQQGHVGIV LNSDWAEPLSPERPEDLRASERFLHFMLGWFAHPVFVDGDYPATLRTQIQQMNRQCSHPV AQLPEFTEAEKQLLKGSADFLGLSHYTSRLISNAPQNTCIPSYDTIGGFSQHVNHVWPQT SSSWIRVVPWGIRRLLQFVSLEYTRGKVPIYLAGNGMPIGESENLFDDSLRVDYFNQYIN EVLKAIKEDSVDVRSYIARSLIDGFEGPSGYSQRFGLHHVNFSDSSKSRTPRKSAYFFTS IIEKNGFLTKGAKRLLPPNTVNLPSKVRAFTFPSEVPSKAKVVWEKFSSQPKFERDLFYH GTFRDDFLWGVSSSAYQIEGAWDADGKGPSIWDNFTHTPGSNVKDNATGDIACDSYHQLD ADLNMLRALKVKAYRFSISWSRIFPTGRNSSINSHGVDYYNRLINGLVASNIFPMVTLFH WDLPQALQDIGGWENPALIDLFDSYADFCFQTFGDRVKFWMTFNEPMYLAWLGYGSGEFP PGVKDPGWAPYRIAHTVIKAHARVYHTYDEKYRQEQKGVISLSLSTHWAEPKSPGVPRDV EAADRMLQFSLGWFAHPIFRNGDYPDTMKWKVGNRSELQHLATSRLPSFTEEEKRFIRAT ADVFCLNTYYSRIVQHKTPRLNPPSYEDDQEMAEEEDPSWPSTAMNRAAPWGTRRLLNWI KEEYGDIPIYITENGVGLTNPNTEDTDRIFYHKTYINEALKAYRLDGIDLRGYVAWSLMD NFEWLNGYTVKFGLYHVDFNNTNRPRTARASARYYTEVITNNGMPLAREDEFLYGRFPEG FIWSAASAAYQIEGAWRADGKGLSIWDTFSHTPLRVENDAIGDVACDSYHKIAEDLVTLQ NLGVSHYRFSISWSRILPDGTTRYINEAGLNYYVRLIDTLLAASIQPQVTIYHWDLPQTL QDVGGWENETIVQRFKEYADVLFQRLGDKVKFWITLNEPFVIAYQGYGYGTAAPGVSNRP GTAPYIVGHNLIKAHAEAWHLYNDVYRASQGGVISITISSDWAEPRDPSNQEDVEAARRY VQFMGGWFAHPIFKNGDYNEVMKTRIRDRSLAAGLNKSRLPEFTESEKRRINGTYDFFGF NHYTTVLAYNLNYATAISSFDADRGVASIADRSWPDSGSFWLKMTPFGFRRILNWLKEEY NDPPIYVTENGVSQREETDLNDTARIYYLRTYINEALKAVQDKVDLRGYTVWSAMDNFEW ATGFSERFGLHFVNYSDPSLPRIPKASAKFYASVVRCNGFPDPATGPHACLHQPDAGPTI SPVRQEEVQFLGLMLGTTEAQTALYVLFSLVLLGVCGLAFLSYKYCKRSKQGKTQRSQQE LSPVSSF >P16235; 26 LUTROPIN-CHORIOGONADOTROPIC HORMONE RECEPTOR PRECURSOR ( MGRRVPALRQLLVLAVLLLKPSQLQSRELSGSRCPEPCDCAPDGALRCPGPRAGLARLSL TYLPVKVIPSQAFRGLNEVVKIEISQSDSLERIEANAFDNLLNLSELLIQNTKNLLYIEP GAFTNLPRLKYLSICNTGIRTLPDVTKISSSEFNFILEICDNLHITTIPGNAFQGMNNES VTLKLYGNGFEEVQSHAFNGTTLISLELKENIYLEKMHSGAFQGATGPSILDISSTKLQA LPSHGLESIQTLIALSSYSLKTLPSKEKFTSLLVATLTYPSHCCAFRNLPKKEQNFSFSI FENFSKQCESTVRKADNETLYSAIFEENELSGWDYDYGFCSPKTLQCAPEPDAFNPCEDI MGYAFLRVLIWLINILAIFGNLTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIA SVDSQTKGQYYNHAIDWQTGSGCGAAGFFTVFASELSVYTLTVITLERWHTITYAVQLDQ KLRLRHAIPIMLGGWLFSTLIATMPLVGISNYMKVSICLPMDVESTLSQVYILSILILNV VAFVVICACYIRIYFAVQNPELTAPNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKV PLITVTNSKILLVLFYPVNSCANPFLYAIFTKAFQRDFLLLLSRFGCCKRRAELYRRKEF SAYTSNCKNGFPGASKPSQATLKLSTVHCQQPIPPRALTH >Q05443; 18 LUMICAN PRECURSOR (LUM) (KERATAN SULFATE PROTEOGLYCAN) ( MNLGVFPLLLALIGGASSTYPDYYEYYDFPQALYGRSSPNCAPECNCPESYPSAMYCDEL KLKSVPMVPPGIKYLYLRNNQIDHIDDKAFENVTDLQWLILDHNLLENSKIKGKVFSKLK QLKKLHINYNNLTESVGPLPKSLVDLQLTNNKISKLGSFDGLVNLTFIHLQHNQLKEDAV SAALKGLKSLEYLDLSFNQMTKLPSGLPVSLLTLYLDNNKISNIPDEYFKRFSALQYLRL SHNELADSGVPGNSFNVSSLLELDLSYNKLKSIPTVNENLENYYLEVNELEKFDVKSFCK ILGPLSYSKIKHLRLDGNHITQTSLPPDMYECLRVANEITVN >P50895; 31 LUTHERAN BLOOD GROUP GLYCOPROTEIN PRECURSOR (B-CAM CELL MEPPDAPAQARGAPRLLLLAVLLAAHPDAQAEVRLSVPPLVEVMRGKSVILDCTPTGTHD HYMLEWFLTDRSGARPRLASAEMQGSELQVTMHDTRGRSPPYQLDSQGRLVLAEAQVGDE RDYVCVVRAGAAGTAEATARLNVFAKPEATEVSPNKGTLSVMEDSAQEIATCNSRNGNPA PKITWYRNGQRLEVPVEMNPEGYMTSRTVREASGLLSLTSTLYLRLRKDDRDASFHCAAH YSLPEGRHGRLDSPTFHLTLHYPTEHVQFWVGSPSTPAGWVREGDTVQLLCRGDGSPSPE YTLFRLQDEQEEVLNVNLEGNLTLEGVTRGQSGTYGCRVEDYDAADDVQLSKTLELRVAY LDPLELSEGKVLSLPLNSSAVVNCSVHGLPTPALRWTKDSTPLGDGPMLSLSSITFDSNG TYVCEASLPTVPVLSRTQNFTLLVQGSPELKTAEIEPKADGSWREGDEVTLICSARGHPD PKLSWSQLGGSPAEPIPGRQGWVSSSLTLKVTSALSRDGISCEASNPHGNKRHVFHFGAV SPQTSQAGVAVMAVAVSVGLLLLVVAVFYCVRRKGGPCCRQRREKGAPPPGEPGLSHSGS EQPEQTGLLMGGASGGARGGSGGFGDEC >P01723; 19 IG LAMBDA-1 CHAIN PRECURSOR V REGION. MAWISLILSLLALSSGAISQAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEK PDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH >P06316; 19 IG LAMBDA CHAIN PRECURSOR V-I REGION (BL2). MTCSPLLLTLLIHCTGSWAQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQVP GTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWNNSLSGWVF GGGTKLTVLG >P05533; 26 LYMPHOCYTE ANTIGEN LY-6A.2/LY-6E.1 PRECURSOR (T-CELL-ACT MDTSHTTKSCLLILLVALLCAERAQGLECYQCYGVPFETSCPSITCPYPDGVCVTQEAAV IVDSQTRKVKNNLCLPICPPNIESMEILGTKVNVKTSCCQEDLCNVAVPNGGSTWTMAGV LLFSLSSVLLQTLL >P11941; 15 LYSOZYME C II PRECURSOR (EC 3.2.1.17) (1,4-BETA-N-ACETYL MRAVVVLLLVAVASAKVYDRCELARALKASGMDGYAGNSLPNWVCLSKWESSYNTQATNR NTDGSTDYGIFQINSRYWCDDGRTPGAKNVCGIRCSQLLTADLTVAIRCAKRVVLDPNGI GAWVAWRLHCQNQDLRSYVAGCGV >P00696; 18 LYSOZYME C PRECURSOR (EC 3.2.1.17) (1,4-BETA-N-ACETYLMUR MKAVIILGLVLLSVTVQGKIFERCELARTLKRLGLDGYRGISLANWVCLAKWESDYNTQA TNYNPGDQSTDYGIFQINSHYWCNNGKTPGAVNACHISCNALLQDNIADAVTCAKRVVSD PQGIRAWVAWRNHCQNRDVSQYVQGCGV >P31723; 35 MANNOSYL-OLIGOSACCHARIDE ALPHA-1,2-MANNOSIDASE PRECURSOR MRLPVSFPLTVLSLLGSTIAHPYGETEAVLRSEPKSNQAKADAVKEAFQHAWNGYMKYAF PHDELTPVSNGHADSRNGWGASAVDALSTAVIMGKADVVNAILEHVADIDFSKTSDTVSL FETTIRYLAGMLSGYDLLQGPAKNLVDNQDLIDGLLDQSRNLADVLKFAFDTPSGVPYNN INITSHGNDGATTNGLAVTGTLVLEWTRLSDLTGDEEYAKLSQKAESYLLKPQPSSSEPF PGLVGSSININDGQFADSRVSWNGGDDSFYEYLIKMYVYDPKRFETYKDRWVLAAESTIK HLKSHPKSRPDLTFLSSYSNRNYDLSSQHLTCFDGGSFLLGGTVLDRQDFIDFGLELVDG CEATYNSTLTKIGPDSWGWDPKKVPSDQKEFYEKAGFYISSGSYVLRPEVIESFYYAHRV TGKEIYRDWVWNAFVAINSTCRTDSGFAAVSDVNKANGGSKYDNQESFLFAEVMKYSYLA HSEDAAWQVQKGGKNTFVYNTEAHPISVARN >O00754; 48 LYSOSOMAL ALPHA-MANNOSIDASE PRECURSOR (EC 3.2.1.24) (MAN MGYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAAGARAGGYETCPTVQPN MLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEI AFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLED TFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRA STSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVAT AQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLW ELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGL AANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALA RLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPN GRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSW SPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYI FRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPV GDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTR IYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGR HLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVH LLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQL REAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG >P08661; 18 MANNOSE-BINDING PROTEIN C PRECURSOR (MBP-C) (MANNAN-BIND MSLFTSFLLLCVLTAVYAETLTEGAQSSCPVIACSSPGLNGFPGKDGHDGAKGEKGEPGQ GLRGLQGPPGKVGPAGPPGNPGSKGATGPKGDRGESVEFDTTNIDLEIAALRSELRAMRK WVLLSMSENVGKKYFMSSVRRMPLNRAKALCSELQGTVATPRNAEENRAIQNVAKDVAFL GITDQRTENVFEDLTGNRVRYTNWNEGEPNNVGSGENCVVLLTNGKWNDVPCSDSFLVVC EFSD >P30659; 23 MAXADILAN PRECURSOR. MKQILLISLVVVLAVFAFNVAEGCDATCQFRKAIDDCQKQAHHSNVLQTSVQTTATFTSM DTSQLPGNSVFKECMKQKKKEFSSGK >P15529; 34 MEMBRANE COFACTOR PROTEIN PRECURSOR (CD46 ANTIGEN) (TROP MEPPGRRECPFPSWRFPGLLLAAMVLLLYSFSDACEEPPTFEAMELIGKPKPYYEIGERV DYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFG YQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEV FEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQIS GFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVSTSSTTKSPASSAS GPRPTYKPPVSNYPGYPKPEEGILDSLDVWVIAVIVIAIVVGVAVICVVPYRYLQRRKKK GTYLTDETHREVKFTSL >P00770; 18 MAST CELL PROTEASE II PRECURSOR (EC 3.4.21.-) (RMCP-II) MQALLFLMALLLPSGAGAEEIIGGVESIPHSRPYMAHLDIVTEKGLRVICGGFLISRQFV LTAAHCKGREITVILGAHDVRKRESTQQKIKVEKQIIHESYNSVPNLHDIMLLKLEKKVE LTPAVNVVPLPSPSDFIHPGAMCWAAGWGKTGVRDPTSYTLREVELRIMDEKACVDYRYY EYKFQVCVGSPTTLRAAFMGDSGGPLLCAGVAHGIVSYGHPDAKPPAIFTRVSTYVPWIN AVINTSS >P21845; 21 MAST CELL PROTEASE 6 PRECURSOR (EC 3.4.21.-) (MMCP-6) (T MLKRRLLLLWALSLLASLVYSAPRPANQRVGIVGGHEASESKWPWQVSLRFKLNYWIHFC GGSLIHPQWVLTAAHCVGPHIKSPQLFRVQLREQYLYYGDQLLSLNRIVVHPHYYTAEGG ADVALLELEVPVNVSTHIHPISLPPASETFPPGTSCWVTGWGDIDNDEPLPPPYPLKQVK VPIVENSLCDRKYHTGLYTGDDFPIVHDGMLCAGNTRRDSCQGDSGGPLVCKVKGTWLQA GVVSWGEGCAQPNKPGIYTRVTYYLDWIHRYVPEHS >P25234; 26 MONO- AND DIACYLGLYCEROL LIPASE PRECURSOR (EC 3.1.1.-) ( MRLSFFTALSAVASLGYALPGKLQSRDVSTSELDQFEFWVQYAAASYYEADYTAQVGDKL SCSKGNCPEVEATGATVSYDFSDSTITDTAGYIAVDHTNSAVVLAFRGSYSVRNWVADAT FVHTNPGLCDGCLAELGFWSSWKLVRDDIIKELKEVVAQNPNYELVVVGHSLGAAVATLA ATDLRGKGYPSAKLYAYASPRVGNAALAKYITAQGNNFRFTHTNDPVPKLPLLSMGYVHV SPEYWITSPNNATVSTSDIKVIDGDVSFDGNTGTGLPLLTDFEAHIWYFVQVDAGKGPGL PFKRV >P16444; 16 MICROSOMAL DIPEPTIDASE PRECURSOR (EC 3.4.13.19) (MDP) MWSGWWLWSLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNRLQDERANLTT LAGTHTNIPKLRAGFVGGQFWSVYTPCDTQNKDAVRRTLEQMDVVHRMCRMYPETFLYVT SSAGIRQAFREGKVASLIGVEGGHSIDSSLGVLRALYQLGMRYLTLTHSCNTPWADNWLV DTGDSEPQSQGLSPFGQRVVKELNRLGVLIDLAHVSVATMKATLQLSRAPVIFSHSSAYS VCASRRNVPDDVLRLVKQTDSLVMVNFYNNYISCTNKANLSQVADHLDHIKEVAGARAVG FGGDFDGVPRVPEGLEDVSKYPDLIAELLRRNWTEAEVKGALADNLLRVFEAVEQASNLT QAPEEEPIPLDQLGGSCRTHYGYSSGASSLHRHWGLLLASLAPLVLCLSLL >P01501; 21 MELITTIN MAJOR PRECURSOR (ALLERGEN API M 3) (API M III). MKFLVNVALVFMVVYISYIYAAPEPEPAPEPEAEADAEADPEAGIGAVLKVLTTGLPALI SWIKRKRQQG >P04824; 18 ALPHA-GALACTOSIDASE 1 PRECURSOR (EC 3.2.1.22) (MELIBIASE MFAFYFLTACISLKGVFGVSPSYNGLGLTPQMGWDNWNTFACDVSEQLLLDTADRISDLG LKDMGYKYIILDDCWSSGRDSDGFLVADEQKFPNGMGHVADHLHNNSFLFGMYSSAGEYT CAGYPGSLGREEEDAQFFANNRVDYLKYDNCYNKGQFGTPEISYHRYKAMSDALNKTGRP IFYSLCNWGQDLTFYWGSGIANSWRMSGDVTAEFTRPDSRCPCDGDEYDCKYAGFHCSIM NILNKAAPMGQNAGVGGWNDLDNLEVGVGNLTDDEEKAHFSMWAMVKSPLIIGANVNNLK ASSYSIYSQASVIAINQDSNGIPATRVWRYYVSDTDEYGQGEIQMWSGPLDNGDQVVALL NGGSVSRPMNTTLEEIFFDSNLGSKKLTSTWDIYDLWANRVDNSTASAILGRNKTATGIL YNATEQSYKDGLSKNDTRLFGQKIGSLSPNAILNTTVPAHGIAFYRLRPSS >P06648; 22 MATING FACTOR ALPHA PRECURSOR (ALPHA MATING PHEROMONE). MKLFTTLSASLIFIHSLGSTRAAPVTGDESSVEIPEESLIGFLDLAGDDISVFPVSNETH YGLMLVNSTIVNLARSESANFKGKREADAEPWHWLSFSKGEPMYKREADAEPWHWLSFSK GEPMY >Q95114; 18 MILK FAT GLOBULE-EGF FACTOR 8 PRECURSOR (MFG-E8) (MGP57/ MPCPRLLAALFCSSGLFAASGDFCDSSLCLHGGTCLLNEDRTPPFYCLCPEGFTGLLCNE TEHGPCFPNPCHNDAECQVTDDSHRGDVFIQYICKCPLGYVGIHCETTCTSPLGMQTGAI ADSQISASSMHLGFMGLQRWAPELARLHQTGIVNAWTSGNYDKNPWIQVNLMRKMWVTGV VTQGASRAGSAEYLKTFKVAYSTDGRQFQFIQVAGRSGDKIFIGNVNNSGLKINLFDTPL ETQYVRLVPIICHRGCTLRFELLGCELNGCTEPLGLKDNTIPNKQITASSYYKTWGLSAF SWFPYYARLDNQGKFNAWTAQTNSASEWLQIDLGSQKRVTGIITQGARDFGHIQYVAAYR VAYGDDGVTWTEYKDPGASESKIFPGNMDNNSHKKNIFETPFQARFVRIQPVAWHNRITL RVELLGC >Q04900; 23 PUTATIVE MUCIN CORE PROTEIN PRECURSOR 24 (MULTI-GLYCOSYL MSRLSRSLLWAATCLGVLCVLSADKNTTQHPNVTTLAPISNVTSAPVTSLPLVTTPAPET CEGRNSCVSCFNVSVVNTTCFWIECKDESYCSHNSTVSDCQVGNTTDFCSVSTATPVPTA NSTAKPTVQPSPSTTSKTVTTSGTTNNTVTPTSQPVRKSTFDAASFIGGIVLVLEIRCHT RNYIPDLKK >P13854; 23 MYELOMONOCYTIC GROWTH FACTOR PRECURSOR (MGF). MCCLTPVLALALVLGAPWQALHGAPLAELSGDHDFQLFLHKNLEFTRKIRGDVAALQRAV CDTFQLCTEEELQLVQPDPHLVQAPLDQCHKRGFQAEVCFTQIRAGLHAYHDSLGAVLRL LPNHTTLVETLQLDAANLSSNIQQQMEDLGLDTVTLPAEQRSPPPTFSGPFQQQVGGFFI LANFQRFLETAYRALRHLARL >P08494; 19 MATRIX GLA-PROTEIN PRECURSOR (MGP). MKSLLPLAILAALAVAALCYESHESMESYEVSPFTTRRNANTFISPQQRWHAKAQERVRE LNKPAQEINREACDDYKLCERYALIYGYNAAYNRYFRQRRGAK >P10855; 23 MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA PRECURSOR (MIP-1 MKVSTTALAVLLCTMTLCNQVFSAPYGADTPTACCFSYSRKIPRQFIVDYFETSSLCSQP GVIFLTKRNRQICADSKETWVQEYITDLELNA >Q10747; 32 MACROPHAGE INFLAMMATORY PROTEIN-2-BETA PRECURSOR (MIP2-B MAPPTRRLLNAALLLLLLLMATSHQPSGTVVARELRCQCLKTLPRVDFENIQSLTVTPPG PHCTQTEVIATLKDGQEVCLNPQAPRLQKIIQKLLKSPSL >Q16674; 24 MELANOMA DERIVED GROWTH REGULATORY PROTEIN PRECURSOR (ME MARSLVCLGVIILLSAFSGPGVRGGPMPKLADRKLCADQECSHPISMAVALQDYMAPDCR FLTIHRGQVVYVFSKLKGRGRLFWGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVD VKTDKWDFYCQ >P14209; 22 T-CELL SURFACE GLYCOPROTEIN E2 PRECURSOR (E2 ANTIGEN) (C MARGAALALLLFGLLGVLVAAPDGGFDLSDALPDNENKKPTAIPKKPSAGDDFDLGDAVV DGENDDPRPPNPPKPMPNPNPNHPSSSGSFSDADLADGVSGGEGKGGSDGGGSHRKEGEE ADAPGVIPGIVGAVVVAVAGAISSFIAYQKKKLCFKENAEQGEVDMESHRNANAEPAVQR TLLEK >P19713; 24 MELANIN-CONCENTRATING HORMONE 1 PRECURSOR. MRHYVLSISFAVALFLECYTPSTAISIGKMDDVALEQDTLDSLLSVEVSENSPDSVRGRS SKIVLLADSGLWMNLNRGLPFYKLRAAAAGPDRALTLDRREAGQDLSPSISIVRRDTMRC MVGRVYRPCWEV >P14200; 21 MELANIN-CONCENTRATING HORMONE PRECURSOR (MCH). MAKMSLSSYMLMLAFSLFSHGILLSASKSIRNVEDDIVFNTFRMGKAFQKEDTAERSVVA PSLEGYKNDESGFMKDDDDKTTKNTGSKQNLVTHGLPLSLAVKPYLALKGPAVFPAENGV QNTESTQEKREIGDEENSAKFPIGRRDFDMLRCMLGRVYRPCWQV >P12872; 25 MOTILIN PRECURSOR. MVSRKAVAALLVVHVAAMLASQTEAFVPIFTYGELQRMQEKERNKGQKKSLSVWQRSGEE GPVDPAEPIREEENEMIKLTAPLEIGMRMNSRQLEKYPATLEGLLSEMLPQHAAK >P25289; 31 MOLLUSCAN INSULIN-RELATED PEPTIDE 2 PRECURSOR (MIP II). MVGVRLVFTNAFVVTVLLTLLLDVVVKPAEGQSSCSLSSRPHPRGICGSNLAGFRAFICS NQNSPSMVKRDAETGWLLPETMVKRNAETDLDDPLRNIKLSSESALTYLTKRQRTTNLVC ECCFNYCTPDVVRKYCY >P24668; 21 CATION-DEPENDENT MANNOSE-6-PHOSPHATE RECEPTOR PRECURSOR MFPFSGCWRTELLLLLLLAVAVRESWQIEEKSCDLVGEKDKESKNEVALLERLRPLFNKS FESTVGQGSDTYSYIFRVCREASNHSSGAGLVQINKSNDKETVVGRINETHIFNGSNWIM LIYKGGDEYDNHCGKEQRRAVVMISCNRHTLAANFNPVSEERGKVQDCFYLFEMDSSLAC SPEVSHLSVGSILLVIFASLVAVYIIGGFLYQRLVVGAKGMEQFPHLAFWQDLGNLVADG CDFVCRSKPRNVPAAYRGVGDDQLGEESEERDDHLLPM >P43121; 23 CELL SURFACE GLYCOPROTEIN MUC18 PRECURSOR (MELANOMA-ASSO MGLPRLVCAFLLAACCCCPRVAGVPGEAEQPAPELVEVEVGSTALLKCGLSQSQGNLSHV DWFSVHKEKRTLIFRVRQGQGQSEPGEYEQRLSLQDRGATLALTQVTPQDERIFLCQGKR PRSQEYRIQLRVYKAPEEPNIQVNPLGIPVNSKEPEEVATCVGRNGYPIPQVIWYKNGRP LKEEKNRVHIQSSQTVESSGLYTLQSILKAQLVKEDKDAQFYCELNYRLPSGNHMKESRE VTVPVFYPTEKVWLEVEPVGMLKEGDRVEIRCLADGNPPPHFSISKQNPSTREAEEETTN DNGVLVLEPARKEHSGRYECQAWNLDTMISLLSEPQELLVNYVSDVRVSPAAPERQEGSS LTLTCEAESSQDLEFQWLREETDQVLERGPVLQLHDLKREAGGGYRCVASVPSIPGLNRT QLVKLAIFGPPWMAFKERKVWVKENMVLNLSCEASGHPRPTISWNVNGTASEQDQDPQRV LSTLNVLVTPELLETGVECTASNDLGKNTSILFLELVNLTTLTPDSNTTTGLSTSTASPH TRANSTSTERKLPEPESRGVVIVAVIVCILVLAVLGAVLYFLYKKGKLPCRRSGKQEITL PPSRKTELVVEVKSDKLPEEMGLLQGSSGDKRAPGDQGEKYIDLRH >P25189; 29 MYELIN P0 PROTEIN PRECURSOR. MAPGAPSSSPSPILAVLLFSSLVLSPAQAIVVYTDREVHGAVGSRVTLHCSFWSSEWVSD DISFTWRYQPEGGRDAISIFHYAKGQPYIDEVGTFKERIQWVGDPRWKDGSIVIHNLDYS DNGTFTCDVKNPPDIVGKTSQVTLYVFEKVPTRYGVVLGAVIGGVLGVVLLLLLLFYVVR YCWLRRQAALQRRLSAMEKGKLHKPGKDASKRGRQTPVLYAMLDHSRSTKAVSEKKAKGL GESRKDKK >P29241; 24 ADP-RIBOSYL CYCLASE PRECURSOR (EC 3.2.2.5) (NAD(+) NUCLE MSPVAIIACVCLAVTLTSISPSEAIVPTRELENVFLGRCKDYEITRYLDILPRVRSDCSA LWKDFFKAFSFKNPCDLDLGSYKDFFTSAQQQLPKNKVMFWSGVYDEAHDYANTGRKYIT LEDTLPGYMLNSLVWCGQRANPGFNEKVCPDFKTCPVQARESFWGMASSSYAHSAEGEVT YMVDGSNPKVPAYRPDSFFGKYELPNLTNKVTRVKVIVLHRLGEKIIEKCGAGSLLDLEK LVKAKHFAFDCVENPRAVLFLLCSDNPNARECRLAKRFYRIA >P17050; 17 ALPHA-N-ACETYLGALACTOSAMINIDASE PRECURSOR (EC 3.2.1.49) MLLKTVLLLGHVAQVLMLDNGLLQTPPMGWLAWERFRCNINCDEDPKNCISEQLFMEMAD RMAQDGWRDMGYTYLNIDDCWIGGRDASGRLMPDPKRFPHGIPFLADYVHSLGLKLGIYA DMGNFTCMGYPGTTLDKVVQDAQTFAEWKVDMLKLDGCFSTPEERAQGYPKMAAALNATG RPIAFSCSWPAYEGGLPPRVNYSLLADICNLWRNYDDIQDSWWSVLSILNWFVEHQDILQ PVAGPGHWNDPDMLLIGNFGLSLEQSRAQMALWTVLAAPLLMSTDLRTISAQNMDILQNP LMIKINQDPLGIQGRRIHKEKSLIEVYMRPLSNKASALVFFSCRTDMPYRYHSSLGQLNF TGSVIYEAQDVYSGDIISGLRDETNFTVIINPSGVVMWYLYPIKNLEMSQQ >P17981; 20 T-CELL ECTO-ADP-RIBOSYLTRANSFERASE PRECURSOR (EC 2.4.2.3 MPSNNFKFFLTWWLTQQVTGLAVPFMLDMAPNAFDDQYEGCVEDMEKKAPQLLQEDFNMN EELKLEWEKAEIKWKEIKNCMSYPAGFHDFHGTALVAYTGNIHRSLNEATREFKINPGNF HYKAFHYYLTRALQLLSDQGCRSVYRGTNVRFRYTGKGSVRFGHFASSSLNRSVATSSPF FNGQGTLFIIKTCLGAHIKHCSYYTHEEEVLIPGYEVFHKVKTQSVERYIQISLDSPKRK KSNFNCFYSGSTQAANVSSLGSRESCVPLFLVVLLGLLVQQLTLAEP >P13591; 19 NEURAL CELL ADHESION MOLECULE, 140 KD ISOFORM PRECURSOR MLQTKDLIWTLFFLGTAVSLQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGE KLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMF KNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIK KTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGF PEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATI HLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKTLDGHMV VRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGN QVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCT AVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAV GEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQG EPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVM LKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTSAQPTAIPANGSPTSGLSTGAIVGILIV IFVLLLVVVDITCYFLNKCGLFMCIAVNLCGKAGPGAKGKDMEEGKAAFSKDESKEPIVE VRTEEERTPNHDGGKHTEPNETTPLTEPEKGPVEAKPECQETETKPAPAEVKTVPNDATQ TKENESKA >Q03333; 25 NEUROENDOCRINE CONVERTASE 2 PRECURSOR (EC 3.4.21.94) (NE MKGGCVSQWKAAAGLLFCVTVFASAERPVFTNHFLVELHKGGEEEARQVAAEHGFGVRKL PFAEGLYHFYHNGLAKAKRRRSLHHKQRLERDPRVKRALQQEGFDRKKRGYRDINEIDIN MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYSSKVAGIRM LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGAVKEWTLMLHGSQSAPYI DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILGKH >P15210; 20 ISOTOCIN-NEUROPHYSIN IT 1 PRECURSOR. MSGSMFSVFSLLYLLSVCSACYISNCPIGGKRAIQDSPSRQCMSCGPGDRGRCFGPSICC GEGLGCLLGSPETQRCLEEDFLPSPCEAGGKVCGYEGRCAAPGVCCDSEGCSVDQSCVDG DGDATAVSQPASSQDLLLKLLHLSNPAHPYRLHQ >P17668; 19 VASOTOCIN-NEUROPHYSIN VT 1 PRECURSOR (VT). MSDSFLPTCILCLLALSSACYIQNCPRGGKRSQPDTSRECVSCGPGNAGRCYGPSICCGA ALGCLVGSPETMSCMEENHLPSPCETGGRPCGDEGRCAAPGVCCDSVSCVMDSECLEDVR SDQSEDPSRLKTVSGEILLRLLNLASRGRRDF >P08949; 24 NEUROMEDIN B PRECURSOR. MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWATGHFMGKKS LEPSSPSHWGQLPTPPLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQ K >P08162; 19 MESOTOCIN-NEUROPHYSIN MT PRECURSOR (MT). MSYTALAVTFFGWLALSSACYIQNCPIGGKRSVIDFMDVRKCIPCGPRNKGHCFGPNICC GEELGCYFGTTETLRCQEENFLPSPCESGRKPCGNNGGNCARSGICCNHESCTMDPACEQ DSVFS >P07808; 29 NEUROPEPTIDE Y PRECURSOR (NPY). MMLGNKRMGLCGLTLALSLLVCLGILAEGYPSKPDNPGEDAPAEDMARYYSALRHYINLI TRQRYGKRSSPETLISDLLMRESTENAPRTRLEDPSMW >Q94734; 21 NITROPHORIN 4 PRECURSOR (NP4). MKSYTSLLAVAILCLFGGVNGACTKNAIAQTGFNKDKYFNGDVWYVTDYLDLEPDDVPKR YCAALAAGTASGKLKEALYHYDPKTQDTFYDVSELQVESLGKYTANFKKVDKNGNVKVAV TAGNYYTFTVMYADDSSALIHTCLHKGNKDLGDLYAVLNRNKDAAAGDKVKSAVSAATLE FSKFISTKENNCAYDNDSLKSLLTK >P35331; 24 NG-CAM RELATED CELL ADHESION MOLECULE PRECURSOR (NR-CAM) MMKEKSISASKASLVFFLCQMISALDVPLDSKLLEELSQPPTITQQSPKDYIVDPRENIV IQCEAKGKPPPSFSWTRNGTHFDIDKDAQVTMKPNSGTLVVNIMNGVKAEAYEGVYQCTA RNERGAAISNNIVIRPSRSPLWTKEKLEPNHVREGDSLVLNCRPPVGLPPPIIFWMDNAF QRLPQSERVSQGLNGDLYFSNVQPEDTRVDYICYARFNHTQTIQQKQPISVKVFSTKPVT ERPPVLLTPMGSTSNKVELRGNVLLLECIAAGLPTPVIRWIKEGGELPANRTFFENFKKT LKIIDVSEADSGNYKCTARNTLGSTHHVISVTVKAAPYWITAPRNLVLSPGEDGTLICRA NGNPKPSISWLTNGVPIAIAPEDPSRKVDGDTIIFSAVQERSSAVYQCNASNEYGYLLAN AFVNVLAEPPRILTPANKLYQVIADSPALIDCAYFGSPKPEIEWFRGVKGSILRGNEYVF HDNGTLEIPVAQKDSTGTYTCVARNKLGKTQNEVQLEVKDPTMIIKQPQYKVIQRSAQAS FECVIKHDPTLIPTVIWLKDNNELPDDERFLVGKDNLTIMNVTDKDDGTYTCIVNTTLDS VSASAVLTVVAAPPTPAIIYARPNPPLDLELTGQLERSIELSWVPGEENNSPITNFVIEY EDGLHEPGVWHYQTEVPGSHTTVQLKLSPYVNYSFRVIAVNEIGRSQPSEPSEQYLTKSA NPDENPSNVQGIGSEPDNLVITWESLKGFQSNGPGLQYKVSWRQKDVDDEWTSVVVANVS KYIVSGTPTFVPYEIKVQALNDLGYAPEPSEVIGHSGEDLPMVAPGNVQVHVINSTLAKV HWDPVPLKSVRGHLQGYKVYYWKVQSLSRRSKRHVEKKILTFRGNKTFGMLPGLEPYSSY KLNVRVVNGKGEGPASPDKVFKTPEGVPSPPSFLKITNPTLDSLTLEWGSPTHPNGVLTS YILKFQPINNTHELGPLVEIRIPANESSLILKNLNYSTRYKFYFNAQTSVGSGSQITEEA VTIMDEAGILRPAVGAGKVQPLYPRIRNVTTAAAETYANISWEYEGPDHANFYVEYGVAG SKEDWKKEIVNGSRSFFVLKGLTPGTAYKVRVGAEGLSGFRSSEDLFETGPAMASRQVDI ATQGWFIGLMCAVALLILILLIVCFIRRNKGGKYPVKEKEDAHADPEIQPMKEDDGTFGE YRSLESDAEDHKPLKKGSRTPSDRTVKKEDSDDSLVDYGEGVNGQFNEDGSFIGQYSGKK EKEPAEGNESSEAPSPVNAMNSFV >P01398; 21 LONG NEUROTOXIN 2 PRECURSOR (KAPPA-BUNGAROTOXIN) (NEURON MKTLLLTLVVVTIVCLDLGYTRTCLISPSSTPQTCPNGQDICFLKAQCDKFCSIRGPVIE QGCVATCPQFRSNYRSLLCCTTDNCNH >P34170; 20 GENERAL ODORANT-BINDING PROTEIN 1 PRECURSOR (GOBP1) (GOB MFSFLILVFVASVADSVIGTAEVMSHVTAHFGKTLEECREESGLSVDILDEFKHFWSDDF DVVHRELGCAIICMSNKFSLMDDDVRMHHVNMDEYIKGFPNGQVLAEKMVKLIHNCEKQF DTETDDCTRVVKVAACFKKDSRKEGIAPEVAMIEAVIEKY >P31418; 22 GENERAL ODORANT-BINDING PROTEIN 1 PRECURSOR (GOBP 1). MGQDTRSLVLVVLVGLVGAVSADVQVMKDVTLGFGQALEQCREESQLTEEKMEEFFHFWR EDFKFEHRELGCALQCMSRHFNLLTDSSRMHHENTDKFIKSFPNGAVLSKTMVELIHNCE LQHDAEEDHCWRILRVAECFKISCTKAGIAPSMEVMMAEFIMELKQ >P31419; 20 GENERAL ODORANT-BINDING PROTEIN 2 PRECURSOR (GOBP 2). MVNRLILMVVVVFITDSVMGTAEVMSHVTAHFGKALEECREESGLPVEVMDEFKHFWRED FEVVHRELGCAIICMSNKFELLQDDTRIHHVKMHDYIKSFPNGQVLSEKMVQLIHNCEKQ YDDIADDCDRVVKVAACFKKDAKKEGIAPEVAMIEAVIEKY >P08937; 15 ODORANT-BINDING PROTEIN PRECURSOR (OBP). MVKFLLIVLALGVSCAHHENLDISPSEVNGDWRTLYIVADNVEKVAEGGSLRAYFQHMEC GDECQELKIIFNVKLDSECQTHTVVGQKHEDGRYTTDYSGRNYFHVLKKTDDIIFFHNVN VDESGRRQCDLVAGKREDLNKAQKQELRKLAEEYNIPNENTQHLVPTDTCNQ >P19879; 19 OSTEOINDUCTIVE FACTOR PRECURSOR (OIF) (OSTEOGLYCIN). MKTLQSTLLLFLFVPLIKPAPPSQQDSRIIYDYGTDNLEETFFSQDYEDKYLDGKSTKEK ETMIIVPDEKSFQLQKDENITPLPPKKENDEMPTCLLCVCLSGSVYCEEVDIDAVPPLPK ESAYLYARFNKIKKLTAKDFADIPNLRRLDFTGNLIEDIEDGTFSKLSLLEELTLAENQL LKLPVLPPKLTLFNAKYNKIKSRGIKANTFKKLHNLSFLYLDHNALESVPLNLPESLRVI HLQFNNITSITDDTFCKANDTSYIRDRIEEIRLEGNPVILGKHPNSFICLKRLPIGSYI >Q07081; 16 OLFACTOMEDIN PRECURSOR (OLFACTORY MUCUS PROTEIN). MYICLLTLVLIHAAAAFVAQNATGILAGKDHCVCEVLLPDSSFPAKRVGALEDETIRLSN RVEDEMQKLEEQDIILDTYSEKIINLTRRVEYLEKLHPESLVEISFEVLKREIRELEMYI SAMRVKPNGNSVQVETLYNEVKNMSKTVGQLETLDKNNVLQAKREIVNLKKRLVDCEKNL KAKPSLMVPLGSCQHQGLAHISKPNLMQLNWKGNAYKSGAWGKDAAWNTTKKSLYWVAPL NTDGRVLESIRIYPSMSDLQMYKNPIDLPLSMLIKNKLNNTFAGQGAGVVVHNNNLYYNC FNSHDMCRASLTSGVYQKKPLLNALFNNRFSYAGTMFQDMDFSSDEKGLWVIFTTEKSAG KIVVGKVNVATFTVDNIWITTQNKSDASNAFMICGVLYVTRSLGPKMEEVFYMFDTKTGK EGHLSIMMEKMAEKVHSLSYNSNDRKLYMFSEGYLLHYDIALKP >P31420; 18 OMMOCHROME-BINDING PROTEIN PRECURSOR (OBP) (YCP). MKLLILTICALHVNQMMALKDCVVVNGKNYGKEVLKDNIHQAYQLSFDPQQNTLFFSYSD EVDSKTVLKMGYLNLATKSFGEISGVKDGMATAVDTTNHIVYLGGKDGIYTYDYATKSAK NIGVTSLSIWQMFYCPIHGLFFTTSDEKPYVFKDGQVNQIVEASSSKTRVMAVGEHHDVF FANSSGIFLFNHHTNKVIDLGDYNVNAFTKDSKGKLYFSSPVGFYAVNEADRKMNKLISE TGEDSIWGAAFDKDDNIVYSNEDNIVKLVPKDKC >P13725; 25 ONCOSTATIN M PRECURSOR (OSM). MGVLLTQRTLLSLVLALLFPSMASMAAIGSCSKEYRVLLGQLQKQTDLMQDTSRLLDPYI RIQGLDVPKLREHCRERPGAFPSEETLRGLGRRGFLQTLNATLGCVLHRLADLEQRLPKA QDLERSGLNIEDLEKLQMARPNILGLRNNIYCMAQLLDNSDTAEPTKAGRGASQPPTPTP ASDAFQRKLEGCRFLHGYHRFMHSVGRVFSKWGESPNRSRRHSPHQALRKGVRRTRPSRK GKRLMTRGQLPR >P11834; 27 OPIOID BINDING PROTEIN/CELL ADHESION MOLECULE PRECURSOR MGVCGSLFQPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID DRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTD NHPKTSRVHLIVQVPPQIMNISSDVTVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGF VSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVGQKG ILSCEASAVPMAEFQWFKEDTRLATGLDGMRIENKGHISTLTFFNVSEKDYGNYTCVATN KLGITNASITLYGPGAVIDGVNSASRALACLWLSGTLFAHFFIKF >P12547; 21 ORYZIN PRECURSOR (EC 3.4.21.63) (ALKALINE PROTEINASE) (A MQSIKRTLLLLGAILPAVLGAPVQETRRAAEKLPGKYIVTFKPGIDEAKIQEHTTWATNI HQRSLERRGATGGDLPVGIERNYKINKFAAYAGSFDDATIEEIRKNEDVAYVEEDQIYYL DGLTTQKSAPWGLGSISHKGQQSTDYIYDTSAGEGTYAYVVDSGVNVDHEEFEGRASKAY NAAGGQHVDSIGHGTHVSGTIAGKTYGIAKKASILSVKVFQGESSSTSVILDGFNWAAND IVSKKRTSKAAINMSLGGGYSKAFNDAVENAFEQGVLSVVAAGNENSDAGQTSPASAPDA ITVAAIQKSNNRASFSNFGKVVDVFAPGQDILSAWIGSSSATNTISGTSMATPHIVGLSL YLAALENLDGPAAVTKRIKELATKDVVKDVKGSPNLLAYNGNA >Q02795; 19 DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE--PROTEIN GLYCOSYLTRANS MQFFKTLAALVSCISFVLAYVAQDVHVSFPSTAGKSRVMIGKVEPRIGIDETVPTTITVE DPNEVIQVNFAIESTNKPFQNTLLIGLPNKNLEMAFEPEIKDNGKLSMYKYRIDLAKLDA ALLQEASRSPEPIKATLILASSTAKPKENLFREILQLNLNFDVDHSDSSLVDKFGIKPEI HHIFHAEPKRVAKPIAVIFVLIIFITILSLIVTWLNSCAAAFNNIPTGVTAVYFLGFIAT IVGFEVIFARYYLGTSIFETLFSSLYLGAPGLLTSTKFLRSFGQTI >P49369; 36 PHOSPHOLIPASE A1 PRECURSOR (EC 3.1.1.32) (ALLERGEN VES V MEENMNLKYLLLFVYFVQVLNCCYGHGDPLSYELDRGPKCPFNSDTVSIIIETRENRNRD LYTLQTLQNHPEFKKKTITRPVVFITHGFTSSASETNFINLAKALVDKDNYMVISIDWQT AACTNEAAGLKYLYYPTAARNTRLVGQYIATITQKLVKHYKISMANIRLIGHSLGAHASG FAGKKVQELKLGKYSEIIGLDPARPSFDSNHCSERLCETDAEYVQIIHTSNYLGTEKTLG TVDFYMNNGKNQPGCGRFFSEVCSHSRAVIYMAECIKHECCLIGIPKSKSSQPISSCTKQ ECVCVGLNAKKYPSRGSFYVPVESTAPFCNNKGKII >P00606; 27 PHOSPHOLIPASE A2 PRECURSOR (EC 3.1.1.4) (PHOSPHATIDYLCHO MNPAHLLILSAVCVSLLGAANVPPQHLNLYQFKNMIVCAGTRPWIGYVNYGCYCGAGGSG TPVDELDRCCYVHDNCYGEAEKIPGCNPKTKTYSYTCTKPNLTCTDAAGTCARIVCDCDR TAAICFAAAPYNINNFMISSSTHCQ >P00626; 16 PHOSPHOLIPASE A2 PRECURSOR (EC 3.1.1.4) (AMMODYTOXIN A) MRTLWIVAVCLIGVEGSLLEFGMMILGETGKNPLTSYSFYGCYCGVGGKGTPKDATDRCC FVHDCCYGNLPDCSPKTDRYKYHRENGAIVCGKGTSCENRICECDRAAAICFRKNLKTYN YIYRNYPDFLCKKESEKC >P14423; 21 PHOSPHOLIPASE A2, MEMBRANE ASSOCIATED PRECURSOR (EC 3.1. MKVLLLLAVVIMAFGSIQVQGSLLEFGQMILFKTGKRADVSYGFYGCHCGVGGRGSPKDA TDWCCVTHDCCYNRLEKRGCGTKFLTYKFSYRGGQISCSTNQDSCRKQLCQCDKAAAECF ARNKKSYSLKYQFYPNKFCKGKTPSC >P10601; 29 PANCREATIC HORMONE PRECURSOR (PANCREATIC POLYPEPTIDE) (P MAVAYCCLSLFLVSTWVALLLQPLQGTWGAPLEPMYPGDYATPEQMAQYETQLRRYINTL TRPRYGKRAEEENTGGLPGVQLSPCTSPPVGLIPCSAPWS >P13909; 23 PLASMINOGEN ACTIVATOR INHIBITOR-1 PRECURSOR, ENDOTHELIAL MRMSPVFACLALGLALIFGEGSASYQPQSAAASLATDFGVKVFQQVVRASKDRNVVFSPY GVASVLAMLQLTTGGETRQQIQEAMQFKIEEKGMAPAFHRLYKELMGPWNKDEISTADAI FVQRDLELVHGFMPNFFRLFRTTVKQVDFSEVERARFIVNDWVKRHTKGMISDLLGEGAV DQLTRLVLVNALYFNGQWKMPFPESNTHHRLFHKSDGSTISVPMMAQTNKFNYTEFTTPD GRYYDILELPYHGNTLSMLIAAPYEKEVPLSALTSILDAELISQWKGNMTRLTRLLVLPK FSLETEIDLRRPLENLGMTDMFRPSQADFSSFSDQEFLYVSQALQKVKIEVNESGTLASS STALVVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP >P25031; 26 PANCREATITIS-ASSOCIATED PROTEIN 1 PRECURSOR (PEPTIDE 23) MLHRLAFPVMSWMLLSCLMLLSQVQGEDSPKKIPSARISCPKGSQAYGSYCYALFQIPQT WFDAELACQKRPEGHLVSVLNVAEASFLASMVKNTGNSYQYTWIGLHDPTLGGEPNGGGW EWSNNDIMNYVNWERNPSTALDRGFCGSLSRSSGFLRWRDTTCEVKLPYVCKFTG >P08469; 27 PROCYCLIC FORM SPECIFIC POLYPEPTIDE B1-ALPHA PRECURSOR ( MAPRSLYLLAVLLFSANLFAGVGFAAAAEGPEDKGLTKGGKGKGEKGTKVGADDTNGTDP DPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP GAATLKSVALPFAIAAAALVAAF >P34174; 23 PHEROMONE-BINDING PROTEIN PRECURSOR (PBP). MSIQGQIALALMVNMAVGSVDASQEVMKNLSLNFGKALDECKKEMTLTDAINEDFYNFWK EGYEIKNRETGCAIMCLSTKLNMLDPEGNLHHGNAMEFAKKHGADETMAQQLIDIVHGCE KSTPANDDKCIWTLGVATCFKAEIHKLNWAPSMDVAVGEILAEV >P18959; 26 PHEROMONE-BINDING PROTEIN PRECURSOR (PBP). MNKTTTKMKVAVVAIVVYLAVGNVDSSPDVMKNLCLNFGKALDECKAEMNLSDSIKDDFA NFWVEGYEVSNRDTGCAILCLSKKLDMIDPDGKLHHGNAMEFAKKHGADEAMAKQLLDII HNCENSTPPNDDACLKTLDIAKCFKKEIHKLNWAPNMDLVVGEVLAEV >P20033; 20 PLATELET-DERIVED GROWTH FACTOR, A CHAIN PRECURSOR (PDGF MRTWACLLLLGCGYLAHALAEEAEIPRELIERLARSQIHSIRDLQRLLEIDSVGAEDALE TSLRAHGSHAINHVPEKRPVPIRRKRSIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIW PPCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLECACA TSNLNPDHREEETGRRRESGKNRKRKRLKPT >P01127; 20 PLATELET-DERIVED GROWTH FACTOR, B CHAIN PRECURSOR (PDGF MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHGDPGEEDGAEL DLNMTRSHSGGELESLARGRRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLV WPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKC ETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKTALKETLG A >P04785; 19 PROTEIN DISULFIDE ISOMERASE PRECURSOR (PDI) (EC 5.3.4.1) MLSRALLCLALAWAARVGADALEEEDNVLVLKKSNFAEALAAHNYLLVEFYAPWCGHCKA LAPEYAKAAAKLKAEGSEIRLAKVDATEESDLAQQYGVRGYPTIKFFKNGDTASPKEYTA GREADDIVNWLKKRTGPAATTLSDTAAAESLVDSSEVTVIGFFKDAGSDSAKQFLLAAEA VDDIPFGITSNSDVFSKYQLDKDGVVLFKKFDEGRNNFEGEITKEKLLDFIKHNQLPLVI EFTEQTAPKIFGGEIKTHILLFLPKSVSDYDGKLSNFKKAAEGFKGKILFIFIDSDHTDN QRILEFFGLKKEECPAVRLITLEEEMTKYKPESDELTAEKITQFCHHFLEGKIKPHLMSQ ELPEDWDKQPVKVLVGKNFEEVAFDEKKNVFVEFYAPWCGHCKQLAPIWDKLGETYKDHE NIVIAKMDSTANEVEAVKVHSFPTLKFFPASADRTVIDYNGERTLDGFKKFLESGGQDGA GDNDDLDLEEALEPDMEEDDDQKAVKDEL >P37109; 26 PEPTIDE PEC-60 PRECURSOR. MAVRLWVVALALAALFIVDREVPVSAEKQVFSRMPICEHMTESPDCSRIYDPVCGTDGVT YESECKLCLARIENKQDIQIVKDGEC >Q08481; 17 PLATELET ENDOTHELIAL CELL ADHESION MOLECULE PRECURSOR (P MLLALGLTLVLYASLQAEENSFTINSIHMESLPSWEVMNGQQLTLECLVDISTTSKSRSQ HRVLFYKDDAMVYNVTSREHTESYVIPQARVFHSGKYKCTVMLNNKEKTTIEYEVKVHGV SKPKVTLDKKEVTEGGVVTVNCSLQEEKPPIFFKIEKLEVGTKFVKRRIDKTSNENFVLM EFPIEAQDHVLVFRCQAGILSGFKLQESEPIRSEYVTVQESFSTPKFEIKPPGMIIEGDQ LHIRCIVQVTHLVQEFTEIIIQKDKAIVATSKQSSEAVYSVMAMVEYSGHYTCKVESNRI SKASSIMVNITELFPKPKLEFSSSRLDQGELLDLSCSVSGTPVANFTIQKEETVLSQYQN FSKIAEESDSGEYSCTAGIGKVVKRSGLVPIQVCEMLSKPSIFHDAKSEIIKGHAIGISC QSENGTAPITYHLMKAKSDFQTLEVTSNDPATFTDKPTRDMEYQCRADNCHSHPAVFSEI LRVRVIAPVDEVVISILSSNEVQSGSEMVLRCSVKEGTSPITFQFYKEKEDRPFHQAVVN DTQAFWHNKQASKKQEGQYYCTASNRASSMRTSPRSSTLAVRVFLAPWKKGLIAVVVIGV VIATLIVAAKCYFLRKAKAKQKPVEMSRPAAPLLNSNSEKISEPSVEANSHYGYDDVSGN DAVKPINQNKDPQNMDVEYTEVEVSSLEPHQALGTRATETVYSEIRKVDPNLMENRYSRT EGSLNGT >P01210; 24 PROENKEPHALIN A PRECURSOR. MARFLTLCTWLLLLGPGLLATVRAECSQDCATCSYRLVRPADINFLACVMECEGKLPSLK IWETCKELLQLSKPELPQDGTSTLRENSKPEESHLLAKRYGGFMKRYGGFMKKMDELYPM EPEEEANGSEILAKRYGGFMKKDAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEE EVSKRYGGFMRGLKRSPQLEDEAKELQKRYGGFMRRVGRPEWWMDYQKRYGGFLKRFAEA LPSDEEGESYSKEVPEMEKRYGGFMRF >P11247; 15 MYELOPEROXIDASE PRECURSOR (EC 1.11.1.7) (MPO). MKLLLALAGLLAPLAMLQTSNGATPALLGEVENSVVLSCMEEAKQLVDRAYKERRESIKR TLQSGSASPTELLFYFKQPVAGTRTAVRAADYLHVALDLLKRKLQPLWPRPFNVTDVLTP AQLNLLSVSSGCAYQDVGVTCPPNDKYRTITGHCNNRRSPTLGASNRAFVRWLPAEYEDG VSMPFGWTPGVNRNGFKVPLARQVSNAIVRFPNDQLTKDQERALMFMQWGQFLDHDITLT PEPATRFSFFTGLNCETSCLQQPPCFPLKIPPNDPRIKNQKDCIPFFRSCPACTRNNITI RNQINALTSFVDASGVYGSEDPLARKLRNLTNQLGLLAVNTRFQDNGRALMPFDSLHDDP CLLTNRSARIPCFLAGDMRSSEMPELTSMHTLFVREHNRLATQLKRLNPRWNGEKLYQEA RKIVGAMVQIITYRDYLPLVLGPAAMKKYLPQYRSYNDSVDPRIANVFTNAFRYGHTLIQ PFMFRLNNQYRPTAANPRVPLSKVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIVVD EIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPSTVGELGTVLKNLEL ARKLMAQYGTPNNIDIWMGGVSEPLEPNGRVGQLLACLIGTQFRKLRDGDRFWWENPGVF SKQQRQALASISLPRLICDNTGITTVSKNNIFMSNTYPRDFVSCNTLPKLNLTSWKET >P19136; 24 PEROXIDASE MANGANESE-DEPENDENT I PRECURSOR (EC 1.11.1.13 MAFGSLLAFVALAAITRAAPTAESAVCPDGTRVTNAACCAFIPLAQDLQETLFQGDCGED AHEVIRLTFHDAIAISQSLGPQAGGGADGSMLHFPTIEPNFSANSGIDDSVNNLLPFMQK HDTISAADLVQFAGAVALSNCPGAPRLEFMAGRPNTTIPAVEGLIPEPQDSVTKILQRFE DAGNFSPFEVVSLLASHTVARADKVDETIDAAPFDSTPFTFDTQVFLEVLLKGTGFPGSN NNTGEVMSPLPLGSGSDTGEMRLQSDFALARDERTACFWQSFVNEQEFMAASFKAAMAKL AILGHSRSSLIDCSDVVPVPKPAVNKPATFPATKGPKDLDTLTCKALKFPTLTSDPGATE TLIPHCSNGGMSCPGVQFDGPA >P28314; 20 PEROXIDASE PRECURSOR (EC 1.11.1.7). MKLSLLSTFAAVIIGALALPQGPGGGGSVTCPGGQSTSNSQCCVWFDVLDDLQTNFYQGS KCESPVRKILRIVFHDAIGFSPALTAAGQFGGGGADGSIIAHSNIELAFPANGGLTDTVE ALRAVGINHGVSFGDLIQFATAVGMSNCPGSPRLEFLTGRSNSSQPSPPSLIPGPGNTVT AILDRMGDAGFSPDEVVDLLAAHSLASQEGLNSAIFRSPLDSTPQVFDTQFYIETLLKGT TQPGPSLGFAEELSPFPGEFRMRSDALLARDSRTACRWQSMTSSNEVMGQRYRAAMAKMS VLGFDRNALTDCSDVIPSAVSNNAAPVIPGGLTVDDIEVSCPSEPFPEIATASGPLPSLA PAP >P02775; 34 PLATELET BASIC PROTEIN PRECURSOR (PBP) [CONTAINS: CONNEC MSLRLDTTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRNLAKGKEESLDSDLYAE LRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKK LAGDESAD >P34095; 21 PORE-FORMING PEPTIDE AMEOBAPORE A PRECURSOR (EH-APP). MKAIVFVLIFAVAFAVTATHQGEILCNLCTGLINTLENLLTTKGADKVKDYISSLCNKAS GFIATLCTKVLDFGIDKLIQLIEDKVDANAICAKIHAC >P05622; 31 BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR ( MGLPGVIPALVLRGQLLLSVLWLLGPQTSRGLVITPPGPEFVLNISSTFVLTCSGSAPVM WEQMSQVPWQEAAMNQDGTFSSVLTLTNVTGGDTGEYFCVYNNSLGPELSERKRIYIFVP DPTMGFLPMDSEDLFIFVTDVTETTIPCRVTDPQLEVTLHEKKVDIPLHVPYDHQRGFTG TFEDKTYICKTTIGDREVDSDTYYVYSLQVSSINVSVNAVQTVVRQGESITIRCIVMGND VVNFQWTYPRMKSGRLVEPVTDYLFGVPSRIGSILHIPTAELSDSGTYTCNVSVSVNDHG DEKAINISVIENGYVRLLETLGDVEIAELHRSRTLRVVFEAYPMPSVLWLKDNRTLGDSG AGELVLSTRNMSETRYVSELILVRVKVSEAGYYTMRAFHEDDEVQLSFKLQVNVPVRVLE LSESHPANGEQTIRCRGRGMPQPNVTWSTCRDLKRCPRKLSPTPLGNSSKEESQLETNVT FWEEDQEYEVVSTLRLRHVDQPLSVRCMLQNSMGGDSQEVTVVPHSLPFKVVVISAILAL VVLTVISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPVQLPYDSTWELPRDQLV LGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPH LNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQRHSNKHCPPSAELYSNALP VGFSLPSHLNLTGESDGGYMDMSKDESIDYVPMLDMKGDIKYADIESPSYMAPYDNYVPS APERTYRATLINDSPVLSYTDLVGFSYQVANGMDFLASKNCVHRDLAARNVLICEGKLVK ICDFGLARDIMRDSNYISKGSTYLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGG TPYPELPMNDQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFETRPPFSQLVLLLERL LGEGYKKKYQQVDEEFLRSDHPAILRSQARFPGIHSLRSPLDTSSVLYTAVQPNESDNDY IIPLPDPKPDVADEGLPEGSPSLASSTLNEVNTSSTISCDSPLELQEEPQQAEPEAQLEQ PQDSGCPGPLAEAEDSFL >P20786; 23 ALPHA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR MGTSQAFLVLSCLLTGPSLIVCQLLLPSILPNENEKIVPLSSSFSLRCFGESEVSWQHPM SEEEDPNVEIRTEENNSSLFVTVLEVVNASAAHTGWYTCYYNHTQTEESEIEGRHIYIYV PDPDMAFVPLGMTDSLVIVEEDDSAIIPCLTTDPDTEVTLHNNGRLVPASYDSRQGFNGT FSVGPYICEATVRGRTFKTSEFNVYALKATSELNLEMDTRQTVYKAGETIVVTCAVFNNE VVDLQWTYPGEVRNKGITMLEEIKLPSIKLVYTLTVPKATVKDSGDYECAARQATKEVKE MKTVTISVHEKGFVQIRPTFGHLETVNLHQVREFVVEVQAYPTPRISWLKDNLTLIENLT EITTDVQRSQETRYQSKLKLIRAKEEDSGHYTIIVQNDDDMKSYTFELSTLVPASILELV DDHHGSGGGQTVRCTAEGTPLPNIEWMICKDIKKCNNDTSWTVLASNVSNIITEFHQRGR STVEGRVSFAKVEETIAVRCLAKNDLGIGNRELKLVAPSLRSELTVAAAVLVLLVIVIVS LIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRILGS GAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLL GACTKSGPIYIITEYCFYGDLVNYLHKNRDSFMSRHPEKPKKDLDIFGLNPADESTRSYV ILSFENNGDYVDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEAKNL LSDDDSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLAR DIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGVLLWEIFSLGGTPYPGMMV DSTFYNKIKSGYRMAKPDHATSEVYEIMVQCWNSEPEKRPSFYHLSEIVENLLPGQYKKS YEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKEWEGGLDEQRLSADSGYIIP LPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSS DLVEDSFL >P05979; 24 PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (C MSRQSISLRFPLLLLLLSPSPVFSADPGAPAPVNPCCYYPCQHQGICVRFGLDRYQCDCT RTGYSGPNCTIPEIWTWLRTTLRPSPSFIHFMLTHGRWLWDFVNATFIRDTLMRLVLTVR SNLIPSPPTYNIAHDYISWESFSNVSYYTRILPSVPRDCPTPMGTKGKKQLPDAEFLSRR FLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLER QYQLRLFKDGKLKYQMLNGEVYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLML YATIWLREHNRVCDLLKAEHPTWGDEQLFQTARLILIGETIKIVIEEYVQQLSGYFLQLK FDPELLFGAQFQYRNRIAMEFNQLYHWHPLMPDSFRVGPQDYSYEQFLFNTSMLVDYGVE ALVDAFSRQPAGRIGGGRNIDHHILHVAVDVIKESRVLRLQPFNEYRKRFGMKPYTSFQE LTGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEMGAPFSLKGLLGNPIC SPEYWKASTFGGEVGFNLVKTATLKKLVCLNTKTCPYVSFHVPDPRQEDRPGVERPPTEL >Q05769; 17 PROSTAGLANDIN G/H SYNTHASE 2 PRECURSOR (EC 1.14.99.1) (C MLFRAVLLCAALGLSQAANPCCSNPCQNRGECMSTGFDQYKCDCTRTGFYGENCTTPEFL TRIKLLLKPTPNTVHYILTHFKGVWNIVNNIPFLRSLIMKYVLTSRSYLIDSPPTYNVHY GYKSWEAFSNLSYYTRALPPVADDCPTPMGVKGNKELPDSKEVLEKVLLRREFIPDPQGS NMMFAFFAQHFTHQFFKTDHKRGPGFTRGLGHGVDLNHIYGETLDRQHKLRLFKDGKLKY QVIGGEVYPPTVKDTQVEMIYPPHIPENLQFAVGQEVFGLVPGLMMYATIWLREHNRVCD ILKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNQQFQYQ NRIASEFNTLYHWHPLLPDTFNIEDQEYSFKQFLYNNSILLEHGLTQFVESFTRQIAGRV AGGRNVPIAVQAVAKASIDQSREMKYQSLNEYRKRFSLKPYTSFEELTGEKEMAAELKAL YSDIDVMELYPALLVEKPRPDAIFGETMVELGAPFSLKGLMGNPICSPQYWKPSTFGGEV GFKIINTASIQSLICNNVKGCPFTSFNVQDPQPTKTATINASASHSRLDDINPTVLIKRR STEL >P41222; 22 PROSTAGLANDIN-H2 D-ISOMERASE PRECURSOR (EC 5.3.99.2) (PR MATHHTLWMGLALLGVLGDLQAAPEAQVSVQPNFQQDKFLGRWFSAGLASNSSWLREKKA ALSMCKSVVAPATDGGLNLTSTFLRKNQCETRTMLLQPAGSLGSYSYRSPHWGSTYSVSV VETDYDQYALLYSQGSKGPGEDFRMATLYSRTQTPRAELKEKFTAFCKAQGFTEDTIVFL PQTDKCMTEQ >Q00293; 22 EXOPOLYGALACTURONASE PRECURSOR (EC 3.2.1.67) (EXOPG) (GA MRLTHVLSHTLGLLALGATAEAFSRSREAACGPKKPFRPLPTSQSRDKTCHVRSHGDGTD DSDYILSALNQCNHGGKVVFDEDKEYIIGTALNMTFLKNIDLEVLGTILFTNDTDYWQAN SFKQGFQNATTFFQLGGEDVNMYGGGTINGNGQVWYDLYAEDDLILRPILMGIIGLNGGT IGPLKLRYSPQYYHFVANSSNVLFDGIDISGYSKSDNEAKNTDGWDTYRSNNIVIQNSVI NNGDDCVSFKPNSTNILVQNLHCNGSHGISVGSLGQYKDEVDIVENVYVYNISMFNASDM ARIKVWPGTPSALSADLQGGGGSGSVKNITYDTALIDNVDWAIEITQCYGQKNTTLCNEY PSSLTISDVHIKNFRGTTSGSEDPYVGTIVCSSPDTCSDIYTSNINVTSPDGTNDFVCDN VDESLLSVNCTATSD >P13609; 25 SECRETORY GRANULE PROTEOGLYCAN CORE PROTEIN PRECURSOR (M MQVPVGSRLVLALAFVLVWGSSVQGYPARRARYQWVRCKPNGFFANCIEEKGPQFDLIDE SNNIGPPMNNPVLMEGPSKDFISNYDDYGSGSGSGSGSGSGSGSGSGSGFLGDMEWEYQP TDESNIVYFNYKPFDRILTEQNQDQPEDDFII >P34752; 23 3-PHYTASE A PRECURSOR (EC 3.1.3.8) (MYO-INOSITOL-HEXAPHO MGVSAVLLPLYLLSGVTSGLAVPASRNQSSCDTVDQGYQCFSETSHLWGQYAPFFSLANE SVISPEVPAGCRVTFAQVLSRHGARYPTDSKGKKYSALIEEIQQNATTFDGKYAFLKTYN YSLGADDLTPFGEQELVNSGIKFYQRYESLTRNIVPFIRSSGSSRVIASGKKFIEGFQST KLKDPRAQPGQSSPKIDVVISEASSSNNTLDPGTCTVFEDSELADTVEANFTATFVPSIR QRLENDLSGVTLTDTEVTYLMDMCSFDTISTSTVDTKLSPFCDLFTHDEWINYDYLQSLK KYYGHGAGNPLGPTQGVGYANELIARLTHSPVHDDTSSNHTLDSSPATFPLNSTLYADFS HDNGIISILFALGLYNGTKPLSTTTVENITQTDGFSSAWTVPFASRLYVEMMQCQAEQEP LVRVLVNDRVVPLHGCPVDALGRCTRDSFVRGLSFARSGGDWAECFA >P34754; 19 3-PHYTASE B PRECURSOR (EC 3.1.3.8) (MYO-INOSITOL-HEXAPHO MPRTSLLTLACALATGASAFSYGAAIPQSTQEKQFSQEFRDGYSILKHYGGNGPYSERVS YGIARDPPTGCEVDQVIMVKRHGERYPSPSAGKSIEEALAKVYSINTTEYKGDLAFLNDW TYYVPNECYYNAETTSGPYAGLLDAYNHGNDYKARYGHLWNGETVVPFFSSGYGRVIETA RKFGEGFFGYNYSTNAALNIISESEVMGADSLTPTCDTDNDQTTCDNLTYQLPQFKVAAA RLNSQNPGMNLTASDVYNLIVMASFELNARPFSNWINAFTQDEWVSFGYVEDLNYYYCAG PGDKNMAAVGAVYANASLTLLNQGPKEAGPLFFNFAHDTNITPILAALGVLIPNEDLPLD RVAFGNPYSIGNIVPMGGHLTIERLSCQATALSDKGTYVRLVLNEAVLPFNDCTSGPGYS CPLANYTSILNKNLPDYTTTCNVSASYPQYLSFWWNYNTTTELNYRSSPIACQEGDAMD >P12273; 28 PROLACTIN-INDUCIBLE PROTEIN PRECURSOR (SECRETORY ACTIN-B MRLLQLLFRASPATLLLVLCLQLGANKAQDNTRKIIIKNFDIPKSVRPNDEVTAVLAVQT ELKECMVVKTYLISSIPLQGAFNYKYTACLCDDNPKTFYWDFYTNRTVQIAAVVDVIREL GICPDDAAVIPIKNNRFYTIEILKVE >P09586; 31 PLACENTAL LACTOGEN II PRECURSOR (PL-II). MKLSLSQPCSFSGALLLLAVSNLLVWEKVTSLPNYRLPTESLYQRVIVVSHNAHDLASKA FMEFEMKFGRTAWTYGLMLSPCHTAAILTPENSEQVHQTTSEDLLKVSITILQAWEEPLK HMVAAVAALPHVPDTLLSRTKELEERIQGLLEGLKIIFNRVYPGAVASDYTFWSAWSDLQ SSDESTKNSALRTLWRCVRRDTHKVDNYLKVLKCRDVHNNNC >P06765; 29 PLATELET FACTOR 4 PRECURSOR (PF-4). MSAAAVFRGLRPSPELLLLGLLLLPAVVAVTRASPEESDGDLSCVCVKTSSSRIHLKRIT SLEVIKAGPHCAVPQLIATLKNGSKICLDRQVPLYKKIIKKLLES >P49763; 18 PLACENTA GROWTH FACTORS 1 AND 2 PRECURSOR (PLGF-1/PLGF-2 MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVD VVSEYPSEVEHMFSPSCVSLLRCTGCCGDEDLHCVPVETANVTMQLLKIRSGDRPSYVEL TFSQHVRCECRPLREKMKPERRRPKGRGKRRRENQRPTDCHLCGDAVPRR >P56513; 20 PHOSPHOLEMMAN PRECURSOR. MAPLHHILVLCVGFLTTATAEAPQEHDPFTYDYQSLRIGGLIIAGILFILGILIVLSRRC RCKFNQQQRTGEPDEEEGTFRSSIRRLSTRRR >Q01172; 20 PECTIN LYASE A PRECURSOR (EC 4.2.2.10) (PLA) (PECTIN LYA MKYSTIFSAAAAVFAGSAAAVGVSGSAEGFAEGVTGGGDATPVYPDTIDELVSYLGDDEA RVIVLTKTFDFTDSEGTTTGTGCAPWGTASACQVAIDQDDWCENYEPDAPSVSVEYYNAG VLGITVTSNKSLIGEGSSGAIKGKGLRIVSGAENIIIQNIAVTDINPKYVWGGDAITLDD CDLVWIDHVTTARIGRQHYVLGTSADNRVSLTNNYIDGVSDYSATCDGYHYWGIYLDGDA DLVTMKGNYIYHTSGRSPKVQDNTLLHCVNNYFYDISGHAFEIGEGGYVLAEGNVFQNVD TVLETYEGAAFTVPSTTAGEVCSTYLGRDCVINGFGCSGTFSEDSTSFLSDFEGKNIASA SAYTSVASRVVANAGQGNL >P22864; 19 PECTIN LYASE D PRECURSOR (EC 4.2.2.10) (PLD) (PECTIN LYA MKYAAALTAIAALAARAAAVGVSGTPVGFASSATGGGDATPVYPTTTDELVSYLGDDEAR VIVLSKTFDFTDTEGTTTTTGCAPWGTASGCQLAINKDDWCTNYEPDAPTTTVTYNTAGE LGITVNSNKSLIGEGTSGVIKGRGLRMVSGVSNIIIQNIAVTDINPEYVWGGDAITLDEA DLVWIDHVTTARIGRQHYVLGTDADSRVSITNNYINGESDYSATCDGHHYWNVYLDGSSD KVTFSGNYLYKTSGRAPKVQDNTYLHIYNNYWENNSGHAFEIGSGGYVLAEGNYFSNVDT VLETDTFEGALFSSDSASSTCESYIGRSCVANVNGGDLTGTSTTVLSNLSGDTLPSADAA STSPASNAGQGNL >P40967; 24 MELANOCYTE PROTEIN PMEL 17 PRECURSOR (MELANOCYTE LINEAGE MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDC WRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQP VYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLG THTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTF ALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTS CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVIS TAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTT TEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRY GSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRL CQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIV GILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQ V >P17872; 17 PECTINESTERASE PRECURSOR (EC 3.1.1.11) (PECTIN METHYLEST MVKSILASVLFAATALAASRMTAPSGAIVVAKSGGDYDTISAAVDALSTTSTETQTIFIE EGSYDEQVYIPALSGKLIVYGQTEDTTTYTSNLVNITHAIALADVDNDDETATLRNYAEG SAIYNLNIANTCGQACHQALAVSAYASEQGYYACQFTGYQDTLLAETGYQVYAGTYIEGA VDFIFGQHARAWFHECDIRVLEGPSSASITANGRSSESDDSYYVIHKSTVAAADGNDVSS GTYYLGRPWSQYARVCFQKTSMTDVINHLGWTEWSTSTPNTENVTFVEYGNTGTGAEGPR ANFSSELTEPITISWLLGSDWEDWVDTSYIN >P08091; 18 ACID PHOSPHATASE PRECURSOR (EC 3.1.3.2). MFLQNLFLGFLAVVCANAQFAEFTAFDGKFDFKEHLTSRSPYHKPYFYGPSIDFPTTCKI KQVHTLQRHGSRNPTGGNAAFDAVGIANFQQRLLNGSVPIDYSVSGNPLSFVPTWTPVIE AANADALSSSGRVELFDMGRQFYERYHELFNASTYNIYTAAQQRVVDSALWYGYGMFGED VHNFTNYILVSENATAGSNSLSSYNACPASDADDFTTPALEAWRNVYMPPIRQRLNPYFS NYNLTNDDILNLYGICSYEIALQDYSEFCKLFNSVDFLNFEYEGDLSFSYGMGNSVKWGS IFGGAYANSLANSLRSVENNTQQVFFAFTHDANIIPVETALGFFTDNTPENPLPTSYQVH SHSMKASEFVPFAGNLITELFQCEDSKYYVRHLVNEEVFPLSDCGFGPSNTSDGMCELYA YLNSPVRVNGTSNGIQNFDTLCNASAVAAVYPY >Q01682; 18 THIAMINE-REPRESSIBLE ACID PHOSPHATASE PRECURSOR (EC 3.1. MKLSGISLWLLAASIVHAGKSQFEAFENEFYFKDHLGTISVYHEPYFNGPTTSFPESCAI KQVHLLQRHGSRNPTGDDTATDVSSAQYIDIFQNKLLNGSIPVNFSYPENPLYFVKHWTP VIKAENADQLSSSGRIELFDLGRQVFERYYELFDTDVYDINTAAQERVVDSAEWFSYGMF GDDMQNKTNFIVLPEDDSAGANSLAMYYSCPVYEDNNIDENTTEAAHTSWRNVFLKPIAN RLNKYFDSGYNLTVSDVRSLYYICVYEIALRDNSDFCSLFTPSEFLNFEYDSDLDYAYWG GPASEWASTLGGAYVNNLANNLRKGVNNASDRKVFLAFTHDSQIIPVEAALGFFPDITPE HPLPTDKNIFTYSLKTSSFVPFAGNLITELFLCSDNKYYVRHLVNQQVYPLTDCGYGPSG ASDGLCELSAYLNSSVRVNSTSNGIANFNSQCQAHSTNVTVYY >P09889; 20 TARTRATE-RESISTANT ACID PHOSPHATASE TYPE 5 PRECURSOR (EC MDTWTVLLILQASLVLPGAVGTRTNTRTAPTPILRFVAVGDWGGVPNAPFHTAREMANAK AIATTVKTLGADFILSLGDNFYFTGVHDAKDKRFQETFEDVFSDPSLRNVPWHVLAGNHD HLGNVSAQIAYSKISKRWNFPSPYYRLRFKIPRSNVSVAIFMLDTVTLCGNSDDFVSQQP ERPRNLALARTQLAWIKKQLAAAKEDYVLVAGHYPVWSIAEHGPTHCLVKQLLPLLTTHK VTAYLCGHDHNLQYLQDENGLGFVLSGAGNFMDPSKKHLRKVPNGYLRFHFGAENSLGGF AYVEITPKEMSVTYIEASGKSLFKTKLPRRARSEHQHRRA >P00635; 17 REPRESSIBLE ACID PHOSPHATASE PRECURSOR (EC 3.1.3.2) (P60 MFKSVVYSILAASLANAGTIPLGKLADVDKIGTQKDIFPFLGGAGPYYSFPGDYGISRDL PEGCEMKQLQMVGRHGERYPTVSLAKTIKSTWYKLSNYTRQFNGSLSFLNDDYEFFIRDD DDLEMETTFANSDDVLNPYTGEMNAKRHARDFLAQYGYMVENQTSFAVFTSNSKRCHDTA QYFIDGLGDQFNITLQTVSEAESAGANTLSACNSCPAWDYDANDDIVNEYDTTYLDDIAK RLNKENKGLNLTSTDASTLFSWCAFEVNAKGYSDVCDIFTKDELVHYSYYQDLHTYYHEG PGYDIIKSVGSNLFNASVKLLKQSEIQDQKVWLSFTHDTDILNFLTTAGIIDDKNNLTAE YVPFMGNTFHRSWYVPQGARVYTEKFQCSNDTYVRYVINDAVVPIETCSTGPGFSCEIND FYDYAEKRVAGTDFLKVCNVSSVSNSTELTFYWDWNTTHYNASLLRQ >P11117; 30 LYSOSOMAL ACID PHOSPHATASE PRECURSOR (EC 3.1.3.2) (LAP). MAGKRSGWSRAALLQLLLGVNLVVMPPTRARSLRFVTLLYRHGDRSPVKTYPKDPYQEEE WPQGFGQLTKEGMLQHWELGQALRQRYHGFLNTSYHRQEVYVRSTDFDRTLMSAEANLAG LFPPNGMQRFNPNISWQPIPVHTVPITEDRLLKFPLGPCPRYEQLQNETRQTPEYQNESS RNAQFLDMVANETGLTDLTLETVWNVYDTLFCEQTHGLRLPPWASPQTMQRLSRLKDFSF RFLFGIYQQAEKARLQGGVLLAQIRKNLTLMATTSQLPKLLVYSAHDTTLVALQMALDVY NGEQAPYASCHIFELYQEDSGNFSVEMYFRNESDKAPWPLSLPGCPHRCPLQDFLRLTEP VVPKDWQQECQLASGPADTEVIVALAVCGSILFLLIVLLLTVLFRMQAQPPGYRHVADGE DHA >P20646; 31 PROSTATIC ACID PHOSPHATASE PRECURSOR (EC 3.1.3.2). MRAVPLHLVGTASLTLGFLLLLSLRLDPGQAKELKFVTLVFRHGDRGPIETFPNDPIKES SWPQGFGQLTKWGMGQHYELGSYIRRRYGRFLNNSYKHDQVYIRSTDVDRTLMSAMTNLA ALFPPEGISIWNPRLLWQPIPVHTVSLSEDRLLYLPFRDCPRFQELKSETLKSEEFLKRL QPYKSFIDTLPSLSGFEDQDLFEIWSRLYDPLYCESVHNFTFRTWATEDAMTKLKELSEL SLLSLYGIHKQKEKSRLQGGVLVNEILKNMKLATQPQKARKLIMYSAYDTTVSGLQMALE LYNGLLPPYASCHIMELYQDNGGTFVEMYYRNETQNEPYPLTLPGCTHSCPLEKFAELLD PVIPQDWATECMGTSNHQASL >P09923; 19 ALKALINE PHOSPHATASE, INTESTINAL PRECURSOR (EC 3.1.3.1) MQGPWVLLLLGLRLQLSLGVIPAEEENPAFWNRQAAEALDAAKKLQPIQKVAKNLILFLG DGLGVPTVTATRILKGQKNGKLGPETPLAMDRFPYLALSKTYNVDRQVPDSAATATAYLC GVKANFQTIGLSAAARFNQCNTTRGNEVISVMNRAKQAGKSVGVVTTTRVQHASPAGTYA HTVNRNWYSDADMPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPADA SQNGIRLDGKNLVQEWLAKHQGAWYVWNRTELMQASLDQSVTHLMGLFEPGDTKYEIHRD PTLDPSLMEMTEAALRLLSRNPRGFYLFVEGGRIDHGHHEGVAYQALTEAVMFDDAIERA GQLTSEEDTLTLVTADHSHVFSFGGYTLRGSSIFGLAPSKAQDSKAYTSILYGNGPGYVF NSGVRPDVNESESGSPDYQQQAAVPLSSETHGGEDVAVFARGPQAHLVHGVQEQSFVAHV MAFAACLEPYTACDLAPPACTTDAAHPVAASLPLLAGTLLLLGASAAP >P08289; 17 ALKALINE PHOSPHATASE, TISSUE-NONSPECIFIC ISOZYME PRECURS MILPFLVLAIGTCLTNSFVPEKEKDPSYWRQQAQETLKNALKLQKLNTNVAKNIIMFLGD GMGVSTVTAARILKGQLHHNTGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCG VKANEGTVGVSAATERTRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAH SADRDWYSDNEMPPEALSQGCKDIAYQLMHNIKDIDVIMGGGRKYMYPKNRTDVEYELDE KARGTRLDGLDLISIWKSFKPRHKHSHYVWNRTELLALDPSRVDYLLGLFEPGDMQYELN RNNLTDPSLSEMVEVALRILTKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDEAIG KAGTMTSQKDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMVSDTDKKPFTAILYGNGPG YKVVDGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFAKGPMAHLLHGVHEQNYI PHVMAYASCIGANLDHCAWASSASSPSPGALLLPLALFPLRTLF >P29523; 36 MEMBRANE-BOUND ALKALINE PHOSPHATASE PRECURSOR (EC 3.1.3. MVVSVVAAAAAAGLVRAEDRYHPERLAAGEASAATRSAAESEASFWVREAQEAIERRERE GAGAKQAAGHAKNVVMFLGDGMSVPTLAAARTLLGQRRGQTGEEASLHFEQFPTLGLAKT YCVNAQVPDSSCTATAYLCGVKANQGTPGVTAAVPRHDCEASTDVTKRVQSIAEWALADG RDVGIVTTTRITHASPAGTFAKVANRNWENDNDVKQEGHDVNRCPDIAHQLIKMAPGNKF KVIFGGGRREFLPTTQVDEEGTRGLRTDGRNLIEEWQNDKESQKVSYKYLWNRQELLKLG SSPPDYLLGLFEGSHLQYHLEGDESTEPTLAELTDVAIRVLSRNERGFFLFVEGGRIDHA HHDNYAHLALDETIEMDRAVKVATDALKEDESLVVVTADHTHVMSFNGYSPRGTDVLGTV RSLDSNRMPFMVLSYTNGPGARIQQNGVRPDVTTDANFGALRWRTHTDVPLDSETHGGDD VTVFAWGVHHWMFSGLYEQTHVPHRMAWAACMGPGRHVCVSAATVPTAALLSLLLAAFIT LRHQCFL >P10279; 24 MAJOR PRION PROTEIN 1 PRECURSOR (PRP) (MAJOR SCRAPIE-ASS MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPGGNRYPPQGGGGW GQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGGWGQGGTHGQWNKPSKPKTNM KHVAGAAAAGAVVGGLGGYMLGSAMSRPLIHFGSDYEDRYYRENMHRYPNQVYYRPVDQY SNQNNFVHDCVNITVKEHTVTTTTKGENFTETDIKMMERVVEQMCITQYQRESQAYYQRG ASVILFSSPPVILLISFLIFLIVG >P27177; 24 MAJOR PRION PROTEIN HOMOLOG PRECURSOR (PR-LP) (ACETYLCHO MARLLTTCCLLALLLAACTDVALSKKGKGKPSGGGWGAGSHRQPSYPRQPGYPHNPGYPH NPGYPHNPGYPHNPGYPHNPGYPQNPGYPHNPGYPGWGQGYNPSSGGSYHNQKPWKPPKT NFKHVAGAAAAGAVVGGLGGYAMGRVMSGMNYHFDSPDEYRWWSENSARYPNRVYYRDYS SPVPQDVFVADCFNITVTEYSIGPAAKKNTSEAVAAANQTEVEMENKVVTKVIREMCVQQ YREYRLASGIQLHPADTWLAVLLLLLTTLFAMH >P09583; 23 PROLACTIN I PRECURSOR (PRL-I). MARRSQGTKLHLAVLCLVVSCHAIGLSDLMERASQRSDKLHSLSTSLTKDLDSHFPPMGR VMMPRPSMCHTSSLQTPKDKEQALKVSENELISLARYLLLAWNDPLLLLSSEAPTLPHTP SNGDISSKIRELQDYSKSLGDGLDIMVNKMGPSSQYISSIPFKGGDLGNDKTSRLINFHF LMSCFRRDSHKIDSFLKVLRCRATNMRPETC >P16471; 24 PROLACTIN RECEPTOR PRECURSOR (PRL-R). MKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNY SLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVD VTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEW EIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWIS VAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQD FPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLL SEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQ PSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVE SFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTP ENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSS KCRLQLGGLDYLDPACFTHSFH >P14676; 30 PROLACTIN PRECURSOR (PRL). MSNRGASLKGLFLAVLLVSNTLLTKEGVTSLPICPIGSVNCQVSLGELFDRAVKLSHYIH YLSSEIFNEFDERYAQGRGFITKAVNGCHTSSLTTPEDKEQAQQIHHEDLLNLVVGVLRS WNDPLIHLASEVQRIKEAPDTILWKAVEIEEQNKRLLEGMEKIVGRVHSGHAGNEIYSHS DGLPSLQLADEDSRLFAFYNLLHCHRRDSHKIDNYLKVLKCRLIHDSNC >P24158; 25 MYELOBLASTIN PRECURSOR (EC 3.4.21.76) (LEUKOCYTE PROTEIN MAHRPPSPALASVLLALLLSGAARAAEIVGGHEAQPHSRPYMASLQMRGNPGSHFCGGTL IHPSFVLTAAHCLRDIPQRLVNVVLGAHNVRTQEPTQQHFSVAQVFLNNYDAENKLNDVL LIQLSSPANLSASVATVQLPQQDQPVPHGTQCLAMGWGRVGAHDPPAQVLQELNVTVVTF FCRPHNICTFVPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYV DWIRSTLRRVEAKGRP >P04280; 16 SALIVARY PROLINE-RICH PROTEIN PRECURSOR (CLONES CP3, CP4 MLLILLSVALLALSSAQNLNEDVSQEESPSLIAGNPQGPSPQGGNKPQGPPPPPGKPQGP PPQGGNKPQGPPPPGKPQGPPPQGDKSRSPRSPPGKPQGPPPQGGNQPQGPPPPPGKPQG PPPQGGNKPQGPPPPGKPQGPPPQGDKSQSPRSPPGKPQGPPPQGGNQPQGPPPPPGKPQ GPPQQGGNRPQGPPPPGKPQGPPPQGDKSRSPQSPPGKPQGPPPQGGNQPQGPPPPPGKP QGPPPQGGNKPQGPPPPGKPQGPPAQGGSKSQSARAPPGKPQGPPQQEGNNPQGPPPPAG GNPQQPQAPPAGQPQGPPRPPQGGRPSRPPQ >P04070; 32 VITAMIN-K DEPENDENT PROTEIN C PRECURSOR (EC 3.4.21.69) MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECI EEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSC DCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVK FPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGA VLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDI ALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVL NFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLV SWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP >P07224; 24 VITAMIN K-DEPENDENT PROTEIN S PRECURSOR. MRVLGGRTGTLLACLALVLPVLEANFLSRQHASQVLIRRRRANTLLEETKKGNLERECIE ELCNKEEAREIFENNPETEYFYPKYLGCLGSFRAGLFTAARLSTNAYPDLRSCVNAISDQ CNPLPCNEDGFMTCKDGQATFTCICKSGWQGEKCESDINECKDPVNINGGCSQICENTPG SYHCSCKNGFVMLSNKKDCKDVDECVLKPSICGTAVCKNIPGDFECECAEGYKYNPVSKS CDDVDECAENLCAQLCVNYPGGYSCYCDGKKGFKLAQDQKSCEAVPVCLPLDLDKNYELL YLAEQFVGVVLYLKFRLPETTRFSAEFDFRTYDSEGVILYAESSDHSAWFLIALREGKIE IQFKNEKTTKMTTGGKVINDGLWHMVSVEELEQSISVKIAKEAVMNINKPGSLFKPTNGF LETKVYFAGVPRKMENALIRPINPRLDGCIRGWNLMNQGTSGVKEIIQEKQNKHCLVNVE KGSYYPGTGVAQFSINYKNESNPEAWQINVSLNIRPSAGTGVMLALVSDNTVPFALSLVD SATEKLQDILVSVESMVIGRIEAISLCSDQQTFLEIRVNRNNLELSTQLRKDSFHSEDFQ RQFAILDEAMKGTVVTYLGGLPDVPFSATPVNAFYQGCMEVNINGVQVDLDEAISKHNDI RAHSCPSVWQKTKHT >P22891; 23 VITAMIN K-DEPENDENT PROTEIN Z PRECURSOR. MAGCVPLLQGLVLVLALHRVEPSVFLPASKANDVLVRWKRAGSYLLEELFEGNLEKECYE EICVYEEAREVFENEVVTDEFWRRYKGGSPCISQPCLHNGSCQDSIWGYTCTCSPGYEGS NCELAKNECHPERTDGCQHFCLPGQESYTCSCAQGYRLGEDHKQCVPHDQCACGVLTSEK RAPDLQDLPWQVKLTNSEGKDFCGGVIIRENFVLTTAKCSLLHRNITVKTYFNRTSQDPL MIKITHVHVHMRYDADAGENDLSLLELEWPIQCPGAGLPVCTPEKDFAEHLLIPRTRGLL SGWARNGTDLGNSLTTRPVTLVEGEECGQVLNVTVTTRTYCERSSVAAMHWMDGSVVTRE HRGSWFLTGVLGSQPVGGQAHMVLVTKVSRYSLWFKQIMN >P04963; 21 CHLOROPEROXIDASE PRECURSOR (EC 1.11.1.10) (CHLORIDE PERO MFSKVLPFVGAVAALPHSVRQEPGSGIGYPYDNNTLPYVAPGPTDSRAPCPALNALANHG YIPHDGRAISRETLQNAFLNHMGIANSVIELALTNAFVVCEYVTGSDCGDSLVNLTLLAE PHAFEHDHSFSRKDYKQGVANSNDFIDNRNFDAETFQTSLDVVAGKTHFDYADMNEIRLQ RESLSNELDFPGWFTESKPIQNVESGFIFALVSDFNLPDNDENPLVRIDWWKYWFTNESF PYHLGWHPPSPAREIEFVTSASSAVLAASVTSTPSSLPSGAIGPGAEAVPLSFASTMTPF LLATNAPYYAQDPTLGPND >P04155; 24 PS2 PROTEIN PRECURSOR (HP1.A) (BREAST CANCER ESTROGEN-IN MATMENKVICALVLVSMLALGTLAEAQTETCTVAPRERQNCGFPGVTPSQCANKGCCFDD TVRGVPWCFYPNTIDVPPEEECEF >P12729; 19 PRESPORE-SPECIFIC CELL SURFACE ANTIGEN PSA PRECURSOR (D1 MKFQHTFIALLSLLTYANAYDYFTTTLANQNPVCASVDVIQNVCTEVCGRFVRYIPDATN TNQFTFAEYTTNQCTVQVTPAVTNTFTCADQTSSHALGSDWSGVCKITATPAPTVTPTVT PTVTPTVTPTPTNTPNPTPSQTSTTTGSASTVVASLSLIIFSMILSLC >P50272; 22 PUTATIVE POLYSACCHARIDE BINDING PROTEIN PRECURSOR. MGFLKGTAAALTLLSAAAAASACGVLYEQCGGIGFDGVTCCSEGLMCMKMGPYYSQCRAM PGMMGQVKPYGQCGGMNYSGKTMCSPGFKCVELNEFFSQCDLANKSPVATPKVSPTSPPG PAQVCGKEYAACGGEMFMGAKCCKFGLVCYETSGKWQSQCRAPPPKMGEVGRYAQCGGMG YMGSTMCVGGYKCMAISEGSMYKQCLPMHP >P07714; 20 PULMONARY SURFACTANT-ASSOCIATED PROTEIN A PRECURSOR (SP- MWLCPLALNLILMAASGAACEVKDVCVGSPGIPGTPGSHGLPGRDGRDGLKGDPGPPGPM GPPGEMPCPPGNDGLPGAPGIPGECGEKGEPGERGPPGLPAHLDEELQATLHDFRHQILQ TRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKK YNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGRGKEQCVEMYTDGQWNDRNCLY SRLTICEF >P35248; 19 PULMONARY SURFACTANT-ASSOCIATED PROTEIN D PRECURSOR (SP- MLHFLSMLVLLVQPLGDLGAEMKTLSQRSITNTCTLVLCSPTENGLPGRDGRDGREGPRG EKGDPGLPGPMGLSGLPGPRGPVGPKGENGSAGEPGPKGERGLVGPPGSPGISGPAGKEG PSGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGAKGPAGPKGERGAPGEQGAPGNAG AAGPAGPAGPQGAPGSRGPPGLKGDRGAPGDRGIKGESGLPDSAALRQQMEALNGKLQRL EAAFSRYKKAALFPDGQSVGDKIFRAANSEEPFEDAKEMCRQAGGQLASPRSATENAAVQ QLVTAHSKAAFLSMTDVGTEGKFTYPTGEALVYSNWAPGEPNNNGGAENCVEIFTNGQWN DKACGEQRLVICEF >P08118; 20 PROSTATE SECRETED SEMINAL PLASMA PROTEIN PRECURSOR (PSP- MNVLLGSVVIFATFVTLCNASCYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETC TCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTCSVSEWII >P01269; 25 PARATHYROID HORMONE PRECURSOR (PARATHYRIN) (PTH). MMSAKDTVKVMVVMLAICFLARSDGKPIKKRSVSEIQLMHNLGKHLSSLERVEWLRKKLQ DVHNFVALGASIVHRDGGSQRPRKKEDNVLVESHQKSLGEADKAAVDVLIKAKPQ >P21246; 32 PLEIOTROPHIN PRECURSOR (PTN) (HEPARIN-BINDING GROWTH-ASS MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSG DCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTG SLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD >P16620; 23 PROTEIN-TYROSINE PHOSPHATASE DPTP PRECURSOR (EC 3.1.3.48 MALLYRRMSMLLNIILAYIFLCAICVQGSVKQEWAEIGKNVSLECASENEAVAWKLGNQT INKNHTRYKIRTEPLKSNDDGSENNDSQDFMKYKNVLTLLDVNINDSGNYTCTAQTGQNH STEFQVKPYLPSKVLQSTPDRIKRKIKQDVMLYCLIEMYPQNETTNRNLKWLKDGSQFEF LDTFSSISKLNDTHLNFTLEFTEVYKKENGTYKCTVFDDTGLEITSKEITLFVMEVPQVS IDFAKAVGANKIYLNWTVNDGNDPIQKFFITLQEAGTPTFTYHKDFINGSHTSYILDHFK PNTTYFLRIVGKNSIGNGQPTQYPQGITTLSYDPIFIPKVETTGSTASTITIGWNPPPPD LIDYIQYYELIVSESGEVPKVIEEAIYQQNSRNLPYMFDKLKTATDYEFRVRACSDLTKT CGPWSENVNGTTMDGVATKPTNLSIQCHHDNVTRGNSIAINWDVPKTPNGKVVSYLIHLL GNPMSTVDREMWGPKIRRIDEPHHKTLYESVSPNTNYTVTVSAITRHKKNGEPATGSCLM PVSTPDAIGRTMWSKVNLDSKYVLKLYLPKISERNGPICCYRLYLVRINNDNKELPDPEK LNIATYQEVHSDNVTRSSAYIAEMISSKYFRPEIFLGAEKRFSENNDIIRGNDEICRKCL EGTPFLRKPEIIHIPPQGSLSNSDSELPILSEKDNLIKGANLTEHALKILESKLRDKRNA VTSDENPILSAVNPNVPLHDSSRDVFDGEIDINSNYTGFLEIIVRDRNNALMAYSKYFDI ITPATEAEPIQSLNNMDYYLSIGVKAGAVLLGVILVFIVLWVFHHKKTKNELQGEDTLTL RDSLSRALFGRRNHNHSHFITSGNHKGFDAGPIHRLDLENAYKNRHKDTDYGFLREYEML PNRFSDRTTKNSDLKENACKNRYPDIKAYDQTRVKLAVINGLQTTDYINANFVIGYKERK KFICAQGPMESTIDDFWRMIWEQHLEIIVILTNLEEYNKAKCAKYWPEKVFDTKQFGDIL VKFAQERKTGDYIERTLNVSKNKANVGEEEDRRQITQYHYLTWKDFMAPEHPHGIIKFIR QINSVYSLQRGPILVHCSAGVGRTGTLVALDSLIQQLEEEDSVSIYNTVCDLRHQRNFLV QSLKQYIFLYRALLDTGTFGNTDICIDTMASAIESLKRKPNEGKCKLEMEFEKLLATADE ISKSCSVGENEENNMKNRSQEIIPYDRNRVILTPLPMRENSTYINASFIEGYDNSETFII AQDPFENTIGDFWRMISEQSVTTLVMISEIGDGPRKCPRYWADDEVQYDHILVKYVHSES CPYYTRREFYVTNCKIDDTLKVTQFQYNGWPTVDGEVPEVCRGIIELVDQAYNHYKNNKN SGCRSPLTVHCSLGTDRSSIFVAMCILVQHLRLEKCVDICATTRKLRSQRTGLINSYAQY EFLHRAIINYSDLHHIAESTLD >P17219; 29 PROTHORACICOTROPIC HORMONE PRECURSOR (PTTH). MITRPIILVILCYAILMIVQSFVPKAVALKRKPDVGGFMVEDQRTHKSHNYMMKRARNDV LGDKENVRPNPYYTEPFDPDTSPEELSALIVDYANMIRNDVILLDNSVETRTRKRGNIQV ENQAIPDPPCTCKYKKEIEDLGENSVPRFIETRNCNKTQQPTCRPPYICKESLYSITILK RRETKSQESLEIPNELKYRWVAESHPVSVACLCTRDYQLRYNNN >P08938; 21 PURPURIN PRECURSOR. MKYAQYVFLASIFSAVEYSLAQTCAVDSFSVKDNFDPKRYAGKWYALAKKDPEGLFLQDN ISAEYTVEEDGTMTASSKGRVKLFGFWVICADMAAQYTVPDPTTPAKMYMTYQGLASYLS SGGDNYWVIDTDYDNYAITYACRSLKEDGSCDDGYSLIFSRNPRGLPPAIQRIVRQKQEE ICMSGQFQPVLQSGAC >P21760; 20 QUIESCENCE-SPECIFIC PROTEIN PRECURSOR (P20K) (CH21 PROTE MRTLALSLALALLCLLHTEAAATVPDRSEVAGKWYIVALASNTDFFLREKGKMKMVMARI SFLGEDELEVSYAAPSPKGCRKWETTFKKTSDDGEVYYSEEAEKTVEVLDTDYKSYAVIF ATRVKDGRTLHMMRLYSRSREVSPTAMAIFRKLARERNYTDEMVAVLPSQEECSVDEV >Q28173; 22 ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR PRE MAAGAVVGAWMLVLSLGGTVTGDQNITARIGKPLVLNCKGAPKKPPQQLEWKLNTGRTEA WKVLSPQGDPWDSVARVLPNGSLLLPAVGIQDEGTFRCRATSRSGKETKSNYRVRVYQIP GKPEIVDPASELMAGVPNKVGTCVSEGGYPAGTLNWLLDGKTLIPDGKGVSVKEETKRHP KTGLFTLHSELMVTPARGGALHPTFSCSFTPGLPRRRALHTAPIQLRVWSEHRGGEGPNV DAVPLKEVQLVVEPEGGAVAPGGTVTLTCEAPAQPPPQIHWIKDGRPLPLPPGPMLLLPE VGPEDQGTYSCVATHPSHGPQESRAVSVTIIETGEEGTTAGSVEGPGLETLALTLGILGG LGTVALLIGVIVWHRRRQRKGQERKVPENQEEEEEERAELNQPEEPEAAESSTGGP >P02752; 17 RIBOFLAVIN-BINDING PROTEIN PRECURSOR (RBP). MLRFAITLFAVITSSTCQQYGCLEGDTHKANPSPEPNMHECTLYSESSCCYANFTEQLAH SPIIKVSNSYWNRCGQLSKSCEDFTKKIECFYRCSPHAARWIDPRYTAAIQSVPLCQSFC DDWYEACKDDSICAHNWLTDWERDESGENHCKSKCVPYSEMYANGTDMCQSMWGESFKVS ESSCLCLQMNKKDMVAIKHLLSESSEESSSMSSSEEHACQKKLLKFEALQQEEGEERR >P04090; 24 PRORELAXIN H2 PRECURSOR. MPRLFFFHLLGVCLLLNQFSRAVADSWMEEVIKLCGRELVRAQIAICGMSTWSKRSLSQE DAPQTPRPVAEIVPSFINKDTETINMMSEFVANLPQELKLTLSEMQPALPQLQQHVPVLK DSSLLFEEFKKLIRNRQSEAADSSPSELKYLGLDTHSRKKRQLYSALANKCCHVGCTKRS LARFC >P01347; 22 PRORELAXIN PRECURSOR. MSSRLLLQLLGFWLFLSQPCRARVSEEWMDQVIQVCGRGYARAWIEVCGASVGRLALSQE EPAPLARQATAEVVPSFINKDAEPFDMTLKCLPNLSEERKAALSEGRAPFPELQQHAPAL SDSVVSLEGFKKTFHNQLGEAEDGGPPELKYLGSDAQSRKKRQSGALLSEQCCHIGCTRR SIAKLC >P13830; 65 RING-INFECTED ERYTHROCYTE SURFACE ANTIGEN PRECURSOR. MRPFHAYSWIFSQQYMGTKNVKEKNPTIYSFDDEEKRNENKSFLKVLCSKRGVLPIIGIL YIILNGNLGYNGSSSSGVQFTDRCSRNLYGETLPVNPYADSENPIVVSQVFGLPFEKPTF TLESPPDIDHTNILGFNEKFMTDVNRYRYSNNYEAIPHISEFNPLIVDKVLFDYNEKVDN LGRSGGDIIKKMQTLWDEIMDINKRKYDSLKEKLQKTYSQYKVQYDMPKEAYESKWTQCI KLIDQGGENLEERLNSQFKNWYRQKYLNLEEYRRLTVLNQIAWKALSNQIQYSCRKIMNS DISSFKHINELKSLEHRAAKAAEAEMKKRAQKPKKKKSRRGWLCCGGGDIETVEPQQEEP VQTVQEQQVNEYGDILPSLRASITNSAINYYDTVKDGVYLDHETSDALYTDEDLLFDLEK QKYMDMLDTSEEESVEENEEEHTVDDEHVEEHTADDEHVEEPTVADDEHVEEPTVADEHV EEPTVAEEHVEEPTVAEEHVEEPASDVQQTSEAAPTIEIPDTLYYDILGVGVNADMNEIT ERYFKLAENYYPYQRSGSTVFHNFRKVNEAYQVLGDIDKKRWYNKYGYDGIKQVNFMNPS IFYLLSSLEKFKDFTGTPQIVTLLRFFFEKRLSMNDLENKSEHLLKFMEQYQKEREAHVS EYLLNILQPCIAGDSKWNVPIITKLEGLKGSRFDIPILESLRWIFKHVAKTHLKKSSKSA KKLQQRTQANKQELANINNNLMSTLKEYLGSSEQMNSITYNFENINSNVDNGNQSKNISD LSYTDQKEILEKIVSYIVDISLYDIENTALNAAEQLLSDNSVDEKTLKKRAQSLKKLSSI MERYAGGKRNDKKSKNFDTKDIVGYIMHGISTINTEMKNQNENVPEHVQHNAEENVEHDA EENVEHDAEENVEHDAEENVEHDAEENVEHDAEENVEENVEEVEENVEENVEENVEENVE EVEENVEENVEENVEENVEENVEENVEENVEENVEENVEEYDEENVEEVEENVEENVEEN VEENVEENVEEVEENVEENVEENVEENVEENVEENVEEYDEENVEEHNEEYDE >Q00001; 18 RHAMNOGALACTURONASE A PRECURSOR (EC 3.2.1.-) (RGASE A) ( MRALFLLALGSIPALVSGQLSGSVGPLTSASTKGATKTCNILSYGAVADNSTDVGPAITS AWAACKSGGLVYIPSGNYALNTWVTLTGGSATAIQLDGIIYRTGTASGNMIAVTDTTDFE LFSSTSKGAVQGFGYVYHAEGTYGARILRLTDVTHFSVHDVILVDAPAFHFTMDTCSDGE VYNMAIRGGNEGGLDGIDVWGSNIWVHDVEVTNKDECVTVKSPANNILVESIYCNWSGGC AMGSLGADTDVTDIVYRNVYTWSSNQMYMIKSNGGSGTVSNVLLENFIGHGNAYSLDIDG YWSSMTAVAGDGVQLNNITVKNWKGTEANGATRPPIRVVCSDTAPCTDLTLEDIAIWTES GSSELYLCRSAYGSGYCLKDSSSHTSYTTTSTVTAAPSGYSATTMAADLATAFGLTASIP IPTIPTSFYPGLTPYSALAG >P04844; 22 DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE--PROTEIN GLYCOSYLTRANS MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSS LGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDS SVTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGLYLQCEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAI FSKKNFESLSEAFSVASAASVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIA NTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQL VDMNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDSASGTYT LYLIIGDATLKNPILWNVADVVIKFPEEEAPSTVLSQNLFTPKQEIQHLFREPEKRPPTV VSNTFTALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGLMYVYWTQLNMF QTLKYLAILGSVTFLAGNRMLAQQAVKRTAH >P10153; 27 NONSECRETORY RIBONUCLEASE PRECURSOR (EC 3.1.27.5) (RIBON MVPKLFTSQICLLLLLGLLAVEGSLHVKPPQFTWAQWFETQHINMTSQQCTNAMQVINNY QRRCKNQNTFLLTTFANVVNVCGNPNMTCPSNKTRKNCHHSGSQVPLIHCNLTTPSPQNI SNCRYAQTPANMFYIVACDNRDQRRDPPQYPVVPVHLDRII >P04389; 27 RIBONUCLEASE MITOGILLIN PRECURSOR (EC 3.1.27.-) (RESTRIC MVAIKNLFLLAATAVSVLAAPSPLDARATWTCINQQLNPKTNKWEDKRLLYSQAKAESNS HHAPLSDGKTGSSYPHWFTNGYDGNGKLIKGRTPIKFGKADCDRPPKHSQNGMGKDDHYL LEFPTFPDGHDYKFDSKKPKEDPGPARVIYTYPNKVFCGIVAHQRGNQGDLRLCSH >P08056; 16 RIBONUCLEASE RH PRECURSOR (EC 3.1.27.1) (RNASE RH). MKAVLALATLIGSTLASSCSSTALSCSNSANSDTCCSPEYGLVVLNMQWAPGYGPDNAFT LHGLWPDKCSGAYAPSGGCDSNRASSSIASVIKSKDSSLYNSMLTYWPSNQGNNNVFWSH EWSKHGTCVSTYDPDCYDNYEEGEDIVDYFQKAMDLRSQYNVYKAFSSNGITPGGTYTAT EMQSAIESYFGAKAKIDCSSGTLSDVALYFYVRGRDTYVITDALSTGSCSGDVEYPTK >P00651; 26 GUANYL-SPECIFIC RIBONUCLEASE T1 PRECURSOR (EC 3.1.27.3) MMYSKLLTLTTLLLPTALALPSLVERACDYTCGSNCYSSSDVSTAQAAGYQLHEDGETVG SNSYPHKYNNYEGFDFSVSSPYYEWPILSSGDVYSGGSPGADRVVFNENNQLAGVITHTG ASGNNFVECT >P10281; 17 RIBONUCLEASE T2 PRECURSOR (EC 3.1.27.1) (RNASE T2). MGMLALGAMQLAAGAVFEFPSCPKDIPFSCQNSTAVADSCCFNSPGGALLQTQFWDTNPP SGPSDSWTIHGLWPDNCDGSYGQFCDKSREYSNITAILQEQGRTELLSYMKKYWPNYEGD DEEFWEHEWNKHGTCINTIEPSCYKDYSPQKEVGDYLQKTVDLFKGLDSYKALAKAGIVP DSSKTYKRSEIESALAAIHDGKKPYISCEDGALNEIWYFYNIKGNAITGEYQPIDTLTSP GCSTSGIKYLPKKSENSTASAWKFRSDKASQSVRFN >P35542; 18 SERUM AMYLOID A-4 PROTEIN PRECURSOR (CONSTITUTIVELY EXPR MRLFTGIVFCSLVMGVTSESWRSFFKEALQGVGDMGRAYWDIMISNHQNSNRYLYARGNY DAAQRGPGGVWAAKLISRSRVYLQGLIDYYLFGNSSTVLEDSKSNEKAEEWGRSGKDPDR FRPDGLPKKY >P02740; 18 SERUM AMYLOID A PROTEIN PRECURSOR (SAA). MRLCICFVLLAVIVCASADNPFTRGGRFVLDAAGGAWDMLRAYRDMREANHIGADKYFHA RGNYDAARRGPGGAWAARVISDARENWQGGVSGRGAEDTRADQEANAWGRNGGDPNRYRP PGLPSKY >P02743; 19 SERUM AMYLOID P-COMPONENT PRECURSOR (SAP) (9.5S ALPHA-1- MNKPLLWISVLTSLLEAFAHTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYS DLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESS SGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWD SVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV >P04928; 23 S-ANTIGEN PROTEIN PRECURSOR. MNRILSVSFYLFFLYLYIYKTYGKVKNTDQEISNIYGTNYYLRNGFLNGKNGKGNKYEDL QEEGEGENDDEEHSNSEESDNDEENEIIVGQDEAPKSDEAEALKSDEAEALKSDEAEARK SDEAEALKSDEAEARKSDEAEALKSDEAEALKSDEAEARKSDEAEALKSDEAEALKSDEA EARKSDEAEARKSDEAEARKSDEAEARKSDEAEALKSDEAEARKSDEAEARKSDEAEALK SDEAEARKSDEAEARKSEAGTEGPKGTGGPGSEAGTEGPKGTGGPGSGGEHSHNKKKSKK SIMNMLILM >P17900; 31 GANGLIOSIDE GM2 ACTIVATOR PRECURSOR (CEREBROSIDE SULFATE MQSLMQAPLLIALGLLLATPAQAHLKKPSQLSSFSWDNCDEGKDPAVIRSLTLEPDPIVV PGNVTLSVVGSTSVPLSSPLKVDLVLEKEVAGLWIKIPCTDYIGSCTFEHFCDVLDMLIP TGEPCPEPLRTYGLPCHCPFKEGTYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKR LGCIKIAASLKGI >P07602; 16 PROACTIVATOR POLYPEPTIDE PRECURSOR [CONTAINS: SAPOSIN A MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASDCGAVKHCLQTVWNKPTVKS LPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDI IKGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIPELDMTEVVAPFMANIPLLLY PQDGPRSKPQPKDNGDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADI CKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQTLVPAKVASKNVIPALELVE PIKKHEVPAKSDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEV VDTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHVTQPKDGGFCEVCKKLVGYLD RNLEKNSTKQEILAALEKGCSFLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIG ACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRHVWN >Q04791; 25 FATTY ACYL-COA HYDROLASE PRECURSOR, MEDIUM CHAIN (EC 3.1 MATEKNTLLSLILTAGITALVATGQKAEQPEVVTNYGSVRGYQVKVNAAERSVNVFLGLP FAKPPVGPLRFSEPQPPEPWKGVRDAASYPPMCLQDKVLGQYLSDAITNRKEKVRLQISE DCLYLNVYTPVSTEEQEKLPVFVWIHGGGLVSGAASSYDGSALAAFDNVVVVTIQYRLGI AGYFSTGDKHARGNWGYLDQVAALQWIQENIIHFRGDPGSVTIFGESAGGVSVSALVLSP LAKGLFHKAISESGTAVRILFTEQPEEQAQRIAAAAGCEKSSSAALVECLREKTEAEMEQ ITLKMPPMFISASLDGVFFPKSPRQLLSEKVINAVPYIIGVNNCEFGWILPRMMKFPEFT EGLEKDVARQVLQSTLALSFKGAPSDIVDLVYNEYIGVAENRAQVRDGLLDSIADPLFVF SAVEVARHHRDAGNPVYFYEFQHRPSSAAGVVPEFVKADHADEIAFVFGKPFLAGNATEE EAKLSRTVMKYWTNFARNGNPNGEGLVHWPQYDMDERYLEIDLTQKAAKKLKERKMEFWM QLTEQIMSDRRRKHTDL >P31226; 19 SAXIPHILIN PRECURSOR (SAX). MAPTFQTALFFTIISLSFAAPNAKQVRWCAISDLEQKKCNDLVGSCNVPDITLVCVLRSS TEDCMTAIKDGQADAMFLDSGEVYEASKDPYNLKPIIAEPYSSNRDLQKCLKERQQALAK KMIGHYIPQCDEKGNYQPQQCHGSTGHCWCVNAMGEKISGTNTPPGQTRATCERHELPKC LKERQVALGGDEKVLGRFVPQCDEKGNYEPQQFHGSTGYSWCVNAIGEEIAGTKTPPGKI PATCQKHDLVTTCHYAVAMVKKSSAFQFNQLKGKRSCHSGVSKTDGWKALVTVLVEKKLL SWDGPAKESIQRAMSKFFSVSCIPGATQTNLCKQCKGEEGKNCKNSHDEPYYGNYGAFRC LKEDMGDVAFLRSTALSDEHSEVYELLCPDNTRKPLNKYKECNLGTVPAGTVVTRKISDK TEDINNFLMEAQKRQCKLFSSAHGKDLMFDDSTLQLALLSSEVDAFLYLGVKLFHAMKAL TGDAHLPSKNKVRWCTINKLEKMKCDDWSAVSGGAIACTEASCPKGCVKQILKGEADAVK LEVQYMYEALMCGLLPAVEEYHNKDDFGPCKTPGSPYTDFGTLRAVALVKKSNKDINWNN IKGKKSCHTGVGDIAGWVIPVSLIRRQNDNSDIDSFFGESCAPGSDTKSNLCKLCIGDPK NSAANTKCSLSDKEAYYGNQGAFRCLVEKGDVAFVPHTVVFENTDGKNPAVWAKNLKSED FELLCLDGSRAPVSNYKSCKLSGIPPPAIVTREESISDVVRIVANQQSLYGRKGFEKDMF QLFSSNKGNNLLFNDNTQCLITFDRQPKDIMEDYFGKPYYTTVYGASRSAMSSELISACT IKHC >P16933; 24 FRUITING BODY PROTEIN SC3 PRECURSOR (HYDROPHOBIN SC3). MFARLPVVFLYAFVAFGALVAALPGGHPGTTTPPVTTTVTVTTPPSTTTIAAGGTCTTGS LSCCNQVQSASSSPVTALLGLLGIVLSDLNVLVGISCSPLTVIGVGGSGCSAQTVCCENT QFNGLINIGCTPINIL >P20826; 25 STEM CELL FACTOR PRECURSOR (SCF) (MAST CELL GROWTH FACTO MKKTQTWIITCIYLQLLLFNPLVKTKEICGNPVTDNVKDITKLVANLPNDYMITLNYVAG MDVLPSHCWLRDMVIQLSLSLTTLLDKFSNISEGLSNYSIIDKLGKIVDDLVLCMEENAP KNIKESPKRPETRSFTPEEFFSIFNRSIDAFKDFMVASDTSDCVLSSTLGPEKDSRVSVT KPFMLPPVAASSLRNDSSSSNRKAAKAPEDSGLQWTAMALPALISLVIGFAFGALYWKKK QSSLTRAVENIQINEEDNEISMLQQKEREFQEV >P45696; 22 KALIOTOXIN 2 PRECURSOR (KTX 2). MKVFSAVLIILFVCSMIIGINAVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK >P01480; 19 NEUROTOXIN III PRECURSOR (AAH III). MNYLVMISLALLLMTGVESVRDGYIVDSKNCVYHCVPPCDGLCKKNGAKSGSCGFLIPSG LACWCVALPDNVPIKDPSYKCHSR >P02852; 32 SECAPIN PRECURSOR. MKNYSKNATHLITVLLFSFVVILLIIPSKCEAVSNDRQSLEARSADLVPEPRYIIDVPPR CPPGSKFIKNRCRVIVP >Q01589; 18 SED1 PROTEIN PRECURSOR. MKLSTVLLSAGLASTTLAQFSNSTSASSTDVTSSSSISTSSGSVTITSSEAPESDNGTST AAPTETSTEAPTTAIPTNGTSTEAPTTAIPTNGTSTEAPTDTTTEAPTTALPTNGTSTEA PTDTTTEAPTTGLPTNGTTSAFPPTTSLPPSNTTTTPPYNPSTDYTTDYTVVTEYTTYCP EPTTFTTNGKTYTVTEPTTLTITDCPCTIEKPTTTSTTEYTVVTEYTTYCPEPTTFTTNG KTYTVTEPTTLTITDCPCTIEKSEAPESSVPVTESKGTTTKETGVTTKQTTANPSLTVST VVPVSSSASSHSVVINSNGANVVVPGALGLAGVAMLFL >P25236; 19 SELENOPROTEIN P PRECURSOR. MWRSLGLALALCLLPYGGAESQGQSPACKQAPPWNIGDQNPMLNSEGTVTVVALLQASCY LCLLQASRLEDLRIKLENQGYFNISYIVVNHQGSPSQLKHAHLKKQVSDHIAVYRQDEHQ TDVWTLLNGNKDDFLIYDRCGRLVYHLGLPYSFLTFPYVEEAIKIAYCEKRCGNCSFTSL EDEAFCKNVSSATASKTTEPSEEHNHHKHHDKHGHEHLGSSKPSENQQPGALDVETSLPP SGLHHHHHHHKHKGQHRQGHLESCDMGASEGLQLSLAQRKLCRRGCINQLLCKLSEESGA ATSSCCCHCRHLIFEKSGSAITCQCAENLPSLCSCQGLFAEEKVIESCQCRSPPAACHSQ HVSPTEASPNCSCNNKTKKCKCNLN >P16014; 20 SECRETOGRANIN I PRECURSOR (SGI) (CHROMOGRANIN B). MQPAMLLGLLGAAALAAVSSAPVDNRDHNEEMVTRCIIEVLSNALSKSSVPTITPECRQV LKKSGKEVKGEEKGENQNSKFEVRLLRDPADASGTRWASSREDAGAPVEDSQGQTKVGNE KWTEGGGHSREGVDDQESLRPSNQQASKEAKIYHSEERVGKEREKEEGKIYPMGEHREDA GEEKKHIEDSGEKPNTFSNKRSEASAKKKDESVARADAHSMELEEKTHSREQSSQESGEE TRRQEKPQELTDQDQSQEESQEGEEGEEGEEGEEGEEDSASEVTKRRPRHHHGRSGSNKS SYEGHPLSEERRPSPKESKEADVATVRLGEKRSHHLAHYRASEEEPEYGEESRSYRGLQY RGRGSEEDRAPRPRSEESQEREYKRNHPDSELESTANRHGEETEEERSYEGANGRQHRGR GREPGAHSALDTREEKRLLDEGHYPVRESPIDTAKRYPQSKWQEQEKNYLNYGEEGDQGR WWQQEEQLGPEESREEVRFPDRQYEPYPITEKRKRLGALFNPYFDPLQWKNSDFEKRGNP DDSFLEDEGEDRNGVTLTEKNSFPEYNYDWWERRPFSEDVNWGYEKRSFARAPQLDLKRQ YDGVAELDQLLHYRKKADEFPDFYDSEEQMGPHQEANDEKARADQRVLTAEEKKELENLA AMDLELQKIAEKFSQRG >P10362; 30 SECRETOGRANIN II PRECURSOR (SGII) (CHROMOGRANIN C). MTESKAYRFGAVLLLIHLIFLVPGTEAASFQRNQLLQKEPDLRLENVQKFPSPEMIRALE YIEKLRQQAHREESSPDYNPYQGISVPLQLKENGEESHLAESSRDVLSEDEWMRIILEAL RQAENEPPSALKENKPYALNLEKNFPVDTPDDYETQQWPERKLKHMRFPLMYEENSRENP FKRTNEIVEEQYTPQSLATLESVFQELGKLTGPSNQKRERVDEEQKLYTDDEDDVYKTNN IAYEDVVGGEDWSPMEEKIETQTQEEVRDSKENTEKNEQINEEMKRSGHLGLPDEGNRKE SKDQLSEDASKVITYLRRLVNAVGSGRSQSGQNGDRAARLLERPLDSQSIYQLIEISRNL QIPPEDLIEMLKAGEKPNGLVEPEQDLELAVDLDDIPEADIDRPDMFQSKTLSKGGYPKA PGRGMMEALPDGLSVEDILNVLGMENVANQKSPYFPNQYSRDKALLRLPYGPGKSRANQI PKVAWIPDVESRQAPYDNLNDKDQELGEYLARMLVKYPELMNTNQLKRVPSPGSSEDDLQ EEEQLEQAIKEHLGQGSSQEMEKLAKVSKRIPAGSLKNEDTPNRQYLDEDMLLKVLEYLN QEQAEQGREHLAKRAMENM >P13730; 23 SALIVARY GLUE PROTEIN SGS-3 PRECURSOR. MKLTIATALVGILLIACAHVANGSDCGCPKRTTPKPCTTARPTCAPVTTTTCRPPTTTRC PPPTTTRCPPPTRPAECTATTKRPTARPTTRRTTVRATTKRATTRRTTKRATTRRTTVRA TTKRATTRRTTTKRAPTRRTTTKRATTRRNPTRRTTTRRAPTKRATTKRATTRRNPTKRK TTRRTTVRATKTTKRATTKRAPTKRATTKRAPTKRVTTKRAPTKRATTKRAPTKRATTKR APTKRATTKRAPTKRATTKRAPTKRATTKRATARPTSKPCGCKPCGPGGEPCQGCAKRDA LCQDLNNILRNLERKVRQCVCGEPQWLL >P02841; 23 SALIVARY GLUE PROTEIN SGS-7 PRECURSOR. MKLIAVTIIACILLIGFSDLALGGACECQPCGPGGKACTGCPEKPQLCQQLISDIRNLQQ KIRKCVCGEPQWMI >P21815; 16 BONE SIALOPROTEIN II PRECURSOR (BSP II) (CELL-BINDING SI MKTALILLSILGMACAFSMKNLHRRVKIEDSEENGVFKYRPRYYLYKHAYFYPHLKRFPV QGSSDSSEENGDDSSEEEEEEEETSNEGENNEESNEDEDSEAENTTLSATTLGYGEDATP GTGYTGLAAIQLPKKAGDITNKATKEKESDEEEEEEEEGNENEESEAEVDENEQGINGTS TNSTEAENGNGSSGVDNGEEGEEESVTGANAEGTTETGGQGKGTSKTTTSPNGGFEPTTP PQVYRTTSPPFGKTTTVEYEGEYEYTGANDYDNGYEIYESENGEPRGDNYRAYEDEYSYF KGQGYDGYDGQNYYHHQ >P24336; 21 DEPRESSANT INSECT TOXIN 2 PRECURSOR (IT-2) (BJ IT2). MKLLLLLVISASMLLECLVNADGYIRKKDGCKVSCIIGNEGCRKECVAHGGSFGYCWTWG LACWCENLPDAVTWKSSTNTCGRKK >P13673; 26 SKIN GRANULE PROTEIN PRECURSOR. METMYHRFLCIPFLLILGLAQGQSKGLQTVTTFRTGLKPIDVTAIRTGLQPIATFHTGQK PIDVTAIRTGLQPIATFHTGLQPVDVTAIRTGLQPIATFQTGVQRVSTFHGEPASTLQGS GSTVIKKIMVSSMNQPVSKNEGIVEVPPPSGGTHVITEEMNWHGGRNGHKMKKLGKKKHH KNRHGGKNHHKMKKIGKHHGGGRKFGKKHRHHK >P01286; 20 SOMATOLIBERIN PRECURSOR (GROWTH HORMONE-RELEASING FACTOR MPLWVFFFVILTLSNSSHCSPPPPLTLRMRRYADAIFTNSYRKVLGQLSARKLLQDIMSR QQGESNQERGARARLGRQVDSMWAEQKQMELESILVALLQKHSRNSQG >P24014; 36 SLIT PROTEIN PRECURSOR. MAAPSRTTLMPPPFRLQLRLLILPILLLLRHDAVHAEPYSGGFGSSAVSSGGLGSVGIHI PGGGVGVITEARCPRVCSCTGLNVDCSHRGLTSVPRKISADVERLELQGNNLTVIYETDF QRLTKLRMLQLTDNQIHTIERNSFQDLVSLERLDISNNVITTVGRRVFKGAQSLRSLQLD NNQITCLDEHAFKGLVELEILTLNNNNLTSLPHNIFGGLGRLRALRLSDNPFACDCHLSW LSRFLRSATRLAPYTRCQSPSQLKGQNVADLHDQEFKCSGLTEHAPMECGAENSCPHPCR CADGIVDCREKSLTSVPVTLPDDTTDVRLEQNFITELPPKSFSSFRRLRRIDLSNNNISR IAHDALSGLKQLTTLVLYGNKIKDLPSGVFKGLGSLRLLLLNANEISCIRKDAFRDLHSL SLLSLYDNNIQSLANGTFDAMKSMKTVHLAKNPFICDCNLRWLADYLHKNPIETSGARCE SPKRMHRRRIESLREEKFKCSWGELRMKLSGECRMDSDCPAMCHCEGTTVDCTGRRLKEI PRDIPLHTTELLLNDNELGRISSDGLFGRLPHLVKLELKRNQLTGIEPNAFEGASHIQEL QLGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSFEHLNSLTSLNLASNPFNCNCH LAWFAECVRKKSLNGGAARCGAPSKVRDVQIKDLPHSEFKCSSENSEGCLGDGYCPPSCT CTGTVVACSRNQLKEIPRGIPAETSELYLESNEIEQIHYERIRHLRSLTRLDLSNNQITI LSNYTFANLTKLSTLIISYNKLQCLQRHALSGLNNLRVVSLHGNRISMLPEGSFEDLKSL THIALGSNPLYCDCGLKWFSDWIKLDYVEPGIARCAEPEQMKDKLILSTPSSSFVCRGRV RNDILAKCNACFEQPCQNQAQCVALPQREYQCLCQPGYHGKHCEFMIDACYGNPCRNNAT CTVLEEGRFSCQCAPGYTGARCETNIDDCLGEIKCQNNATCIDGVESYKCECQPGFSGEF CDTKIQFCSPEFNPCANGAKCMDHFTHYSCDCQAGFHGTNCTDNIDDCQNHMCQNGGTCV DGINDYQCRCPDDYTGKYCEGHNMISMMYPQTSPCQNHECKHGVCFQPNAQGSDYLCRCH PGYTGKWCEYLTSISFVHNNSFVELEPLRTRPEANVTIVFSSAEQNGILMYDGQDAHLAV ELFNGRIRVSYDVGNHPVSTMYSFEMVADGKYHAVELLAIKKNFTLRVDRGLARSIINEG SNDYLKLTTPMFLGGLPVDPAQQAYKNWQIRNLTSFKGCMKEVWINHKLVDFGNAQRQQK ITPGCALLEGEQQEEEDDEQDFMDETPHIKEEPVDPCLENKCRRGSRCVPNSNARDGYQC KCKHGQRGRYCDQGEGSTEPPTVTAASTCRKEQVREYYTENDCRSRQPLKYAKCVGGCGN QCCAAKIVRRRKVRMVCSNNRKYIKNLDIVRKCGCTKKCY >P23126; 35 ANTIGENIC INTEGRAL MEMBRANE GLYCOPROTEIN PRECURSOR (SM25 MFSFHERMKKKHVTIRVYKHERILVFLFVLFISTTDFSTEIIMIQTINWIVWKLFIIYIS LDLFSLKLVNSEENSNSIITDEDYDHYNSSLDSSNNVKHSQEAFHRNSDPDGFPEYEFLN ETSIEIKEELGQELHQLQLILDELSRRIRATPNSANKYMKNEFLMSSCIVITLNLFIFMY KS >P11994; 15 50 KD SPICULE MATRIX PROTEIN PRECURSOR. MKGVLFIVASLIAFATGQDCPAYYVRSQSGQSCYRYFNMRVPYRMASEFCEMVTPCGNGP AKMGALASVSSPQENMEIYQLVAGFSQDNQMENEVWLGWNSQSPFFWEDGTPAYPNGFAA FSSSPASPPRPGMPPTRSWPVNPQNPMSGPPGRAPVMKRQNPPVRPGQGGRQIPQGVGPQ WEAVEVTAMRAFVCEVPAGRNIPIGQQPGMGQGGFGNQQPGMGGRQPGFGNQPGMGGRQP GFGNQPGMGGRQPGWGNQPGVGGRQPGMGGQQPGWGNQPGVGGRQPGMGGQPGVGGRQPG FGNQPGMVDNNQAWWTTTRLGNQPGVGGRQPGMGGQPGVGGRQPGVGGRQPGFGNQPGVG GRQPGMGGQQPGMGGQPGVGGRQPGMGGRQPGFGNQPGVGGRQPGMGGQQPNNPNNPNPN NPNNPNNPNPRFNRPRMLQEADALA >Q92154; 17 SCHWANN CELL MYELIN PROTEIN PRECURSOR. MELLVLTVLLMGTGCISAPWAAWMPPKMAALSGTCVQLPCRFDYPEELRPASIGGLWYFG SPYPKNYPPVVARSRPSSAVHESFAGRASFLGDPTGRDCTLNIARLSEELAGKYYFRGDL GGYNQYSFSEHAELDVWAAPHLEVPHELVAGSEAEILCRVPDNCPPLRPLLTWTGTEELL DPIGKERIEDDLGSKSLLGSLRFRPRKEDLGRRVGCGVTFINSSLSFQADVGLDVQYEPQ VVGLWGPTEVVEGSDVELGCEAEGRPAPLISWFRGSEVLREEPGRNLRLLLSNVGPDDGG SFSCVAENRHGRHNRSLQLRVAYAPRAPVINGSLWVVSGDPVSVTCRAESEPAAILTVLR GGKVMAAAIYEDHVTMEMRPARPEDGGTYSCVAENQHGASSTSFNISVEYPPLVLPASRC TAGGDGVRCVCMVNSIPDSSLVFELPTRNQTVSDGHRDFTAAPPGSDGSITGILTLRGPL EPRLLVLCAARNRHGTTARQLRFHHPGGLVWAKVGPVGAVVAFAIVIAVVCYLSQSRRKK GAGSPEVTPVQPMAGPGGDPDLDLRPQQVRWLRGAMERWALGVKEGSGAPQEVTPTSHPP MKPTRGPLEDPPEYAEIRVK >P01170; 24 SOMATOSTATIN II PRECURSOR. MQCIRCPAILALLALVLCGPSVSSQLDREQSDNQDLDLELRQHWLLERARSAGLLSQEWS KRAVEELLAQMSLPEADVQREAEDASMATGGRMNLERSVDSTNNLPPRERKAGCKNFYWK GFTSC >P01167; 24 SOMATOSTATIN PRECURSOR. MLSCRLQCALAALCIVLALGGVTGAPSDPRLRQFLQKSLAAATGKQELAKYFLAELLSEP NQTENDALEPEDLPQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC >P11228; 25 SOMATOTROPIN PRECURSOR (GROWTH HORMONE). MAPGSWFSPLFITVITLGLQWPQEAATFPAMPLSNLFANAVLRAQHLHLLAAETYKEFER SYIPEDQRHTNKNSQAFCYSETIPAPTGKDDAQQKSDMELLRFSLVLIQSWLTPVQYLSK VFTNNLVFGTSDRVFEKLKDLEEGIQALMRELEDRSPRGPQLLKPTYDKFDIHLRNEDAL LKNYGLLSCFKKDLHKVETYLKVMKCRRFGESNCTI >P10298; 23 SOMATOTROPIN PRECURSOR (GROWTH HORMONE). MARVLVLLSVVLVSLLVNQGRASDNQRLFNNAVIRVQHLHQLAAKMINDFEDSLLPEERR QLSKIFPLSFCNSDYIEAPAGKDETQKSSMLKLLRISFHLIESWEFPSQSLSGTVSNSLT VGNPNQLTEKLADLKMGISVLIQACLDGQPNMDDNDSLPLPFEDFYLTMGENNLRESFRL LACFKKDMHKVETYLRVANCRRSLDSNCTL >P08591; 17 SOMATOTROPIN PRECURSOR (GROWTH HORMONE). MDRVVLMLSVLSLGVSSQPITDGQRLFSIAVSRVQHLHLLAQRLFSDFESSLQTEEQLKL NKIFPDFCNSDYIISPIDKHETQRSSVLKLLSISYRLVESWEFPSRSLSGGSAPRNQISP KLSELKMGIHLLIRANEDGAEIFPDSSALQLAPYGNYYQSLGADESLRRTYELLACFKKD MHKVETYLTVAKCRLSPEANCTL >P10813; 25 SOMATOTROPIN PRECURSOR (GROWTH HORMONE). MASGLGSSLVLLVVICLQSPQGFNAFPQMSLSNLFTNAVIRAQHLHQMVADTYRDYERTY IPEDQRFSNKHSYSVYCYSETIPAPTDKDNTHQKSDIDLLRFSLTLLQSWMTPIQIVNRV FGNNQVFGNIDRVYDRLRDLDEGLHILIRELDDGNVRNYGVLTFTYDKFDVNLRSEEGRA KNYGLLSCFKKDMHKVETYLKVMKCRRFVESNCTF >P21919; 26 SOMATOLACTIN PRECURSOR (SL). MHTLAAVVVLQVCWAAVLWPCPPTHSSPVDCREEQAGSSQCPTISQEKLLDRVIQHTELI YRVSEESCSMFEDMFVPFPVRLQRNQAGNTCITKDFPIPTSKNELQQISDTWLLHSVLML VQSWIEPLVYLQTTLDRYDDVPDVLLNKTKWMSEKLISLEQGVVVLIRKMLDGAILNSSY NEYSAVQLDVQPEVLESILRDYNVLCCFKKDAHKIETILKLLKCRQIDKYNCALY >P01242; 26 GROWTH HORMONE VARIANT I PRECURSOR (GH-V) (PLACENTA-SPEC MAAGSRTSLLLAFGLLCLSWLQEGSAFPTIPLSRLFDNAMLRARRLYQLAYDTYQEFEEA YILKEQKYSFLQNPQTSLCFSESIPTPSNRVKTQQKSNLELLRISLLLTQSWLEPVQLLR SVFANSLVYGASDSNVYRHLKDLEEGIQTLMWRLEDGSPRTGQIFNQSYSKFDTKSHNDD ALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF >Q27022; 7 SPERMATOPHORIN SP23 PRECURSOR. MVASIAGEEEPAAEKSQQSPDHFQPYRPYYYPPYRGYPITYPYPYPHGYPKPYHNFQTIA KPNEGPTDQPEANSANSIEEGGVSKRLFIEPIFNLFRPRPRDPIVVNQAPPPPPVIYQAP PPPPPPPIFQQAPPTIYQQPSPTIIQQAPQPSVTKLVYSQPEPSHSVIYQTQPKTELVYL NQ >Q27967; 20 SECRETED PHOSPHOPROTEIN 24 PRECURSOR (SPP-24). MAMKMLVIFVLGMNHWTCTGFPVYDYDPASLKEALSASVAKVNSQSLSPYLFRAFRSSVK RVNALDEDSLTMDLEFRIQETTCRRESEADPATCDFQRGYHVPVAVCRSTVRMSAEQVQN VWVRCHWSSSSGSSSSEEMFFGDILGSSTSRNSYLLGLTPDRSRGEPLYEPSREMRRNFP LGNRRYSNPWPRARVNPGFE >P15270; 23 SPORE COAT PROTEIN SP60 PRECURSOR. MKILSLLVVGALCMGGKVYGEVNGDWNNNGDWNNNGDWNNNGDWNNNGPILDCSTLQCPP RYHCEVNNGNRQCVEDQITLPPFDKCDNVHCPKGFNCKYDWEKDLALCVPWRPYPPVCRT RCPEGHECKVDEWGKECCVKIKCDDICDLRCPKGHECKIKHDGSKCCVRSWRPRPHKPHP RPPICRLRCPPGHECKHDEHGKECCVKKRHHDRCDLKCKRGYECKIKHDGSKCCVKRTPK RPCCKPNSCARDEKCVATKDRIICVKPTCDNTRCPPNYHCICGDKIDGVKCVPDCKKARC DDVECPDFHRCVERRGGILSCEFDPPRQPRSLDWAENENDDRDYDDRDYDDDEYDGDYDG RDGDYDGDYDGDYDDDNYYGDDDYDNDWDNDNDWGNDWDNDWDNEDGDNWNDDDFQDAND EWDY >P15269; 20 SPORE COAT PROTEIN SP70 PRECURSOR (BEEJIN PROTEIN). MRILKLAALSCLLFIAPSLSINCDGLSKDQCEQNFPQCQILTAKSCCGESKSYCAERDSN DCLASKISCKKDPQGNIYEFWSSCTPSSGFTDFIPSNATCSSLNCNAQQMSCKYVQQACH ETSCCPDIPQCQIPATGGGPATGSATGQGTSGGTPGSCDKVNCPNGYICTIVNQLAVCVS PSSSSSSSSSTTGSHTTTGGSTTGSHTTTGGSTTGSHTTTGGSTTGSHTTTGGSTTGSHT TTGGSTTGPTCGNVNCPRGYHCEVRGSQAVCVADEFDSCANVDCGSGYHCKNGECIRDKV ECDACDQINCPKVIIVYLNQKVAGLVPIRKRHWQLHPEHCGGRPNKIKVICVPSPKGTCK TVQCPKGYKCKLYADGPTCVKIEKPKCLTCKDMHCESNGLLCVLTPQKKTDEECCPIIPI CINPSTIAASTIATTTASTRHSTASTIASLVTGTTSGGGGMGSFGGRSDEESSDPNAILG LFEDDIFWGDNDEYFSDNYRYVDEEDIDEDFNGNDEFEIDVEGDFQEDDFEEEYAFY >P16225; 21 SODIUM/POTASSIUM ATPASE INHIBITOR SPAI-2 PRECURSOR (WAP- MRSRSFLVLVAVFLICETLVAQRLDRIRGPKGQGQDPVEGQDQDEGPGPVKVEILDIGQD PVKGQDPVKGQDPVKGQDPVKGQDLVKSQDPVKAELPDIGQDVVKGHEPVEGQDPVNAQL PDKVQDPVKAQPAVPGRFLLSKRGHCPRILFRCPLSNPSNKCWRDYDCPGVKKCCEGFCG KDCLYPK >P08723; 17 PROSTATIC SPERMINE-BINDING PROTEIN PRECURSOR (SBP). MLLLVTLALLAGPTCRAQNILGNNVGTYFYVAGEEHGQLRGIRIFLTVIDLIKGIQLRFG GNWSDVYGSRSLKYKEFLLEDGEHVTQVSGTRKLCLTSLSFTTNKGRVVTFGVRRGLSFN ESGGSDKYLVTVNGLYAPGLCLNGMGFKWKNIHDDFDDNDDDKEDDDDEHDDDNEEDHGD KDNDNDHDDDHDDDDDDKEDDNEEDVDDERDDKDDDEEDDDNDKENDKDDGEGSGDDDDN DDEDDDKDDDGGSGDDGDDGDDDEDDDGGDDDNGDEEEE >P16264; 30 EGG PEPTIDE SPERACT RECEPTOR PRECURSOR. MGLPMMLQQYCWAACLVICIAISSVDDVGAEQNYGREAVEGNIRLIHGRTENEGSVEIYH ATRWGGVCDWWWHMENANVTCKQLGFPGARQFYRRAYFGAHVTTFWVYKMNCLGNETRLE DCYHRPYGRPWLCNAQWAAGVECLPKDEPQGSLRMILGDVPNEGTLETFWDGAWGSVCHT DFGTPDGNVACRQMGYSRGVKSIKTDGHFGFSTGPIILDAVDCEGTEAHITECNMPVTPY QHACPYTHNWDVGVVCKPNVEGDIRLMDGSGPHEGRVEIWHDDAWGTICDDGWDWADANV VCRQAGYRGAVKASGFKGEDFGFTWAPIHTSFVMCTGVEDRLIDCILRDGWTHSCYHVED ASVVCATDDDDTIEIEPKHTRVRIVGMGQGQGRVEVSLGNGWGRVCDPDWSDHEAKTVCY HAGYKWGASRAAGSAEVSAPFDLEAPFIIDGITCSGVENETLSQCQMKVSADMTCATGDV GVVCEGSTAPPSGMSIAVIGGAAGGGVAGLAVAAFAFYYIKFVKPAGGGGQA >P09350; 19 SPHERULIN 1A PRECURSOR. MKSTFLFALFVLFLAASEAATDYPTNPPTTPPTPAPTSTPLPSSAASPELVAQLLNAPSE LDRIKLLKDNQFVFDFKNSKLGVTQGTGGKTVATSRTNFPAVIGHNVAMTVGFIEACGIN LPHTHPRATEINFIASGKFEAGFFLENQAKFIGHTLEAGMATVFPQGAIHFEINMNCEPA MFVAAFNNEDPGVQTTASSFFGLPADVVGVSLNISSIQTVEDLGKHLPQNPAVAMQACMK RCGFSD >P08375; 23 SARCOTOXIN IA PRECURSOR. MNFQNIFIFVALILAVFAGQSQAGWLKKIGKKIERVGQHTRDATIQGLGIAQQAANVAAT ARG >P09351; 20 SPHERULIN 1B PRECURSOR. MQVRNILVALVVVCFAVSEAATQAPTSPPDSSASAEQVAQLLNAPSELDRLKLLKDNQFV FDFKNSKLGVTQSAGGKTVATSRTDFPAVIGHNIAMTVGFIEACGINLPHTHPRATEINF IAKGRFQAGFFLENQATFIGHILEEGMATVFPQGAIHFEINLECEPAMFVAAFNNEDPGV QTTASSFFGLPADVAAVSLNISSIQTVEDLAKYLPHNPAIAMKECMQRCGMTGSSESSES SEDSSCSD >P14667; 22 SARCOTOXIN IIA PRECURSOR. MKSFVFFAACMAIIALSSLVQAYPQKLPVPIPPPTNPPVAAFHNSVATNSKGGQDVSVKL AATNLGNKHVQPIAEVFAEGNTKGGNVLRGATVGVQGHGLGASVTKSQDGIAESFRKQAE ANLRLGDSASLIGKVSQTDTKIKGIDFKPQLSSSSLALQGDRLGASISRDVNRGVSDTLT KSVSANLFRNDNHNLDASVFRSDVRQNNGFNFQKTGGMLDYSHANGHGLNAGLTRFSGIG NQATVGGYSTLFRSNDGLTSLKANAGGSQWLSGPFANQRDYSFGLGLSHNAWRG >P11113; 22 SPHERULIN 4 PRECURSOR. MNIKIVVLVIFAILLGSALAWHGSKHHNPTKAPTEAPHRGGGGGGGHNTPAPTQPPRQNT PAPTFQALNVWFFFWLLLLARAPLTYVHITATSSEPIKLLVPLYVYPGAAWDSVANAAKT GVKIIAIINPNSGPASSGPDSSYTTYMNKLTAAGVDMVGYVHTSYGARAVGDVNADIDTY ASKYPGLKGIFLDEASASASEISYYTNVYNHIKSKSGYVNSILNPGTQPDQGYLAISSNI VIFEDAGSNLKNNYASWVKCAPSASQKSGYKYKFSGIAHSTSSGSMSGIINTMVSVLAMG LVYVTDGAAGCCTYNTLTSYLSQEASAVHALN >P23327; 28 SARCOPLASMIC RETICULUM HISTIDINE-RICH CALCIUM-BINDING PR MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLSEEASAELRHH LHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVSKEYGHLLPGHRSQDHKVGDEGVSG EEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRSHSHQDEDEDEVVSSEHHHHILRH GHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRH QGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSH EEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTE RWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHH RVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKD DSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDK EEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGA SSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQ FCYLCPLVCETVCAPGSYVDYFSSSLYQALADMLETPEP >P13130; 18 SPORULATION-SPECIFIC WALL MATURATION PROTEIN PRECURSOR. MKFTSVLAFFLATLTASATPLYKRQNVTSGGGTVPVIITGGPAVSGSQSNVTTTTLFNST STLNITQLYQIATQVNQTLQSESSSGIIIVTNWRSIETLSFFCSIVFNTSKTIVITENFL WGVPILSSSDAEGRGTLVAGRDKVVYSGVFPPYTVPVGVLSGQKNVQWFFDACEPTLIAS NSTIRTQYSNFTSAQISSNASSGTNTSSSSSSPLVPIIYEEGYSQSLIQSLSSSIQGLVV VSSGTSHNSTVASWTSVDFPVVYASDGSSGHDGSGIGFISNTSIPQGAISAGYLSPIQAQ TLLSIAIHNQVTSSSELQQIFPVSQQ >P09179; 15 SEX-SPECIFIC STORAGE-PROTEIN 1 PRECURSOR (METHIONINE-RIC MRVLVLLACLAAASASAISGGYGTMVFTKEPMVNLDMKMKELCIMKLLDHILQPTMFEDI KEIAKEYNIEKSCDKYMNVDVVKQFMEMYKMGMLPRGETFVHTNELQMEEAVKVFRVLYY AKDFDVFMRTACWMRERINGGMFVYAFTAACFHRTDCKGLYLPAPYEIYPYFFVDSHVIS KAFMMKMTKAAKDPVLWKYYGITVTDDNLVVIDWRKGVRRSLSQNDVMSYFMEDVDLNTY MYYLHMNYPFWMTDDAYGINKERRGEIMMYANQQLLARMRLERLSHKMCDVKPMMWNEPL ETGYWPKIRLPSGDEMPVRQNNMVVATKDNLKMKQMMDDVEMMIREGILTGKIERRDGTV ISLKKSEDIENLARLVLGGLEIVGDDAKVIHLTNLMKKMLSYGQYNMDKYTYVPTSLDMY TTCLRDPVFWMIMKRVCNIFTVFKNMLPKYTREQFSFPGVKVEKITTDELVTFVDEYDMD ISNAMYLDATEMQNKTSDMTFMARMRRLNHHPFQVSIDVMSDKTVDAVVRIFLGPKYDCM GRLMSVNDKRLDMFELDSFMYKLVNGKNTIVRSSMDMQGFIPEYLSTRRVMESEMMPSGD GQTMVKDWWCKSRNGFPQRLMLPLGTIGGLEMQMYVIVSPVRTGMLLPTLDMTMMKDRCA CRWSSCISTMPLGYPFDRPIDMASFFTSNMKFADVMIYRKDLGMSNTSKTVDTSEMVMMK DDLTYLDSDMLVKRTYKDVMMMSSMMN >P23438; 17 TRANSLOCON-ASSOCIATED PROTEIN, BETA SUBUNIT PRECURSOR (T MRLLASVLLALFAVSHAEEGARLLASKSLLNRYAVEGRDLTLQYNIYNVGSSAALDVELS DDSFPPEDFGIVSGMLNVKWDRIAPASNVSHTVVLRPLKAGYFNFTSATVTYLAQEDGPV VIGFTSAPGQGGILAQREFDRRFSPHFLDWAAFGVMTLPSIGIPLLLWYSSKRKYDTPKS KKN >P22006; 22 SEMINAL VESICLE SECRETORY PROTEIN II PRECURSOR (SVS II). MKSSVFILSLFLLLERQAAVVGQYGGTKGHFQSSSSGFMLGQKGHLNFGLKGGSEEAAEE SIFMQSQHQMFGQDGGDMAQTSVSQEHTGVKGAAICRKGQVSQLKSQESQIKSFRQVKSS GQLKSGGSQLKSFGQVKSSESQLKSFGQVKASGSQLKSFGQVKASGSQLKSYGQMKSSGS QVKSFGQMKSSGSQVKSFGQMKASESQIKSFGQRKSQGGQLQSYGQMKSYGQTKSLESQA KSFGQVKSQSGQMKSSYGQRKSYGEETQLKSFDQDAQLKSYGQQKSQKQSSFSQVKSQSA QLKSFGQQKSLKGFSQQTQQKGFAMDEDLSQVRKQFDDDDLSVQQKSTQQMKTEEDLSQF GQQRQFGQERSQSYKGYLAQYRKKLQEQQQQKNFNQDNFFTKGGAGLYQAQLKG >P14213; 23 TACHYPLESIN I PRECURSOR. MKKLVIALCLMMVLAVMVEEAEAKWCFRVCYRGICYRRCRGKRNEVRQYRDRGYDVRAIP EETFFTRQDEDEDDDEE >P20062; 18 TRANSCOBALAMIN II PRECURSOR. MRHLGAFLFLLGVLGALTEMCEIPEMDSHLVEKLGQHLLPWMDRLSLEHLNPSIYVGLRL SSLQAGTKEDLYLHSLKLGYQQCLLGSAFSEDDGDCQGKPSMGQLALYLLALRANCEFVR GHKGDRLVSQLKWFLEDEKRAIGHDHKGHPHTSYYQYGLGILALCLHQKRVHDSVVDKLL YAVEPFHQGHHSVDTAAMAGLAFTCLKRSNFNPGRRQRITMAIRTVREEILKAQTPEGHF GNVYSTPLALQFLMTSPMPGAELGTACLKARVALLASLQDGAFQNALMISQLLPVLNHKT YIDLIFPDCLAPRVMLEPAAETIPQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLK KAHELGGFTYETQASSSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETI ELRLVSW >P10039; 22 TENASCIN PRECURSOR (TN) (HEXABRACHION) (CYTOTACTIN) (NEU MGLPSQVLACAILGLLYQHASGGLIKRIIRQKRETGLNVTLPEDNQPVVFNHVYNIKLPV GSLCSVDLDTASGDADLKAEIEPVKNYEEHTVNEGNQIVFTHRINIPRRACGCAAAPDIK DLLSRLEELEGLVSSLREQCASGAGCCPNSQTAEGRLDTAPYCSGHGNYSTEICGCVCEP GWKGPNCSEPACPRNCLNRGLCVRGKCICEEGFTGEDCSQAACPSDCNDQGKCVDGVCVC FEGYTGPDCGEELCPHGCGIHGRCVGGRCVCHEGFTGEDCNEPLCPNNCHNRGRCVDNEC VCDEGYTGEDCGELICPNDCFDRGRCINGTCFCEEGYTGEDCGELTCPNNCNGNGRCENG LCVCHEGFVGDDCSQKRCPKDCNNRGHCVDGRCVCHEGYLGEDCGELRCPNDCHNRGRCI NGQCVCDEGFIGEDCGELRCPNDCHNRGRCVNGQCECHEGFIGEDCGELRCPNDCNSHGR CVNGQCVCDEGYTGEDCGELRCPNDCHNRGRCVEGRCVCDNGFMGEDCGELSCPNDCHQH GRCVDGRCVCHEGFTGEDCRERSCPNDCNNVGRCVEGRCVCEEGYMGIDCSDVSPPTELT VTNVTDKTVNLEWKHENLVNEYLVTYVPTSSGGLDLQFTVPGNQTSATIHELEPGVEYFI RVFAILKNKKSIPVSARVATYLPAPEGLKFKSVRETSVQVEWDPLSISFDGWELVFRNMQ KKDDNGDITSSLKRPETSYMQPGLAPGQQYNVSLHIVKNNTRGPGLSRVITTKLDAPSQI EAKDVTDTTALITWSKPLAEIEGIELTYGPKDVPGDRTTIDLSEDENQYSIGNLRPHTEY EVTLISRRGDMESDPAKEVFVTDLDAPRNLKRVSQTDNSITLEWKNSHANIDNYRIKFAP ISGGDHTELTVPKGNQATTRATLTGLRPGTEYGIGVTAVRQDRESAPATINAGTDLDNPK DLEVSDPTETTLSLRWRRPVAKFDRYRLTYVSPSGKKNEMEIPVDSTSFILRGLDAGTEY TISLVAEKGRHKSKPTTIKGSTEEEPELGNLSVSETGWDGFQLTWTAADGAYENFVIQVQ QSDNPEETWNITVPGGQHSVNVTGLKANTPYNVTLYGVIRGYRTKPLYVETTTGAHPEVG ELTVSDITPESFNLSWTTTNGDFDAFTIEIIDSNRLLEPMEFNISGNSRTAHISGLSPST DFIVYLYGISHGFRTQAISAAATTEAEPEVDNLLVSDATPDGFRLSWTADDGVFDSFVLK IRDTKRKSDPLELIVPGHERTHDITGLKEGTEYEIELYGVSSGRRSQPINSVATTVVGSP KGISFSDITENSATVSWTPPRSRVDSYRVSYVPITGGTPNVVTVDGSKTRTKLVKLVPGV DYNVNIISVKGFEESEPISGILKTALDSPSGLVVMNITDSEALATWQPAIAAVDNYIVSY SSEDEPEVTQMVSGNTVEYDLNGLRPATEYTLRVHAVKDAQKSETLSTQFTTGLDAPKDL SATEVQSETAVITWRPPRAPVTDYLLTYESIDGRVKEVILDPETTSYTLTELSPSTQYTV KLQALSRSMRSKMIQTVFTTTGLLYPYPKDCSQALLNGEVTSGLYTIYLNGDRTQPLQVF CDMAEDGGGWIVFLRRQNGKEDFYRNWKNYVAGFGDPKDEFWIGLENLHKISSQGQYELR VDLRDRGETAYAVYDKFSVGDAKTRYRLRVDGYSGTAGDSMTYHNGRSFSTFDKDNDSAI TNCALSYKGAFWYKNCHRVNLMGRYGDNNHSQGVNWFHWKGHEYSIQFAEMKLRPSSFRN LEGRRKRA >P24821; 22 TENASCIN PRECURSOR (TN) (HEXABRACHION) (CYTOTACTIN) (NEU MGAMTQLLAGVFLAFLALATEGGVLKKVIRHKRQSGVNATLPEENQPVVFNHVYNIKLPV GSQCSVDLESASGEKDLAPPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVK ELLSRLEELENLVSSLREQCTAGAGCCLQPATGRLDTRPFCSGRGNFSTEGCGCVCEPGW KGPNCSEPECPGNCHLRGRCIDGQCICDDGFTGEDCSQLACPSDCNDQGKCVNGVCICFE GYAGADCSREICPVPCSEEHGTCVDGLCVCHDGFAGDDCNKPLCLNNCYNRGRCVENECV CDEGFTGEDCSELICPNDCFDRGRCINGTCYCEEGFTGEDCGKPTCPHACHTQGRCEEGQ CVCDEGFAGLDCSEKRCPADCHNRGRCVDGRCECDDGFTGADCGELKCPNGCSGHGRCVN GQCVCDEGYTGEDCSQLRCPNDCHSRGRCVEGKCVCEQGFKGYDCSDMSCPNDCHQHGRC VNGMCVCDDGYTGEDCRDRQCPRDCSNRGLCVDGQCVCEDGFTGPDCAELSCPNDCHGQG RCVNGQCVCHEGFMGKDCKEQRCPSDCHGQGRCVDGQCICHEGFTGLDCGQHSCPSDCNN LGQCVSGRCICNEGYSGEDCSEVSPPKDLVVTEVTEETVNLAWDNEMRVTEYLVVYTPTH EGGLEMQFRVPGDQTSTIIQELEPGVEYFIRVFAILENKKSIPVSARVATYLPAPEGLKF KSIKETSVEVEWDPLDIAFETWEIIFRNMNKEDEGEITKSLRRPETSYRQTGLAPGQEYE ISLHIVKNNTRGPGLKRVTTTRLDAPSQIEVKDVTDTTALITWFKPLAEIDGIELTYGIK DVPGDRTTIDLTEDENQYSIGNLKPDTEYEVSLISRRGDMSSNPAKETFTTGLDAPRNLR RVSQTDNSITLEWRNGKAAIDSYRIKYAPISGGDHAEVDVPKSQQATTKTTLTGLRPGTE YGIGVSAVKEDKESNPATINAATELDTPKDLQVSETAETSLTLLWKTPLAKFDRYRLNYS LPTGQWVGVQLPRNTTSYVLRGLEPGQEYNVLLTAEKGRHKSKPARVKASTEQAPELENL TVTEVGWDGLRLNWTAADQAYEHFIIQVQEANKVEAARNLTVPGSLRAVDIPGLKAATPY TVSIYGVIQGYRTPVLSAEASTGETPNLGEVVVAEVGWDALKLNWTAPEGAYEYFFIQVQ EADTVEAAQNLTVPGGLRSTDLPGLKAATHYTITIRGVTQDFSTTPLSVEVLTEEVPDMG NLTVTEVSWDALRLNWTTPDGTYDQFTIQVQEADQVEEAHNLTVPGSLRSMEIPGLRAGT PYTVTLHGEVRGHSTRPLAVEVVTEDLPQLGDLAVSEVGWDGLRLNWTAADNAYEHFVIQ VQEVNKVEAAQNLTLPGSLRAVDIPGLEAATPYRVSIYGVIRGYRTPVLSAEASTAKEPE IGNLNVSDITPESFNLSWMATDGIFETFTIEIIDSNRLLETVEYNISGAERTAHISGLPP STDFIVYLSGLAPSIRTKTISATATTEALPLLENLTISDINPYGFTVSWMASENAFDSFL VTVVDSGKLLDPQEFTLSGTQRKLELRGLITGIGYEVMVSGFTQGHQTKPLRAEIVTEAE PEVDNLLVSDATPDGFRLSWTADEGVFDNFVLKIRDTKKQSEPLEITLLAPERTRDLTGL REATEYEIELYGISKGRRSQTVSAIATTAMGSPKEVIFSDITENSATVSWRAPTAQVESF RITYVPITGGTPSMVTVDGTKTQTRLVKLIPGVEYLVSIIAMKGFEESEPVSGSFTTALD GPSGLVTANITDSEALARWQPAIATVDSYVISYTGEKVPEITRTVSGNTVEYALTDLEPA TEYTLRIFAEKGPQKSSTITAKFTTDLDSPRDLTATEVQSETALLTWRPPRASVTGYLLV YESVDGTVKEVIVGPDTTSYSLADLSPSTHYTAKIQALNGPLRSNMIQTIFTTIGLLYPF PKDCSQAMLNGDTTSGLYTIYLNGDKAQALEVFCDMTSDGGGWIVFLRRKNGRENFYQNW KAYAAGFGDRREEFWLGLDNLNKITAQGQYELRVDLRDHGETAFAVYDKFSVGDAKTRYK LKVEGYSGTAGDSMAYHNGRSFSTFDKDTDSAITNCALSYKGAFWYRNCHRVNLMGRYGD NNHSQGVNWFHWKGHEHSIQFAEMKLRPSNFRNLEGRRKRA >P15242; 17 TESTIN 1/2 PRECURSOR (CMB-22/CMB-23). MIAVLFLAILCLEVDSTAPTPDPSLDVEWNEWRTKHGKTYNMNEERLKRAVWEKNFKMIE LHNWEYLEGRHDFTMAMNAFGDLTNIEFVKMMTGFQRQKIKKTHIFQDHQFLYVPKRVDW RQLGYVTPVKNQGHCASSWAFSATGSLEGQMFRKTERLIPLSEQNLLDCMGSNVTHGCSG GFMQYAFQYVKDNGGLATEESYPYRGQGRECRYHAENSAANVRDFVQIPGSEEALMKAVA KVGPISVAVDASHGSFQFYGSGIYYEPQCKRVHLNHAVLVVGYGFEGEESDGNSFWLVKN SWGEEWGMKGYMKLAKDWSNHCGIATYSTYPIV >P48307; 22 TISSUE FACTOR PATHWAY INHIBITOR 2 PRECURSOR (TFPI-2) (PL MDPARPLGLSILLLFLTEAALGDAAQEPTGNNAEICLLPLDYGPCRALLLRYYYDRYTQS CRQFLYGGCEGNANNFYTWEACDDACWRIEKVPKVCRLQVSVDDQCEGSTEKYFFNLSSM TCEKFFSGGCHRNRIENRFPDEATCMGFCAPKKIPSFCYSPKDEGLCSANVTRYYFNPRY RTCDAFTYTGCGGNDNNFVSREDCKRACAKALKKKKKMPKLRFASRIRKIRKKQF >P30931; 35 TISSUE FACTOR PRECURSOR (TF) (COAGULATION FACTOR III). MATPNGPRVPCPQAAVARALLFGLVLIQGAGVAGTTDVVVAYNITWKSTNFKTILEWEPK PINHVYTVQISPRLGNWKNKCFYTTNTECDVTDEIVKNVRETYLARVLSYPADTSSSTVE PPFTNSPEFTPYLETNLGQPTIQSFEQVGTKLNVTVQDARTLVRANSAFLSLRDVFGKDL NYTLYYWKASSTGKKKATTNTNGFLIDVDKGENYCFHVQAVILSRRVNQKSPESPIKCTS HEKVLSTELFFIIGTVMLVIIIFIVVLSVSLHKCRKVRAERSGKENTPLNAA >P24055; 32 TISSUE FACTOR PRECURSOR (TF) (COAGULATION FACTOR III). MAPPTRLQVPRPGTAVPYTVLLGWLLAQVARAADTTGRAYNLTWKSTNFKTILEWEPKSI DHVYTVQISTRLENWKSKCFLTAETECDLTDEVVKDVGQTYMARVLSYPARNGNTTGFPE EPPFRNSPEFTPYLDTNLGQPTIQSFEQVGTKLNVTVQDARTLVRRNGTFLSLRAVFGKD LNYTLYYWRASSTGKKTATTNTNEFLIDVDKGENYCFSVQAVIPSRKRKQRSPESLTECT SREQGRAREMFFIIGAVVVVALLIIVLSVTVYKCRKARAGPSGKESSPLNIA >Q03167; 16 TGF-BETA RECEPTOR TYPE III PRECURSOR (TGFR-3) (BETAGLYCA MTSHYVIAIFALMSFCLATAGPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGL PQEVHVLNLALRQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLAT GVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIAR NIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPN SNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIG FGKESERSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVAIVFHLRLENNEEM GDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLP RPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTL LDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSGWPDGYED LESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDL FLVPSQGVFSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENICPK DESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPK CVPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMKEPNPISPPIFHGL DTLTVMGIAFAAFVIGALLTGALWYIYSHTGETAGRQQVPTSPPASENSSAAHSIGSTQS TPCSSSSTA >P05543; 20 THYROXINE-BINDING GLOBULIN PRECURSOR (T4-BINDING GLOBULI MSPFLYLVLLVLGLHATIHCASPEGKVTACHSSQPNATLYKMSSINADFAFNLYRRFTVE TPDKNIFFSPVSISAALVMLSFGACCSTQTEIVETLGFNLTDTPMVEIQHGFQHLICSLN FPKKELELQIGNALFIGKHLKPLAKFLNDVKTLYETEVFSTDFSNISAAKQEINSHVEMQ TKGKVVGLIQDLKPNTIMVLVNYIHFKAQWANPFDPSKTEDSSSFLIDKTTTVQVPMMHQ MEQYYHLVDMELNCTVLQMDYSKNALALFVLPKEGQMESVEAAMSSKTLKKWNRLLQKGW VDLFVPKFSISATYDLGATLLKMGIQHAYSENADFSGLTEDNGLKLSNAAHKAVLHIGEK GTEAAAVPEVELSDQPENTFLHPIIQIDRSFMLLILERSTRSILFLGKVVNPTEA >P01831; 19 THY-1 MEMBRANE GLYCOPROTEIN PRECURSOR (THY-1 ANTIGEN) (C MNPAISVALLLSVLQVSRGQKVTSLTACLVNQNLRLDCRHENNTKDNSIQHEFSLTREKR KHVLSGTLGIPEHTYRSRVTLSNQPYIKVLTLANFTTKDEGDYFCELQVSGANPMSSNKS ISVYRDKLVKCGGISLLVQNTSWMLLLLLSLSLLQALDFISL >P01266; 19 THYROGLOBULIN PRECURSOR. MALVLEIFTLLASICWVSANIFEYQVDAQPLRPCELQRETAFLKQADYVPQCAEDGSFQT VQCQNDGRSCWCVGANGSEVLGSRQPGRPVACLSFCQLQKQQILLSGYINSTDTSYLPQC QDSGDYAPVQCDVQQVQCWCVDAEGMEVYGTRQLGRPKRCPRSCEIRNRRLLHGVGDKSP PQCSAEGEFMPVQCKFVNTTDMMIFDLVHSYNRFPDAFVTFSSFQRRFPEVSGYCHCADS QGRELAETGLELLLDEIYDTIFAGLDLPSTFTETTLYRILQRRFLAVQSVISGRFRCPTK CEVERFTATSFGHPYVPSCRRNGDYQAVQCQTEGPCWCVDAQGKEMHGTRQQGEPPSCAE GQSCASERQQALSRLYFGTSGYFSQHDLFSSPEKRWASPRVARFATSCPPTIKELFVDSG LLRPMVEGQSQQFSVSENLLKEAIRAIFPSRGLARLALQFTTNPKRLQQNLFGGKFLVNV GQFNLSGALGTRGTFNFSQFFQQLGLASFLNGGRQEDLAKPLSVGLDSNSSTGTPEAAKK DGTMNKPTVGSFGFEINLQENQNALKFLASLLELPEFLLFLQHAISVPEDVARDLGDVME TVLSSQTCEQTPERLFVPSCTTEGSYEDVQCFSGECWCVNSWGKELPGSRVRGGQPRCPT DCEKQRARMQSLMGSQPAGSTLFVPACTSEGHFLPVQCFNSECYCVDAEGQAIPGTRSAI GKPKKCPTPCQLQSEQAFLRTVQALLSNSSMLPTLSDTYIPQCSTDGQWRQVQCNGPPEQ VFELYQRWEAQNKGQDLTPAKLLVKIMSYREAASGNFSLFIQSLYEAGQQDVFPVLSQYP SLQDVPLAALEGKRPQPRENILLEPYLFWQILNGQLSQYPGSYSDFSTPLAHFDLRNCWC VDEAGQELEGMRSEPSKLPTCPGSCEEAKLRVLQFIRETEEIVSASNSSRFPLGESFLVA KGIRLRNEDLGLPPLFPPREAFAEQFLRGSDYAIRLAAQSTLSFYQRRRFSPDDSAGASA LLRSGPYXPQCDAFGSWEPVQCHAGTGHCWCVDEKGGFIPGSLTARSLQIPQCPTTCEKS RTSGLLSSWKQARSQENPSPKDLFVPACLETGEYARLQASGAGTWCVDPASGEELRPGSS SSAQCPSLCNVLKSGVLSRRVSPGYVPACRAEDGGFSPVQCDQAQGSCWCVMDSGEEVPG TRVTGGQPACESPRCPLPFNASEVVGGTILCETISGPTGSAMQQCQLLCRQGSWSVFPPG PLICSLESGRWESQLPQPRACQRPQLWQTIQTQGHFQLQLPPGKMCSADYAGLLQTFQVF ILDELTARGFCQIQVKTFGTLVSIPVCNNSSVQVGCLTRERLGVNVTWKSRLEDIPVASL PDLHDIERALVGKDLLGRFTDLIQSGSFQLHLDSKTFPAETIRFLQGDHFGTSPRTWFGC SEGFYQVLTSEASQDGLGCVKCPEGSYSQDEECIPCPVGFYQEQAGSLACVPCPVGRTTI SAGAFSQTHCVTDCQRNEAGLQCDQNGQYRASQKDRGSGKAFCVDGEGRRLPWWETEAPL EDSQCLMMQKFEKVPESKVIFDANAPVAVRSKVPDSEFPVMQCLTDCTEDEACSFFTVST TEPEISCDFYAWTSDNVACMTSDQKRDALGNSKATSFGSLRCQVKVRSHGQDSPAVYLKK GQGSTTTLQKRFEPTGFQNMLSGLYNPIVFSASGANLTDAHLFCLLACDRDLCCDGFVLT QVQGGAIICGLLSSPSVLLCNVKDWMDPSEAWANATCPGVTYDQESHQVILRLGDQEFIK SLTPLEGTQDTFTNFQQVYLWKDSDMGSRPESMGCRKXTVPRPASPTEAGLTTELFSPVD LNQVIVNGNQSLSSQKHWLFKHLFSAQQANLWCLSRCVQEHSFCQLAEITESASLYFTCT LYPEAQVCDDIMESNAQGCRLILPQMPKALFRKKVILEDKVKNFYTRLPFQKLMGISIRN KVPMSEKSISNGFFECERRCDADPCCTGFGFLNVSQLKGGEVTCLTLNSLGIQMCSEENG GAWRILDCGSPDIEVHTYPFGWYQKPIAQNNAPSFCPLVVLPSLTEKVSLDSWQSLALSS VVVDPSIRHFDVAHVSTAATSNFSAVRDLCLSECSQHEACLITTLQTQPGAVRCMFYADT QSCTHSLQGQNCRLLLREEATHIYRKPGISLLSYEASVPSVPISTHGRLLGRSQAIQVGT SWKQVDQFLGVPYAAPPLAERRFQAPEPLNWTGSWDASKPRASCWQPGTRTSTSPGVSED CLYLNVFIPQNVAPNASVLVFFHNTMDREESEGWPAIDGSFLAAVGNLIVVTASYRVGVF GFLSSGSGEVSGNWGLLDQVAALTWVQTHIRGFGGDPRRVSLAADRGGADVASIHLLTAR ATNSQLFRRAVLMGGSALSPAAVISHERAQQQAIALAKEVSCPMSSSQEVVSCLRQKPAN VLNDAQTKLLAVSGPFHYWGPVIDGHFLREPPARALKRSLXVEVDLLIGSSQDDGLINRA KAVKQFEESQGRTSSKTAFYQALQNSLGGEDSDARVEAAATWYYSLEHSTDDYASFSRAL ENATRDYFIICPIIDMASAWAKRARGNVFMYHAPENYGHGSLELLADVQFALGLPFYPAY EGQFSLEEKSLSLKIMQYFSHFIRSGNPNYPYEFSRKVPTFATPWPDFVPRAGGENYKEF SELLPNRQGLKKADCSFWSKYISSLKTSADGAKGGQSAESEEEELTAGSGLREDLLSLQE PGSKTYSK >Q06805; 23 TYROSINE-PROTEIN KINASE RECEPTOR TIE-1 PRECURSOR (EC 2.7 MVWLEPPLLLPIFFLASHVGAAVDLTLLADLRLTEPQRFFLTCVSGEAGAGRGSDAWGPP LLLEKDDRIVRTPRPWQPPHIARNGSSRVTVRGFSQPSDLVGVFSCVGGGGTRVLYVHNS PGAHLLPDKVTHTVNKGDTAVLSARVRKEKQTDVIWKSNGSYFYTLDRHEAQDGQFLLQL PNVQPSSSGIYSATYLEASPLGSAFFRLIVRGCEAGRWGQDCTKECPGCLHGGVCHDQDG ECVCPPGFTGTRCEQACREGRFGQSCQEQCPGTSGCRGLTFCLPDPYGCSCGSGWRGSQC QEACAPGRFGADCHLQCQCQNGGTCDRFSGCVCPSGWHGMHCEKSDRIPQILDMVSELEF NLDTMPRINCAAAGNPFPVRGSMELRKPDGTVLLSTKAIVEPDRTTAEFEVPRLALGDSG LWECRVSTSGGQDSRRFRINVKVPPVPLTAPRLLAKQSRQLVVSPLVSFSGDGPIASVRL HYRPQDSTMAWSTIVVDPSENVTLMNLRPKTGYSVRVQLSRPGEGGEGAWGPPTLMTTDC PEPLLKPWLEGWHVEGPDRLRVSWSLPPVPGPLVGDGFLLRLWDGARGQERRENVSSPQA RTALLTGLTPGTYYQLDVRLYHCTLLGPASPAARVLLPPSGPPAPRHLHAQALSDSEIQL MWQRPEAAAGPISKYIVEVQVAGGSGDPLWMDVDRPEETSTIVRGLNASTRYLFRVRASV QGPGDWSNVVEQSTLGNGLQIEGPVQEIHAAEEGLDQQLVLAVVGSVSATCLTILAALLT LACIRKSCLHRRRTFTYQSGSGEETILQFSSGTLTLTRRPKPQPEPLNYPVLEWEDITFE DLIGEGNFGQVIRAMIKKDGLKMNAAIKMLKEYASENDHRDFAGELEVLCKLGHHPNIIN LLGACENRGYLYIAIEYAPYGNLLDFLRKSRVLETDPAFAREHGTASTLSSRQLLRFASD AANGMQYLSEKQFIHRDLAARNVLVGENLASKIADFGLSRGEEVYVKKTMGRLPVRWMAI ESLNYSVYTTKSDVWSFGVLLWEIVSLGGTPYCGMTCAELYEKLPQAYRMEQPRNCDDEV YELMRQCWRDRPYERPPFAQIALQLGRMLEARKAYVNMSLFENFTYAGIDATAEEA >Q06807; 18 ANGIOPOIETIN 1 RECEPTOR PRECURSOR (EC 2.7.1.112) (TYROSI MDSLAGLVLCGVSLLLSATVDGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRD FEALMNQHQDPLEVTQDATREWAKKVVWKREKASKINGAYFCEGRVRGQAIRIRTMKMRQ QASFLPATLTMTVDRGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVQVPH AQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNRICTACMNNGICHEDTGEC ICPPGFMGRTCEKACEPHTFGRTCKERCSEPEGCKSFVFCLPDPYGCSCATGWKGLQCNE ACQPGYYGPDCKLRCSCTNGEKCDRFQGCLCSPGRQGLQCEKEGVPRMTPKIEDLPDHIE VNSGKFNPICKASGWPRPANEEMTLVKPDGTVLRPKDFNHTGHLSVATFTINRILPPDSG VWVCSVNTVSGMVEKPFNISVKVLPKPLNAPKVIDTGHNFAVINISSEPYFGDGPIKSKK LLYKPVNHYEAWRHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTAS IGLPPPRGLSLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQMNSDQQNIKVPGNLTS VLLNNLHPREQYIVRARVNTKAQGEWSEDLIAWTLSDIVPPQPENIKIFNITDSSAVISW TILDGYSISAIIIRYKVQGKNEDQHIDVKIKNATITQYQLKGLEPQTVYQVDIFAENNIG SSNPTSSHELTTLSESQAPADLGGRKMLLIAILGSAGMTCLTVLLAFLIMLQLKRANVQR RMAQAFQNVREEPAVQFNSGTLALNRKAKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVL KARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLY LAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQ FIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNS DVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKP YERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA >P01033; 23 METALLOPROTEINASE INHIBITOR 1 PRECURSOR (TIMP-1) (ERYTHR MAPFEPLASGILLLLWLIAPSRACTCVPPHPQTAFCNSDLVIRAKFVGTPEVNQTTLYQR YEIKMTKMYKGFQALGDAADIRFVYTPAMESVCGYFHRSHNRSEEFLIAGKLQDGLLHIT TCSFVAPWNSLSLAQRRGFTKTYTVGCEECTVFPCLSIPCKLQSGTHCLWTDQLLQGSEK GFQSRHLACLPREPGLCTWQSLRSQIA >P16368; 26 METALLOPROTEINASE INHIBITOR 2 PRECURSOR (TIMP-2) (TISSUE MGAAARSLPLAFCLLLLGTLLPRADACSCSPVHPQQAFCNADIVIRAKAVNKKEVDSGND IYGNPIKRIQYEIKQIKMFKGPDQDIEFIYTAPAAAVCGVSLDIGGKKEYLIAGKAEGNG NMHITLCDFIVPWDTLSATQKKSLNHRYQMGCECKITRCPMIPCYISSPDECLWMDWVTE KNINGHQAKFFACIKRSDGSCAWYRGAAPPKQEFLDIEDP >P27654; 19 TEMPERATURE-SHOCK INDUCIBLE PROTEIN 1 PRECURSOR (EC 3.1. MSVSKIAFVLSAIASLAVADTSAAETAELQAIIGDINSHLSDYLGLETGNSGFQIPSDVL SVYQQVMTYTDDAYTTLFSELDFDAITKTIVKLPWYTTRLSSEIAAALASVSPASSEAAS SSEAASSSKAASSSEATSSAAPSSSAAPSSSAAPSSSAESSSKAVSSSVAPTTSSVSTST VETASNAGQRVNAGAASFGAVVAGAAALLL >P09225; 33 LYMPHOTOXIN-ALPHA PRECURSOR (LT-ALPHA) (TNF-BETA). MTLLGRLHLLRVLGTPPVFLLGLLLALPLGAQGLSGVRFSAARTAHPLPQKHLTHGILKP AAHLVGYPSKQNSLLWRASTDRAFLRHGFSLSNNSLLIPTSGLYFVYSQVVFSGESCSPR AIPTPIYLAHEVQLFSSQYPFHVPLLSAQKSVYPGLQGPWVRSMYQGAVFLLSKGDQLST HTDGISHLHFSPSSVFFGAFAL >P20333; 22 TUMOR NECROSIS FACTOR RECEPTOR 2 PRECURSOR (TUMOR NECROS MAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPG QHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTC RPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICR PHQICNVVAIPGNASRDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTS FLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKV PHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGE ARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQ VPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS >P19972; 18 SALT-MEDIATED KILLER TOXIN 1 PRECURSOR (SMK TOXIN). MRKETLIGLAFITANVIAWSLRWRMQKSTTIAAIAGCSGAATFGGLAGGIVGCIAAGILA ILQGFEVNWHNGGGGDRSNPVKRSSDLFSIVNHNGEKVDSYAHLVPGKVGKVIIDNIELS AIRYANNHTSLGYHFTLDGSGPAARGEATTIWGVGADEAIDKGTPSKNDLQNMSADLAKN GFKGHQGVACSTVKDGNKDVYMIKFLLAGGSNDPGGSPCSDD >P32358; 15 TREHALASE PRECURSOR (EC 3.2.1.28) (ALPHA,ALPHA-TREHALASE MRLFLLLVGLTTVIADDLPPTCIRPVYCNSTLLHYVQMARLYPDSKTFVDFQMRKDENAT LSAFQELLDRTNHNPTKEDLQEFVVDFFDETSELEEWKPDDHKENPPFLAKIRDQGFREF AKALNDIWPTLARRVKPSVLEKPEQSSLVPMTHGFIVPGGRFKEIYYWDAYWIIEGLLIT DMTETAKGMIENLIELLYKFGHIPNGSRWYYQERSQPPLLAAMIKLYYEKTKDIEFIRKY ISALEKELEYWLDTHLIAFNKDDRVYTLLRYYIPSAGPRPESYYEDYELAQKLDKNTDPN DIYADLKSAAESGWDFSTRWFISESGDNSGNLTNLNTKNVIPVDLNAIFAGALQITANFQ AILKNPRRAAHWGYMAEQWRSSIEQALWDEEDGVWHDYDILNNKPRRYFYTSNLAPLWMN AVEKPFLAKHGARVLEYLHESQALEYPGGVPVSLVNSGEQWDFPNAWPPEVSIVVTAIQN IGSEESSKLAKELAQVWVRACKSGFTEKKQMFEKYDALNAGKYGGGGEYTVQDGFGWSNG VVLEFLDRYGAVLTSVDSVDASANNGQSNEESETDSKEK >P80426; 18 SEROTRANSFERRIN I PRECURSOR (SIDEROPHILIN I) (STF I). MKLLLLSALLGCLATAYAAPAEGIVKWCVKSEQELRKCHDLAAKVAEFSCVRKDGSFECI QAIKGGEADAITLDGGDIYTAGLTNYGLQPIIAEDYGEDSDTCYYAVAVAKKGTAFGFKT LRGKKSCHTGLGKSAGWNIPIGTLVTESQIRWAGIEDRPVESAVSDFFNASCAPGATMGS KLCQLCKGDCSRSHKEPYYDYAGAFQCLKDGAGDVAFIKPLAVPAAEKASYELLCKDGTR ASIDSYKTCHLARVPAHAVVSRKDPELANRIYNKLVAVKDFNLFSSDGYAAKNLMFKDSA QKLVQLPTTTDSFLYLGAEYMSTIRSLKKSQATGASSRAIKWCAVGHAEKGKCDTWTINS FADGESKISCQDAPTVEECIKKIMRKEADAIAVDGGEVYTAGKCGLVPVMVEQYDADLCS APGEASSYYAVAVAKKGSGLTWKTLKGKRSCHTGLGRTAGWNIPMGLIHQETNDCDFTKY FSKGCAPGSEVGSPFCAQCKGSGKAVGDEYRCKARSEEQYYGYTGAFRCLVEDAGDVAFI KHTIVPESTDGNGPDWAKDLKSSDFELLCQDGTTQPVTKFSECHLAKVPAHAVITRPETR GDVVSILLELQAKFGSSGSDSSFRMFQSSVEKNLLFKDSTKCLQEIPKGTKYQDFLGKEY MIAMQSLRKCSDSTSDLEKACTFHSCQQKE >P02789; 19 OVOTRANSFERRIN PRECURSOR (CONALBUMIN) (ALLERGEN GAL D 3) MKLILCTVLSLGIAAVCFAAPPKSVIRWCTISSPEEKKCNNLRDLTQQERISLTCVQKAT YLDCIKAIANNEADAISLDGGQAFEAGLAPYKLKPIAAEVYEHTEGSTTSYYAVAVVKKG TEFTVNDLQGKTSCHTGLGRSAGWNIPIGTLLHRGAIEWEGIESGSVEQAVAKFFSASCV PGATIEQKLCRQCKGDPKTKCARNAPYSGYSGAFHCLKDGKGDVAFVKHTTVNENAPDQK DEYELLCLDGSRQPVDNYKTCNWARVAAHAVVARDDNKVEDIWSFLSKAQSDFGVDTKSD FHLFGPPGKKDPVLKDLLFKDSAIMLKRVPSLMDSQLYLGFEYYSAIQSMRKDQLTPSPR ENRIQWCAVGKDEKSKCDRWSVVSNGDVECTVVDETKDCIIKIMKGEADAVALDGGLVYT AGVCGLVPVMAERYDDESQCSKTDERPASYFAVAVARKDSNVNWNNLKGKKSCHTAVGRT AGWVIPMGLIHNRTGTCNFDEYFSEGCAPGSPPNSRLCQLCQGSGGIPPEKCVASSHEKY FGYTGALRCLVEKGDVAFIQHSTVEENTGGKNKADWAKNLQMDDFELLCTDGRRANVMDY RECNLAEVPTHAVVVRPEKANKIRDLLERQEKRFGVNGSEKSKFMMFESQNKDLLFKDLT KCLFKVREGTTYKEFLGDKFYTVISSLKTCNPSDILQMCSFLEGK >P20233; 22 TRANSFERRIN PRECURSOR. MDFSLRVALCLSMLALCLAIQKEKQVRWCVKSNSELKKCKDLVDTCKNKEIKLSCVEKSN TDECSTAIQEDHADAICVDGGDVYKGSLQPYNLKPIMAENYGSHTETDTCYYAVAVVKKS SKFTFDELKDKKSCHTGIGKTAGWNIIIGLLLERKLLKWAGPDSETWRNAVSKFFKASCV PGAKEPKLSQLCAGIKEHKCSRSNNEPYYNYAGAFKCLQDDQGDVAFVKQSTVPEEFHKD YELLCPDNTRKSIKEYKNCNLAKVPAHAVLTRGRDDKSKDIIEFLQEAQKTQECKLFSSP VWGRDLIFKDSAVSLIPLPSSMDSFLFLGADYFQCIQALKEGVKEDDSAAQVKVRWCTQS KAEKTKCDDWTTISGGAIECTEASTAEECIVQILKGDADAVTLDGGYMYTAGLCGLVPVM GEYYDQDDLTPCQRSCSQAKGVYYAVAIVKKGTQVSWSNLRGVKTCHTAVGRTAGWNIPV GLITSETANCDFASYVGESCAPGSDVKSNLCALCIGDPEKLSEREKKCSPSASEAYYGYS GAFRCLVEKGQVGFAKHTTVFENTDGKNPAGWAKDLKSEDFELLCPDGSRAPVTDYKRCN LAEVPAHAVVTLPDKREQVAKIVVNQQSLYGRKGFQKDIFQMFQSTGGKDLLFKDSTQCL LEIPSKTTMQEFLGDKYHTAVTSLNKCSTSRLLAACTFHAA >Q16288; 31 NT-3 GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (TR MDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDDGNLFPLLEGQ DSGNSNGNANINITDISRNITSIHIENWRSLHTLNAVDMELYTGLQKLTIKNSGLRSIQP RAFAKNPHLRYINLSSNRLTTLSWQLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEA KLNSQNLYCINADGSQLPLFRMNISQCDLPEISVSHVNLTVREGDNAVITCNGSGSPLPD VDWIVTGLQSINTHQTNLNWTNVHAINLTLVNVTSEDNGFTLTCIAENVVGMSNASVALT VYYPPRVVSLEEPELRLEHCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISE GCLLFNKPTHYNNGNYTLIAKNPLGTANQTINGHFLKEPFPESTDNFILFDEVSPTPPIT VTHKPEEDTFGVSIAVGLAAFACVLLVVLFVMINKYGRRSKFGMKGPVAVISGEEDSASP LHHINHGITTPSSLDAGPDTVVIGMTRIPVIENPQYFRQGHNCHKPDTYVQHIKRRDIVL KRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHI VKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIA SQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRLFNPSGNDF CIWCEVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVI ECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG >P06871; 15 TRYPSINOGEN, CATIONIC PRECURSOR (EC 3.4.21.4). MKTFIFLALLGATVAFPIDDDDKIVGGYTCSRNSVPYQVSLNSGYHFCGGSLINSQWVVS AAHCYKSRIQVRLGEYNIAVSEGGEQFINAAKIIRHPRYNANTIDNDIMLIKLSSPATLN SRVSAIALPKSCPAAGTQCLISGWGNTQSIGQNYPDVLQCLKAPILSDSVCRNAYPGQIS SNMMCLGYMEGGKDSCQGDSGGPVVCNGELQGVVSWGAGCAQKGKPGVSPKVCKYVSWIQ QTIAAN >P07478; 15 TRYPSINOGEN II PRECURSOR (EC 3.4.21.4). MNLLLILTFVAAAVAAPFDDDDKIVGGYICEENSVPYQVSLNSGYHFCGGSLISEQWVVS AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVIN SRVSAISLPTAPPAAGTESLISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKIT NNMFCVGFLEGGKDSCQGDSGGPVVSNGELQGIVSWGYGCAQKNRPGVYTKVYNYVDWIK DTIAANS >P19236; 19 MASTOCYTOMA PROTEASE PRECURSOR (EC 3.4.21.-). MAPLIRMLDLLGTLSPKVGIVGGCKVPARRYPWQVSLRFHGMGSGQWQHICGGSLIHPQW VLTAAHCVELEGLEAATLRVQVGQLRLYDHDQLCNVTEIIRHPNFNMSWYGWDTADIALL KLEAPLTLSEDVNLVSLPSPSLIVPPGMLCWVTGWGDIADHTPLPPPYHLQEVEVPIVGN RECNCHYQTILEQDDEVIKQDMLCAGSEGHDSCQMDSGGPLVCRWKCTWIQVGVVSWGYG CGYNLPGVYARVTSYVSWIHQHIPLSPGP >P15944; 30 TRYPTASE PRECURSOR (EC 3.4.21.59). MPSPLVLALALLGSLVPVSPAPGQALQRVGIVGGREAPGSKWPWQVSLRLKGQYWRHICG GSLIHPQWVLTAAHCVGPNVVCPEEIRVQLREQHLYYQDHLLPVNRIVMHPNYYTPENGA DIALLELEDPVNVSAHVQPVTLPPALQTFPTGTPCWVTGWGDVHSGTPLPPPFPLKQVKV PIVENSMCDVQYHLGLSTGDGVRIVREDMLCAGNSKSDSCQGDSGGPLVCRVRGVWLQAG VVSWGEGCAQPNRPGIYTRVAYYLDWIHQYVPKEP >P21849; 17 MAJOR SURFACE-LABELED TROPHOZOITE ANTIGEN PRECURSOR. MFGRFLLAIVILQLARTACTQEADDGKCKTCGVTIGQDTWCSECNGANYAPVNGQCVDVN AEGPSKTLCPQHSAGKCTQCGGNSFMYKDGCYSSGEGLPGHSLCLSSDGDGVCTEAAPGY FAPVGAANTEQSVIACGDTTGVTIAAGGNTYKGIADCAECSAPDATAGAEAGKVATCTKC GVSKYLKDNVCVDKAQCNSGSTNKFVAVDDSENGNKCVSCSDNLNGGVANCDTCSYDEQS KKIKCTKCTDNNYLKTTSEGTSCVQKDQCKDGFFPKDDSSAGNKCLPCNDSTDGIANCAT CALVSGRSGAALVTCSACTDGYKPSADKTTCEAVSNCKTPGCKACSNEGKENEVCTDCDG STYLTPTSQCIDSCAKIGNYYGATEGAKKLCKECTAANCKTCDDQGQCQACNDGFYKNGD ACSPCHESCKTCSAGTASDCTECPTGKALRYGDDGTKGTCGEGCTTGTGAGACKTCGLTI DGASYCSECATTTEYPQNGVCAPKASRATPTCNDSPIQNGVCGTCADNYFKMNGGCYETV KYPGKTVCISAPNGGTCQKAADGYKLDSGTLTVCSEGCKECASSTDCTTCLDGYVKSASA CTKCDASCETCNGAATTCKACATGYYKTASGEGACTSCESDSNGVTGIKGCLNCAPPPNN KGSVLCYLIKDSGSTNKSGLSTGAIAGISVAVIVVVGGLIGFLCWWFLCRGKA >P01222; 20 THYROTROPIN BETA CHAIN PRECURSOR (THYROID-STIMULATING HO MTALFLMSMLFGLACGQAMSFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKL FLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAI KTNYCTKPQKSYLVGFSV >P07996; 18 THROMBOSPONDIN 1 PRECURSOR. MGLAWGLGVLFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFR IEDANLIPPVPDDKFQDLVDAVRTEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVV SNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELD VPIQSVFTRDLASIARLRIAKGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLL TLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRK VTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKKVSCPIMPCSN ATVPDGECCPRCWPSDSADDGWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQT RTCHIQECDKRFKQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARE TKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQI CNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACF NHNGEHRCENTDPGYNCLPCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKN AKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPN LPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPFHYNPAQYDYDRDDVGDRCDNCPYN HNPDQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRDTDMDGVGDQCDNCPLEH NPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDN DGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHDSVPDIDDICPENVDISETDFRRF QMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDD DYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNAL WHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPKTGFIRVVMYEGKKIMADSGPIYD KTYAGGRLGLFVFSQEMVFFSDLKYECRDP >P02766; 20 TRANSTHYRETIN PRECURSOR (PREALBUMIN) (TBPA) (TTR) (ATTR) MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDT WEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDS GPRRYTIAALLSPYSYSTTAVVTNPKE >P06322; 20 T-CELL RECEPTOR ALPHA CHAIN PRECURSOR V REGION (RL-5). MFSASCSVTVVVLLITVRRTNGASVTQTEGPVILSEGSSLTLNCNYQTSYSGFLFWYVQY LHEGPQLLLQSTTENQRMEHQGFHATFVKKDSSFHLHKSSLQLSDSAVYYCALRRGASNK LTLGTGTLLKVELN >P04437; 27 T-CELL RECEPTOR ALPHA CHAIN PRECURSOR V REGION (CTL-L17) MAMLLGASVLILWLQPDWVNSQQKNDDQQVKQNSPSLSVQEGRISILNCDYTNSMFDYFL WYKKYPAEGPTFLISISSIKDKNEDGRFTVFLNKSAKHLSLHIVPSQPGDSAVYFCAAKG AGTASKLTFGTGTRLQVTL >P01737; 20 T-CELL RECEPTOR ALPHA CHAIN PRECURSOR V REGION (PY14). MLLLLVPVLEVIFTLGGTRAQSVTQLGSHVSVSEGALVLLRCNYSSSVPPYLFWYVQYPN QGLQLLLKYTSAATLVKGINGFEAEFKKSETSFHLTKPSAHMSDAAEYFCAVSDLEPNSS ASKIIFGSGTRLSIR >P06323; 22 T-CELL RECEPTOR ALPHA CHAIN PRECURSOR V REGION (CTL-F3). MNMRPDTCSVLVLLLMLRRNNGDSVTQTEGLVTLTEGLPVMLNCTYQSTYSPFLFWYVQH LNEAPKLLFKSFTDNKRPEHQGFHATLHKSSSSFHLQKSSAQLSDSALYYCALSNAGAKL TFGGGTRLTVRP >P04435; 21 T-CELL RECEPTOR BETA CHAIN PRECURSOR V REGION (CTL-L17). MGTSLLCWMALCLLGADHADTGVSQNPRHNITKRGQNVTFRCDPISEHNRLYWYRQTLGQ GPEFLTYFQNEAQLEKSRLLSDRFSAERPKGSFSTLEIQRTEQGDSAMYLCASSLAGLNQ PQHFGDGTRLSIL >P01735; 21 T-CELL RECEPTOR BETA CHAIN PRECURSOR V REGION (86T1). MSCRLLLYVSLCLVETALMNTKITQSPRYLILGRANKSLECEQHLGHNAMYWYKQSAEKP PELMFLYNLKQLIRNETVPSRFIPECPDSSKLLLHISAVDPEDSAVYFCASSHGQGVSGN TLYFGEGSRLIVV >P01740; 18 T-CELL RECEPTOR GAMMA CHAIN PRECURSOR V REGION (V108A). MLLLRWFTSCCLWVFGLGQLEQTELSVTRETDENVQISCIVYLPYFSNTAIHWYRQKTNQ QFEYLIYVATNYNQRPLGGKHKKIEASKDFKSSTSTLEINYLKKEDEATYYCAVWMRWSS GFHKVFAEGTKLIVI >P20798; 39 TOXIN TXP-I PRECURSOR. MKICTFFIPLFKMNLFFLFIIPTILAVKPFRSFNNISLIDNGNVESVRAVVIDYCDIRHP NNLCKKHFEIDSYWNDDTDCFTNIGCKVYGGFDIIGGHTPKVGTVCRLKKGENKFGYCNS KGNCVERDFKESFGISIKIKGISNKGDDEPACPQYKNTWINYGKCNEPYYCGTNHGLFYA NKRKLDYFPTDGEKCNSNNIPYAVCYLGRCHTTGGFFSEFGTIVKNVEIVTLSDGKNSSR RGKHKNLPTSKVFDSYSIYDIDPKNWKIEDDDKDVTVHENTLDPKSDSRLC >P07147; 24 5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID OXIDASE PRECURSOR MKSYNVLPLAYISLFLMLFYQVWAQFPRECANIEALRRGVCCPDLLPSSGPGTDPCGSSS GRGRCVAVIADSRPHSRHYPHDGKDDREAWPLRFFNRTCQCNDNFSGHNCGTCRPGWRGA ACNQKILTVRRNLLDLSPEEKSHFVRALDMAKRTTHPQFVIATRRLEDILGPDGNTPQFE NISVYNYFVWTHYYSVKKTFLGTGQESFGDVDFSHEGPAFLTWHRYHLLQLERDMQEMLQ EPSFSLPYWNFATGKNVCDVCTDDLMGSRSNFDSTLISPNSVFSQWRVVCESLEEYDTLG TLCNSTEGGPIRRNPAGNVGRPAVQRLPEPQDVTQCLEVRVFDTPPFYSNSTDSFRNTVE GYSAPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNA DISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYAYEVQWPGQEFTVSEIIT IAVVAALLLVAAIFGVASCLIRSRSTKNEANQPLLTDHYQRYAEDYEELPNPNHSMV >Q09332; 22 UDP-GLUCOSE:GLYCOPROTEIN GLUCOSYLTRANSFERASE PRECURSOR ( MLRAVALCVSVVLIALYTPTSGESSQSYPITTLINAKWTQTPLYLEIAEYLADEQAGLFW DYVSGVTKLDTVLNEYDTESQQYNAALELVKSHVSSPQLPLLRLVVSMHSLTPRIQTHFQ LAEELRSSGSCQSFTFAQVGSELACSFNELQKKLEVPLAKDSLDAPVVTYSFDHIFPGSE NNTRTVVLYGDLGSSQFRTYHKLLEKEANAGRIRYILRHQLAKKDKRPVRLSGYGVELHL KSTEYKSQDDAPKPEAGSTSDEDLANESDVQGFDFKVLKQKHPTLKRALDQLRQRLLQGN DEIAQLKAWEFQDLGLQAAAAIAEIQGDETLQILQYTAHNFPMLARTLLAHKVTDGLRAE VKHNTEAFGRSLNVAPPDGALFINGLFFDADTMDLYSLIETLRSEMRVLESLHSNNVRGS LASSLLALDLTASSKKEFAIDIRDTAVQWVNDIENDVQYRRWPSSVMDLLRPTFPGMLRN IRKNVFNLVLVVDALQPTARSVIKLSESFVIHQAPIRLGLVFDARDANEDNLADYVAITC AYNYVSQKKDARAALSFLTDIYAAVGETKVVTKKDIVKQLTKEFTSLSFAKAEEFLEEDS TYDYGRELAAEFIQRLGFGDKEQPQALLNGVPMPSNVVTADSDFEEAIFTEIMTHTSNLQ KAVYKGELTDNDVAIDYLMNQPHVMPRLNQRILSQEDVKYLDINGVAYKNLGNVGVLNRL SNRDMTATLMDNLKYFGGKKSTELIGRTSLQFLTIWVFADLETDQGRDLLTHALDYVQSG ESVRVAFIPNTESSSASSRRNLNRLVWAAMQSLPPTQATEQVLKWLKKPKEKIEIPTQLE DILGSTELHLKMLRVYSQRVLGLNKSQRLVIGNGRLYGPLSSDESFDSADFALLARFSSL QYSDKVRQVLKESAQDVNEEFNSDTLLKLYASLLPRQTKTRFKLPTDLKTDHSVVKLPPK QEKLPHFDVAAVLDPASRAAQKLTPILILLRQVLNCQLNLYLIPVPQHSDMPVKNFYRYV VEPEVQFEANGGRSDGPLAKFSGLPANPLLTQQLQVPENWLVEAVRAVYDLDNIKLTDIG GPVHSEFDLEYLLLEGHCFDAASGAPPRGLQLVLGTQSQPTLVDTIVMANLGYFQLKANP GAWSLRLREGKSADIYAISHIEGTNTHHSAGSSEVQVLITSLRSHVVKLRVSKKPGMQQA ELLSDDNEQAAQSGMWNSIASSFGGGSANQAASDEDTETINIFSVASGHLYERLLRIMMV SLLKHTKSPVKFWFLKNYLSPQFTDFLPHMASEYNFQYELVQYKWPRWLHQQTEKQRTIW GYKILFLDVLFPLNVRKIIFVDADAIVRTDIKELYDMDLGGAPYAYTPFCDSRKEMEGFR FWKQGYWRSHLMGRRYHISALYVVDLKRFRKIAAGDRLRGQYQALSQDPNSLSNLDQDLP NNMIHQVAIKSLPDDWLWCQTWCSDSNFKTAKVIDLCNNPQTKEAKLTAAQRIVPEWKDY DAELKTLMSRIEDHENSHSRDSAVDDSVDDSVEVTTVTPSHEPKHGEL >P04560; 21 UROTENSIN II, ALPHA PRECURSOR. MMCNLLLSFSVLLLSCTHLVAHPVTDTADMTYSGPDSVEEAGGVSPDDFAVSDLNDLLQR AAVVEYSPLLSRENIKVPGQIPKEALRELLLEKPYRLIPPSGLWGSRRQFRKRGGGADCF WKYCV >P00749; 20 UROKINASE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC 3.4.2 MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ HCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII GGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLG RSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL PSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML CAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR SHTKEENGLAL >P35775; 19 VENOM ALLERGEN II PRECURSOR (ALLERGEN SOL I 2) (SOL I II MKSFVLATCLLGFAQIIYADNKELKIIRKDVAECLRTLPKCGNQPDDPLARVDVWHCAMA KRGVYDNPDPAVIKERSMKMCTKIITDPANVENCKKVASRCVDRETQGPKSNRQKAVNII GCALRAGVAETTVLARKK >Q05110; 23 VENOM ALLERGEN 5 PRECURSOR (ANTIGEN 5) (AG5) (ALLERGEN V MEISGLVYLIIIVTIIDLPYGKANNYCKIKCLKGGVHTACKYGSLKPNCGNKVVVSYGLT KQEKQDILKEHNDFRQKIARGLETRGNPGPQPPAKNMKNLVWNDELAYVAQVWANQCQYG HDTCRDVAKYQVGQNVALTGSTAAKYDDPVKLVKMWEDEVKDYNPKKKFSGNDFLKTGHY TQMVWANTKEVGCGSIKYIQEKWHKHYLVCNYGPSGNFMNEELYQTK >P42660; 19 VITELLOGENIC CARBOXYPEPTIDASE PRECURSOR (EC 3.4.16.-). MVKFHLLVLIAFTCYTCSDATLWNPYKKLMRGSASPPRPGESGEPLFLTPLLQDGKIEEA RNKARVNHPMLSSVESYSGFMTVDAKHNSNLFFWYVPAKNNREQAPILVWLQGGPGASSL FGMFEENGPFHIHRNKSVKQREYSWHQNHHMIYIDNPVGTGFSFTDSDEGYSTNEEHVGE NLMKFIQQFFVLFPNLLKHPFYISGESYGGKFVPAFGYAIHNSQSQPKINLQGLAIGDGY TDPLNQLNYGEYLYELGLIDLNGRKKFDEDTAAAIACAERKDMNSANRLIQGLFDGLDGQ ESYFKKVTGFSSYYNFIKGDEESKQDSVLMEFLSNPEVRKGIHVGELPFHDSDGHNKVAE MLSEDTLDTVAPWVSKLLSHYRVLFYNGQLDIICAYPMTVDFLMKMPFDGDSEYKRANRE IYRVDGEIAGYKKRAGRLQEVLIRNAGHMVPRDQPKWAFDMITSFTHKNYL >P31025; 18 VON EBNER'S GLAND PROTEIN PRECURSOR (VEG PROTEIN) (TEAR MKPLLLAVSLGLIAALQAHHLLASDEEIQDVSGTWYLKAMTVDREFPEMNLESVTPMTLT TLEGGNLEAKVTMLISGRCQEVKAVLEKTDEPGKYTADGGKHVAYIIRSHVKDHYIFYCE GELHGKPVRGVKLVGRDPKNNLEALEDFEKAAGARGLSTESILIPRQSETCSPGSD >P01283; 21 VASOACTIVE INTESTINAL PEPTIDE PRECURSOR (VIP). MESRSKPQFLAILTLFSVLFSQSLAWPLYGPPSSVRLDDRLQFEGAGDPDQVSLKADSDI LQNALAENDTPYYDVSRNARHADGVFTSDYSRLLGQISAKKYLESLIGKRISSSISEDPV PVKRHSDAVFTDNYTRLRKQMAVKKYLNSILNGKRSSEGDSPDFLEELEK >Q16927; 16 VITELLOGENIN A1 PRECURSOR (VG) (PVG1) [CONTAINS: VITELLI MLAKLLLLALAGLTAAYQYENSFKGYNPGYKGYDAGYKGYGYDAGYKGYGYDAGYKYNNQ GYSYKNGFEYGYQNAYQAAFYKHRPNVTEFEFSSWMPNYEYVYNVTSKTMTALAELDDQW TGVFTRAYLVIRPKSRDYVVAYVKQPEYAVFNERLPHGYATKFYHDMFKFQPMPMSSKPF GIRYHKGAIKGLYVEKTIPNNEVNILKAWISQLQVDTRGANLMHSSKPIHPSKNEWNGHY KVMEPLVTGECETHYDVNLIPAYMIQAHKQWVPQGQLRGEDDQFIQVTKTQNFDRCDQRM GYHFGFTGYSDFRPNTNQMGNVASKSLVSYMYLTGNWYNFTIQSSSMINKVAIAPSLVNK EPALVYAQVNMTLNDVHPYDKVPMGPAEDLKVFVDLVYSYNMPSDKKNYVRPGNETSSSS SSSSSSSSSSSESSSSSSESVENPKISPVEQYKPLLDKVEKRGNRYRRDLNAIKEKKYYE AYKMDQYRLHRLNDTSSDSSSSDSSSSSSSESKEHRNGTSSYSSSSSSSSSSSSSESSSY SSSSSSSSESYSISSEEYYYQPTPANFSYAPEAPFLPFFTGYKGYNIFYARNVDAIRSVG KLVEEIASDLENPSNLPKANTMSKFNILTRAIRAMGYEDIYELAQKYFVSQKERQVAQFS DKKFSKRVDAWVTLRDAVAEAGTPSAFKLIFDFIKEKKLRGYEAATVIASLAQSIRYPTE HLLHEFFLLVTSDVVLHQEYLNATALFAYSNFVNQAHVSNRSAYNYYPVFSFGRLADADY KIIEHKIVPWFAHQLREAVNEGDSVKIQVYIRSLGNLGHPQILSVFEPYLEGTIQITDFQ RLAIMVALDNLVIYYPSLARSVLYRAYQNTADVHEVRCAAVHLLMRTDPPADMLQRMAEF THHDPRLYVRAAVKSAIETAALADDYDEDSKLALNAKAAINFLNPEDVSIQYSFNHIRDY ALENLELSYRLHYGEIASNDHRYPSGLFYHLRQNFGGFKKYTSFYYLVSSMEAFFDIFKK QYNTKYFADYYKSADYSTNYYNFDKYSKYYKQYYYSKDSEYYQKFYGQKKDYYNDKEPFK FTAPRIAKLLNIDAEEAEQLEGQLLFKLFNGYFFTAFDNQTIENLPHKMRHLFENLEDGY AFDVTKFYQQQDVVLAWPLATGFPFIYTLKAPTVFKFEVDASAKTHPQVYKMPAGHPETE NDDFFYMPQSINGSVDVNLLYHRMVDAKVGFVTPFDHQRYIAGYQKKLHGYLPFNVELGL DFVKDEYEFEFKFLEPKDDHLLFHMSSWPYTGYKDITDMRPIAENPNAKIVHDDNQSTKT MEHTFGQDMTGVALRFHAKYDFDLINFQQFWSLIQKNDFVSAVNYPFAYQPYEYHQFNLF YDSQRTHAKSFKFFAYQKFGAPSFEETGPKHPANRHSYSGNYYESNYAQPFVYSPGSQRR YEQFFRNAASGIRNSFVRYYDFGFEFYAPQYKSEFTFTTAFADSPVDKTSRQLYYFYASP MFPSQSYFKDIPFSGKQFQFCATATSEFPRVPYLKFSDFDKYYGDASQYFDFLYGESCQG GAHIAVKGKQKQTGKCREYLRFSDVAKACKEQMANGYYQFEECQQAIDQAYYYDFYDYAI EYKDVGSVAKNLTNKFYNYFQYAFYPYFESNFFYHGKSNYIKAEFEFAPYGDYYNASFFG PSYAFQVQNYPVFNDYSTYFPYFFKYTFFPRYQPYYMHRLPSHKPRNRPYYELSNYEQFA IFDRKPQYPSCSFSNDNFYTFDNKKYFYDMGECWHAVMYTVKPDYDFYAQQSHFYNSDFE YKYKNGFEEYEQFAALARRGSDNQLYFKFLFGDNYIEVFPNNGGVPFVKYNGRPYDISKS NIAHFEYKEGYPSFPFFYAFAYPNKDLEVSFFGGKLKFATDGYRARFFSDYSFYNNFVGL CGTNNGEYFDEFVTADQCYMRKPEFFAASYAITGQNCTGPAKAFNYAYQQKAKQECVKRE VYYGDIIYNQEYYHPRYRYYNHNVEESSSSSSSSSSDSSSSSSSSEFSSLGRSGSSSSSS SSEEQKEFHPHKQEHSMKECPVQHQHQFFEQGDRICFSLRPLPVCHSKCAATEKISKYFD VHCFEKDSTQAKKYKSEIGRGYTPDFKSFAPHKTYKFNYPKSCVYKAY >P02844; 20 VITELLOGENIN II PRECURSOR (YOLK PROTEIN 2). MNPLRTLCVMACLLAVAMGNPQSGNRSGRRSNSLDNVEQPSNWVNPREVEELPNLKEVTL KKLQEMSMEEGATLLDKLYHLSQFNHVFKPDYTPEPSQIRGYIVGERGQKIEFNLNTLVE KVKRQQKFGDDEVTIFIQGLPETNTQVQKATRKLVQAYQQRYNLQPYETTDYSNEEQSQR SSSEEQQTQRRKQNGEQDDTKTGDLIVIQLGNAIEDFEQYATLNIERLGEIIGNRLVELT NTVNVPQEIIHLIGSGPAAHVAGVAGRQFTRQTGHKLRRITALDPTKIYGKPEERLTGLA RGDADFVDAIHTSAYGMGTSQRLANVDFFPNGPSTGVPGADNVVEATMRATRYFAESVRP GNERNFPSVAASSYQEYKQNKGYGKRGYMGIATDFDLQGDYILQVNSKSPFGRSTPAQKQ TGYHQVHQPWRQSSSNQGSRRQ >P19616; 17 MICROVITELLOGENIN PRECURSOR. MLRTTVVLLTLAAIAFAAPTSDDIYNNVVIGDIDGAVAKSKELQKQGKGDIITEAVNRLI RDSQRNTMEYAYQLWSLEARDIVKERFPIQFRMMLGEHSIKLINKRDNLAMKLGVATDNS GDRIAYGAADDKTSDRVAWKFVPLSEDKRVYFKILNVQRGQYLKLGVETDSDGEHMAYAS SGADTFRHQWYLQPAKADGNLVFFIVNREYNHALKLGRSVDSMGDRQVWGHNGNVIGNPE LFGWSVVAF >Q27309; 15 VITELLOGENIN PRECURSOR [CONTAINS: VITELLIN LIGHT CHAIN ( MKLFVLAAIIAAVSSDRFSSQSQSTGGQTYPSPWQVGKQYRYEVTSRTLAHLQEGPSSGS AFKAQFTIRVKSPGRLQAKLENPQHGNFNEQLPDPRELPVDLKYQPTPNIDKVFEIEIDG GRIVSLDFPTSVPVPQENLIKGLISALQLDTSAHRVIHDSQNNYDREQQQGLFRKMETDV TGDCETLYTVSPVASEWRRELPKFANEQDPVEVTKSTNYGHCHHRVAYHFGVPVGAEWTG TAHKTQEQQLIGRATYSRILTGKEGPIYKAETTSTVHVHPHLYGKQKAEVYSHVHMELIS VDQDSGAEWPRAGAMRPAQSILYSLSTKQMTKHYESSSSSSSSESHEFNFPEQHEHPHQS NQRSRRSYMRSKLVTVHKVLKKRNSESSSGSSSSSADSSSTYINDDIPDIDEPAYAALYM SPQPHADKKQNAMNAQKILQDIAQQLQNPNNMPKSDFLSKFNILVRLIASMSTEQLSQTS RSIETAKTSNNIIKSDMWMIFRDGVTQAGTLPAFKQIQSWIENKKIQEEEAAQVVVALPR TLRYPTKQIMTQFFNFARSPAVKDQMFLNSSALMAATKLINLGQVNNYTAHSYYPTHMYG RLTHKHDAFVLEEILPTLAADLKATVEYKDSTKAQVYIQAIGNLGHREILKVFAPYLEGK VEISTYLRTHIVKNLKTLAKLRDRHVRAVLFSILRNTAEPYPVRVAAIQSIFISHPTGEM MQAMAEMTHNDPSVEVRAVLKSAILSAAELQHPRNFYLSRTAQAARYLVTNEEFGYQHSF KFIDDSYDEDNDIGTFVISHIGSEDSLLPKDFKIVTNSKGGAWERNTIEASFSSAERFLD YLRDSVFAPHPKFDRAHKYSAEKIAKLLNIKNDEEEPLEASFYVDFMNNQRLFSFSESDL QQLSQYISEYMKKVESGAEKHYTKVYNQDQVSIMFPVASGMPFIFKYKEPAVIHFQSKLK GKFSFPSKDNKYYEANMIKDVQFTYAINIDGNVGFMDTLSNQYSSVGVVNKLQFNIPFKF GIEIKSGLIKFRVEPLHPDQDQTLVHYSVWPYSASQKKDSLVAISQDPATKIVERRSKVF SVDSKYGQSTHAVIYAQGYTYSSDWRNFGAKFTSRDYFTNLASLLTQEDIALTHFNLKHL CKQSQSKALTITAYYDEYYNQQNSGILTDATDRNDLSPNSETRRAEMVKLVSAGINKARV RVVDLSASFEGSQDQNYVLTGTWGDSPVDSKVQGMLFAGTKSATQGNQQINAVFATTKPE IHSLSFSKPLQSDLRAPFGMHFKYGQSGEIRVSGSFDRTKKYTTELENHPLAKQCSQQTT LNNFYQDSCHKAIVMAHAPDHVEFSVSFQDMSPQYRNFSYHTYRLYEYLGYWYTEANPLK LTQNGKMDFKIDFSYFDRTYTVDIASPSGEARMRDMPIATMAPGALSFYQPLKAYELVAN YFTGHQYQPYCSIDGTRIHTFSNRSYEYPLSRSWHVVMQDESTQRGNWHELAILSRRQQR DQQEIYISYKSESGQDLEIEIQPASGDSAYQVKVTTNTKKITDDDLTMYWDDVKEQPFLQ YHTHKDGVLVINIEDDRIRAIYDGQRFVVFTQDYRNSTRGICGRMSGEQRDDYLTPEGLV DKPELYAAAYSLNEENSDPKTQELKALATQQAYYPEYKYTSILRSDPTWQEESQSCGEDQ WQSETVYKSRSYDKHKGACEVRQQVQFYENHGDICITTSRVPSCQSHCRAGDYKIQHVQV TCKSKLDHDFRMYKEQIKKGQNPEVSGIPSVKQFKVPVTCQP >P06015; 29 VARIANT SURFACE GLYCOPROTEIN ANTAT 1.1 PRECURSOR (VSG) ( MVTKERNAALKIVMLVASALTLHPQQALAQTAGRPLADVVGKTLCTYSKTAKRQAANLAQ TLQRASSAAKQSRQAQQLAALALAKLPDYKEAAATLLIYATHKIQDAQASIENWTGENTK LVGQAMYSSGRIDELMLLLEGHREDGANGQDKTCLGAAAGGNTVNEFVKTECDTESGHNI EADNSNIGQAATTLSQESTDPEASGGASCKITANLATDYDSHANELPLLGGLLTIHNAGG FKTGQSLQTAAPTNKLISALKNKGAGVAAKLATVTSAAPTSKQELKTLLASKGERAKLQA ANDEYNNWKPGAKPEDFDAHIKKVFGAEDGKDSAYAIALEGISIEAPLGGGQTQNKQLYS MQPKDLMAALIGTIAELQTAAATKPACPGHKQTTTESDALCSKIKDANECNSKHFCSYNG TETDSAKKCKYNATKASASDAPVTQAQTTSRSETPAEKCTGKKKDDCKDGCKWEAETCKD SSILLTKNFALSVVSAALVALLF >P26326; 21 VARIANT SURFACE GLYCOPROTEIN ILTAT 1.21 PRECURSOR (VSG). MLRALLPSTTLALILAGGGHAAVGDAFPAFAVLCAAWDAATNKQIKPWSEDRELPELNDI YNMNMSIASEEWQTIFDGQAEQQTWSQFAQANAGKYKGIDWKQNWDRWRKQRQQTKDAGG AWQTKNHRPEWAATPRDVRPVILAIAEEATELSRKLEPPRTADGKDLIAEINSKLASARC SGELKAAAGNIGCTGPEGTPDKTTTCTTAKAGGSIGHDMLCLCSVAEATDKCSSTGVGDA VPNSGEKLRSNGFQHIVARCPKGPESGTLPQAIDLALAMLATALGTQQPGSNNMILGKSG GGTCTATNSACVDYHEKFSKQQAGITGIPWVALLQQARALYGTYVDAKLAAQTARQQIVM LAGQAKREYRRPAGSLKDPAGVIQEQATNRRRHGADDTNQCTSNNATADECPETRCEYDS EKNECRPKKGTETTATGPGERTTPADGKANNTVSDSLLIKTSPLWLAFLLF >P26327; 12 VARIANT SURFACE GLYCOPROTEIN ILTAT 1.22 PRECURSOR (VSG). MDTAQVFALFYMATVMAAGTKNKASQAVSDPCSEIHFDEQLANYFENEVSAATTQLDENQ NFERSWKLLQYLQMDHQKSKGAAALAAYASTINIRTAANVKAASGELLTAASLLRQRAAN VSAAFQLQGQGVIKLGTPDIDNGAKSITHADAGCNYAAISKTVPTQRCTPPQQQADTITA ADMQPDKLDELQLITEAYTTTITIAASAYSKGTPATGHTVYTYGNCQSTGGSASAQLGDT HALGIHVKTIGTKAVTEKTTLQPSSSNKCPDEGTTAELTPIKRLARAICLARKASLAKPK ALSRLQYSDLQTDTDFKRIAAIFLSRNGKQLDPEKDSQEINELIKETYGPNEEHFHKSYV EALDNKKWEFKIKESKIEGTVNALANGVDAGLATAYYASKRQSTCGQAAADTPIVSSDVE KCKGKTQDDCRTADECEMRDGECNAKVAKTAEPDSKTNTTGNNSFAIKTSTLLLAVLLF >P26328; 23 VARIANT SURFACE GLYCOPROTEIN ILTAT 1.23 PRECURSOR (VSG). MFKNINAAVLLLILSTRNDYANAAAGDNENLFLDLCNLLELGKRAVSKLAPTNLGELAYS EIQKLNMSLSDDAWKAKFAPKKGKQENSNNADGAPRSQEKTHARNHAWRQAATDLAGDEG DKPTLRLAGLEAVTQVEKLQYLSALQPLAERAAAILEQLKTLHSGSAGLTDTNIRQEIQT ALYGTGATAPEKTTLQLLKGKGNVGSTRKDICGQDNTAAKADTVLAYLFCICAGHATDSG GAIKVCSQTQPANNKADADVSDAHTHAAALAGQCHGSDTTNDIKAAEIDSAILEFTSKLK AANQKPYFGKYSATGCTGSDAEGICVMFKTTAKGEGKAVKQIPWVLTLHNAAEMIRKQQA VNGKIDSLNQELQAIQTAAYALKPQLEMYKRLQQTTEKARPGKQLTEMQAGECNTHKSNS TCPKNNCKWEEKDGKDGKCVADDSKVTTQGNAPAGAGDGTAGTTTTPNCASHTDKTKCEE ENKGKTTPVCGWRKGKEGESDQDKEMCRNGSFLAKKKFALSVVSAAFTALLF >P26329; 23 VARIANT SURFACE GLYCOPROTEIN ILTAT 1.24 PRECURSOR (VSG). MVYRNILQLSVLKVLLIVLIVEATHFGVKYELWQPECELTAELRKTAGVAKMKVNSDLNS FKTLELTKMKLLTFAAKFPESKEALTLRALEAALNTDLRALRDNIANGIDRAVRATAYAS EAAGALFSGIQTLHDATDGTTYCLSASGQGSNGNAAMASQGCKPLALPELLTEDSYNTDV ISDKGFPKISPLTNAQGQGKSGECGLFQAASGAQATNTGVQFSGGSRINLGLGAIVASAA QQPTRPDLSDFSGTARNQADTLYGKAHASITELLQLAQGPKPGQTEVETMKLLAQKTAAL DSIKFQLAASTGKKTSDYKEDENLKTEYFGKTESNIEALWNKVKEEKVKGADPEDPSKES KISDLNTEEQLQRVLDYYAVATMLKLAKQAEDIAKLETEIADQRGKSPEAECNKITEEPK CSEEKICSWHKEVKAGEKNCQFNSTKASKSGVPVTQTQTAGADTTAEKCKGKGEKDCKSP DCKWEGGTCKDSSILANKQFALSVASAAFVALLF >P26330; 21 VARIANT SURFACE GLYCOPROTEIN ILTAT 1.25 PRECURSOR (VSG). MQSQQQPVFISIILLAINTDAAAPTTAVNAREFGLLCTLVRAEDNLEDRRSAGQAAKEVV ALAAKIELILANLKHIERLAAAEPEAAPKESRSDETPEACKASKATVCSQAAQTYKTIRP DEKLALAFLAETTGDLRSTFNVTLKQITAAAASHARYFGENTESRPALDKIKKALYGSPE AKGDAIIESGDGTRSAACGNTDGNAANSAAKRATAALICLCGGDNTNTGNDACFTQTTAD INYAKKGGEVERAWTEIRQKCKAGAAANKVTAAQLKAAAAELAALIHQKRGEKAVAGLLG AAQINNGAVDCDGSEANGKGSCVILSTSASKYKVETPDWLNALEAAIADLEQEQIELDNG RKAEAQILALNSSXTTLLAQAVEPTKQPPAKAAAAPEKKSNPQKDCNKNTKKRDCKEGDG CKWSSTEATEGAFCKPKDGEGQTSAAGAGDAGASDTEAKKCSDKKKEEECKSPNCKWDGK ECKDSSILANKQFALSVASAAFVALLF >P26331; 32 VARIANT SURFACE GLYCOPROTEIN MITAT 1.1 PRECURSOR (VSG). MATGRAKNTKWARWLSTAGLIIVVTLPATTMAAERTGLKATAWKPLCKLTTELSKVSGEM LNKGQEVISNIQKIKAAEYKVSIYLAKNPETQALQQSTLLRGYFARKTNGGLESYKTMGL ATQIRSARAAAYLKGSIDEFLNLLESLKGGSENKCLVTTNADTAATRRETKLDDQECALS MPETKPEAATRTELTQTGYPNLQHGGGGTANTFQPTTSTGTCKLLSGHSTNGYPTTSALD TTAKVLAGYMTIPNTQVEATLANMQAMGNGHKATAPAWHEAWEARNREAKAKDLAYTNET GNLDTQPTLKALVKTLLLPKDNTEHNAEATKLEALFGGLAADKTKTYLDMVDAEIIPAGI AGRTTEAPLGKIHDTVELGDILSNYEMIAAQNVVTLKKNLDAVSKKQQTESAENKEKICN AAKDNQKACENLKEKGCVFNTESNKCELKKDVKEKLEKESKETEGKDEKANTTGSNSFLI HKAPLLLAFLLF >P26332; 26 VARIANT SURFACE GLYCOPROTEIN MITAT 1.2 PRECURSOR (VSG 22 MPSNQEARLFLAVLVLAQVLPILVDSAAEKGFKQAFWQPLCQVSEELDDQPKGALFTLQA AASKIQKMRDAALRASIYAEINHGTNRAKAAVIVANHYAMKADSGLEALKQTLSSQEVTA TATASYLKGRIDEYLNLLLQTKESGTSGCMMDTSGTNTVTKAGGTIGGVPCKLQLSPIQP KRPAATYLGKAGYVGLTRQADAANNFHDNDAECRLASGHNTNGLGKSGQLSAAVTMAAGY VTVANSQTAVTVQALDALQEASGAAHQPWIDAWKAKKALTGAETAEFRNETAGIAGKTGV TKLVEEALLKKKDSEASEIQTELKKYFSGHENEQWTAIEKLISEQPVAQNLVGDNQPTKL GELEGNAKLTTILAYYRMETAGKFEVLTQKHKPAESQQQAAETEGSCNKKDQNECKSPCK WHNDAENKKCTLDKEEAKKVADETAKDGKTGNTNTTGSSNSFVISKTPLWLAVLLF >P02896; 33 VARIANT SURFACE GLYCOPROTEIN MITAT 1.4A PRECURSOR (VSG 1 MDCHTKETLGVTQWRRSTMLTLSLLYAITPADGAKEALEYKTWTNHCGLAATLRKVAGGV LTKLKSHISYRKKLEEMETKLRIYALKGDGVGEQKSAEILATTAALMRQKALTPEEANLK TALKAAGFAGEGAAAVSSYLMTLGTLTTSGSAHCLSNEGGDGDGKDQLAPKGCRHGTEAD FDAGAGPAESEVADSGFAQVPGKQDGANAGQANMCALFTHQATPHSSQGIYITGAQTKPS FGYGMLTIGTTDQTIGLKLSDIKGKQADSAQKFWSSCHAAVKAAQDMKADPALKVDQTLL AVLVASPEMAEILKLEAAASQQKGPEEVTIDLATEKNNYFGTNNNKLEPLWTKIKGQNIV DLAATKGSTKELGTVTDTAELQKLLSYYYTVNKEEQKKTAEKITKLETELADQKGKSPES ECNKISEEPKCNEDKICSWHKEVKAGEKHCKFNSTKAKEKGVSVTQTQTAGGTEATTDKC KGKLEDTCKKESNCKWENNACKDSSILVTKKFALTVVSAAFVALLF >P26333; 22 VARIANT SURFACE GLYCOPROTEIN MITAT 1.5 PRECURSOR (VSG 11 MIHSNKVATVVLALISSWPADGTNNHGLKLQKAQAICKMSKELKATAMRAANDAKLKITE ILELENVFAAMIPNATKGTEADGCTDYNAVFLEANNTAAETVSKIATLAESATKAAGAAG RAAGVLDEFIAALAQAQGATGLYCIQGSGTGAATHTELADCFNGDLKPRNMLSIRDPKVS AAATGSTDLTTLAKAMAASGTDTTFHGDQQSKGCGLMKGTSDGIMIGQALTGTFAWAQGL LRFGALGANGIASTGVTGYAHTATASGNGVHWASDPEKIPVIAEAIALVSNYNTLADSIG TRAKDAIEKVKKCMKATNKEIKREHIFLNVSHLNRELQKAVTELDKALNKQDAKAEAKQQ PNCDDKKQIECGDTPGCGWHKAEGKCEAKDGEGQKNQATGEKDANKNRCTQHGTNKEACE KENTPGQSAVCGFRKGKDGETDEPDKEKCRNGSFLTSKQFAFSVVSAAFMALLF >P26334; 24 VARIANT SURFACE GLYCOPROTEIN MITAT 1.6 PRECURSOR (VSG). MAVHRALAAYAISLYVLLPRKSGATDKGAIKFETWEPLCLLTQDFGNLYNRAHKLNLDID TYVTAAQADQLRLQILLSRASSKIEAAAAAAATAAIAADLAGKAKHVASCKLAATTLTAT TGYLHGRIAEFLEVMTAHRGTTNKYGCLSKSRSDNSNSITDSVANLKDKCKLTVQQISPD NKATEQITKAGFTKLTATGGLTSSDLGGSGQAVCMILSTTASEVVNNGNLDEPVPYAGGY LRRKHDLTSDGNDNLATITDSASAPATRAKTDPYLQIWRAFKNLEDCESTFTSGYSRPSP ETLKAADETKTAIKNYVVQKEGKYDQATDKEDDYKNLDKIFKDGKDFYPQKLWDAMDKKD LLKDATQTNEIKKLADITDRSELNKVLLYYTRQKEQTLTKELKEAQEKATQANQNDAAAK AAEDSCNKLVGGEKCNADKKCSYETETDGTKKCKFNATKAEKSGAPVTQAQTVGETEATP EKCKGKDAKTCGTTQGCKWEGETCKDSSILVTKKFALTVVSAAFVALLF >P20948; 28 VARIANT SURFACE GLYCOPROTEIN YNAT 1.1 PRECURSOR (VSG). MKRVLSNVLKAWIFTIVAFHNFSTSVTADAPVNAAEYNALCRLYNIARAGEGLKEEDWLP CAGKAACEKTAASIEDVFMKLNFSEPSAVVTTLDGTRVELQNSASTRIKRAKLAKVLAAA ETIKAQQLKYHESSKSLLESAKANFTKAIVGGWGNPTTPDESGLPTTFKTNRADDCKLAG GNGGKSLVFDIACLCTTSDSASGSKYTCGPKSGDNGSGWLDNNGDNQGKPAAKEAWKNLR ADCRRQSAGVRVTPELISQSLVIFEGLIGTRAASGHDNARYIFGTVATAQSCGHSTATNK GSIDYKASNAQQRGDIEWEKNLRMAEGDLRGLLTAKQLVAALQARAEHLEDAAFTIFNES VLETQIAWESSRPPSTDANTSQKGPLQRPEKSGESSHLPSGSSHGTKAIRSILHVALLM >P20949; 22 VARIANT SURFACE GLYCOPROTEIN YNAT 1.3 PRECURSOR (VSG). MLDNSRARSIVHLLILLKAHVITQIIKNTQEFTSLCTFVKVTLKATDGLTSAASKSQTDW ALGENPTSRIKKLITELETSSDRIRLGEEPNLTIQLPQGDPKQRLRRKLEVFLARAKYTE ELVRQAQGDVGGRCNEAKAELEEAVTGRKGPDLETQATAAAAALHNKARGTACKVAGATT DTNFAGTSLVADLMCLCAAETNSREKHICGFESHASGVWANAGTNSNAGEIWGKILDACK NREIQVEVTPQFLRIAITKFEGLLGAQAHKLTSNGNAGAWLLGYSMNAGSVTCDGQSSTN GICVDYKGSSDARGPIAWLGHIKNAITALENRDKNLQRVRKLQRQAEAILMSAEDALIEA NISLGGKDMVPASEVTVPNSSNPTSRQNSVVQEPTTVSAAAITPLILPWTLLI >P18709; 15 VITELLOGENIN A2 PRECURSOR (VTG A2) [CONTAINS: LIPOVITELL MKGIVLALLLALAGSERTHIEPVFSESKISVYNYEAVILNGFPESGLSRAGIKINCKVEI SAYAQRSYFLKIQSPEIKEYNGVWPKDPFTRSSKLTQALAEQLTKPARFEYSNGRVGDIF VADDVSDTVANIYRGILNLLQVTIKKSQDVYDLQESSVGGICHTRYVIQEDKRGDQIRII KSTDFNNCQDKVSKTIGLELAEFCHSCKQLNRVIQGAATYTYKLKGRDQGTVIMEVTARQ VLQVTPFAERHGAATMESRQVLAWVGSKSGQLTPPQIQLKNRGNLHYQFASELHQMPIHL MKTKSPEAQAVEVLQHLVQDTQQHIREDAPAKFLQLVQLLRASNFENLQALWKQFAQRTQ YRRCLLDALPMAGTVDCLKFIKQLIHNEELTTQEAAVLITFAMRSARPGQRNFQISADLV QDSKVQKYSTVHKAAILAYGTMVRRYCDQLSSCPEHALEPLHELAAEAANKGHYEDIALA LKALGNAGQPESIKRIQKFLPGFSSSADQLPVRIQTDAVMALRNIAKEDPRKVQEILLQI FMDRDVRTEVRMMACLALFETRPGLATVTAIANVAARESKTNLQLASFTFSQMKALSKSS VPHLEPLAAACSVALKILNPSLDNLGYRYSKVMRVDTFKYNLMAGAAAKVFIMNSANTMF PVFILAKFREYTSLVENDDIEIGIRGEGIEEFLRKQNIQFANFPMRKKISQIVKSLLGFK GLPSQVPLISGYIKLFGQEIAFTELNKEVIQNTIQALNQPAERHTMIRNVLNKLLNGVVG QYARRWMTWEYRHIIPTTVGLPAELSLYQSAIVHAAVNSDVKVKPTPSGDFSAAQLLESQ IQLNGEVKPSVLVHTVATMGINSPLFQAGIEFHGKVHAHLPAKFTAFLDMKDRNFKIETP PFQQENHLVEIRAQTFAFTRNIADLDSARKTLVVPRNNEQNILKKHFETTGRTSAEGASM MEDSSEMGPKKYSAEPGHHQYAPNINSYDACTKFSKAGVHLCIQCKTHNAASRRNTIFYQ AVGEHDFKLTMKPAHTEGAIEKLQLEITAGPKAASKIMGLVEVEGTEGEPMDETAVTKRL KMILGIDESRKDTNETALYRSKQKKKNKIHNRRLDAEVVEARKQQSSLSSSSSSSSSSSS SSSSSSSSSSSSSPSSSSSSSYSKRSKRREHNPHHQRESSSSSSQEQNKKRNLQENRKHG QKGMSSSSSSSSSSSSSSSSSSSSSSSSSSSSEENRPHKNRQHDNKQAKMQSNQHQQKKN KFSESSSSSSSSSSSEMWNKKKHHRNFYDLNFRRTARTKGTEHRGSRLSSSSESSSSSSE SAYRHKAKFLGDKEPPVLVVTFKAVRNDNTKQGYQMVVYQEYHSSKQQIQAYVMDISKTR WAACFDAVVVNPHEAQASLKWGQNCQDYKINMKAETGNFGNQPALRVTANWPKIPSKWKS TGKVVGEYVPGAMYMMGFQGEYKRNSQRQVKLVFALSSPRTCDVVIRIPRLTVYYRALRL PVPIPVGHHAKENVLQTPTWNIFAEAPKLIMDSIQGECKVAQDQITTFNGVDLASALPEN CYNVLAQDCSPEMKFMVLMRNSKESPNHKDINVKLGEYDIDMYYSADAFKMKINNLEVSE EHLPYKSFNYPTVEIKKKGNGVSLSASEYGIDSLDYDGLTFKFRPTIWMKGKTCGICGHN DDESEKELQMPDGSVAKDQMRFIHSWILPAESCSEGCNLKHTLVKLEKAIATDGAKAKCY SVQPVLRCAKGCSPVKTVEVSTGFHCLPSDVSLDLPEGQIRLEKSEDFSEKVEAHTACSC ETSPCAA >P01174; 19 WHEY ACIDIC PROTEIN PRECURSOR (WHEY PHOSPHOPROTEIN) (WAP MRCSISLVLGLLALEVALARNLQEHVFNSVQSMCSDDSFSEDTECINCQTNEECAQNDMC CPSSCGRSCKTPVNIEVQKAGRCPWNPIQMIAAGPCPKDNPCSIDSDCSGTMKCCKNGCI MSCMDPEPKSPTVISFQ >P04628; 27 WNT-1 PROTO-ONCOGENE PROTEIN PRECURSOR. MGLWALLPGWVSATLLLALAALPAALAANSSGRWWGIVNVASSTNLLTDSKSLQLVLEPS LQLLSRKQRRLIRQNPGILHSVSGGLQSAVRECKWQFRNRRWNCPTAPGPHLFGKIVNRG CRETAFIFAITSAGVTHSVARSCSEGSIESCTCDYRRRGPGGPDWHWGGCSDNIDFGRLF GREFVDSGEKGRDLRFLMNLHNNEAGRTTVFSEMRQECKCHGMSGSCTVRTCWMRLPTLR AVGDVLRDRFDGASRVLYGNRGSNRASRAELLRLEPEDPAHKPPSPHDLVYFEKSPNFCT YSGRLGTAGTAGRACNSSSPALDGCELLCCGRGHRTRTQRVTERCNCTFHWCCHVSCRNC THTRVLHECL >P55328; 27 ENDO-1,4-BETA-XYLANASE I PRECURSOR (EC 3.2.1.8) (XYLANAS MKVTAAFAGLLVTAFAAPVPEPVLVSRSAGINYVQNYNGNLGDFTYDESAGTFSMYWEDG VSSDFVVGLGWTTGSSNAITYSAEYSASGSSSYLAVYGWVNYPQAEYYIVEDYGDYNPCS SATSLGTVYSDGSTYQVCTDTRTNEPSITGTSTFTQYFSVRESTRTSGTVTVANHFNFWA QHGFGNSDFNYQVMAVEAWSGAGSASVTISS >P36217; 32 ENDO-1,4-BETA-XYLANASE 2 PRECURSOR (EC 3.2.1.8) (XYLANAS MVSFTSLLAASPPSRASCRPAAEVESVAVEKRQTIQPGTGYNNGYFYSYWNDGHGGVTYT NGPGGQFSVNWSNSGNFVGGKGWQPGTKNKVINFSGSYNPNGNSYLSVYGWSRNPLIEYY IVENFGTYNPSTGATKLGEVTSDGSVYDIYRTQRVNQPSIIGTATFYQYWSVRRNHRSSG SVNTANHFNAWAQQGLTLGTMDYQIVAVEGYFSSGSASITVS >P33559; 25 ENDO-1,4-BETA-XYLANASE A PRECURSOR (EC 3.2.1.8) (XYLANAS MVQIKAAALAMLFASHVLSEPIEPRQASVSIDSKFKAHGKKYLGNIGDQYTLTKNSKTPA VIKADFGALTPENSMKWDATEPSRGQFSFSGSDYLVNFAQSNNKLIRGHTLVWHSQLPSW VQAITDKNTLIEVMKNHITTVMQHYKGKIYAWDVVNEIFNEDGSLRDSVFYKVIGDDYVR IAFETARAADPNAKLYINDYNLDSASYPKLAGMVSHVKKWIEAGIPIDGIGSQTHLSAGG GAGISGALNALAGAGTKEIAVTELDIAGASSTDYVEVVEACLDQPKCIGITVWGVADPDS WRSSSTPLLFDSNYNPKPAYTAIANAL >O43097; 31 ENDO-1,4-BETA-XYLANASE PRECURSOR (EC 3.2.1.8) (XYLANASE) MVGFTPVALAALAATGALAFPAGNATELEKRQTTPNSEGWHDGYYYSWWSDGGAQATYTN LEGGTYEISWGDGGNLVGGKGWNPGLNARAIHFEGVYQPNGNSYLAVYGWTRNPLVEYYI VENFGTYDPSSGATDLGTVECDGSIYRLGKTTRVNAPSIDGTQTFDQYWSVRQDKRTSGT VQTGCHFDAWARAGLNVNGDHYYQIVATEGYFSSGYARITVADVG >P20239; 34 ZONA PELLUCIDA SPERM-BINDING PROTEIN 2 PRECURSOR (ZONA P MARWQRKASVSSPCGRSIYRFLSLLFTLVTSVNSVSLPQSENPAFPGTLICDKDEVRIEF SSRFDMEKWNPSVVDTLGSEILNCTYALDLERFVLKFPYETCTIKVVGGYQVNIRVGDTT TDVRYKDDMYHFFCPAIQAETHEISEIVVCRRDLISFSFPQLFSRLADENQNVSEMGWIV KIGNGTRAHILPLKDAIVQGFNLLIDSQKVTLHVPANATGIVHYVQESSYLYTVQLELLF STTGQKIVFSSHAICAPDLSVACNATHMTLTIPEFPGKLESVDFGQWSIPEDQWHANGID KEATNGLRLNFRKSLLKTKPSEKCPFYQFYLSSLKLTFYFQGNMLSTVIDPECHCESPVS IDELCAQDGFMDFEVYSHQTKPALNLDTLLVGNSSCQPIFKVQSVGLARFHIPLNGCGTR QKFEGDKVIYENEIHALWENPPSNIVFRNSEFRMTVRCYYIRDSMLLNAHVKGHPSPEAF VKPGPLVLVLQTYPDQSYQRPYRKDEYPLVRYLRQPIYMEVKVLSRNDPNIKLVLDDCWA TSSEDPASAPQWQIVMDGCEYELDNYRTTFHPAGSSAAHSGHYQRFDVKTFAFVSEARGL SSLIYFHCSALICNQVSLDSPLCSVTCPASLRSKREANKEDTMTVSLPGPILLLSDVSSS KGVDPSSSEITKDIIAKDIASKTLGAVAALVGSAVILGFICYLYKKRTIRFNH